{"pages":[{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-01","page":1,"lines":[{"cnt":[[471,533],[1652,533],[1652,629],[471,629]],"region":{"top_left_x":470,"top_left_y":532,"width":1183,"height":98},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bb4719c20c484e619c88727b1b51f96e","type":"title","conversion_output":false,"children_ids":["03de5f378c0744e19c4797435a23a546","9e616eb4e70d4a95a2bc2b7c9658690e"],"text":"","text_display":""},{"cnt":[[477,537],[1648,537],[1648,582],[477,582]],"region":{"top_left_x":476,"top_left_y":537,"width":1172,"height":46},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"03de5f378c0744e19c4797435a23a546","type":"text","conversion_output":true,"parent_id":"bb4719c20c484e619c88727b1b51f96e","text":"Randomized Clinical Trial of Vitamin D and Omega-3 Fatty Acids","text_display":"\\title{\nRandomized Clinical Trial of Vitamin D and Omega-3 Fatty Acids","confidence":1,"confidence_rate":1},{"cnt":[[804,580],[1317,580],[1317,625],[804,625]],"region":{"top_left_x":803,"top_left_y":580,"width":514,"height":46},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9e616eb4e70d4a95a2bc2b7c9658690e","type":"text","conversion_output":true,"parent_id":"bb4719c20c484e619c88727b1b51f96e","text":"for Diabetic Kidney Disease","text_display":" for Diabetic Kidney Disease\n}","confidence":1,"confidence_rate":1},{"cnt":[[975,709],[1147,709],[1147,754],[975,754]],"region":{"top_left_x":975,"top_left_y":708,"width":173,"height":47},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ba992fc59a184587b3b103180430c7ab","type":"section_header","conversion_output":false,"children_ids":["b2e9db7e6b1f4915ae47b30ee189faca"],"text":"","text_display":""},{"cnt":[[982,713],[1143,713],[1143,750],[982,750]],"region":{"top_left_x":981,"top_left_y":713,"width":162,"height":37},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b2e9db7e6b1f4915ae47b30ee189faca","type":"text","conversion_output":true,"parent_id":"ba992fc59a184587b3b103180430c7ab","text":"Protocol","text_display":"\n\n\\section*{Protocol}","confidence":1,"confidence_rate":1},{"cnt":[[937,756],[1188,756],[1188,797],[937,797]],"region":{"top_left_x":936,"top_left_y":756,"width":253,"height":42},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b673e3aec30b4e54be92f2c0a8dee159","type":"text","conversion_output":true,"text":"June 28, 2010","text_display":"\n\nJune 28, 2010","confidence":1,"confidence_rate":1},{"cnt":[[958,885],[1162,885],[1162,930],[958,930]],"region":{"top_left_x":958,"top_left_y":885,"width":205,"height":46},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0087f1572c834ceea50e381989e7014b","type":"section_header","conversion_output":false,"children_ids":["1b85125db7c54ee7ba013621c358f8d8"],"text":"","text_display":""},{"cnt":[[962,889],[1158,889],[1158,930],[962,930]],"region":{"top_left_x":962,"top_left_y":889,"width":197,"height":42},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1b85125db7c54ee7ba013621c358f8d8","type":"text","conversion_output":true,"parent_id":"0087f1572c834ceea50e381989e7014b","text":"Short title:","text_display":"\n\n\\section*{Short title:}","confidence":1,"confidence_rate":1},{"cnt":[[924,932],[1201,932],[1201,973],[924,973]],"region":{"top_left_x":923,"top_left_y":932,"width":278,"height":42},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b12ac2e70f244d2284e5ec221695220e","type":"text","conversion_output":true,"text":"VITAL Diabetes","text_display":"\n\nVITAL Diabetes","confidence":1,"confidence_rate":1},{"cnt":[[846,1061],[1278,1061],[1278,1111],[846,1111]],"region":{"top_left_x":846,"top_left_y":1061,"width":433,"height":50},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9468bbe71f0e45a38154c16b21ae121a","type":"section_header","conversion_output":false,"children_ids":["f5a0ceab9a054174be743d07e8a5d09d"],"text":"","text_display":""},{"cnt":[[849,1066],[1274,1066],[1274,1106],[849,1106]],"region":{"top_left_x":848,"top_left_y":1065,"width":427,"height":42},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f5a0ceab9a054174be743d07e8a5d09d","type":"text","conversion_output":true,"parent_id":"9468bbe71f0e45a38154c16b21ae121a","text":"Principal Investigators:","text_display":"\n\n\\section*{Principal Investigators:}","confidence":0.9990234375,"confidence_rate":0.9999663095451973},{"cnt":[[761,1109],[1373,1109],[1373,1149],[761,1149]],"region":{"top_left_x":760,"top_left_y":1108,"width":613,"height":42},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"09e3447fd01047c0825ca9fb0a7ad20b","type":"text","conversion_output":true,"text":"Overall PI: Ian H. de Boer, MD, MS","text_display":"\n\nOverall PI: Ian H. de Boer, MD, MS","confidence":0.9050125190988183,"confidence_rate":0.997444130729943},{"cnt":[[447,1152],[1678,1152],[1678,1197],[447,1197]],"region":{"top_left_x":446,"top_left_y":1151,"width":1232,"height":46},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e89fe32bf1b4453fbb7cbdaace12a8f3","type":"text","conversion_output":true,"text":"Brigham Women's Hospital Site PI: Debra Schaumberg, ScD, OD, MPH","text_display":"\nBrigham Women's Hospital Site PI: Debra Schaumberg, ScD, OD, MPH","confidence":0.9970715045928955,"confidence_rate":0.9999574966737284},{"cnt":[[928,1280],[1195,1280],[1195,1330],[928,1330]],"region":{"top_left_x":928,"top_left_y":1280,"width":267,"height":50},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2bf7c699abe441ad83029c3250d1377b","type":"section_header","conversion_output":false,"children_ids":["5cf245d823fe464a8698b9310cc238f1"],"text":"","text_display":""},{"cnt":[[932,1285],[1192,1285],[1192,1330],[932,1330]],"region":{"top_left_x":932,"top_left_y":1284,"width":261,"height":46},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5cf245d823fe464a8698b9310cc238f1","type":"text","conversion_output":true,"parent_id":"2bf7c699abe441ad83029c3250d1377b","text":"Supported by:","text_display":"\n\n\\section*{Supported by:}","confidence":1,"confidence_rate":1},{"cnt":[[825,1328],[1300,1328],[1300,1366],[825,1366]],"region":{"top_left_x":825,"top_left_y":1327,"width":475,"height":40},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e43398748a84493a862360709be699ce","type":"text","conversion_output":true,"text":"National Institutes of Health","text_display":"\n\nNational Institutes of Health","confidence":0.99951171875,"confidence_rate":0.9999856353826395},{"cnt":[[902,1371],[1222,1371],[1222,1412],[902,1412]],"region":{"top_left_x":902,"top_left_y":1370,"width":321,"height":42},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5b694c4c83a34c42a60e4835db6bdfc2","type":"text","conversion_output":true,"text":"R01 DK088762-01","text_display":"\nR01 DK088762-01","confidence":1,"confidence_rate":1},{"cnt":[[795,1500],[1328,1500],[1328,1549],[795,1549]],"region":{"top_left_x":794,"top_left_y":1499,"width":534,"height":51},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"431af5c52fa242b5902b816d2ac36afe","type":"section_header","conversion_output":false,"children_ids":["98330339b5dc4d50b165837d4ae4a3e1"],"text":"","text_display":""},{"cnt":[[797,1504],[1326,1504],[1326,1549],[797,1549]],"region":{"top_left_x":797,"top_left_y":1503,"width":529,"height":47},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"98330339b5dc4d50b165837d4ae4a3e1","type":"text","conversion_output":true,"parent_id":"431af5c52fa242b5902b816d2ac36afe","text":"Study Interventions and IND:","text_display":"\n\n\\section*{Study Interventions and IND:}","confidence":0.9951171875,"confidence_rate":0.9998516845641634},{"cnt":[[327,1547],[1800,1547],[1800,1592],[327,1592]],"region":{"top_left_x":326,"top_left_y":1546,"width":1475,"height":46},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"91b6fab0e8094b059847614c4169a5b3","type":"text","conversion_output":true,"text":"Described separately as part of the parent Vitamin D and Omega-3 Trial (VITAL) Study","text_display":"\n\nDescribed separately as part of the parent Vitamin D and Omega-3 Trial (VITAL) Study","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-02","page":2,"lines":[{"cnt":[[120,125],[479,125],[479,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":360,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e41592914ed54121bd6b40259186d349","type":"section_header","conversion_output":false,"children_ids":["cb879687a8dc403caeeb0a69306c11f2"],"text":"","text_display":""},{"cnt":[[125,129],[475,129],[475,174],[125,174]],"region":{"top_left_x":124,"top_left_y":128,"width":351,"height":47},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cb879687a8dc403caeeb0a69306c11f2","type":"text","conversion_output":true,"parent_id":"e41592914ed54121bd6b40259186d349","text":"Study Team Roster","text_display":"\n\n\\section*{Study Team Roster}","confidence":1,"confidence_rate":1},{"cnt":[[120,213],[535,213],[535,260],[120,260]],"region":{"top_left_x":120,"top_left_y":212,"width":415,"height":48},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d9017e11f99c4b32a2076851c72af060","type":"section_header","conversion_output":false,"children_ids":["1aab472bd11045418782caf574777727"],"text":"","text_display":""},{"cnt":[[125,215],[531,215],[531,260],[125,260]],"region":{"top_left_x":124,"top_left_y":214,"width":407,"height":46},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1aab472bd11045418782caf574777727","type":"text","conversion_output":true,"parent_id":"d9017e11f99c4b32a2076851c72af060","text":"lan H. de Boer, MD MS","text_display":"\n\n\\section*{lan H. de Boer, MD MS}","confidence":1,"confidence_rate":1},{"cnt":[[125,260],[483,260],[483,303],[125,303]],"region":{"top_left_x":124,"top_left_y":259,"width":360,"height":44},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a3608b91b69e46ebb07a67b885341a33","type":"text","conversion_output":true,"text":"Principal Investigator","text_display":"\n\nPrincipal Investigator","confidence":1,"confidence_rate":1},{"cnt":[[122,305],[662,305],[662,342],[122,342]],"region":{"top_left_x":122,"top_left_y":305,"width":540,"height":37},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"16f1d7cc247e4c81bb41f763ab7ef0eb","type":"text","conversion_output":true,"text":"Assistant Professor of Medicine","text_display":"\nAssistant Professor of Medicine","confidence":1,"confidence_rate":1},{"cnt":[[125,348],[1029,348],[1029,391],[125,391]],"region":{"top_left_x":124,"top_left_y":348,"width":906,"height":44},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1e12860db3a24ef28e89f8a532f07718","type":"text","conversion_output":true,"text":"Division of Nephrology and Kidney Research Institute","text_display":"\nDivision of Nephrology and Kidney Research Institute","confidence":1,"confidence_rate":1},{"cnt":[[125,391],[552,391],[552,434],[125,434]],"region":{"top_left_x":124,"top_left_y":391,"width":429,"height":43},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9881a5b4ef0948e1a4c05cda4010270a","type":"text","conversion_output":true,"text":"University of Washington","text_display":"\nUniversity of Washington","confidence":1,"confidence_rate":1},{"cnt":[[125,434],[578,434],[578,479],[125,479]],"region":{"top_left_x":124,"top_left_y":433,"width":454,"height":47},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ee0d800955fd49b988db9911ba1df4d2","type":"text","conversion_output":true,"text":"Telephone (206) 616-5403","text_display":"\nTelephone (206) 616-5403","confidence":1,"confidence_rate":1},{"cnt":[[125,477],[458,477],[458,522],[125,522]],"region":{"top_left_x":124,"top_left_y":476,"width":334,"height":47},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1165b2e954684c0d83b36b2fef182b0c","type":"text","conversion_output":true,"text":"Fax (206) 685-8661","text_display":"\nFax (206) 685-8661","confidence":1,"confidence_rate":1},{"cnt":[[125,524],[501,524],[501,567],[125,567]],"region":{"top_left_x":124,"top_left_y":524,"width":377,"height":44},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"989b746c1ff44c8bbbad0c404c239f34","type":"text","conversion_output":true,"text":"Pager (206) 540-9789","text_display":"\nPager (206) 540-9789","confidence":1,"confidence_rate":1},{"cnt":[[125,567],[587,567],[587,612],[125,612]],"region":{"top_left_x":124,"top_left_y":567,"width":463,"height":46},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"80c9d754c5fc4178b8e9c6536726bca1","type":"text","conversion_output":true,"text":"deboer@u.washington.edu","text_display":"\ndeboer@u.washington.edu","confidence":0.99951171875,"confidence_rate":0.9999825572771935},{"cnt":[[122,653],[758,653],[758,698],[122,698]],"region":{"top_left_x":122,"top_left_y":653,"width":637,"height":46},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3e14ec37a51f4769b224649790569a67","type":"section_header","conversion_output":false,"children_ids":["0ff3962272f34c55aac95678613c7539"],"text":"","text_display":""},{"cnt":[[125,655],[754,655],[754,698],[125,698]],"region":{"top_left_x":124,"top_left_y":655,"width":631,"height":44},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0ff3962272f34c55aac95678613c7539","type":"text","conversion_output":true,"parent_id":"3e14ec37a51f4769b224649790569a67","text":"Debra Schaumberg, ScD, OD, MPH","text_display":"\n\n\\section*{Debra Schaumberg, ScD, OD, MPH}","confidence":1,"confidence_rate":1},{"cnt":[[125,700],[1029,700],[1029,741],[125,741]],"region":{"top_left_x":124,"top_left_y":700,"width":906,"height":42},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2ff2f4a1cdea4707912d789ddfb855f2","type":"text","conversion_output":true,"text":"Brigham Women's Hospital Site Principal Investigator","text_display":"\n\nBrigham Women's Hospital Site Principal Investigator","confidence":1,"confidence_rate":1},{"cnt":[[122,743],[1016,743],[1016,786],[122,786]],"region":{"top_left_x":122,"top_left_y":743,"width":895,"height":44},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"84d6827fe47c4488a8a856c7bf8b7a84","type":"text","conversion_output":true,"text":"Associate Professor of Medicine and Ophthalmology","text_display":"\nAssociate Professor of Medicine and Ophthalmology","confidence":0.99951171875,"confidence_rate":0.9999909555872323},{"cnt":[[125,786],[655,786],[655,823],[125,823]],"region":{"top_left_x":124,"top_left_y":786,"width":532,"height":37},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"087f8db56ce4460cadc7d44bc04a170e","type":"text","conversion_output":true,"text":"Division of Preventive Medicine","text_display":"\nDivision of Preventive Medicine","confidence":1,"confidence_rate":1},{"cnt":[[125,829],[623,829],[623,874],[125,874]],"region":{"top_left_x":124,"top_left_y":829,"width":500,"height":46},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"802953cf63ba413492ad4ff712677b92","type":"text","conversion_output":true,"text":"Brigham \\& Women's Hospital","text_display":"\nBrigham \\& Women's Hospital","confidence":1,"confidence_rate":1},{"cnt":[[125,877],[535,877],[535,913],[125,913]],"region":{"top_left_x":124,"top_left_y":876,"width":411,"height":38},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ed6b3c1fb0b44ce5b52b476aa5265623","type":"text","conversion_output":true,"text":"Harvard Medical School","text_display":"\nHarvard Medical School","confidence":1,"confidence_rate":1},{"cnt":[[125,920],[578,920],[578,960],[125,960]],"region":{"top_left_x":124,"top_left_y":919,"width":454,"height":42},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ee0f0cf3a01841fea577fc3048a98873","type":"text","conversion_output":true,"text":"Telephone (617) 278-0849","text_display":"\nTelephone (617) 278-0849","confidence":1,"confidence_rate":1},{"cnt":[[125,962],[462,962],[462,1003],[125,1003]],"region":{"top_left_x":124,"top_left_y":962,"width":338,"height":42},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ff69e4031ff34446afe8be1de2b2c303","type":"text","conversion_output":true,"text":"Fax (617) 731-3843","text_display":"\nFax (617) 731-3843","confidence":1,"confidence_rate":1},{"cnt":[[125,1005],[750,1005],[750,1051],[125,1051]],"region":{"top_left_x":124,"top_left_y":1005,"width":626,"height":46},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"65ab7aef25694451b1aa03cb7aa00816","type":"text","conversion_output":true,"text":"dschaumberg@rics.bwh.harvard.edu","text_display":"\ndschaumberg@rics.bwh.harvard.edu","confidence":1,"confidence_rate":1},{"cnt":[[120,1091],[599,1091],[599,1137],[120,1137]],"region":{"top_left_x":120,"top_left_y":1091,"width":480,"height":46},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7c597adb8fb5432395232e88d2345d61","type":"section_header","conversion_output":false,"children_ids":["15ccce2921674de184d06882e0de9431"],"text":"","text_display":""},{"cnt":[[125,1096],[595,1096],[595,1137],[125,1137]],"region":{"top_left_x":124,"top_left_y":1095,"width":472,"height":42},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"15ccce2921674de184d06882e0de9431","type":"text","conversion_output":true,"parent_id":"7c597adb8fb5432395232e88d2345d61","text":"JoAnn Manson, MD, DrPH","text_display":"\n\n\\section*{JoAnn Manson, MD, DrPH}","confidence":0.99951171875,"confidence_rate":0.9999819112562659},{"cnt":[[125,1139],[385,1139],[385,1179],[125,1179]],"region":{"top_left_x":124,"top_left_y":1138,"width":261,"height":42},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a36f81f989214d08b5d823dfa32086be","type":"text","conversion_output":true,"text":"Co-investigator","text_display":"\n\nCo-investigator","confidence":1,"confidence_rate":1},{"cnt":[[125,1182],[496,1182],[496,1218],[125,1218]],"region":{"top_left_x":124,"top_left_y":1181,"width":373,"height":38},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"47e97bb93e614487a1c3680d7e791052","type":"text","conversion_output":true,"text":"Professor of Medicine","text_display":"\nProfessor of Medicine","confidence":1,"confidence_rate":1},{"cnt":[[125,1225],[655,1225],[655,1261],[125,1261]],"region":{"top_left_x":124,"top_left_y":1224,"width":532,"height":38},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"14b2b5e6ad67481390fba3a4ebc84e41","type":"text","conversion_output":true,"text":"Division of Preventive Medicine","text_display":"\nDivision of Preventive Medicine","confidence":1,"confidence_rate":1},{"cnt":[[125,1272],[623,1272],[623,1313],[125,1313]],"region":{"top_left_x":124,"top_left_y":1271,"width":500,"height":42},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1866cb28d0a540568c19d130137ae86f","type":"text","conversion_output":true,"text":"Brigham \\& Women's Hospital","text_display":"\nBrigham \\& Women's Hospital","confidence":1,"confidence_rate":1},{"cnt":[[125,1315],[535,1315],[535,1351],[125,1351]],"region":{"top_left_x":124,"top_left_y":1314,"width":411,"height":38},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"266288cb50e245c78de8b2b792012251","type":"text","conversion_output":true,"text":"Harvard Medical School","text_display":"\nHarvard Medical School","confidence":1,"confidence_rate":1},{"cnt":[[125,1358],[574,1358],[574,1401],[125,1401]],"region":{"top_left_x":124,"top_left_y":1357,"width":450,"height":44},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5c29e29f705a449cac7a6aead13d447f","type":"text","conversion_output":true,"text":"Telephone (617) 278-0871","text_display":"\nTelephone (617) 278-0871","confidence":1,"confidence_rate":1},{"cnt":[[125,1401],[462,1401],[462,1446],[125,1446]],"region":{"top_left_x":124,"top_left_y":1400,"width":338,"height":46},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"10b50beabba245e4b4bf2954c5293615","type":"text","conversion_output":true,"text":"Fax (617) 731-3843","text_display":"\nFax (617) 731-3843","confidence":1,"confidence_rate":1},{"cnt":[[122,1448],[664,1448],[664,1489],[122,1489]],"region":{"top_left_x":122,"top_left_y":1448,"width":542,"height":41},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9e19db0c465e4335b552426d358c2acc","type":"text","conversion_output":true,"text":"jmanson@rics.bwh.harvard.edu","text_display":"\njmanson@rics.bwh.harvard.edu","confidence":1,"confidence_rate":1},{"cnt":[[120,1532],[363,1532],[363,1575],[120,1575]],"region":{"top_left_x":120,"top_left_y":1531,"width":244,"height":44},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1222eda802cd4719a923c6a6376e637d","type":"section_header","conversion_output":false,"children_ids":["73bb53491e7449588bc988e6b3d305f9"],"text":"","text_display":""},{"cnt":[[125,1534],[363,1534],[363,1575],[125,1575]],"region":{"top_left_x":124,"top_left_y":1533,"width":240,"height":42},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"73bb53491e7449588bc988e6b3d305f9","type":"text","conversion_output":true,"parent_id":"1222eda802cd4719a923c6a6376e637d","text":"Julie Lin, MD","text_display":"\n\n\\section*{Julie Lin, MD}","confidence":1,"confidence_rate":1},{"cnt":[[125,1577],[385,1577],[385,1618],[125,1618]],"region":{"top_left_x":124,"top_left_y":1576,"width":261,"height":42},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"508fbab175f344c2b11361f0fd068226","type":"text","conversion_output":true,"text":"Co-investigator","text_display":"\n\nCo-investigator","confidence":1,"confidence_rate":1},{"cnt":[[125,1620],[662,1620],[662,1656],[125,1656]],"region":{"top_left_x":124,"top_left_y":1619,"width":538,"height":38},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5f9107ed4ceb45dbbb97d4d127450466","type":"text","conversion_output":true,"text":"Assistant Professor of Medicine","text_display":"\nAssistant Professor of Medicine","confidence":1,"confidence_rate":1},{"cnt":[[125,1667],[370,1667],[370,1699],[125,1699]],"region":{"top_left_x":124,"top_left_y":1667,"width":246,"height":33},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"db1a3554b5b942d299164e5a11f7dc7d","type":"text","conversion_output":true,"text":"Renal Division","text_display":"\nRenal Division","confidence":1,"confidence_rate":1},{"cnt":[[125,1710],[660,1710],[660,1751],[125,1751]],"region":{"top_left_x":124,"top_left_y":1710,"width":536,"height":41},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0b5fdee7cbf640cca0d4e213c68cbfe8","type":"text","conversion_output":true,"text":"Brigham and Women's Hospital","text_display":"\nBrigham and Women's Hospital","confidence":1,"confidence_rate":1},{"cnt":[[125,1753],[354,1753],[354,1790],[125,1790]],"region":{"top_left_x":124,"top_left_y":1753,"width":231,"height":37},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d2c343e3a17b44b99451b8e202e28c4f","type":"text","conversion_output":true,"text":"75 Francis St","text_display":"\n75 Francis St","confidence":1,"confidence_rate":1},{"cnt":[[125,1796],[440,1796],[440,1837],[125,1837]],"region":{"top_left_x":124,"top_left_y":1796,"width":317,"height":41},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6aefefb857ef40a69c27869958dcaf0e","type":"text","conversion_output":true,"text":"Boston, MA 02115","text_display":"\nBoston, MA 02115","confidence":1,"confidence_rate":1},{"cnt":[[125,1843],[556,1843],[556,1884],[125,1884]],"region":{"top_left_x":124,"top_left_y":1843,"width":433,"height":42},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"13662577ee154d8b8190b81df9285f08","type":"text","conversion_output":true,"text":"Telephone 617-732-6432","text_display":"\nTelephone 617-732-6432","confidence":1,"confidence_rate":1},{"cnt":[[125,1886],[440,1886],[440,1923],[125,1923]],"region":{"top_left_x":124,"top_left_y":1886,"width":317,"height":37},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"02fd762c1e6042719ed2d43664e4f93a","type":"text","conversion_output":true,"text":"Fax 617-732-6392","text_display":"\nFax 617-732-6392","confidence":1,"confidence_rate":1},{"cnt":[[125,1929],[492,1929],[492,1972],[125,1972]],"region":{"top_left_x":124,"top_left_y":1929,"width":368,"height":44},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b85a67556b404c77b1ed247e97b09aee","type":"text","conversion_output":true,"text":"JLIN11@partners.org","text_display":"\nJLIN11@partners.org","confidence":0.9970703125,"confidence_rate":0.9998777579957132},{"cnt":[[122,2015],[466,2015],[466,2065],[122,2065]],"region":{"top_left_x":122,"top_left_y":2015,"width":345,"height":50},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"79e00f39efd642e28d543bbd101941e3","type":"section_header","conversion_output":false,"children_ids":["27834901c1e749caa92f8ccb077e117a"],"text":"","text_display":""},{"cnt":[[125,2017],[466,2017],[466,2060],[125,2060]],"region":{"top_left_x":124,"top_left_y":2017,"width":343,"height":44},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"27834901c1e749caa92f8ccb077e117a","type":"text","conversion_output":true,"parent_id":"79e00f39efd642e28d543bbd101941e3","text":"Robert Glynn, PhD","text_display":"\n\n\\section*{Robert Glynn, PhD}","confidence":1,"confidence_rate":1},{"cnt":[[125,2062],[638,2062],[638,2103],[125,2103]],"region":{"top_left_x":124,"top_left_y":2062,"width":515,"height":42},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"791b00b4251c4c2e9f9412dcde30be67","type":"text","conversion_output":true,"text":"Biostatistician, Co-investigator","text_display":"\n\nBiostatistician, Co-investigator","confidence":1,"confidence_rate":1},{"cnt":[[125,2105],[672,2105],[672,2142],[125,2142]],"region":{"top_left_x":124,"top_left_y":2105,"width":549,"height":37},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"eab939527c9a472d8e7e79e8609f59e2","type":"text","conversion_output":true,"text":"Associate Professor of Medicine","text_display":"\nAssociate Professor of Medicine","confidence":1,"confidence_rate":1},{"cnt":[[125,2148],[655,2148],[655,2185],[125,2185]],"region":{"top_left_x":124,"top_left_y":2148,"width":532,"height":37},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7b35c60e08f7481e82fb4206c621ef82","type":"text","conversion_output":true,"text":"Division of Preventive Medicine","text_display":"\nDivision of Preventive Medicine","confidence":1,"confidence_rate":1},{"cnt":[[125,2191],[625,2191],[625,2237],[125,2237]],"region":{"top_left_x":124,"top_left_y":2191,"width":502,"height":46},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1f53c1b096fe46d881add287e3f2c8f7","type":"text","conversion_output":true,"text":"Brigham \\& Women's Hospital","text_display":"\nBrigham \\& Women's Hospital","confidence":1,"confidence_rate":1},{"cnt":[[125,2237],[535,2237],[535,2271],[125,2271]],"region":{"top_left_x":124,"top_left_y":2236,"width":411,"height":35},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9566b79a95c44977882087e12d31170d","type":"text","conversion_output":true,"text":"Harvard Medical School","text_display":"\nHarvard Medical School","confidence":1,"confidence_rate":1},{"cnt":[[125,2279],[580,2279],[580,2322],[125,2322]],"region":{"top_left_x":124,"top_left_y":2279,"width":457,"height":44},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"edba59918dbe4cf8b37a4bbe4642e98b","type":"text","conversion_output":true,"text":"Telephone (617) 278-0792","text_display":"\nTelephone (617) 278-0792","confidence":1,"confidence_rate":1},{"cnt":[[125,2325],[462,2325],[462,2368],[125,2368]],"region":{"top_left_x":124,"top_left_y":2324,"width":338,"height":44},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"557cdafd66e240d998694fda898acb5e","type":"text","conversion_output":true,"text":"Fax (617) 731-3843","text_display":"\nFax (617) 731-3843","confidence":1,"confidence_rate":1},{"cnt":[[125,2368],[623,2368],[623,2413],[125,2413]],"region":{"top_left_x":124,"top_left_y":2367,"width":500,"height":46},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4c507093e2c84c4da89931062a9bec99","type":"text","conversion_output":true,"text":"rglynn@rics.bwh.harvard.edu","text_display":"\nrglynn@rics.bwh.harvard.edu","confidence":0.99951171875,"confidence_rate":0.9999847376009057},{"cnt":[[122,2454],[402,2454],[402,2494],[122,2494]],"region":{"top_left_x":122,"top_left_y":2453,"width":280,"height":42},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fbd75376eebb403e8bf6557b276be15c","type":"section_header","conversion_output":false,"children_ids":["883c4751b23a466b8ee9c4a0b33544f8"],"text":"","text_display":""},{"cnt":[[125,2454],[400,2454],[400,2494],[125,2494]],"region":{"top_left_x":124,"top_left_y":2453,"width":276,"height":42},"line":55,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"883c4751b23a466b8ee9c4a0b33544f8","type":"text","conversion_output":true,"parent_id":"fbd75376eebb403e8bf6557b276be15c","text":"Elaine Zaharris","text_display":"\n\n\\section*{Elaine Zaharris}","confidence":1,"confidence_rate":1},{"cnt":[[125,2501],[458,2501],[458,2546],[125,2546]],"region":{"top_left_x":124,"top_left_y":2500,"width":334,"height":46},"line":56,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c26afa4ffbbc411b8d56e2a2e23f77ca","type":"text","conversion_output":true,"text":"Project Coordinator","text_display":"\n\nProject Coordinator","confidence":1,"confidence_rate":1},{"cnt":[[1977,2582],[2007,2582],[2007,2628],[1977,2628]],"region":{"top_left_x":1976,"top_left_y":2582,"width":31,"height":46},"line":57,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"49cec94233384835aef20ecab5865ace","type":"page_info","conversion_output":false,"text":"2","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-03","page":3,"lines":[{"cnt":[[116,125],[662,125],[662,170],[116,170]],"region":{"top_left_x":116,"top_left_y":124,"width":546,"height":46},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ce34d89cd0804cd994a4fd92abe6e1cd","type":"text","conversion_output":true,"text":"Division of Preventive Medicine","text_display":"\n\nDivision of Preventive Medicine","confidence":1,"confidence_rate":1},{"cnt":[[116,168],[629,168],[629,217],[116,217]],"region":{"top_left_x":116,"top_left_y":167,"width":514,"height":50},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fc7fd6f3f8224e58b61219a503e728a6","type":"text","conversion_output":true,"text":"Brigham \\& Women's Hospital","text_display":"\nBrigham \\& Women's Hospital","confidence":1,"confidence_rate":1},{"cnt":[[116,213],[571,213],[571,260],[116,260]],"region":{"top_left_x":116,"top_left_y":212,"width":456,"height":48},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b31f5a251b6f4a8eb6278c2bdf799843","type":"text","conversion_output":true,"text":"Telephone (617) 2780893","text_display":"\nTelephone (617) 2780893","confidence":1,"confidence_rate":1},{"cnt":[[116,254],[471,254],[471,307],[116,307]],"region":{"top_left_x":116,"top_left_y":253,"width":355,"height":55},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"20d35f02fea44cfaa7f157f87baea254","type":"text","conversion_output":true,"text":"Fax (617) 731-3843","text_display":"\nFax (617) 731-3843","confidence":1,"confidence_rate":1},{"cnt":[[1970,2578],[2009,2578],[2009,2628],[1970,2628]],"region":{"top_left_x":1970,"top_left_y":2578,"width":39,"height":50},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"43dad7871d1c4ed0a5d39f44d344a85d","type":"page_info","conversion_output":false,"text":"3","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-04","page":4,"lines":[{"cnt":[[114,122],[2007,122],[2007,1164],[114,1164]],"region":{"top_left_x":113,"top_left_y":122,"width":1894,"height":1043},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bc1e1b86c69e4468a1f734bbb9be4a4d","type":"abstract","conversion_output":false,"children_ids":["a8a0b3013ed647cb8440ec36d2063442","e72fedd1012341caa2f726f960ced1c1","c2d04fc336f046ddab3388e27e708888","5f0a4220ed84496aac421f31d8965edf","f18f50cc3a104500bf2017e3377318f2","56d05795422741ff954fcbd034da327e","12d3e80817394c4c99bafb87ad4b14ac","037661385971419ca6a5ca09928ff885","9a8910f8830b45bb8916208be1ecd7f0","e85aabd3bb4543fea1b2fa7233ac0e3d","cdc11bd44b84432bb26aeb8461efa80d","e68062aeee554150a209e20eaa5c43c4","931b947fd0ea4eb5986aebcf23121fb9","8dfe5190e2dc48e6a161c4696e46c6b7","cb3aecab16a34e1da439fa2c1f7ff27a","c38161c33ed24396a4b634b72ed0f6f4","1c09c92893714b648697e672c5f10928","1afe0a80482f4a8280d317970dbd26a2","ad970f277f2444519a0670e13b179700","ca9b3a2e504840ad9eb84ea579bebc75","00f29401e1a54236ae54200d21d8fc21","25d3ab4dc38b4dc1b646ffb3c4d3763b","5d0be9141b47498d9b0ae5fe5ddfe555"],"text":"","text_display":""},{"cnt":[[120,129],[286,129],[286,165],[120,165]],"region":{"top_left_x":120,"top_left_y":128,"width":166,"height":38},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a8a0b3013ed647cb8440ec36d2063442","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"Abstract","text_display":"\n\n\\begin{abstract}\n","confidence":1,"confidence_rate":1},{"cnt":[[185,193],[1962,193],[1962,236],[185,236]],"region":{"top_left_x":184,"top_left_y":193,"width":1778,"height":44},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e72fedd1012341caa2f726f960ced1c1","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"Diabetic kidney disease (DKD) is a cause of substantial morbidity and mortality. Despite widespread use","text_display":"Diabetic kidney disease (DKD) is a cause of substantial morbidity and mortality. Despite widespread use","confidence":1,"confidence_rate":1},{"cnt":[[120,236],[1931,236],[1931,281],[120,281]],"region":{"top_left_x":120,"top_left_y":236,"width":1812,"height":46},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c2d04fc336f046ddab3388e27e708888","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"of intensive glycemic control and renin-angiotensin-aldosterone system inhibitors, renal and cardiovascular","text_display":" of intensive glycemic control and renin-angiotensin-aldosterone system inhibitors, renal and cardiovascular","confidence":1,"confidence_rate":1},{"cnt":[[120,279],[1919,279],[1919,324],[120,324]],"region":{"top_left_x":120,"top_left_y":279,"width":1799,"height":46},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5f0a4220ed84496aac421f31d8965edf","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"consequences of DKD remain common. This study will evaluate whether vitamin D3 and/or omega-3 fatty","text_display":" consequences of DKD remain common. This study will evaluate whether vitamin D3 and/or omega-3 fatty","confidence":1,"confidence_rate":1},{"cnt":[[120,322],[1966,322],[1966,367],[120,367]],"region":{"top_left_x":120,"top_left_y":322,"width":1846,"height":46},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f18f50cc3a104500bf2017e3377318f2","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"acids are safe and effective interventions to reduce the burden of DKD among the large and growing diabetic","text_display":" acids are safe and effective interventions to reduce the burden of DKD among the large and growing diabetic","confidence":1,"confidence_rate":1},{"cnt":[[120,367],[1979,365],[1979,412],[120,415]],"region":{"top_left_x":120,"top_left_y":365,"width":1859,"height":50},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"56d05795422741ff954fcbd034da327e","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"population. Specifically, we aim to test whether vitamin D3 and/or omega-3 fatty acids prevent progression of","text_display":" population. Specifically, we aim to test whether vitamin D3 and/or omega-3 fatty acids prevent progression of","confidence":1,"confidence_rate":1},{"cnt":[[120,412],[1953,412],[1953,458],[120,458]],"region":{"top_left_x":120,"top_left_y":412,"width":1833,"height":46},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"12d3e80817394c4c99bafb87ad4b14ac","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"albuminuria and loss of glomerular filtration rate, two complementary manifestations of DKD, over 4 years of","text_display":" albuminuria and loss of glomerular filtration rate, two complementary manifestations of DKD, over 4 years of","confidence":0.99951171875,"confidence_rate":0.9999957896597419},{"cnt":[[120,455],[2000,455],[2000,501],[120,501]],"region":{"top_left_x":120,"top_left_y":455,"width":1881,"height":46},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"037661385971419ca6a5ca09928ff885","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"treatment. To effectively and efficiently test our hypotheses, we will conduct an ancillary study to the Vitamin D","text_display":" treatment. To effectively and efficiently test our hypotheses, we will conduct an ancillary study to the Vitamin D","confidence":1,"confidence_rate":1},{"cnt":[[120,501],[1869,501],[1869,544],[120,544]],"region":{"top_left_x":120,"top_left_y":500,"width":1750,"height":44},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9a8910f8830b45bb8916208be1ecd7f0","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"and Omega-3 Trial (VITAL), an NIH-funded randomized clinical trial. In the parent VITAL study, 20,000","text_display":" and Omega-3 Trial (VITAL), an NIH-funded randomized clinical trial. In the parent VITAL study, 20,000","confidence":0.845703125,"confidence_rate":0.9984202406728814},{"cnt":[[120,544],[2000,544],[2000,589],[120,589]],"region":{"top_left_x":120,"top_left_y":543,"width":1881,"height":46},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e85aabd3bb4543fea1b2fa7233ac0e3d","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"participants (men ages \\(\\geq 60\\) years, women ages \\(\\geq 65\\) years) will be randomly assigned in a \\(2 \\times 2\\) factorial design","text_display":" participants (men ages \\(\\geq 60\\) years, women ages \\(\\geq 65\\) years) will be randomly assigned in a \\(2 \\times 2\\) factorial design","confidence":1,"confidence_rate":1},{"cnt":[[120,589],[1727,589],[1727,632],[120,632]],"region":{"top_left_x":120,"top_left_y":588,"width":1608,"height":44},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cdc11bd44b84432bb26aeb8461efa80d","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"to vitamin D3 (cholecalciferol) 2000 IU daily versus placebo, and to eicosapentaenoic acid plus","text_display":" to vitamin D3 (cholecalciferol) 2000 IU daily versus placebo, and to eicosapentaenoic acid plus","confidence":1,"confidence_rate":1},{"cnt":[[120,632],[1953,632],[1953,677],[120,677]],"region":{"top_left_x":120,"top_left_y":631,"width":1833,"height":46},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e68062aeee554150a209e20eaa5c43c4","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"docosahexaenoic acid 840 mg daily versus placebo, and followed for a mean of 5 years to assess effects on","text_display":" docosahexaenoic acid 840 mg daily versus placebo, and followed for a mean of 5 years to assess effects on","confidence":1,"confidence_rate":1},{"cnt":[[120,675],[1946,675],[1946,720],[120,720]],"region":{"top_left_x":120,"top_left_y":674,"width":1827,"height":46},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"931b947fd0ea4eb5986aebcf23121fb9","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"cardiovascular disease and cancer events. Leveraging the established infrastructure of VITAL, the ancillary","text_display":" cardiovascular disease and cancer events. Leveraging the established infrastructure of VITAL, the ancillary","confidence":1,"confidence_rate":1},{"cnt":[[120,718],[1931,718],[1931,765],[120,765]],"region":{"top_left_x":120,"top_left_y":717,"width":1812,"height":48},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8dfe5190e2dc48e6a161c4696e46c6b7","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"study described herein (the VITAL Diabetes sub-study) will identify and recruit a sub-cohort of 1,500 VITAL","text_display":" study described herein (the VITAL Diabetes sub-study) will identify and recruit a sub-cohort of 1,500 VITAL","confidence":0.9249823093414307,"confidence_rate":0.9993221370991182},{"cnt":[[120,763],[1906,763],[1906,810],[120,810]],"region":{"top_left_x":120,"top_left_y":762,"width":1786,"height":48},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cb3aecab16a34e1da439fa2c1f7ff27a","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"participants with diabetes at baseline. Among this VITAL subgroup, we will ascertain effects of the VITAL","text_display":" participants with diabetes at baseline. Among this VITAL subgroup, we will ascertain effects of the VITAL","confidence":1,"confidence_rate":1},{"cnt":[[120,808],[1979,808],[1979,853],[120,853]],"region":{"top_left_x":120,"top_left_y":807,"width":1859,"height":46},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c38161c33ed24396a4b634b72ed0f6f4","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"interventions on albuminuria and glomerular filtration rate by obtaining additional questionnaire data and urine","text_display":" interventions on albuminuria and glomerular filtration rate by obtaining additional questionnaire data and urine","confidence":1,"confidence_rate":1},{"cnt":[[120,851],[1981,851],[1981,896],[120,896]],"region":{"top_left_x":120,"top_left_y":850,"width":1861,"height":46},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1c09c92893714b648697e672c5f10928","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"and blood samples. Following the simple and cost-efficient design of the parent VITAL trial, biospecimens will","text_display":" and blood samples. Following the simple and cost-efficient design of the parent VITAL trial, biospecimens will","confidence":1,"confidence_rate":1},{"cnt":[[120,894],[1979,894],[1979,939],[120,939]],"region":{"top_left_x":120,"top_left_y":893,"width":1859,"height":46},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1afe0a80482f4a8280d317970dbd26a2","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"be collected locally and delivered to the VITAL central laboratory by mail. First morning voids will be collected","text_display":" be collected locally and delivered to the VITAL central laboratory by mail. First morning voids will be collected","confidence":1,"confidence_rate":1},{"cnt":[[120,937],[1910,937],[1910,984],[120,984]],"region":{"top_left_x":120,"top_left_y":936,"width":1790,"height":48},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ad970f277f2444519a0670e13b179700","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"at baseline and year 4 for measurement of urine albumin-creatinine ratio. Blood samples will be collected","text_display":" at baseline and year 4 for measurement of urine albumin-creatinine ratio. Blood samples will be collected","confidence":1,"confidence_rate":1},{"cnt":[[120,982],[1884,982],[1884,1027],[120,1027]],"region":{"top_left_x":120,"top_left_y":981,"width":1765,"height":46},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ca9b3a2e504840ad9eb84ea579bebc75","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"simultaneously for measurement of glomerular filtration rate (using serum creatinine and cystatin C), 25-","text_display":" simultaneously for measurement of glomerular filtration rate (using serum creatinine and cystatin C), 25","confidence":1,"confidence_rate":1},{"cnt":[[120,1027],[1992,1027],[1992,1072],[120,1072]],"region":{"top_left_x":120,"top_left_y":1026,"width":1872,"height":47},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"00f29401e1a54236ae54200d21d8fc21","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"hydroxyvitamin D, eicosapentaenoic acid plus docosahexaenoic acid, C-reactive protein, and hemoglobin A1c.","text_display":"hydroxyvitamin D, eicosapentaenoic acid plus docosahexaenoic acid, C-reactive protein, and hemoglobin A1c.","confidence":0.966796875,"confidence_rate":0.9996958402977384},{"cnt":[[120,1070],[1970,1070],[1970,1115],[120,1115]],"region":{"top_left_x":120,"top_left_y":1069,"width":1851,"height":47},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"25d3ab4dc38b4dc1b646ffb3c4d3763b","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"This ancillary study is designed to determine whether vitamin D3 and/or omega-3 fatty acids have causal and","text_display":" This ancillary study is designed to determine whether vitamin D3 and/or omega-3 fatty acids have causal and","confidence":1,"confidence_rate":1},{"cnt":[[120,1113],[1313,1113],[1313,1158],[120,1158]],"region":{"top_left_x":120,"top_left_y":1112,"width":1193,"height":47},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5d0be9141b47498d9b0ae5fe5ddfe555","type":"text","conversion_output":true,"parent_id":"bc1e1b86c69e4468a1f734bbb9be4a4d","text":"clinically relevant effects on the development and progression of DKD.","text_display":" clinically relevant effects on the development and progression of DKD.\n\\end{abstract}","confidence":1,"confidence_rate":1},{"cnt":[[1972,2582],[2007,2582],[2007,2628],[1972,2628]],"region":{"top_left_x":1972,"top_left_y":2582,"width":35,"height":46},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bfb981b5af5a4d98acfdf96a3105a404","type":"page_info","conversion_output":false,"text":"4","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-05","page":5,"lines":[{"cnt":[[116,120],[389,120],[389,178],[116,178]],"region":{"top_left_x":116,"top_left_y":120,"width":273,"height":59},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"211441a267d34d1da72362912447c5e6","type":"section_header","conversion_output":false,"children_ids":["b0b5e9f1887441eba66226408238162a"],"text":"","text_display":""},{"cnt":[[120,125],[385,125],[385,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":265,"height":51},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b0b5e9f1887441eba66226408238162a","type":"text","conversion_output":true,"parent_id":"211441a267d34d1da72362912447c5e6","text":"I. Background","text_display":"\n\n\\section*{I. Background}","confidence":1,"confidence_rate":1},{"cnt":[[114,185],[1115,185],[1115,245],[114,245]],"region":{"top_left_x":113,"top_left_y":184,"width":1003,"height":61},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"30722213b00a4f41b26578b7dfb2a556","type":"section_header","conversion_output":false,"children_ids":["6165e0c2bff848a685d7c07bf7db7a97"],"text":"","text_display":""},{"cnt":[[120,189],[1109,189],[1109,238],[120,238]],"region":{"top_left_x":120,"top_left_y":189,"width":989,"height":50},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6165e0c2bff848a685d7c07bf7db7a97","type":"text","conversion_output":true,"parent_id":"30722213b00a4f41b26578b7dfb2a556","text":"I.a. Public health impact of diabetic kidney disease","text_display":"\n\n\\section*{I.a. Public health impact of diabetic kidney disease}","confidence":0.99951171875,"confidence_rate":0.9999914316069175},{"cnt":[[120,254],[1944,254],[1944,303],[120,303]],"region":{"top_left_x":120,"top_left_y":253,"width":1825,"height":50},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"65d748009775459097d8996b973cead5","type":"text","conversion_output":true,"text":"I.a.1. Definition of DKD. Chronic kidney disease is defined by albuminuria or impaired glomerular filtration","text_display":"\nI.a.1. Definition of DKD. Chronic kidney disease is defined by albuminuria or impaired glomerular filtration","confidence":0.9956109506310895,"confidence_rate":0.9999610741246902},{"cnt":[[120,296],[1854,296],[1854,346],[120,346]],"region":{"top_left_x":120,"top_left_y":296,"width":1735,"height":50},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d17e073686064e4fa798ede94d035dd9","type":"text","conversion_output":true,"text":"rate (GFR). \\({ }^{1}\\) Diabetic kidney disease (DKD), defined as chronic kidney disease clinically attributable to","text_display":" rate (GFR). \\({ }^{1}\\) Diabetic kidney disease (DKD), defined as chronic kidney disease clinically attributable to","confidence":1,"confidence_rate":1},{"cnt":[[120,339],[1876,339],[1876,391],[120,391]],"region":{"top_left_x":120,"top_left_y":339,"width":1756,"height":53},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6e564c40f92146dba2ae6f4f1d037013","type":"text","conversion_output":true,"text":"diabetes, \\({ }^{1,2}\\) is the most common cause of kidney disease in the developed world. \\({ }^{3}\\) The large majority of","text_display":" diabetes, \\({ }^{1,2}\\) is the most common cause of kidney disease in the developed world. \\({ }^{3}\\) The large majority of","confidence":0.9990234375,"confidence_rate":0.9999924260779239},{"cnt":[[120,387],[1880,387],[1880,436],[120,436]],"region":{"top_left_x":120,"top_left_y":386,"width":1760,"height":51},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b4ee61b95d4c4c53965ce40a5d26b5ec","type":"text","conversion_output":true,"text":"persons with DKD do not undergo kidney biopsy to definitively establish a pathology-based diagnosis of","text_display":" persons with DKD do not undergo kidney biopsy to definitively establish a pathology-based diagnosis of","confidence":1,"confidence_rate":1},{"cnt":[[120,430],[1983,430],[1983,479],[120,479]],"region":{"top_left_x":120,"top_left_y":429,"width":1864,"height":51},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0d1845702f0b4058a50c278fb79cb415","type":"text","conversion_output":true,"text":"diabetic glomerulopathy, and some persons diagnosed with DKD have a nondiabetic cause of kidney disease.","text_display":" diabetic glomerulopathy, and some persons diagnosed with DKD have a nondiabetic cause of kidney disease.","confidence":1,"confidence_rate":1},{"cnt":[[120,473],[1931,473],[1931,522],[120,522]],"region":{"top_left_x":120,"top_left_y":472,"width":1812,"height":51},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6d1a4c238d74481783464a7de3c49e03","type":"text","conversion_output":true,"text":"However, biopsy series confirm that the majority of persons diagnosed clinically with DKD do have diabetic","text_display":" However, biopsy series confirm that the majority of persons diagnosed clinically with DKD do have diabetic","confidence":1,"confidence_rate":1},{"cnt":[[120,520],[1964,520],[1964,565],[120,565]],"region":{"top_left_x":120,"top_left_y":519,"width":1844,"height":47},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"377497cf9ce3463ead884fb3f3981e59","type":"text","conversion_output":true,"text":"glomerulopathy, and diagnosis and treatment of DKD in practice is currently based on clinical assessment of","text_display":" glomerulopathy, and diagnosis and treatment of DKD in practice is currently based on clinical assessment of","confidence":1,"confidence_rate":1},{"cnt":[[120,559],[1871,559],[1871,610],[120,610]],"region":{"top_left_x":120,"top_left_y":558,"width":1752,"height":53},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cc039c11d04b4dbaa2d51bca11c6fce2","type":"text","conversion_output":true,"text":"albuminuria and GFR in the setting of diagnosed diabetes. \\({ }^{1,2,4}\\) The American Diabetes Association and","text_display":" albuminuria and GFR in the setting of diagnosed diabetes. \\({ }^{1,2,4}\\) The American Diabetes Association and","confidence":1,"confidence_rate":1},{"cnt":[[120,606],[1966,606],[1966,655],[120,655]],"region":{"top_left_x":120,"top_left_y":605,"width":1846,"height":51},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7affbf1411344f0795b9572d7bb7ddcf","type":"text","conversion_output":true,"text":"National Kidney Foundation recommend that albuminuria be assessed as albumin-creatinine ratio (ACR) in a","text_display":" National Kidney Foundation recommend that albuminuria be assessed as albumin-creatinine ratio (ACR) in a","confidence":0.99365234375,"confidence_rate":0.9999415807130537},{"cnt":[[120,649],[1955,649],[1955,698],[120,698]],"region":{"top_left_x":120,"top_left_y":648,"width":1836,"height":51},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c2153d94fdcb4aa48b83a8b575295c5f","type":"text","conversion_output":true,"text":"spot urine sample, with abnormal defined as ACR \\(\\geq 30 mg\\) albumin/g creatinine, and that GFR be calculated","text_display":" spot urine sample, with abnormal defined as ACR \\(\\geq 30 mg\\) albumin/g creatinine, and that GFR be calculated","confidence":0.99951171875,"confidence_rate":0.9999956778810385},{"cnt":[[120,688],[1644,688],[1644,741],[120,741]],"region":{"top_left_x":120,"top_left_y":687,"width":1524,"height":55},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f8a810d86a374ced96abeca498e9d703","type":"text","conversion_output":true,"text":"from serum creatinine, with estimated GFR \\(<60 mL / min / 1.73 m^{2}\\) defined as abnormal. \\({ }^{1,2,4}\\)","text_display":" from serum creatinine, with estimated GFR \\(<60 mL / min / 1.73 m^{2}\\) defined as abnormal. \\({ }^{1,2,4}\\)","confidence":0.9712052345275879,"confidence_rate":0.9997459673244702},{"cnt":[[120,758],[1248,758],[1248,810],[120,810]],"region":{"top_left_x":120,"top_left_y":758,"width":1129,"height":52},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9a4e9a9c25084c1aa8b7b3b0a3e5acac","type":"text","conversion_output":true,"text":"I.a.2. DKD is common. The prevalence of diabetes is increasing","text_display":"\nI.a.2. DKD is common. The prevalence of diabetes is increasing","confidence":0.4143876041052863,"confidence_rate":0.9869375049677694},{"cnt":[[120,804],[1308,804],[1308,851],[120,851]],"region":{"top_left_x":120,"top_left_y":803,"width":1189,"height":48},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"df5b8fb596014dd08079005ada3e3d93","type":"text","conversion_output":true,"text":"worldwide, reaching \\(30 \\%\\) among US adults ages \\(\\geq 60\\) years based on","text_display":" worldwide, reaching \\(30 \\%\\) among US adults ages \\(\\geq 60\\) years based on","confidence":0.9990234375,"confidence_rate":0.9999867968486782},{"cnt":[[120,842],[1225,842],[1225,896],[120,896]],"region":{"top_left_x":120,"top_left_y":842,"width":1105,"height":54},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"14cb025498fa4ffaa6114ac959dfbb06","type":"text","conversion_output":true,"text":"recent NHANES data (diagnosed diabetes \\(15-18 \\%\\) prevalence). \\({ }^{5}\\)","text_display":" recent NHANES data (diagnosed diabetes \\(15-18 \\%\\) prevalence). \\({ }^{5}\\)","confidence":0.96875,"confidence_rate":0.9995710555592722},{"cnt":[[120,889],[1199,889],[1199,939],[120,939]],"region":{"top_left_x":120,"top_left_y":889,"width":1079,"height":50},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"68cd8f001bf047e2a6a3188e0cc03414","type":"text","conversion_output":true,"text":"Individuals with diabetes are at high risk of developing DKD. In","text_display":" Individuals with diabetes are at high risk of developing DKD. In","confidence":1,"confidence_rate":1},{"cnt":[[120,932],[1321,932],[1321,982],[120,982]],"region":{"top_left_x":120,"top_left_y":932,"width":1202,"height":50},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1ebc22cf6f854f1382c6d7118e802545","type":"text","conversion_output":true,"text":"NHANES III, 42\\% of persons with self-reported diabetes had prevalent","text_display":" NHANES III, 42\\% of persons with self-reported diabetes had prevalent","confidence":0.9921875,"confidence_rate":0.9998925649844174},{"cnt":[[120,980],[1298,980],[1298,1025],[120,1025]],"region":{"top_left_x":120,"top_left_y":979,"width":1178,"height":46},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a665f814517e48c1b23c1e0d74b60ec1","type":"text","conversion_output":true,"text":"elevated urine ACR and/or elevated serum creatinine, compared with","text_display":" elevated urine ACR and/or elevated serum creatinine, compared with","confidence":1,"confidence_rate":1},{"cnt":[[120,1018],[1222,1018],[1222,1072],[120,1072]],"region":{"top_left_x":120,"top_left_y":1018,"width":1103,"height":55},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"05f6ef3bb0144d7dafe9529148b57a88","type":"text","conversion_output":true,"text":"\\(14 \\%\\) of the unselected United States population. \\({ }^{6}\\) In addition, the","text_display":" \\(14 \\%\\) of the unselected United States population. \\({ }^{6}\\) In addition, the","confidence":0.99951171875,"confidence_rate":0.9999938950124092},{"cnt":[[120,1066],[1270,1066],[1270,1115],[120,1115]],"region":{"top_left_x":120,"top_left_y":1065,"width":1150,"height":51},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"658ca26fc7f34f02a027d8a7ecb1ecf1","type":"text","conversion_output":true,"text":"prevalence of kidney disease is highest and increasing most rapidly","text_display":" prevalence of kidney disease is highest and increasing most rapidly","confidence":1,"confidence_rate":1},{"cnt":[[120,1104],[1330,1104],[1330,1158],[120,1158]],"region":{"top_left_x":120,"top_left_y":1104,"width":1210,"height":55},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"403478392a524ef4a75f2741205ede2f","type":"text","conversion_output":true,"text":"among older adults (Figure 1). \\({ }^{7}\\) Thus, from a public health perspective,","text_display":" among older adults (Figure 1). \\({ }^{7}\\) Thus, from a public health perspective,","confidence":1,"confidence_rate":1},{"cnt":[[120,1156],[1149,1156],[1149,1201],[120,1201]],"region":{"top_left_x":120,"top_left_y":1155,"width":1030,"height":46},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"25c1ee61183e48fe8ca58d1a62923713","type":"text","conversion_output":true,"text":"targeting older persons with diabetes offers the highest yield","text_display":" targeting older persons with diabetes offers the highest yield","confidence":1,"confidence_rate":1},{"cnt":[[120,1199],[1298,1199],[1298,1248],[120,1248]],"region":{"top_left_x":120,"top_left_y":1198,"width":1178,"height":51},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8e64194bbcb445ef97584b69538b4103","type":"text","conversion_output":true,"text":"opportunity to prevent and treat kidney disease and its complications.","text_display":" opportunity to prevent and treat kidney disease and its complications.","confidence":1,"confidence_rate":1},{"cnt":[[120,1244],[1240,1244],[1240,1291],[120,1291]],"region":{"top_left_x":120,"top_left_y":1243,"width":1120,"height":49},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0b9b336a3ce04f01ad18e5c650741263","type":"text","conversion_output":true,"text":"Moreover, as the United States population continues to age, grow","text_display":" Moreover, as the United States population continues to age, grow","confidence":1,"confidence_rate":1},{"cnt":[[120,1285],[1257,1285],[1257,1334],[120,1334]],"region":{"top_left_x":120,"top_left_y":1284,"width":1137,"height":51},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"63e7363d5ae6473e87bdb58c9e095af2","type":"text","conversion_output":true,"text":"more obese, and develop more diabetes, the prevalence of DKD is","text_display":" more obese, and develop more diabetes, the prevalence of DKD is","confidence":1,"confidence_rate":1},{"cnt":[[120,1323],[924,1323],[924,1377],[120,1377]],"region":{"top_left_x":120,"top_left_y":1323,"width":804,"height":55},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"153a2d0e76e8493aad7a9a6844225ab9","type":"text","conversion_output":true,"text":"expected to rise for the foreseeable future. \\({ }^{5,7-10}\\)","text_display":" expected to rise for the foreseeable future. \\({ }^{5,7-10}\\)","confidence":0.95263671875,"confidence_rate":0.9992176989710626},{"cnt":[[129,1394],[1244,1394],[1244,1442],[129,1442]],"region":{"top_left_x":128,"top_left_y":1394,"width":1116,"height":48},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3f04fa5e3b0e4ddcac8604de4054c3c2","type":"text","conversion_output":true,"text":"I.a.3. DKD health outcomes are poor. The major adverse health","text_display":"\nI.a.3. DKD health outcomes are poor. The major adverse health","confidence":0.9012740347534418,"confidence_rate":0.9984263013447274},{"cnt":[[120,1439],[1244,1439],[1244,1487],[120,1487]],"region":{"top_left_x":120,"top_left_y":1439,"width":1124,"height":48},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6258a7b42927432197ba51dd97833daa","type":"text","conversion_output":true,"text":"outcomes of DKD are end-stage renal disease (ESRD), CVD, and","text_display":" outcomes of DKD are end-stage renal disease (ESRD), CVD, and","confidence":0.998046875,"confidence_rate":0.9999699229933099},{"cnt":[[120,1482],[1231,1482],[1231,1532],[120,1532]],"region":{"top_left_x":120,"top_left_y":1482,"width":1112,"height":50},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e73203f156e646078e65566602e9f7cd","type":"text","conversion_output":true,"text":"death. The natural renal history of DKD consists of progressively","text_display":" death. The natural renal history of DKD consists of progressively","confidence":1,"confidence_rate":1},{"cnt":[[120,1525],[1233,1525],[1233,1575],[120,1575]],"region":{"top_left_x":120,"top_left_y":1525,"width":1114,"height":50},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"82d6b35166e04053b363777652fba1f8","type":"text","conversion_output":true,"text":"increasing levels of urine albumin excretion and relentless loss of","text_display":" increasing levels of urine albumin excretion and relentless loss of","confidence":1,"confidence_rate":1},{"cnt":[[1355,754],[1999,754],[1999,1555],[1355,1555]],"region":{"top_left_x":1355,"top_left_y":754,"width":644,"height":801},"line":34,"column":0,"font_size":31,"is_printed":true,"is_handwritten":false,"id":"157538bd0ac245c2830a14d8eca5c421","type":"column","conversion_output":false,"children_ids":["c8c7eee783f24a82ba606ccd68ec2e6d","84b0da94713b402a8b03d62c33385529"],"text":"","text_display":""},{"cnt":[[1358,756],[1996,756],[1996,1412],[1358,1412]],"region":{"top_left_x":1357,"top_left_y":756,"width":639,"height":656},"line":35,"column":1,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"c8c7eee783f24a82ba606ccd68ec2e6d","type":"chart","conversion_output":true,"parent_id":"157538bd0ac245c2830a14d8eca5c421","selected_labels":["84b0da94713b402a8b03d62c33385529"],"text":"","text_display":"\n\n\\begin{figure}\n\\includegraphics[alt={},max width=\\textwidth]{https://cdn.mathpix.com/cropped/7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-05.jpg?height=656&width=639&top_left_y=756&top_left_x=1357}\n\\captionsetup{labelformat=empty}\n\\caption{Figure 1. Prevalence of chronic kidney disease by age group in two NHANES surveys. From Coresh et al (ref 7).}\n\\end{figure}","subtype":"column"},{"cnt":[[1369,1409],[1992,1409],[1992,1551],[1369,1551]],"region":{"top_left_x":1368,"top_left_y":1409,"width":624,"height":143},"line":36,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"84b0da94713b402a8b03d62c33385529","type":"figure_label","conversion_output":false,"parent_id":"157538bd0ac245c2830a14d8eca5c421","children_ids":["b0a2a7537be14162af52cea2d98204b9","1659e4b396b046f5ad266d4dc5a7ccad","77cb08062a8e49d589ae2c38bdbcff3c"],"text":"","text_display":""},{"cnt":[[1379,1414],[1987,1414],[1987,1459],[1379,1459]],"region":{"top_left_x":1379,"top_left_y":1413,"width":609,"height":46},"line":37,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b0a2a7537be14162af52cea2d98204b9","type":"text","conversion_output":false,"parent_id":"84b0da94713b402a8b03d62c33385529","text":"Figure 1. Prevalence of chronic kidney","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[1379,1457],[1983,1457],[1983,1502],[1379,1502]],"region":{"top_left_x":1379,"top_left_y":1456,"width":605,"height":46},"line":38,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1659e4b396b046f5ad266d4dc5a7ccad","type":"text","conversion_output":false,"parent_id":"84b0da94713b402a8b03d62c33385529","text":"disease by age group in two NHANES","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[1377,1500],[1919,1500],[1919,1545],[1377,1545]],"region":{"top_left_x":1377,"top_left_y":1499,"width":542,"height":46},"line":39,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"77cb08062a8e49d589ae2c38bdbcff3c","type":"text","conversion_output":false,"parent_id":"84b0da94713b402a8b03d62c33385529","text":"surveys. From Coresh et al (ref 7).","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[120,1568],[1790,1568],[1790,1618],[120,1618]],"region":{"top_left_x":120,"top_left_y":1568,"width":1670,"height":50},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"89305b6768f941dba6fb59e576fca43c","type":"text","conversion_output":true,"text":"GFR. \\({ }^{11}\\) While it is now clear that low levels of albuminuria (\"microalbuminuria\") may regress, either","text_display":" GFR. \\({ }^{11}\\) While it is now clear that low levels of albuminuria (\"microalbuminuria\") may regress, either","confidence":1,"confidence_rate":1},{"cnt":[[120,1611],[1949,1611],[1949,1661],[120,1661]],"region":{"top_left_x":120,"top_left_y":1611,"width":1829,"height":50},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cc70c649539d4cefb2b4857ff8cff413","type":"text","conversion_output":true,"text":"spontaneously or with treatment, many individuals progress to advanced stages of DKD. \\({ }^{3,11-14}\\) In 2006, DKD","text_display":" spontaneously or with treatment, many individuals progress to advanced stages of DKD. \\({ }^{3,11-14}\\) In 2006, DKD","confidence":0.9888083514706495,"confidence_rate":0.9999069898939082},{"cnt":[[120,1654],[1970,1654],[1970,1708],[120,1708]],"region":{"top_left_x":120,"top_left_y":1654,"width":1851,"height":55},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d43626100c364525ad771ef62607a2ed","type":"text","conversion_output":true,"text":"was the attributed cause of 49,224 cases of incident ESRD ( \\(44 \\%\\) ) in the United States alone. \\({ }^{3}\\) In addition, the","text_display":" was the attributed cause of 49,224 cases of incident ESRD ( \\(44 \\%\\) ) in the United States alone. \\({ }^{3}\\) In addition, the","confidence":0.7822568767005578,"confidence_rate":0.9981552967517742},{"cnt":[[120,1697],[1871,1697],[1871,1751],[120,1751]],"region":{"top_left_x":120,"top_left_y":1697,"width":1752,"height":54},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b68fb64cfc0e44ae857c3c182fe15b8f","type":"text","conversion_output":true,"text":"presence and severity of DKD potently amplifies CVD risk. \\({ }^{15-18}\\) Albuminuria and impaired GFR are each","text_display":" presence and severity of DKD potently amplifies CVD risk. \\({ }^{15-18}\\) Albuminuria and impaired GFR are each","confidence":1,"confidence_rate":1},{"cnt":[[120,1747],[1944,1747],[1944,1794],[120,1794]],"region":{"top_left_x":120,"top_left_y":1746,"width":1825,"height":48},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"182abd9952f64d6d83e51956a3fce051","type":"text","conversion_output":true,"text":"associated with increased prevalence and severity of traditional CVD risk factors, such as hypertension and","text_display":" associated with increased prevalence and severity of traditional CVD risk factors, such as hypertension and","confidence":0.99951171875,"confidence_rate":0.9999956392907748},{"cnt":[[120,1783],[1869,1783],[1869,1837],[120,1837]],"region":{"top_left_x":120,"top_left_y":1783,"width":1750,"height":54},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8c6b1a66b86548068557f6362c06e1df","type":"text","conversion_output":true,"text":"dyslipidemia. \\({ }^{19-24}\\) Kidney disease is also associated with novel CVD risk factors, including inflammation,","text_display":" dyslipidemia. \\({ }^{19-24}\\) Kidney disease is also associated with novel CVD risk factors, including inflammation,","confidence":1,"confidence_rate":1},{"cnt":[[120,1830],[1867,1830],[1867,1880],[120,1880]],"region":{"top_left_x":120,"top_left_y":1830,"width":1747,"height":50},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cf6155eb59b1468c980ad21719734d99","type":"text","conversion_output":true,"text":"oxidative stress, anemia, disordered mineral metabolism, and vascular calcification. \\({ }^{24-29}\\) As a result, the","text_display":" oxidative stress, anemia, disordered mineral metabolism, and vascular calcification. \\({ }^{24-29}\\) As a result, the","confidence":0.9990236759185791,"confidence_rate":0.9999919934665097},{"cnt":[[120,1878],[1987,1878],[1987,1927],[120,1927]],"region":{"top_left_x":120,"top_left_y":1877,"width":1868,"height":51},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a933a63be5614625abbaba05deca1eb1","type":"text","conversion_output":true,"text":"prevalence and incidence of CVD are directly proportional to the severity of DKD. Moreover, as demonstrated","text_display":" prevalence and incidence of CVD are directly proportional to the severity of DKD. Moreover, as demonstrated","confidence":1,"confidence_rate":1},{"cnt":[[122,1922],[1480,1922],[1480,2601],[122,2601]],"region":{"top_left_x":122,"top_left_y":1922,"width":1358,"height":679},"line":48,"column":0,"font_size":25,"is_printed":true,"is_handwritten":false,"id":"4c1234738d4941379dc40d41fab07049","type":"column","conversion_output":false,"children_ids":["2791f480fb044cde87ff8c21c9be13f9","f8df3ce0b50c433f8806bab385c5896f"],"text":"","text_display":""},{"cnt":[[125,1927],[1476,1925],[1477,2531],[126,2533]],"region":{"top_left_x":124,"top_left_y":1924,"width":1353,"height":609},"line":49,"column":2,"font_size":22,"is_printed":true,"is_handwritten":false,"id":"2791f480fb044cde87ff8c21c9be13f9","type":"diagram","conversion_output":true,"parent_id":"4c1234738d4941379dc40d41fab07049","selected_labels":["f8df3ce0b50c433f8806bab385c5896f"],"text":"","text_display":"\n\n\\begin{figure}\n\\includegraphics[alt={},max width=\\textwidth]{https://cdn.mathpix.com/cropped/7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-05.jpg?height=609&width=1353&top_left_y=1924&top_left_x=124}\n\\captionsetup{labelformat=empty}\n\\caption{Figure 2. Mortality rates (per year) in the UKPDS, by DKD stage, from Adler et al (ref 14).}\n\\end{figure}"},{"cnt":[[174,2548],[1433,2548],[1433,2597],[174,2597]],"region":{"top_left_x":174,"top_left_y":2548,"width":1260,"height":50},"line":50,"column":2,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"f8df3ce0b50c433f8806bab385c5896f","type":"figure_label","conversion_output":false,"parent_id":"4c1234738d4941379dc40d41fab07049","text":"Figure 2. Mortality rates (per year) in the UKPDS, by DKD stage, from Adler et al (ref 14).","text_display":"","confidence":0.98095703125,"confidence_rate":0.9997997427484893},{"cnt":[[1508,1921],[1893,1921],[1893,1970],[1508,1970]],"region":{"top_left_x":1508,"top_left_y":1920,"width":385,"height":51},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"34241cfb79bb44d8b5bd7a0b6bf18211","type":"text","conversion_output":true,"text":"in the United Kingdom","text_display":"\nin the United Kingdom","confidence":1,"confidence_rate":1},{"cnt":[[1508,1968],[1987,1968],[1987,2013],[1508,2013]],"region":{"top_left_x":1508,"top_left_y":1967,"width":480,"height":47},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4539e2baf4da44769034faa78a672815","type":"text","conversion_output":true,"text":"Prospective Diabetes Study","text_display":" Prospective Diabetes Study","confidence":1,"confidence_rate":1},{"cnt":[[1508,2011],[1848,2011],[1848,2058],[1508,2058]],"region":{"top_left_x":1508,"top_left_y":2010,"width":340,"height":49},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"42db9bf72fbf4bd184fa76b6293674bd","type":"text","conversion_output":true,"text":"(UKPDS) and other","text_display":" (UKPDS) and other","confidence":1,"confidence_rate":1},{"cnt":[[1508,2054],[1850,2054],[1850,2103],[1508,2103]],"region":{"top_left_x":1508,"top_left_y":2053,"width":342,"height":51},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"db0b7232d6754cb5a4a94ab165e9821d","type":"text","conversion_output":true,"text":"longitudinal studies,","text_display":" longitudinal studies,","confidence":1,"confidence_rate":1},{"cnt":[[1508,2097],[1867,2097],[1867,2146],[1508,2146]],"region":{"top_left_x":1508,"top_left_y":2096,"width":359,"height":51},"line":55,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a1692a4156b7421c94b215ab2f30966a","type":"text","conversion_output":true,"text":"mortality is markedly","text_display":" mortality is markedly","confidence":1,"confidence_rate":1},{"cnt":[[1508,2142],[1897,2142],[1897,2189],[1508,2189]],"region":{"top_left_x":1508,"top_left_y":2141,"width":390,"height":49},"line":56,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"904c2652d7f24e0bbc8cd828bc751647","type":"text","conversion_output":true,"text":"increased with greater","text_display":" increased with greater","confidence":1,"confidence_rate":1},{"cnt":[[1508,2187],[1923,2187],[1923,2232],[1508,2232]],"region":{"top_left_x":1508,"top_left_y":2187,"width":415,"height":46},"line":57,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3dc05e6a42d64d3ba75263e47b48bd29","type":"text","conversion_output":true,"text":"severity of DKD (Figure","text_display":" severity of DKD (Figure","confidence":1,"confidence_rate":1},{"cnt":[[1508,2226],[1966,2226],[1966,2279],[1508,2279]],"region":{"top_left_x":1508,"top_left_y":2225,"width":458,"height":55},"line":58,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ef71045c542b4a1589673e64bb891e91","type":"text","conversion_output":true,"text":"2). \\({ }^{14, ~ 30-33}\\) More specifically,","text_display":" 2). \\({ }^{14, ~ 30-33}\\) More specifically,","confidence":0.6732296943664551,"confidence_rate":0.991616853044148},{"cnt":[[1508,2275],[1979,2275],[1979,2318],[1508,2318]],"region":{"top_left_x":1508,"top_left_y":2275,"width":471,"height":44},"line":59,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"33e6873e6338463084c96db2ea553edd","type":"text","conversion_output":true,"text":"we have demonstrated that","text_display":" we have demonstrated that","confidence":1,"confidence_rate":1},{"cnt":[[1508,2316],[1966,2316],[1966,2361],[1508,2361]],"region":{"top_left_x":1508,"top_left_y":2316,"width":458,"height":46},"line":60,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d08f70e5f9b64f2f83d6465b87f2921a","type":"text","conversion_output":true,"text":"albuminuria and estimated","text_display":" albuminuria and estimated","confidence":1,"confidence_rate":1},{"cnt":[[1508,2359],[1987,2359],[1987,2408],[1508,2408]],"region":{"top_left_x":1508,"top_left_y":2358,"width":480,"height":51},"line":61,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d3a420f358334e4c82974e864aa61fd9","type":"text","conversion_output":true,"text":"GFR are independently and","text_display":" GFR are independently and","confidence":1,"confidence_rate":1},{"cnt":[[1508,2406],[1949,2406],[1949,2451],[1508,2451]],"region":{"top_left_x":1508,"top_left_y":2406,"width":441,"height":46},"line":62,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d13c179929384a30bb6e4aef6bae85d1","type":"text","conversion_output":true,"text":"additively associated with","text_display":" additively associated with","confidence":1,"confidence_rate":1},{"cnt":[[1508,2449],[2000,2449],[2000,2494],[1508,2494]],"region":{"top_left_x":1508,"top_left_y":2449,"width":493,"height":46},"line":63,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5b95844646d7463d9b8bb942958c5d24","type":"text","conversion_output":true,"text":"all-cause- and CVD-specific-","text_display":" all-cause- and CVD-specific","confidence":1,"confidence_rate":1},{"cnt":[[1508,2492],[1996,2492],[1996,2542],[1508,2542]],"region":{"top_left_x":1508,"top_left_y":2492,"width":488,"height":50},"line":64,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d3c59cdd74a843fab7d3b4b01f4c407f","type":"text","conversion_output":true,"text":"mortality among older adults","text_display":"mortality among older adults","confidence":1,"confidence_rate":1},{"cnt":[[1977,2582],[2007,2582],[2007,2628],[1977,2628]],"region":{"top_left_x":1976,"top_left_y":2582,"width":31,"height":46},"line":65,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ea19b0679dae4b398afef1562056ab77","type":"page_info","conversion_output":false,"text":"5","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-06","page":6,"lines":[{"cnt":[[120,127],[1128,127],[1128,174],[120,174]],"region":{"top_left_x":120,"top_left_y":126,"width":1008,"height":49},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2ef3d097b6c447c5803765307263de2e","type":"text","conversion_output":true,"text":"with diabetes who participated in the Cardiovascular Health","text_display":"\nwith diabetes who participated in the Cardiovascular Health","confidence":1,"confidence_rate":1},{"cnt":[[120,163],[1072,163],[1072,217],[120,217]],"region":{"top_left_x":120,"top_left_y":163,"width":953,"height":54},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c18a6ed2fe26498a817dafab60fd8edf","type":"text","conversion_output":true,"text":"Study (Figure 3). \\({ }^{34}\\) In randomized clinical trials of renin-","text_display":" Study (Figure 3). \\({ }^{34}\\) In randomized clinical trials of renin-","confidence":0.99951171875,"confidence_rate":0.9999934880145616},{"cnt":[[120,215],[1025,215],[1025,260],[120,260]],"region":{"top_left_x":120,"top_left_y":214,"width":905,"height":46},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f529760a3ca143f891aae4855959d672","type":"text","conversion_output":true,"text":"angiotensin-aldosterone system (RAAS) antagonists,","text_display":"angiotensin-aldosterone system (RAAS) antagonists,","confidence":1,"confidence_rate":1},{"cnt":[[120,258],[988,258],[988,303],[120,303]],"region":{"top_left_x":120,"top_left_y":257,"width":869,"height":46},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c9f4b52299464c35876a734c0c909a39","type":"text","conversion_output":true,"text":"reduction of albuminuria on therapy correlated with","text_display":" reduction of albuminuria on therapy correlated with","confidence":1,"confidence_rate":1},{"cnt":[[120,296],[1079,296],[1079,350],[120,350]],"region":{"top_left_x":120,"top_left_y":296,"width":959,"height":55},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"54dbfc2b9ae14a9e84f570439653fe8b","type":"text","conversion_output":true,"text":"improved renal and CVD outcomes. \\({ }^{35,36}\\) Taken together,","text_display":" improved renal and CVD outcomes. \\({ }^{35,36}\\) Taken together,","confidence":0.9990234375,"confidence_rate":0.9999858401053562},{"cnt":[[120,348],[1068,348],[1068,393],[120,393]],"region":{"top_left_x":120,"top_left_y":348,"width":948,"height":46},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a69fbf5829f94dc099340f90052381a5","type":"text","conversion_output":true,"text":"these observations suggest that reducing the burden of","text_display":" these observations suggest that reducing the burden of","confidence":1,"confidence_rate":1},{"cnt":[[120,391],[1106,391],[1106,436],[120,436]],"region":{"top_left_x":120,"top_left_y":391,"width":987,"height":46},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"048ed58cfab24761b6ac079075a2ea9f","type":"text","conversion_output":true,"text":"DKD in its early stages will help prevent ESRD, CVD, and","text_display":" DKD in its early stages will help prevent ESRD, CVD, and","confidence":0.9990234375,"confidence_rate":0.9999839830848651},{"cnt":[[120,434],[965,434],[965,479],[120,479]],"region":{"top_left_x":120,"top_left_y":433,"width":845,"height":47},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e7df569bc42c400daf6eee768fe6ad63","type":"text","conversion_output":true,"text":"death. Because diabetes and kidney disease are","text_display":" death. Because diabetes and kidney disease are","confidence":1,"confidence_rate":1},{"cnt":[[120,477],[1059,477],[1059,524],[120,524]],"region":{"top_left_x":120,"top_left_y":476,"width":940,"height":49},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1a559adbbe25432ca00d92ce899392bb","type":"text","conversion_output":true,"text":"particularly strong risk factors for mortality among older","text_display":" particularly strong risk factors for mortality among older","confidence":1,"confidence_rate":1},{"cnt":[[120,522],[935,522],[935,565],[120,565]],"region":{"top_left_x":120,"top_left_y":522,"width":815,"height":44},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cd03a9c93f8d4611b988120abb14a0e2","type":"text","conversion_output":true,"text":"adults, for whom other CVD risk factors such as","text_display":" adults, for whom other CVD risk factors such as","confidence":1,"confidence_rate":1},{"cnt":[[120,563],[1102,563],[1102,612],[120,612]],"region":{"top_left_x":120,"top_left_y":562,"width":983,"height":51},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f952da75204f47a8bfabc95cbb19f454","type":"text","conversion_output":true,"text":"hyperlipidemia have reduced prognostic utility, prevention","text_display":" hyperlipidemia have reduced prognostic utility, prevention","confidence":1,"confidence_rate":1},{"cnt":[[120,610],[1042,610],[1042,655],[120,655]],"region":{"top_left_x":120,"top_left_y":610,"width":922,"height":46},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e0d6d81526644282afdd449f34265bb9","type":"text","conversion_output":true,"text":"and treatment of DKD may have particularly beneficial","text_display":" and treatment of DKD may have particularly beneficial","confidence":1,"confidence_rate":1},{"cnt":[[120,649],[696,649],[696,700],[120,700]],"region":{"top_left_x":120,"top_left_y":648,"width":577,"height":53},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"54735b39b3c6485cbc2558b5ef09108a","type":"text","conversion_output":true,"text":"effects in this age group. \\({ }^{18,34,37,38}\\)","text_display":" effects in this age group. \\({ }^{18,34,37,38}\\)","confidence":0.998046875,"confidence_rate":0.9999601021258229},{"cnt":[[120,718],[993,718],[993,763],[120,763]],"region":{"top_left_x":120,"top_left_y":717,"width":873,"height":46},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7f481111b3db4614bb324d1a77606062","type":"text","conversion_output":true,"text":"I.a.4 Novel interventions for DKD prevention and","text_display":"\nI.a.4 Novel interventions for DKD prevention and","confidence":0.7446225066405532,"confidence_rate":0.9944517151002575},{"cnt":[[120,765],[1072,765],[1072,806],[120,806]],"region":{"top_left_x":120,"top_left_y":764,"width":953,"height":42},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d93fd5d06a7f4143a2af66093dd56731","type":"text","conversion_output":true,"text":"treatment are urgently needed. Current interventions to","text_display":" treatment are urgently needed. Current interventions to","confidence":1,"confidence_rate":1},{"cnt":[[120,808],[1089,808],[1089,853],[120,853]],"region":{"top_left_x":120,"top_left_y":807,"width":970,"height":46},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6a8e684e44ce44468a2972fef5b2dbe1","type":"text","conversion_output":true,"text":"prevent and treat DKD are limited. The Diabetes Control","text_display":" prevent and treat DKD are limited. The Diabetes Control","confidence":1,"confidence_rate":1},{"cnt":[[120,851],[1074,851],[1074,896],[120,896]],"region":{"top_left_x":120,"top_left_y":850,"width":955,"height":46},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c2a957d70a22490eb3f0a5e446a9ad7e","type":"text","conversion_output":true,"text":"and Complications Trial (DCCT) and the UKPDS clearly","text_display":" and Complications Trial (DCCT) and the UKPDS clearly","confidence":1,"confidence_rate":1},{"cnt":[[120,894],[1132,894],[1132,939],[120,939]],"region":{"top_left_x":120,"top_left_y":893,"width":1013,"height":46},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"debe744099ae4f90b565843f847a8de8","type":"text","conversion_output":true,"text":"demonstrated that intensive glycemic control decreases the","text_display":" demonstrated that intensive glycemic control decreases the","confidence":1,"confidence_rate":1},{"cnt":[[120,932],[1130,932],[1130,984],[120,984]],"region":{"top_left_x":120,"top_left_y":932,"width":1011,"height":52},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"138b46f398b541248ea12e15e7c188cc","type":"text","conversion_output":true,"text":"incidence of DKD, and perhaps its progression. \\({ }^{39-41}\\) Despite","text_display":" incidence of DKD, and perhaps its progression. \\({ }^{39-41}\\) Despite","confidence":1,"confidence_rate":1},{"cnt":[[120,982],[1005,982],[1005,1027],[120,1027]],"region":{"top_left_x":120,"top_left_y":981,"width":886,"height":46},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"375cd4ea19084067b3d0f22eb6a0efb1","type":"text","conversion_output":true,"text":"these exceptionally important findings, however, the","text_display":" these exceptionally important findings, however, the","confidence":1,"confidence_rate":1},{"cnt":[[120,1027],[1087,1027],[1087,1072],[120,1072]],"region":{"top_left_x":120,"top_left_y":1026,"width":968,"height":47},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6fc6942ee34c4fd18322991d95f3a409","type":"text","conversion_output":true,"text":"incidence of DKD in these studies remained high even in","text_display":" incidence of DKD in these studies remained high even in","confidence":1,"confidence_rate":1},{"cnt":[[120,1070],[986,1070],[986,1115],[120,1115]],"region":{"top_left_x":120,"top_left_y":1069,"width":867,"height":47},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"90cc02fa8e544aab97d6d0c9726ecc83","type":"text","conversion_output":true,"text":"the intensive glycemic control treatment arms. For","text_display":" the intensive glycemic control treatment arms. For","confidence":1,"confidence_rate":1},{"cnt":[[120,1113],[1016,1113],[1016,1158],[120,1158]],"region":{"top_left_x":120,"top_left_y":1112,"width":897,"height":47},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"33c019d693a94943a38d3f87f112615f","type":"text","conversion_output":true,"text":"example, of DCCT participants assigned to intensive","text_display":" example, of DCCT participants assigned to intensive","confidence":1,"confidence_rate":1},{"cnt":[[1166,109],[1987,109],[1987,1131],[1166,1131]],"region":{"top_left_x":1166,"top_left_y":109,"width":821,"height":1022},"line":24,"column":0,"font_size":31,"is_printed":true,"is_handwritten":false,"id":"b588b444244a4ff2a77dbc9b4ad3a74e","type":"column","conversion_output":false,"children_ids":["7f64f528a92a4470ba388f5c9ee79ee7","3ff301313c44452693265c3d87d341cf"],"text":"","text_display":""},{"cnt":[[1169,112],[1983,112],[1983,904],[1169,904]],"region":{"top_left_x":1168,"top_left_y":111,"width":816,"height":794},"line":25,"column":1,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"7f64f528a92a4470ba388f5c9ee79ee7","type":"chart","conversion_output":true,"parent_id":"b588b444244a4ff2a77dbc9b4ad3a74e","selected_labels":["3ff301313c44452693265c3d87d341cf"],"text":"","text_display":"\n\n\\begin{figure}\n\\includegraphics[alt={},max width=\\textwidth]{https://cdn.mathpix.com/cropped/7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-06.jpg?height=794&width=816&top_left_y=111&top_left_x=1168}\n\\captionsetup{labelformat=empty}\n\\caption{Figure 3. Survival by estimated GFR (eGFR in \\(mL / min / 1.73 m^{2}\\) ) and urine albumin-creatinine ratio (ACR in \\(mg / g\\) ) among 691 Cardiovascular Health Study participants with diabetes, from de Boer et al (ref 34).}\n\\end{figure}","subtype":"line"},{"cnt":[[1182,900],[1972,900],[1972,1128],[1182,1128]],"region":{"top_left_x":1181,"top_left_y":900,"width":792,"height":228},"line":26,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3ff301313c44452693265c3d87d341cf","type":"figure_label","conversion_output":false,"parent_id":"b588b444244a4ff2a77dbc9b4ad3a74e","children_ids":["f3cfb3c7107c49c88724a1ceaa76a52e","54058ffd9b3b4609aad8e78930df71ae","226f5c76d298469da831f41e9b4d3e3f","e7df4644c01a4684b2e9ff2578d5a311","3b8e268fac1b4e63b9d0009b9f9540f5"],"text":"","text_display":""},{"cnt":[[1207,907],[1946,907],[1946,952],[1207,952]],"region":{"top_left_x":1207,"top_left_y":906,"width":740,"height":46},"line":27,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f3cfb3c7107c49c88724a1ceaa76a52e","type":"text","conversion_output":false,"parent_id":"3ff301313c44452693265c3d87d341cf","text":"Figure 3. Survival by estimated GFR (eGFR in","text_display":"","confidence":0.99951171875,"confidence_rate":0.9999900326925697},{"cnt":[[1216,950],[1938,950],[1938,993],[1216,993]],"region":{"top_left_x":1216,"top_left_y":949,"width":722,"height":44},"line":28,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"54058ffd9b3b4609aad8e78930df71ae","type":"text","conversion_output":false,"parent_id":"3ff301313c44452693265c3d87d341cf","text":"\\(mL / min / 1.73 m^{2}\\) ) and urine albumin-creatinine","text_display":"","confidence":0.99951171875,"confidence_rate":0.999992368771335},{"cnt":[[1203,990],[1953,990],[1953,1038],[1203,1038]],"region":{"top_left_x":1203,"top_left_y":990,"width":750,"height":48},"line":29,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"226f5c76d298469da831f41e9b4d3e3f","type":"text","conversion_output":false,"parent_id":"3ff301313c44452693265c3d87d341cf","text":"ratio (ACR in \\(mg / g\\) ) among 691 Cardiovascular","text_display":"","confidence":0.90869140625,"confidence_rate":0.9984568414194663},{"cnt":[[1259,1036],[1893,1036],[1893,1079],[1259,1079]],"region":{"top_left_x":1258,"top_left_y":1035,"width":635,"height":44},"line":30,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e7df4644c01a4684b2e9ff2578d5a311","type":"text","conversion_output":false,"parent_id":"3ff301313c44452693265c3d87d341cf","text":"Health Study participants with diabetes,","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[1362,1074],[1790,1074],[1790,1124],[1362,1124]],"region":{"top_left_x":1362,"top_left_y":1074,"width":428,"height":50},"line":31,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3b8e268fac1b4e63b9d0009b9f9540f5","type":"text","conversion_output":false,"parent_id":"3ff301313c44452693265c3d87d341cf","text":"from de Boer et al (ref 34).","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[120,1156],[1949,1156],[1949,1205],[120,1205]],"region":{"top_left_x":120,"top_left_y":1155,"width":1829,"height":51},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1049a103cd604e64bfdeae3fb343e5dd","type":"text","conversion_output":true,"text":"diabetes therapy, \\(5 \\%\\) had prevalent microalbuminuria (albumin excretion rate \\(\\geq 28 \\mu g / min\\) ) at baseline, \\(16 \\%\\)","text_display":" diabetes therapy, \\(5 \\%\\) had prevalent microalbuminuria (albumin excretion rate \\(\\geq 28 \\mu g / min\\) ) at baseline, \\(16 \\%\\)","confidence":0.9854029913344037,"confidence_rate":0.9998774692306587},{"cnt":[[120,1199],[1757,1199],[1757,1248],[120,1248]],"region":{"top_left_x":120,"top_left_y":1198,"width":1638,"height":51},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"85015e074182498b89e9338972de7442","type":"text","conversion_output":true,"text":"developed incident microalbuminuria during the DCCT, and an additional \\(7 \\%\\) developed incident","text_display":" developed incident microalbuminuria during the DCCT, and an additional \\(7 \\%\\) developed incident","confidence":0.95654296875,"confidence_rate":0.9995558030025624},{"cnt":[[120,1240],[1897,1240],[1897,1291],[120,1291]],"region":{"top_left_x":120,"top_left_y":1239,"width":1778,"height":53},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c41be1a80fb04a718038d082a79cbb9c","type":"text","conversion_output":true,"text":"microalbuminuria over the subsequent 8 years of follow-up. \\({ }^{39,40}\\) In addition, effects of glycemic control on","text_display":" microalbuminuria over the subsequent 8 years of follow-up. \\({ }^{39,40}\\) In addition, effects of glycemic control on","confidence":0.9990234375,"confidence_rate":0.9999922457471451},{"cnt":[[120,1289],[1848,1289],[1848,1336],[120,1336]],"region":{"top_left_x":120,"top_left_y":1289,"width":1728,"height":48},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d19c7655919a4444832813887c9f257a","type":"text","conversion_output":true,"text":"prevention of CVD remain unclear: while intensive glycemic control in the DCCT resulted in a modest","text_display":" prevention of CVD remain unclear: while intensive glycemic control in the DCCT resulted in a modest","confidence":1,"confidence_rate":1},{"cnt":[[120,1332],[1951,1332],[1951,1381],[120,1381]],"region":{"top_left_x":120,"top_left_y":1332,"width":1831,"height":50},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b4212a47828244e8a7cd5ddc3b5befaa","type":"text","conversion_output":true,"text":"reduction in CVD events (myocardial infarction, stroke, CVD death, angina, coronary revascularization) over","text_display":" reduction in CVD events (myocardial infarction, stroke, CVD death, angina, coronary revascularization) over","confidence":1,"confidence_rate":1},{"cnt":[[120,1377],[1863,1377],[1863,1424],[120,1424]],"region":{"top_left_x":120,"top_left_y":1377,"width":1743,"height":48},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7b1ff6ca6d9c4c55916eedb9e4920dc1","type":"text","conversion_output":true,"text":"long-term follow-up, the ACCORD, ADVANCE and Veterans Affairs Diabetes Trial did not demonstrate","text_display":" long-term follow-up, the ACCORD, ADVANCE and Veterans Affairs Diabetes Trial did not demonstrate","confidence":1,"confidence_rate":1},{"cnt":[[120,1416],[1964,1416],[1964,1467],[120,1467]],"region":{"top_left_x":120,"top_left_y":1415,"width":1844,"height":53},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0190f5426c9845bb89472115f044c4b3","type":"text","conversion_output":true,"text":"benefits of tight glycemic control on CVD events. \\({ }^{41-45}\\) In addition to glycemic control, blood pressure control is","text_display":" benefits of tight glycemic control on CVD events. \\({ }^{41-45}\\) In addition to glycemic control, blood pressure control is","confidence":1,"confidence_rate":1},{"cnt":[[120,1465],[1863,1465],[1863,1510],[120,1510]],"region":{"top_left_x":120,"top_left_y":1465,"width":1743,"height":46},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7d0a0def43ba436fb7bbf8cab5860e10","type":"text","conversion_output":true,"text":"clearly important for DKD prevention and treatment. In particular, angiotensin coverting enzyme (ACE)","text_display":" clearly important for DKD prevention and treatment. In particular, angiotensin coverting enzyme (ACE)","confidence":1,"confidence_rate":1},{"cnt":[[120,1508],[1895,1508],[1895,1555],[120,1555]],"region":{"top_left_x":120,"top_left_y":1508,"width":1775,"height":48},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3871554f8caa4fdda675ee532b317552","type":"text","conversion_output":true,"text":"inhibitors and angiotensin II receptor blockers are proven to prevent the development and progression of","text_display":" inhibitors and angiotensin II receptor blockers are proven to prevent the development and progression of","confidence":1,"confidence_rate":1},{"cnt":[[120,1547],[1927,1547],[1927,1601],[120,1601]],"region":{"top_left_x":120,"top_left_y":1546,"width":1808,"height":55},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bd55a3021efd4e879999d6a983f20e77","type":"text","conversion_output":true,"text":"DKD. \\({ }^{46-51}\\) Again, however, DKD incidence and progression remain high despite treatment with these RAAS","text_display":" DKD. \\({ }^{46-51}\\) Again, however, DKD incidence and progression remain high despite treatment with these RAAS","confidence":1,"confidence_rate":1},{"cnt":[[120,1594],[1944,1594],[1944,1644],[120,1644]],"region":{"top_left_x":120,"top_left_y":1594,"width":1825,"height":50},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c7997a5d805e425ca701d8dfe56cf1d3","type":"text","conversion_output":true,"text":"antagonists. Therefore, glycemic control and RAAS inhibition on their own do not meet the clinical need for","text_display":" antagonists. Therefore, glycemic control and RAAS inhibition on their own do not meet the clinical need for","confidence":1,"confidence_rate":1},{"cnt":[[120,1641],[1927,1641],[1927,1687],[120,1687]],"region":{"top_left_x":120,"top_left_y":1641,"width":1808,"height":46},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"deb16e71806e458fbfe954ba1baded44","type":"text","conversion_output":true,"text":"DKD prevention and treatment, and novel approaches to therapy are needed. Given the high incidence of","text_display":" DKD prevention and treatment, and novel approaches to therapy are needed. Given the high incidence of","confidence":1,"confidence_rate":1},{"cnt":[[120,1684],[1996,1684],[1996,1732],[120,1732]],"region":{"top_left_x":120,"top_left_y":1684,"width":1876,"height":48},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c828343779314e78b09d7da352de2e93","type":"text","conversion_output":true,"text":"DKD among persons with diabetes, ideal new interventions would be sufficiently accessible, inexpensive, safe,","text_display":" DKD among persons with diabetes, ideal new interventions would be sufficiently accessible, inexpensive, safe,","confidence":1,"confidence_rate":1},{"cnt":[[120,1727],[1222,1727],[1222,1777],[120,1777]],"region":{"top_left_x":120,"top_left_y":1727,"width":1103,"height":50},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5052585fd9d640d18a44463ea3978e80","type":"text","conversion_output":true,"text":"and effective to apply to large numbers of persons with diabetes.","text_display":" and effective to apply to large numbers of persons with diabetes.","confidence":1,"confidence_rate":1},{"cnt":[[116,1788],[1783,1788],[1783,1846],[116,1846]],"region":{"top_left_x":116,"top_left_y":1787,"width":1668,"height":59},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3b0baa8cab35487899d235b3bc989b41","type":"section_header","conversion_output":false,"children_ids":["2787ffbda59949898acf10a9d42484ae"],"text":"","text_display":""},{"cnt":[[120,1794],[1777,1794],[1777,1841],[120,1841]],"region":{"top_left_x":120,"top_left_y":1793,"width":1657,"height":49},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2787ffbda59949898acf10a9d42484ae","type":"text","conversion_output":true,"parent_id":"3b0baa8cab35487899d235b3bc989b41","text":"l.b. Vitamin D is a promising therapeutic intervention for DKD prevention and treatment.","text_display":"\n\n\\section*{l.b. Vitamin D is a promising therapeutic intervention for DKD prevention and treatment.}","confidence":0.9897668227813483,"confidence_rate":0.9998894050823082},{"cnt":[[120,1905],[120,1856],[1983,1858],[1983,1908]],"region":{"top_left_x":120,"top_left_y":1856,"width":1864,"height":52},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8eb6199ee033420dacbf39785abead04","type":"text","conversion_output":true,"text":"I.b.1. Overview of vitamin D metabolism. Vitamin D is a critical regulator of calcium, phosphorous, and bone","text_display":"\nI.b.1. Overview of vitamin D metabolism. Vitamin D is a critical regulator of calcium, phosphorous, and bone","confidence":0.9829459190368652,"confidence_rate":0.9998477887836424},{"cnt":[[120,1897],[1858,1897],[1858,1949],[120,1949]],"region":{"top_left_x":120,"top_left_y":1897,"width":1739,"height":52},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"563151ccfbc54ce1abd5e027c165a2d3","type":"text","conversion_output":true,"text":"homeostasis. \\({ }^{52-55}\\) Humans derive substrate forms of vitamin D (cholecalciferol and ergocalciferol) from","text_display":" homeostasis. \\({ }^{52-55}\\) Humans derive substrate forms of vitamin D (cholecalciferol and ergocalciferol) from","confidence":0.99951171875,"confidence_rate":0.9999958610212935},{"cnt":[[120,1944],[1970,1944],[1970,1992],[120,1992]],"region":{"top_left_x":120,"top_left_y":1944,"width":1851,"height":48},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"dafee868cbbc49af92c67bc95a2b6ac8","type":"text","conversion_output":true,"text":"cutaneous synthesis and dietary intake. Cholecalciferol and ergocalciferol have little inherent biologic activity","text_display":" cutaneous synthesis and dietary intake. Cholecalciferol and ergocalciferol have little inherent biologic activity","confidence":1,"confidence_rate":1},{"cnt":[[120,1989],[1876,1989],[1876,2035],[120,2035]],"region":{"top_left_x":120,"top_left_y":1989,"width":1756,"height":46},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f525337daba042119437bf9b86503ff5","type":"text","conversion_output":true,"text":"and require two hydroxylation steps for full hormonal activity. 25-hydroxylation occurs in the liver and is","text_display":" and require two hydroxylation steps for full hormonal activity. 25-hydroxylation occurs in the liver and is","confidence":0.78271484375,"confidence_rate":0.9978150081352118},{"cnt":[[120,2032],[1901,2032],[1901,2082],[120,2082]],"region":{"top_left_x":120,"top_left_y":2032,"width":1782,"height":50},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4fd0155daa9e48f8b029f1a0befbe4ab","type":"text","conversion_output":true,"text":"unregulated and non-rate-limiting. Circulating 25-hydroxyvitamin D [25(OH)D] concentration increases in","text_display":" unregulated and non-rate-limiting. Circulating 25-hydroxyvitamin D [25(OH)D] concentration increases in","confidence":0.9434139595832676,"confidence_rate":0.9994607925436709},{"cnt":[[120,2075],[1938,2075],[1938,2125],[120,2125]],"region":{"top_left_x":120,"top_left_y":2075,"width":1818,"height":50},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"558166576f794c369cead57c33708275","type":"text","conversion_output":true,"text":"proportional to UV light exposure and dietary supplement intake, has a half-life of 10-21 days, and is widely","text_display":" proportional to UV light exposure and dietary supplement intake, has a half-life of 10-21 days, and is widely","confidence":0.62255859375,"confidence_rate":0.9958514577717484},{"cnt":[[120,2116],[1858,2116],[1858,2168],[120,2168]],"region":{"top_left_x":120,"top_left_y":2116,"width":1739,"height":52},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4849c679a79747dca79543b1aa86213a","type":"text","conversion_output":true,"text":"accepted as a summary measure of vitamin D intake from cutaneous and dietary sources. \\({ }^{56-62}\\) Further","text_display":" accepted as a summary measure of vitamin D intake from cutaneous and dietary sources. \\({ }^{56-62}\\) Further","confidence":0.99951171875,"confidence_rate":0.9999957157942815},{"cnt":[[120,2166],[1987,2166],[1987,2211],[120,2211]],"region":{"top_left_x":120,"top_left_y":2165,"width":1868,"height":46},"line":55,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"80e67358362a499daec361a5b6fe8f3a","type":"text","conversion_output":true,"text":"hydroxylation to 1,25-dihydroxyvitamin D (calcitriol) occurs predominantly in the kidney and is dependent upon","text_display":" hydroxylation to 1,25-dihydroxyvitamin D (calcitriol) occurs predominantly in the kidney and is dependent upon","confidence":0.994636058807373,"confidence_rate":0.9999532325825292},{"cnt":[[120,2204],[1987,2204],[1987,2256],[120,2256]],"region":{"top_left_x":120,"top_left_y":2204,"width":1868,"height":52},"line":56,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f43e144c03704c40a7760c90f9c560ed","type":"text","conversion_output":true,"text":"sufficient \\(25( OH )\\) D availability, particularly among persons with kidney disease. \\({ }^{28,63-68}\\) 1,25-dihydroxyvitamin D","text_display":" sufficient \\(25( OH )\\) D availability, particularly among persons with kidney disease. \\({ }^{28,63-68}\\) 1,25-dihydroxyvitamin D","confidence":0.8558976076454117,"confidence_rate":0.9988480378907062},{"cnt":[[120,2254],[2000,2254],[2000,2299],[120,2299]],"region":{"top_left_x":120,"top_left_y":2253,"width":1881,"height":46},"line":57,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d12b41ec5f1c4d78b033824805e1cc91","type":"text","conversion_output":true,"text":"is a pleiotropic steroid hormone that binds to the vitamin D receptor and regulates gene expression in a diverse","text_display":" is a pleiotropic steroid hormone that binds to the vitamin D receptor and regulates gene expression in a diverse","confidence":0.6612763404846191,"confidence_rate":0.9966431795894186},{"cnt":[[120,2290],[535,2290],[535,2344],[120,2344]],"region":{"top_left_x":120,"top_left_y":2290,"width":415,"height":54},"line":58,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"49120e856a6749fea712968b5fe593bc","type":"text","conversion_output":true,"text":"array of target tissues. \\({ }^{69}\\)","text_display":" array of target tissues. \\({ }^{69}\\)","confidence":1,"confidence_rate":1},{"cnt":[[120,2359],[1970,2359],[1970,2408],[120,2408]],"region":{"top_left_x":120,"top_left_y":2358,"width":1851,"height":51},"line":59,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b65e710ead474eddb90abd5159b4b8c3","type":"text","conversion_output":true,"text":"l.b.2. Vitamin D and the kidney. Traditional effects of 1,25-dihydroxyvitamin D include stimulation of dietary","text_display":"\nl.b.2. Vitamin D and the kidney. Traditional effects of 1,25-dihydroxyvitamin D include stimulation of dietary","confidence":0.826592996250838,"confidence_rate":0.9983453456706863},{"cnt":[[120,2406],[1974,2406],[1974,2451],[120,2451]],"region":{"top_left_x":120,"top_left_y":2406,"width":1855,"height":46},"line":60,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"60a3ce54af7142a0a77c496a758b88d8","type":"text","conversion_output":true,"text":"calcium and phosphorous absorption, suppression of parathyroid hormone, and maintenance of bone mineral","text_display":" calcium and phosphorous absorption, suppression of parathyroid hormone, and maintenance of bone mineral","confidence":0.9990236759185791,"confidence_rate":0.9999909555872323},{"cnt":[[120,2449],[2004,2449],[2004,2494],[120,2494]],"region":{"top_left_x":120,"top_left_y":2449,"width":1885,"height":46},"line":61,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b86bb34faad6455791b8b4646dc8be1a","type":"text","conversion_output":true,"text":"density. Recently, the potential impact of vitamin D on metabolic and cell regulatory pathways other than those","text_display":" density. Recently, the potential impact of vitamin D on metabolic and cell regulatory pathways other than those","confidence":0.99267578125,"confidence_rate":0.9999366298309822},{"cnt":[[120,2488],[1934,2488],[1934,2539],[120,2539]],"region":{"top_left_x":120,"top_left_y":2487,"width":1814,"height":53},"line":62,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c3d631b2dc7146acaa57013dc74a4af4","type":"text","conversion_output":true,"text":"related to traditional mineral homeostasis has attracted increased attention. \\({ }^{55,69-71}\\) As one of these potential","text_display":" related to traditional mineral homeostasis has attracted increased attention. \\({ }^{55,69-71}\\) As one of these potential","confidence":0.99755859375,"confidence_rate":0.9999807530093062},{"cnt":[[1977,2582],[2007,2582],[2007,2628],[1977,2628]],"region":{"top_left_x":1976,"top_left_y":2582,"width":31,"height":46},"line":63,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7d3e7582620e4ee790612a6f36c58c91","type":"page_info","conversion_output":false,"text":"6","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-07","page":7,"lines":[{"cnt":[[120,125],[1936,125],[1936,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":1816,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"841122ef44ae4b40a59d4a5127a7f200","type":"text","conversion_output":true,"text":"pleiotropic actions, 1,25-dihydroxyvitamin D appears to have direct renoprotective effects - this evidence is","text_display":"\npleiotropic actions, 1,25-dihydroxyvitamin D appears to have direct renoprotective effects - this evidence is","confidence":0.8822976353845343,"confidence_rate":0.9989021309521711},{"cnt":[[120,172],[1957,172],[1957,217],[120,217]],"region":{"top_left_x":120,"top_left_y":171,"width":1838,"height":46},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7eb484fb114d4a8fb4f28e6911a2b645","type":"text","conversion_output":true,"text":"described below and forms the rationale for Specific Aim 1. It is also possible that calcitriol deficiency due to","text_display":" described below and forms the rationale for Specific Aim 1. It is also possible that calcitriol deficiency due to","confidence":1,"confidence_rate":1},{"cnt":[[120,215],[1996,215],[1996,260],[120,260]],"region":{"top_left_x":120,"top_left_y":214,"width":1876,"height":46},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"620f8d76745b4ea593387db93e201603","type":"text","conversion_output":true,"text":"impaired renal synthesis is a mechanism through which kidney disease leads to CVD and other adverse health","text_display":" impaired renal synthesis is a mechanism through which kidney disease leads to CVD and other adverse health","confidence":1,"confidence_rate":1},{"cnt":[[120,258],[1390,258],[1390,305],[120,305]],"region":{"top_left_x":120,"top_left_y":257,"width":1271,"height":49},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c738597c8a03487faf7e523edf158a86","type":"text","conversion_output":true,"text":"outcomes - this latter hypothesis is not the focus of the current application.","text_display":" outcomes - this latter hypothesis is not the focus of the current application.","confidence":1,"confidence_rate":1},{"cnt":[[129,322],[973,322],[973,370],[129,370]],"region":{"top_left_x":128,"top_left_y":322,"width":846,"height":48},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b39fa33ba72b419f853dc75dfd511ff5","type":"text","conversion_output":true,"text":"I.b.3. Mechanisms through which vitamin D may","text_display":"\nI.b.3. Mechanisms through which vitamin D may","confidence":0.9858465194702148,"confidence_rate":0.9997149487095961},{"cnt":[[120,367],[1036,367],[1036,415],[120,415]],"region":{"top_left_x":120,"top_left_y":367,"width":916,"height":48},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b1e52ad1f42143a0b9256a05d3a398e0","type":"text","conversion_output":true,"text":"prevent DKD. Vitamin D may prevent kidney damage","text_display":" prevent DKD. Vitamin D may prevent kidney damage","confidence":1,"confidence_rate":1},{"cnt":[[120,412],[1063,412],[1063,458],[120,458]],"region":{"top_left_x":120,"top_left_y":412,"width":944,"height":46},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e19c40623c974c4aa0e9cc9cb81cdc32","type":"text","conversion_output":true,"text":"by suppressing the RAAS, reducing renal inflammation,","text_display":" by suppressing the RAAS, reducing renal inflammation,","confidence":1,"confidence_rate":1},{"cnt":[[120,455],[1012,455],[1012,501],[120,501]],"region":{"top_left_x":120,"top_left_y":455,"width":892,"height":46},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ad219c9222f44dc08b035add7528e481","type":"text","conversion_output":true,"text":"and exerting direct pro-survival effects on podocytes","text_display":" and exerting direct pro-survival effects on podocytes","confidence":1,"confidence_rate":1},{"cnt":[[120,498],[1016,498],[1016,546],[120,546]],"region":{"top_left_x":120,"top_left_y":498,"width":897,"height":48},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"444d918a31cf4868a35ad62d3f9953f2","type":"text","conversion_output":true,"text":"(Figure 4). First, vitamin D deficiency stimulates the","text_display":" (Figure 4). First, vitamin D deficiency stimulates the","confidence":0.9990234375,"confidence_rate":0.9999834401430849},{"cnt":[[120,541],[954,541],[954,589],[120,589]],"region":{"top_left_x":120,"top_left_y":541,"width":834,"height":48},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d13645fdc95f4177924d29af11ff7b53","type":"text","conversion_output":true,"text":"transcription and release of renin in experimental","text_display":" transcription and release of renin in experimental","confidence":1,"confidence_rate":1},{"cnt":[[120,587],[1068,587],[1068,634],[120,634]],"region":{"top_left_x":120,"top_left_y":586,"width":948,"height":48},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d3e1312eccde454abd603d98e7440f3a","type":"text","conversion_output":true,"text":"animals, thus activating the RAAS, and renin is potently","text_display":" animals, thus activating the RAAS, and renin is potently","confidence":1,"confidence_rate":1},{"cnt":[[120,632],[819,632],[819,677],[120,677]],"region":{"top_left_x":120,"top_left_y":631,"width":699,"height":46},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"714c8f233ed943e5bbbad14b60761f4a","type":"text","conversion_output":true,"text":"downregulated by administration of 1,25-","text_display":" downregulated by administration of 1,25","confidence":1,"confidence_rate":1},{"cnt":[[120,670],[982,670],[982,724],[120,724]],"region":{"top_left_x":120,"top_left_y":670,"width":862,"height":55},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"20733fe0dda346d499fe2fc03a96ffb9","type":"text","conversion_output":true,"text":"dihydroxyvitamin D. \\({ }^{72,73}\\) RAAS stimulation leads to","text_display":"dihydroxyvitamin D. \\({ }^{72,73}\\) RAAS stimulation leads to","confidence":0.9647003685489608,"confidence_rate":0.9994556372378234},{"cnt":[[120,718],[771,718],[771,763],[120,763]],"region":{"top_left_x":120,"top_left_y":717,"width":652,"height":46},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6d6b5719bdf548f2b1e999ec42fe4056","type":"text","conversion_output":true,"text":"vasoconstriction, oxidative stress, and","text_display":" vasoconstriction, oxidative stress, and","confidence":1,"confidence_rate":1},{"cnt":[[120,761],[990,761],[990,810],[120,810]],"region":{"top_left_x":120,"top_left_y":760,"width":871,"height":50},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"82f9420d7a814e5f97bda0e7190800ad","type":"text","conversion_output":true,"text":"glomerulosclerosis through both hemodynamic and","text_display":" glomerulosclerosis through both hemodynamic and","confidence":1,"confidence_rate":1},{"cnt":[[120,799],[993,799],[993,853],[120,853]],"region":{"top_left_x":120,"top_left_y":799,"width":873,"height":54},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e4394ed72a8143bd8e3978dc82e47343","type":"text","conversion_output":true,"text":"nonhemodynamic (e.g. fibrotic) mechanisms. \\({ }^{74-77} In\\)","text_display":" nonhemodynamic (e.g. fibrotic) mechanisms. \\({ }^{74-77} In\\)","confidence":0.6144203525036573,"confidence_rate":0.9924183249382998},{"cnt":[[120,851],[879,851],[879,896],[120,896]],"region":{"top_left_x":120,"top_left_y":850,"width":759,"height":46},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"afeee157e9024984b725abb7921ac453","type":"text","conversion_output":true,"text":"humans, circulating 1,25-dihydroxyvitamin D","text_display":" humans, circulating 1,25-dihydroxyvitamin D","confidence":1,"confidence_rate":1},{"cnt":[[120,894],[969,894],[969,939],[120,939]],"region":{"top_left_x":120,"top_left_y":893,"width":849,"height":46},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"948ce1d6d05d4639a0ee056209368c1a","type":"text","conversion_output":true,"text":"concentrations are inversely correlated with blood","text_display":" concentrations are inversely correlated with blood","confidence":1,"confidence_rate":1},{"cnt":[[120,932],[1068,932],[1068,984],[120,984]],"region":{"top_left_x":120,"top_left_y":932,"width":948,"height":52},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"054a1df83fa14728bfb6c3adb0b3b1cd","type":"text","conversion_output":true,"text":"pressure, \\({ }^{78-80}\\) and lower circulating 25 -hydroxyvitamin D","text_display":" pressure, \\({ }^{78-80}\\) and lower circulating 25 -hydroxyvitamin D","confidence":0.99853515625,"confidence_rate":0.9999807117954607},{"cnt":[[1123,328],[1974,328],[1974,960],[1123,960]],"region":{"top_left_x":1123,"top_left_y":328,"width":851,"height":632},"line":20,"column":0,"font_size":25,"is_printed":true,"is_handwritten":false,"id":"c8cf91caed214b67907ca1a8038bcf84","type":"column","conversion_output":false,"children_ids":["1d237ae855424c22829bc03540eb24a1","7e66d210e54047498d30f819611c08b1"],"text":"","text_display":""},{"cnt":[[1134,331],[1970,331],[1970,836],[1134,836]],"region":{"top_left_x":1134,"top_left_y":330,"width":837,"height":506},"line":21,"column":1,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"1d237ae855424c22829bc03540eb24a1","type":"diagram","conversion_output":true,"parent_id":"c8cf91caed214b67907ca1a8038bcf84","selected_labels":["7e66d210e54047498d30f819611c08b1"],"text":"","text_display":"\n\n\\begin{figure}\n\\includegraphics[alt={},max width=\\textwidth]{https://cdn.mathpix.com/cropped/7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-07.jpg?height=506&width=837&top_left_y=330&top_left_x=1134}\n\\captionsetup{labelformat=empty}\n\\caption{Figure 4. Mechanisms through which vitamin D may prevent diabetic kidney disease. RAAS = renin-angiotensin-aldosterone system.}\n\\end{figure}"},{"cnt":[[1126,838],[1957,838],[1957,956],[1126,956]],"region":{"top_left_x":1125,"top_left_y":837,"width":833,"height":120},"line":22,"column":1,"font_size":22,"is_printed":true,"is_handwritten":false,"id":"7e66d210e54047498d30f819611c08b1","type":"figure_label","conversion_output":false,"parent_id":"c8cf91caed214b67907ca1a8038bcf84","children_ids":["561028f062334ba1ae18d547e42579d9","1734daa655eb4f5da732eca603b17722","3e616edb469c444d9d6263b85f0d040d"],"text":"","text_display":""},{"cnt":[[1130,842],[1916,842],[1916,881],[1130,881]],"region":{"top_left_x":1130,"top_left_y":842,"width":787,"height":39},"line":23,"column":1,"font_size":22,"is_printed":true,"is_handwritten":false,"id":"561028f062334ba1ae18d547e42579d9","type":"text","conversion_output":false,"parent_id":"7e66d210e54047498d30f819611c08b1","text":"Figure 4. Mechanisms through which vitamin D may prevent","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[1130,879],[1955,879],[1955,917],[1130,917]],"region":{"top_left_x":1130,"top_left_y":878,"width":826,"height":40},"line":24,"column":1,"font_size":22,"is_printed":true,"is_handwritten":false,"id":"1734daa655eb4f5da732eca603b17722","type":"text","conversion_output":false,"parent_id":"7e66d210e54047498d30f819611c08b1","text":"diabetic kidney disease. RAAS = renin-angiotensin-aldosterone","text_display":"","confidence":0.98486328125,"confidence_rate":0.9997689290009381},{"cnt":[[1130,915],[1235,915],[1235,952],[1130,952]],"region":{"top_left_x":1130,"top_left_y":915,"width":106,"height":37},"line":25,"column":1,"font_size":22,"is_printed":true,"is_handwritten":false,"id":"3e616edb469c444d9d6263b85f0d040d","type":"text","conversion_output":false,"parent_id":"7e66d210e54047498d30f819611c08b1","text":"system.","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[120,975],[2002,975],[2002,1029],[120,1029]],"region":{"top_left_x":120,"top_left_y":975,"width":1883,"height":55},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7d2f49a38f6b440d89b2e80d4d07db11","type":"text","conversion_output":true,"text":"concentrations have been associated with increased risk of incident hypertension. \\({ }^{81}\\) Second, in vitro cell culture","text_display":"\nconcentrations have been associated with increased risk of incident hypertension. \\({ }^{81}\\) Second, in vitro cell culture","confidence":0.9990236759185791,"confidence_rate":0.9999924279279224},{"cnt":[[120,1025],[1944,1025],[1944,1072],[120,1072]],"region":{"top_left_x":120,"top_left_y":1024,"width":1825,"height":49},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"20321722a37b406fb1f4dd7382e8cd43","type":"text","conversion_output":true,"text":"studies and in vivo animal-experimental models demonstrate potent immunomodulatory functions of vitamin","text_display":" studies and in vivo animal-experimental models demonstrate potent immunomodulatory functions of vitamin","confidence":0.99951171875,"confidence_rate":0.9999954777833909},{"cnt":[[120,1066],[2000,1066],[2000,1119],[120,1119]],"region":{"top_left_x":120,"top_left_y":1065,"width":1881,"height":55},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1d4b2f5971c94b639ae0c2e25813aa49","type":"text","conversion_output":true,"text":"D. \\({ }^{82}\\) In antigen presenting cells (including monocytes), vitamin D therapy alters cytokine expression (decreased","text_display":" D. \\({ }^{82}\\) In antigen presenting cells (including monocytes), vitamin D therapy alters cytokine expression (decreased","confidence":0.9970703125,"confidence_rate":0.9999768980035891},{"cnt":[[120,1113],[1813,1113],[1813,1160],[120,1160]],"region":{"top_left_x":120,"top_left_y":1112,"width":1694,"height":49},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4d5aa57257194d758861631601d7e8a7","type":"text","conversion_output":true,"text":"IL-1, IL-6, IL-8, IL-12, and TNF- \\(\\alpha\\); increased IL-10) and regulates cell growth and cell-cell interaction","text_display":" IL-1, IL-6, IL-8, IL-12, and TNF- \\(\\alpha\\); increased IL-10) and regulates cell growth and cell-cell interaction","confidence":0.9658203125,"confidence_rate":0.9996949809665674},{"cnt":[[120,1156],[2000,1156],[2000,1205],[120,1205]],"region":{"top_left_x":120,"top_left_y":1155,"width":1881,"height":51},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3e5f45c2d06340bbbf078dfa09a001a0","type":"text","conversion_output":true,"text":"(decreased differentiation, maturation, MHC-II expression, costimulatory molecule expression, and interferon- \\(\\gamma\\);","text_display":" (decreased differentiation, maturation, MHC-II expression, costimulatory molecule expression, and interferon- \\(\\gamma\\);","confidence":0.9853649139404297,"confidence_rate":0.9998781625020308},{"cnt":[[120,1197],[1876,1197],[1876,1248],[120,1248]],"region":{"top_left_x":120,"top_left_y":1196,"width":1756,"height":53},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3f22002c25e44d8babc6a5cddceb77d1","type":"text","conversion_output":true,"text":"increased apoptosis). \\({ }^{83-86}\\) Net effects of vitamin D on immune function include inhibition of cell-mediated","text_display":" increased apoptosis). \\({ }^{83-86}\\) Net effects of vitamin D on immune function include inhibition of cell-mediated","confidence":1,"confidence_rate":1},{"cnt":[[120,1240],[1869,1240],[1869,1291],[120,1291]],"region":{"top_left_x":120,"top_left_y":1239,"width":1750,"height":53},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bc4b00de2d6641a7a65b2200cae4a5e6","type":"text","conversion_output":true,"text":"immunity, which contributes to the tubulointersitial fibrosis responsible for progression of DKD. \\({ }^{71,87,88}\\) In","text_display":" immunity, which contributes to the tubulointersitial fibrosis responsible for progression of DKD. \\({ }^{71,87,88}\\) In","confidence":0.6202985141972022,"confidence_rate":0.9961561610323375},{"cnt":[[120,1289],[1979,1289],[1979,1336],[120,1336]],"region":{"top_left_x":120,"top_left_y":1289,"width":1859,"height":48},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"37d6c5769a5149bab2495d0c416ff46d","type":"text","conversion_output":true,"text":"support of this hypothesis, circulating \\(25( OH )\\) D concentration is inversely correlated with renal inflammation in","text_display":" support of this hypothesis, circulating \\(25( OH )\\) D concentration is inversely correlated with renal inflammation in","confidence":0.515262657776475,"confidence_rate":0.9946668647278083},{"cnt":[[120,1328],[1893,1328],[1893,1381],[120,1381]],"region":{"top_left_x":120,"top_left_y":1327,"width":1773,"height":55},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"198503dc4ab94e708f1a4c2e164d76b7","type":"text","conversion_output":true,"text":"human kidney biopsies. \\({ }^{89}\\) Third, vitamin D is known to affect cell proliferation, differentiation, and survival","text_display":" human kidney biopsies. \\({ }^{89}\\) Third, vitamin D is known to affect cell proliferation, differentiation, and survival","confidence":1,"confidence_rate":1},{"cnt":[[120,1371],[1989,1371],[1989,1424],[120,1424]],"region":{"top_left_x":120,"top_left_y":1370,"width":1870,"height":55},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4d6396a0900149c28665269bcee95a1c","type":"text","conversion_output":true,"text":"through regulation of cell cycle progression and modulation of apoptosis. \\({ }^{90-94}\\) In animal models of kidney injury,","text_display":" through regulation of cell cycle progression and modulation of apoptosis. \\({ }^{90-94}\\) In animal models of kidney injury,","confidence":0.99951171875,"confidence_rate":0.9999962139567942},{"cnt":[[122,1422],[1826,1422],[1826,1467],[122,1467]],"region":{"top_left_x":122,"top_left_y":1422,"width":1705,"height":46},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b532ed153ecb4818bd3a2e927c86f1f0","type":"text","conversion_output":true,"text":"1,25-dihydroxyvitamin D has direct pro-survival effects on kidney podocytes, preventing damage and","text_display":" 1,25-dihydroxyvitamin D has direct pro-survival effects on kidney podocytes, preventing damage and","confidence":0.99951171875,"confidence_rate":0.9999952582588333},{"cnt":[[120,1461],[1837,1461],[1837,1510],[120,1510]],"region":{"top_left_x":120,"top_left_y":1460,"width":1717,"height":51},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"979f9e7ae984484382275368e2009a0b","type":"text","conversion_output":true,"text":"apoptosis. \\({ }^{95-100}\\) Podocytes form a critical component of the glomerular barrier to albumin filtration, and","text_display":" apoptosis. \\({ }^{95-100}\\) Podocytes form a critical component of the glomerular barrier to albumin filtration, and","confidence":1,"confidence_rate":1},{"cnt":[[120,1504],[1858,1504],[1858,1555],[120,1555]],"region":{"top_left_x":120,"top_left_y":1503,"width":1739,"height":53},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5d6bddd9da2149fa985016cae3273c85","type":"text","conversion_output":true,"text":"dysfunction and loss of podocytes is a seminal feature of proteinuric kidney diseases including DKD. \\({ }^{101}\\)","text_display":" dysfunction and loss of podocytes is a seminal feature of proteinuric kidney diseases including DKD. \\({ }^{101}\\)","confidence":1,"confidence_rate":1},{"cnt":[[129,1573],[1904,1573],[1904,1620],[129,1620]],"region":{"top_left_x":128,"top_left_y":1572,"width":1776,"height":48},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"28ddd44515fe45889b8e342dcb0c6675","type":"text","conversion_output":true,"text":"I.b.4. Vitamin D reduces albuminuria and glomerulosclerosis in animal-experimental models. In animal-","text_display":"\nI.b.4. Vitamin D reduces albuminuria and glomerulosclerosis in animal-experimental models. In animal","confidence":0.9546747207641602,"confidence_rate":0.9995625051339829},{"cnt":[[120,1616],[1790,1616],[1790,1663],[120,1663]],"region":{"top_left_x":120,"top_left_y":1615,"width":1670,"height":48},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"107bb514b1bf4c1fba643a9d001517b6","type":"text","conversion_output":true,"text":"experimental models, vitamin D deficiency promotes and 1,25-dihydroxyvitamin D therapy reduces","text_display":"experimental models, vitamin D deficiency promotes and 1,25-dihydroxyvitamin D therapy reduces","confidence":0.990234375,"confidence_rate":0.9999008774235902},{"cnt":[[120,1659],[1876,1659],[1876,1708],[120,1708]],"region":{"top_left_x":120,"top_left_y":1658,"width":1756,"height":51},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4ae01a038469423c8ffe287319c8b258","type":"text","conversion_output":true,"text":"albuminuria, glomerulosclerosis, and loss of GFR. \\({ }^{96,100,102}\\) These actions have been observed in animal","text_display":" albuminuria, glomerulosclerosis, and loss of GFR. \\({ }^{96,100,102}\\) These actions have been observed in animal","confidence":0.9517735778354108,"confidence_rate":0.9995812054232879},{"cnt":[[120,1706],[1897,1706],[1897,1753],[120,1753]],"region":{"top_left_x":120,"top_left_y":1705,"width":1778,"height":49},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c31a5fa78050413285b361a59dfe612d","type":"text","conversion_output":true,"text":"models of DKD as well as the nondiabetic \\(5 / 6\\) nephrectomy model. Effects are mediated, at least in part,","text_display":" models of DKD as well as the nondiabetic \\(5 / 6\\) nephrectomy model. Effects are mediated, at least in part,","confidence":0.87060546875,"confidence_rate":0.9987524331989882},{"cnt":[[120,1749],[1944,1749],[1944,1796],[120,1796]],"region":{"top_left_x":120,"top_left_y":1748,"width":1825,"height":49},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"835f44ea49bb4355981f034895febdc6","type":"text","conversion_output":true,"text":"through mechanisms described in Section B2c and Figure 4. One particularly provocative study suggested","text_display":" through mechanisms described in Section B2c and Figure 4. One particularly provocative study suggested","confidence":1,"confidence_rate":1},{"cnt":[[120,1792],[1996,1792],[1996,1841],[120,1841]],"region":{"top_left_x":120,"top_left_y":1791,"width":1876,"height":51},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e65b061d645049aabd629baa8faddd11","type":"text","conversion_output":true,"text":"that treatment with an angiotensin-II receptor blocker (losartan) and paricalcitol (an activated analogue of 1,25-","text_display":" that treatment with an angiotensin-II receptor blocker (losartan) and paricalcitol (an activated analogue of 1,25","confidence":0.98583984375,"confidence_rate":0.9998801637536546},{"cnt":[[120,1835],[1863,1835],[1863,1884],[120,1884]],"region":{"top_left_x":120,"top_left_y":1834,"width":1743,"height":51},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fa5b6a86e05c495f8a3e95fa2a93125c","type":"text","conversion_output":true,"text":"dihydroxyvitamin D) acted synergistically to completely abrogate the development of albuminuria in the","text_display":"dihydroxyvitamin D) acted synergistically to completely abrogate the development of albuminuria in the","confidence":0.94482421875,"confidence_rate":0.9994697071905155},{"cnt":[[120,1882],[930,1882],[930,1927],[120,1927]],"region":{"top_left_x":120,"top_left_y":1882,"width":811,"height":46},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7d565fe9255f42ea96b7ab34388f2135","type":"text","conversion_output":true,"text":"streptozotocin model of DKD (Figure 5), in part","text_display":" streptozotocin model of DKD (Figure 5), in part","confidence":1,"confidence_rate":1},{"cnt":[[120,1925],[960,1925],[960,1972],[120,1972]],"region":{"top_left_x":120,"top_left_y":1925,"width":841,"height":48},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c142778daf2945a8bc543a1bd1e51aa8","type":"text","conversion_output":true,"text":"because paricalcitol prevented the compensatory","text_display":" because paricalcitol prevented the compensatory","confidence":1,"confidence_rate":1},{"cnt":[[120,1968],[1033,1968],[1033,2013],[120,2013]],"region":{"top_left_x":120,"top_left_y":1967,"width":914,"height":47},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9e0ba184954b4f8c8bd0c3011a97d41d","type":"text","conversion_output":true,"text":"increase in renal renin production normally stimulated","text_display":" increase in renal renin production normally stimulated","confidence":1,"confidence_rate":1},{"cnt":[[120,2007],[1033,2007],[1033,2060],[120,2060]],"region":{"top_left_x":120,"top_left_y":2006,"width":914,"height":55},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5e795cb6e77e42de9437a1a97c0bf48d","type":"text","conversion_output":true,"text":"by RAAS blockade. \\({ }^{102}\\) These data raise the possibility","text_display":" by RAAS blockade. \\({ }^{102}\\) These data raise the possibility","confidence":1,"confidence_rate":1},{"cnt":[[120,2056],[1070,2056],[1070,2103],[120,2103]],"region":{"top_left_x":120,"top_left_y":2056,"width":950,"height":48},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"98d6689daa6a4eb59e790936d3dd3a06","type":"text","conversion_output":true,"text":"that vitamin D interventions may prove to be particularly","text_display":" that vitamin D interventions may prove to be particularly","confidence":1,"confidence_rate":1},{"cnt":[[120,2101],[913,2101],[913,2142],[120,2142]],"region":{"top_left_x":120,"top_left_y":2101,"width":794,"height":41},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2cdd7546257c4907a49dd1ff25db23a1","type":"text","conversion_output":true,"text":"valuable when added to current standard DKD","text_display":" valuable when added to current standard DKD","confidence":1,"confidence_rate":1},{"cnt":[[120,2144],[294,2144],[294,2191],[120,2191]],"region":{"top_left_x":120,"top_left_y":2144,"width":175,"height":48},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"845e36b13003415abc1664cb75f3fb45","type":"text","conversion_output":true,"text":"therapies.","text_display":" therapies.","confidence":1,"confidence_rate":1},{"cnt":[[120,2209],[1033,2209],[1033,2258],[120,2258]],"region":{"top_left_x":120,"top_left_y":2208,"width":914,"height":51},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6f2c4cf659704aea958890a206fc950c","type":"text","conversion_output":true,"text":"I.b.5. Epidemiologic studies of vitamin D and kidney","text_display":"\nI.b.5. Epidemiologic studies of vitamin D and kidney","confidence":0.8378410339355469,"confidence_rate":0.9969008317801132},{"cnt":[[120,2252],[1046,2252],[1046,2301],[120,2301]],"region":{"top_left_x":120,"top_left_y":2251,"width":927,"height":50},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"aafb85c0578a4431a27b2681f1cf0b3c","type":"text","conversion_output":true,"text":"disease. Human studies examining the relationship of","text_display":" disease. Human studies examining the relationship of","confidence":1,"confidence_rate":1},{"cnt":[[120,2299],[1053,2299],[1053,2344],[120,2344]],"region":{"top_left_x":120,"top_left_y":2298,"width":933,"height":46},"line":55,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4e79eb3165d14e1c804017834770cf32","type":"text","conversion_output":true,"text":"vitamin D with clinical manifestations of kidney disease","text_display":" vitamin D with clinical manifestations of kidney disease","confidence":1,"confidence_rate":1},{"cnt":[[120,2342],[1008,2342],[1008,2387],[120,2387]],"region":{"top_left_x":120,"top_left_y":2341,"width":888,"height":46},"line":56,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5c4d432575af4b279db12d86f3979109","type":"text","conversion_output":true,"text":"suggest that effects observed in animal models may","text_display":" suggest that effects observed in animal models may","confidence":1,"confidence_rate":1},{"cnt":[[120,2385],[1072,2385],[1072,2432],[120,2432]],"region":{"top_left_x":120,"top_left_y":2384,"width":953,"height":49},"line":57,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"41c61008e8a141778990e5fb672cb0f8","type":"text","conversion_output":true,"text":"have clinical relevance. Comparing Italian subjects with","text_display":" have clinical relevance. Comparing Italian subjects with","confidence":1,"confidence_rate":1},{"cnt":[[120,2428],[982,2428],[982,2477],[120,2477]],"region":{"top_left_x":120,"top_left_y":2427,"width":862,"height":51},"line":58,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"060bb5163b2547d5b0c9d109277fb108","type":"text","conversion_output":true,"text":"type 1 diabetes and persistent microalbuminuria to","text_display":" type 1 diabetes and persistent microalbuminuria to","confidence":1,"confidence_rate":1},{"cnt":[[120,2471],[1033,2471],[1033,2516],[120,2516]],"region":{"top_left_x":120,"top_left_y":2470,"width":914,"height":46},"line":59,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"755dd6c580aa41368efc55d9561279e2","type":"text","conversion_output":true,"text":"those with normal albumin excretion rate, lower levels","text_display":" those with normal albumin excretion rate, lower levels","confidence":1,"confidence_rate":1},{"cnt":[[120,2514],[1003,2514],[1003,2563],[120,2563]],"region":{"top_left_x":120,"top_left_y":2513,"width":884,"height":51},"line":60,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"17e600ae87104d2a8b45465f38dd30fb","type":"text","conversion_output":true,"text":"of both \\(25( OH ) D (27 \\pm 5\\) vs \\(36 \\pm 5 ng / mL , p <0.01)\\) and","text_display":" of both \\(25( OH ) D (27 \\pm 5\\) vs \\(36 \\pm 5 ng / mL , p <0.01)\\) and","confidence":0.5253958611976949,"confidence_rate":0.9909761268338912},{"cnt":[[1102,1912],[1999,1912],[1999,2653],[1102,2653]],"region":{"top_left_x":1102,"top_left_y":1912,"width":897,"height":741},"line":61,"column":0,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"27db9fa5e25845c285ff77a9fee078f8","type":"column","conversion_output":false,"children_ids":["93995b5d2b764de2aefc10a533babfcb","a33378bcb5464ce5ad640fd3c0484706"],"text":"","text_display":""},{"cnt":[[1104,1914],[1996,1914],[1996,2469],[1104,2469]],"region":{"top_left_x":1104,"top_left_y":1914,"width":892,"height":555},"line":62,"column":2,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"93995b5d2b764de2aefc10a533babfcb","type":"chart","conversion_output":true,"parent_id":"27db9fa5e25845c285ff77a9fee078f8","selected_labels":["a33378bcb5464ce5ad640fd3c0484706"],"text":"","text_display":"\n\n\\begin{figure}\n\\includegraphics[alt={},max width=\\textwidth]{https://cdn.mathpix.com/cropped/7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-07.jpg?height=555&width=892&top_left_y=1914&top_left_x=1104}\n\\captionsetup{labelformat=empty}\n\\caption{Figure 5. Losartan and paricalcitol each reduced the development of albuminuria in the streptozotocin model of DKD, while the combination (L+P) completely prevented albuminuria. From Zhang et al (ref 102).}\n\\end{figure}"},{"cnt":[[1117,2479],[1953,2479],[1953,2649],[1117,2649]],"region":{"top_left_x":1117,"top_left_y":2479,"width":836,"height":171},"line":63,"column":2,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"a33378bcb5464ce5ad640fd3c0484706","type":"figure_label","conversion_output":false,"parent_id":"27db9fa5e25845c285ff77a9fee078f8","children_ids":["52f7ff47226d4f67819f597b48769025","854a54c9a5874a4da1a29cf9b862050b","c2f49640a222403996d5ff6e7a9f528f","341b4ef5135a42fe80832e9fd724be7c"],"text":"","text_display":""},{"cnt":[[1121,2484],[1899,2484],[1899,2524],[1121,2524]],"region":{"top_left_x":1121,"top_left_y":2483,"width":779,"height":42},"line":64,"column":2,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"52f7ff47226d4f67819f597b48769025","type":"text","conversion_output":false,"parent_id":"a33378bcb5464ce5ad640fd3c0484706","text":"Figure 5. Losartan and paricalcitol each reduced the","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[1121,2522],[1949,2522],[1949,2563],[1121,2563]],"region":{"top_left_x":1121,"top_left_y":2522,"width":828,"height":42},"line":65,"column":2,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"854a54c9a5874a4da1a29cf9b862050b","type":"text","conversion_output":false,"parent_id":"a33378bcb5464ce5ad640fd3c0484706","text":"development of albuminuria in the streptozotocin model","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[1121,2561],[1841,2561],[1841,2606],[1121,2606]],"region":{"top_left_x":1121,"top_left_y":2560,"width":721,"height":47},"line":66,"column":2,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"c2f49640a222403996d5ff6e7a9f528f","type":"text","conversion_output":false,"parent_id":"a33378bcb5464ce5ad640fd3c0484706","text":"of DKD, while the combination (L+P) completely","text_display":"","confidence":0.9834520816802979,"confidence_rate":0.9996728698995744},{"cnt":[[1121,2602],[1876,2602],[1876,2645],[1121,2645]],"region":{"top_left_x":1121,"top_left_y":2601,"width":755,"height":44},"line":67,"column":2,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"341b4ef5135a42fe80832e9fd724be7c","type":"text","conversion_output":false,"parent_id":"a33378bcb5464ce5ad640fd3c0484706","text":"prevented albuminuria. From Zhang et al (ref 102).","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-08","page":8,"lines":[{"cnt":[[122,120],[1974,120],[1974,174],[122,174]],"region":{"top_left_x":122,"top_left_y":120,"width":1853,"height":55},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8037c3125e6d419c82f0880d7f3f54be","type":"text","conversion_output":true,"text":"1,25-dihydroxy vitamin D ( \\(25 \\pm 6\\) vs \\(39 \\pm 9 pg / mL , p <0.01\\) ) were reported. \\({ }^{103}\\) Among 100 Japanese persons with","text_display":"\n\n1,25-dihydroxy vitamin D ( \\(25 \\pm 6\\) vs \\(39 \\pm 9 pg / mL , p <0.01\\) ) were reported. \\({ }^{103}\\) Among 100 Japanese persons with","confidence":0.6527995804579909,"confidence_rate":0.9968918103954529},{"cnt":[[120,168],[1901,168],[1901,217],[120,217]],"region":{"top_left_x":120,"top_left_y":167,"width":1782,"height":50},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"47d90e411ed14771bf0890326be6c485","type":"text","conversion_output":true,"text":"type 2 diabetes, 1,25 -dihydroxyvitamin D concentration was inversely correlated with urine ACR ( \\(r=-0.21\\),","text_display":" type 2 diabetes, 1,25 -dihydroxyvitamin D concentration was inversely correlated with urine ACR ( \\(r=-0.21\\),","confidence":0.7917698247265434,"confidence_rate":0.9980722361088568},{"cnt":[[120,211],[1955,211],[1955,260],[120,260]],"region":{"top_left_x":120,"top_left_y":210,"width":1836,"height":50},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f2901145e9fc4b86a25b95335a9ddb50","type":"text","conversion_output":true,"text":"\\(p <0.05\\) ). \\({ }^{104}\\) We have demonstrated an inverse association of serum \\(25( OH )\\) D concentration with albuminuria","text_display":" \\(p <0.05\\) ). \\({ }^{104}\\) We have demonstrated an inverse association of serum \\(25( OH )\\) D concentration with albuminuria","confidence":0.8969537448137999,"confidence_rate":0.9991573243608383},{"cnt":[[120,251],[1966,251],[1966,305],[120,305]],"region":{"top_left_x":120,"top_left_y":251,"width":1846,"height":55},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9e53a0d7641048f19b1ea7970bed3571","type":"text","conversion_output":true,"text":"prevalence in the United States population, as represented by NHANES III (preliminary data Section C2a). \\({ }^{105}\\)","text_display":" prevalence in the United States population, as represented by NHANES III (preliminary data Section C2a). \\({ }^{105}\\)","confidence":0.99951171875,"confidence_rate":0.9999958958025558},{"cnt":[[120,296],[1833,296],[1833,350],[120,350]],"region":{"top_left_x":120,"top_left_y":296,"width":1713,"height":55},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"544a08a17dcc41fabf4acd0d24c9e42f","type":"text","conversion_output":true,"text":"Among 168 persons with moderate-severe CKD (mean estimated GFR \\(34 mL / min / 1.73 m^{2}\\) ), 25(OH)D","text_display":" Among 168 persons with moderate-severe CKD (mean estimated GFR \\(34 mL / min / 1.73 m^{2}\\) ), 25(OH)D","confidence":1,"confidence_rate":1},{"cnt":[[120,339],[1137,339],[1137,393],[120,393]],"region":{"top_left_x":120,"top_left_y":339,"width":1017,"height":55},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a2ad70a776b645368f087f68b77908db","type":"text","conversion_output":true,"text":"concentration was directly correlated with estimated GFR. \\({ }^{28}\\)","text_display":" concentration was directly correlated with estimated GFR. \\({ }^{28}\\)","confidence":1,"confidence_rate":1},{"cnt":[[120,408],[1931,408],[1931,458],[120,458]],"region":{"top_left_x":120,"top_left_y":408,"width":1812,"height":50},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e89e44ba79674d99842a76676e96aca5","type":"text","conversion_output":true,"text":"I.b.6. Clinical trials of vitamin D agents in kidney disease. Two small studies reported that paricalcitol (an","text_display":"\nI.b.6. Clinical trials of vitamin D agents in kidney disease. Two small studies reported that paricalcitol (an","confidence":0.4120796984061599,"confidence_rate":0.9923206078820369},{"cnt":[[120,453],[1957,453],[1957,503],[120,503]],"region":{"top_left_x":120,"top_left_y":453,"width":1838,"height":50},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bb356476b93f492c8a74882ac1e27a7f","type":"text","conversion_output":true,"text":"activated analogue of 1,25-dihydroxyvitamin D) significantly reduced albuminuria in stage \\(3-4\\) chronic kidney","text_display":" activated analogue of 1,25-dihydroxyvitamin D) significantly reduced albuminuria in stage \\(3-4\\) chronic kidney","confidence":0.9922072710517114,"confidence_rate":0.9999325604557838},{"cnt":[[120,494],[1867,494],[1867,546],[120,546]],"region":{"top_left_x":120,"top_left_y":494,"width":1747,"height":52},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"26a8a32671e145e4ac00fa6b6c1286de","type":"text","conversion_output":true,"text":"disease (estimated GFR \\(15-59 mL / min / 1.73 m^{2}\\) ). In the first study, among 118 participants with dipstick","text_display":" disease (estimated GFR \\(15-59 mL / min / 1.73 m^{2}\\) ). In the first study, among 118 participants with dipstick","confidence":0.9975595474243164,"confidence_rate":0.999980910843654},{"cnt":[[120,541],[1867,541],[1867,591],[120,591]],"region":{"top_left_x":120,"top_left_y":541,"width":1747,"height":50},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ba8094d1b07d4d84acff882a28640f46","type":"text","conversion_output":true,"text":"positive albuminuria at baseline, urine dipstick results improved among \\(51 \\%\\) of participants assigned to","text_display":" positive albuminuria at baseline, urine dipstick results improved among \\(51 \\%\\) of participants assigned to","confidence":0.97265625,"confidence_rate":0.9997502604872686},{"cnt":[[120,580],[1893,580],[1893,634],[120,634]],"region":{"top_left_x":120,"top_left_y":580,"width":1773,"height":54},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9e1bf307286f4b91a7816046a7ea1602","type":"text","conversion_output":true,"text":"paricalcitol versus \\(25 \\%\\) of participants assigned to placebo after 24 weeks of therapy ( \\(p =0.004\\) ). \\({ }^{106}\\) In the","text_display":" paricalcitol versus \\(25 \\%\\) of participants assigned to placebo after 24 weeks of therapy ( \\(p =0.004\\) ). \\({ }^{106}\\) In the","confidence":0.4612054905125058,"confidence_rate":0.9943256340106436},{"cnt":[[120,629],[1850,629],[1850,677],[120,677]],"region":{"top_left_x":120,"top_left_y":629,"width":1730,"height":48},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"73d53114ca044de5804e20ce8a9f9343","type":"text","conversion_output":true,"text":"second study, 24 -hour urine albumin excretion rate increase by \\(35 \\%\\) over 1 month among participants","text_display":" second study, 24 -hour urine albumin excretion rate increase by \\(35 \\%\\) over 1 month among participants","confidence":0.98828125,"confidence_rate":0.9998956872484575},{"cnt":[[120,675],[1983,675],[1983,724],[120,724]],"region":{"top_left_x":120,"top_left_y":674,"width":1864,"height":51},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"779cdbc76d9a4a9f9b53fc9d9abd3008","type":"text","conversion_output":true,"text":"assigned to placebo and decreased by \\(48 \\%\\) and \\(46 \\%\\) among participants assigned to paricalcitol 1 mcg and 2","text_display":" assigned to placebo and decreased by \\(48 \\%\\) and \\(46 \\%\\) among participants assigned to paricalcitol 1 mcg and 2","confidence":0.8966397698968649,"confidence_rate":0.9990836042489522},{"cnt":[[120,713],[1951,713],[1951,767],[120,767]],"region":{"top_left_x":120,"top_left_y":713,"width":1831,"height":54},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"71e77526f4e745eca54cad932968abed","type":"text","conversion_output":true,"text":"mcg daily, respectively ( 8 participants per group, \\(p <0.001\\) ). \\({ }^{107}\\) An industry-sponsored clinical trial is currently","text_display":" mcg daily, respectively ( 8 participants per group, \\(p <0.001\\) ). \\({ }^{107}\\) An industry-sponsored clinical trial is currently","confidence":0.9207808911270376,"confidence_rate":0.9994106510610761},{"cnt":[[120,761],[2004,761],[2004,810],[120,810]],"region":{"top_left_x":120,"top_left_y":760,"width":1885,"height":50},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c4a4277de27f4cbfad65dd2ef9e64e22","type":"text","conversion_output":true,"text":"recruited to follow up on these data by testing whether paricalcitol reduces albuminuria among participants with","text_display":" recruited to follow up on these data by testing whether paricalcitol reduces albuminuria among participants with","confidence":1,"confidence_rate":1},{"cnt":[[120,799],[1929,799],[1929,853],[120,853]],"region":{"top_left_x":120,"top_left_y":799,"width":1810,"height":54},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"869e7dad46254811821d594b56ff3c9e","type":"text","conversion_output":true,"text":"advanced DKD (diabetes with urine ACR \\(100-3000 mg / g\\) and estimated GFR \\(15-90 mL / min / 1.73 m^{2}\\) ) over 1","text_display":" advanced DKD (diabetes with urine ACR \\(100-3000 mg / g\\) and estimated GFR \\(15-90 mL / min / 1.73 m^{2}\\) ) over 1","confidence":1,"confidence_rate":1},{"cnt":[[120,844],[1962,844],[1962,898],[120,898]],"region":{"top_left_x":120,"top_left_y":844,"width":1842,"height":55},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2a4dfed1e9bf4e65bc43bd2ed47b6b7a","type":"text","conversion_output":true,"text":"year. \\({ }^{108}\\) While results of this trial may have important implications for the studies proposed in this application,","text_display":" year. \\({ }^{108}\\) While results of this trial may have important implications for the studies proposed in this application,","confidence":1,"confidence_rate":1},{"cnt":[[120,894],[1876,894],[1876,941],[120,941]],"region":{"top_left_x":120,"top_left_y":893,"width":1756,"height":49},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"45bc2065d5154926897bd46fcf699b47","type":"text","conversion_output":true,"text":"they will not determine whether cholecalciferol prevents the development or progression of DKD among","text_display":" they will not determine whether cholecalciferol prevents the development or progression of DKD among","confidence":0.99755859375,"confidence_rate":0.9999767203534344},{"cnt":[[120,937],[1919,937],[1919,986],[120,986]],"region":{"top_left_x":120,"top_left_y":936,"width":1799,"height":51},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4bfbfa43f29547ce9878689c1b82ec76","type":"text","conversion_output":true,"text":"persons with early or inapparent DKD, for whom renal activation of \\(25( OH ) D\\) to 1,25-dihydroxyvitamin D is","text_display":" persons with early or inapparent DKD, for whom renal activation of \\(25( OH ) D\\) to 1,25-dihydroxyvitamin D is","confidence":0.9402231416880082,"confidence_rate":0.9994777800728346},{"cnt":[[120,980],[1989,980],[1989,1029],[120,1029]],"region":{"top_left_x":120,"top_left_y":979,"width":1870,"height":51},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6da36effa0c4449d9e289648e70cdc1d","type":"text","conversion_output":true,"text":"largely preserved (thus abrogating the need for an activated form of vitamin D) and for whom activated vitamin","text_display":" largely preserved (thus abrogating the need for an activated form of vitamin D) and for whom activated vitamin","confidence":0.9380183219909668,"confidence_rate":0.9994437565249049},{"cnt":[[120,1023],[1919,1023],[1919,1072],[120,1072]],"region":{"top_left_x":120,"top_left_y":1022,"width":1799,"height":51},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"26a0f101eb964dc5ac1972be9e15e9a8","type":"text","conversion_output":true,"text":"D analogues may be associated with unnecessary risk and cost. Currently, there are no published clinical","text_display":" D analogues may be associated with unnecessary risk and cost. Currently, there are no published clinical","confidence":1,"confidence_rate":1},{"cnt":[[120,1070],[1869,1070],[1869,1119],[120,1119]],"region":{"top_left_x":120,"top_left_y":1069,"width":1750,"height":51},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ab25d7d1896241eda4efdac78114fdc2","type":"text","conversion_output":true,"text":"trials data examining effects of cholecalciferol or ergocalciferol treatment on the presence or severity of","text_display":" trials data examining effects of cholecalciferol or ergocalciferol treatment on the presence or severity of","confidence":1,"confidence_rate":1},{"cnt":[[120,1113],[827,1113],[827,1162],[120,1162]],"region":{"top_left_x":120,"top_left_y":1112,"width":708,"height":51},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"269d447a166149e99e2fbff51d1efc78","type":"text","conversion_output":true,"text":"diabetic or other forms of kidney disease.","text_display":" diabetic or other forms of kidney disease.","confidence":1,"confidence_rate":1},{"cnt":[[120,1177],[1781,1177],[1781,1227],[120,1227]],"region":{"top_left_x":120,"top_left_y":1177,"width":1662,"height":50},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7bb7413bb73d402389f32da4c83e178d","type":"text","conversion_output":true,"text":"I.b.7. Race/ethnicity, vitamin D, and DKD. 25-hydroxyvitamin D concentration varies strongly by","text_display":"\nI.b.7. Race/ethnicity, vitamin D, and DKD. 25-hydroxyvitamin D concentration varies strongly by","confidence":0.8600263933817536,"confidence_rate":0.9984932143408711},{"cnt":[[120,1220],[1987,1220],[1987,1270],[120,1270]],"region":{"top_left_x":120,"top_left_y":1220,"width":1868,"height":50},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"35579e1ab23c409088d62f3441c57874","type":"text","conversion_output":true,"text":"race/ethnicity due to differences in skin pigmentation and cutaneous cholecalciferol synthesis, being highest in","text_display":" race/ethnicity due to differences in skin pigmentation and cutaneous cholecalciferol synthesis, being highest in","confidence":1,"confidence_rate":1},{"cnt":[[120,1265],[1876,1265],[1876,1313],[120,1313]],"region":{"top_left_x":120,"top_left_y":1265,"width":1756,"height":48},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5430ddaeee944db5b038b3070815c847","type":"text","conversion_output":true,"text":"Caucasian populations, intermediate in Hispanic and Asian populations, and lowest in African American","text_display":" Caucasian populations, intermediate in Hispanic and Asian populations, and lowest in African American","confidence":1,"confidence_rate":1},{"cnt":[[120,1306],[1972,1306],[1972,1360],[120,1360]],"region":{"top_left_x":120,"top_left_y":1306,"width":1853,"height":54},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"26f43c9d62f147f89eea02968ba3d4f7","type":"text","conversion_output":true,"text":"populations. \\({ }^{68,105,109}\\) The prevalence and incidence of chronic kidney disease in general and DKD specifically","text_display":" populations. \\({ }^{68,105,109}\\) The prevalence and incidence of chronic kidney disease in general and DKD specifically","confidence":0.9985356330871582,"confidence_rate":0.9999882765475527},{"cnt":[[120,1349],[1835,1349],[1835,1401],[120,1401]],"region":{"top_left_x":120,"top_left_y":1349,"width":1715,"height":52},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3ea18af0bfe742c9ab44bc6f13c331f6","type":"text","conversion_output":true,"text":"also vary strongly by race/ethnicity, with higher rates among minority populations. \\({ }^{3,110-113}\\) Given these","text_display":" also vary strongly by race/ethnicity, with higher rates among minority populations. \\({ }^{3,110-113}\\) Given these","confidence":1,"confidence_rate":1},{"cnt":[[120,1396],[1927,1396],[1927,1446],[120,1446]],"region":{"top_left_x":120,"top_left_y":1396,"width":1808,"height":50},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"44526b2b7ab1402993ccbcc7d387eedb","type":"text","conversion_output":true,"text":"observations, and the biologic hypothesis that vitamin D helps prevent DKD, it is possible to speculate that","text_display":" observations, and the biologic hypothesis that vitamin D helps prevent DKD, it is possible to speculate that","confidence":0.7177734375,"confidence_rate":0.9970697766740673},{"cnt":[[120,1439],[1901,1439],[1901,1489],[120,1489]],"region":{"top_left_x":120,"top_left_y":1439,"width":1782,"height":50},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e010e870d5bf432382e571486bd7483b","type":"text","conversion_output":true,"text":"vitamin D deficiency mediates, in part, the increased prevalence and incidence of DKD in non-Caucasian","text_display":" vitamin D deficiency mediates, in part, the increased prevalence and incidence of DKD in non-Caucasian","confidence":0.99951171875,"confidence_rate":0.9999954355197808},{"cnt":[[120,1487],[1631,1487],[1631,1536],[120,1536]],"region":{"top_left_x":120,"top_left_y":1486,"width":1511,"height":51},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"22b80450fcb14ea5acf22e7908ded3dc","type":"text","conversion_output":true,"text":"populations. If so, vitamin D supplementation may reduce this racial and ethnic disparity.","text_display":" populations. If so, vitamin D supplementation may reduce this racial and ethnic disparity.","confidence":1,"confidence_rate":1},{"cnt":[[112,1543],[1998,1543],[1998,1607],[112,1607]],"region":{"top_left_x":111,"top_left_y":1542,"width":1888,"height":66},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"926db5303a8246969a33ecf85eef6b3a","type":"section_header","conversion_output":false,"children_ids":["b3acd1ce1051459aa5cdc941b52855cf"],"text":"","text_display":""},{"cnt":[[120,1549],[1992,1549],[1992,1601],[120,1601]],"region":{"top_left_x":120,"top_left_y":1549,"width":1872,"height":52},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b3acd1ce1051459aa5cdc941b52855cf","type":"text","conversion_output":true,"parent_id":"926db5303a8246969a33ecf85eef6b3a","text":"I.c. Omega-3 fatty acids are a promising therapeutic intervention for DKD prevention and treatment.","text_display":"\n\n\\section*{I.c. Omega-3 fatty acids are a promising therapeutic intervention for DKD prevention and treatment.}","confidence":0.580413103569299,"confidence_rate":0.9947827422068619},{"cnt":[[120,1611],[1931,1611],[1931,1663],[120,1663]],"region":{"top_left_x":120,"top_left_y":1611,"width":1812,"height":52},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"da963d09aa7f4880a349bcee13803689","type":"text","conversion_output":true,"text":"I.c.1. Omega-3 fatty acids ( \\(\\omega\\)-3 FA). Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are","text_display":"\nI.c.1. Omega-3 fatty acids ( \\(\\omega\\)-3 FA). Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are","confidence":0.4749226135626354,"confidence_rate":0.9931920558524111},{"cnt":[[120,1659],[1938,1659],[1938,1708],[120,1708]],"region":{"top_left_x":120,"top_left_y":1658,"width":1818,"height":51},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b07f270ecc804827930c116b9adef7c9","type":"text","conversion_output":true,"text":"omega-3 long chain polyunsaturated fatty acids which are found mainly in fatty fish. Diets rich in \\(\\omega-3\\) FA or","text_display":" omega-3 long chain polyunsaturated fatty acids which are found mainly in fatty fish. Diets rich in \\(\\omega-3\\) FA or","confidence":0.8213013182102031,"confidence_rate":0.9983043252904523},{"cnt":[[120,1704],[1955,1704],[1955,1751],[120,1751]],"region":{"top_left_x":120,"top_left_y":1703,"width":1836,"height":48},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"745c204ca12b4a70874b825f223ae00e","type":"text","conversion_output":true,"text":"supplemented with \\(\\omega-3\\) FA have been associated with diverse health benefits, including prevention of type 2","text_display":" supplemented with \\(\\omega-3\\) FA have been associated with diverse health benefits, including prevention of type 2","confidence":0.7337425276637077,"confidence_rate":0.997263952547898},{"cnt":[[120,1794],[120,1739],[2000,1741],[2000,1796]],"region":{"top_left_x":120,"top_left_y":1738,"width":1881,"height":59},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"49edc126c5374bacba64e59ff291b3fc","type":"text","conversion_output":true,"text":"diabetes, CVD, dyslipidemia, and thrombosis. \\({ }^{114-116}\\) Recently, it was reported that EPA 1.8 grams daily reduced","text_display":" diabetes, CVD, dyslipidemia, and thrombosis. \\({ }^{114-116}\\) Recently, it was reported that EPA 1.8 grams daily reduced","confidence":1,"confidence_rate":1},{"cnt":[[120,1790],[1210,1790],[1210,1837],[120,1837]],"region":{"top_left_x":120,"top_left_y":1789,"width":1090,"height":48},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"635efb816744477792989dbd511e7590","type":"text","conversion_output":true,"text":"the incidence of major CVD events by \\(19 \\%\\) among persons with","text_display":" the incidence of major CVD events by \\(19 \\%\\) among persons with","confidence":0.9990234375,"confidence_rate":0.9999854174250159},{"cnt":[[120,1835],[1089,1835],[1089,1880],[120,1880]],"region":{"top_left_x":120,"top_left_y":1834,"width":970,"height":46},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"64713992806849afb003051cee9b4fdc","type":"text","conversion_output":true,"text":"elevated LDL cholesterol, compared with placebo (JELIS","text_display":" elevated LDL cholesterol, compared with placebo (JELIS","confidence":1,"confidence_rate":1},{"cnt":[[120,1873],[256,1873],[256,1927],[120,1927]],"region":{"top_left_x":120,"top_left_y":1873,"width":136,"height":55},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5da861f6c5dd42fc8b4a57d51057db64","type":"text","conversion_output":true,"text":"trial). \\({ }^{117}\\)","text_display":" trial). \\({ }^{117}\\)","confidence":1,"confidence_rate":1},{"cnt":[[120,1942],[1210,1942],[1210,1989],[120,1989]],"region":{"top_left_x":120,"top_left_y":1942,"width":1090,"height":48},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fea364518e1347cc90f094ea3c79cafd","type":"text","conversion_output":true,"text":"I.c.2. Potential reno-protective actions of w-3 FA. Intervention","text_display":"\nI.c.2. Potential reno-protective actions of w-3 FA. Intervention","confidence":0.483269402757287,"confidence_rate":0.9895164839264743},{"cnt":[[120,1989],[1102,1989],[1102,2035],[120,2035]],"region":{"top_left_x":120,"top_left_y":1989,"width":983,"height":46},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9f8ac7a9df4540abb986728f016dfef2","type":"text","conversion_output":true,"text":"studies in humans suggest that \\(\\omega-3\\) FA have a number of","text_display":" studies in humans suggest that \\(\\omega-3\\) FA have a number of","confidence":0.7619022993603721,"confidence_rate":0.9956235250007485},{"cnt":[[120,2032],[1128,2032],[1128,2078],[120,2078]],"region":{"top_left_x":120,"top_left_y":2032,"width":1008,"height":46},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"462f5e71ddcf4169b073a6d5f9984341","type":"text","conversion_output":true,"text":"actions that may directly help prevent the development and","text_display":" actions that may directly help prevent the development and","confidence":1,"confidence_rate":1},{"cnt":[[120,2075],[1167,2075],[1167,2123],[120,2123]],"region":{"top_left_x":120,"top_left_y":2075,"width":1047,"height":48},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"10428e64c6fd4b4bae88387a135f743e","type":"text","conversion_output":true,"text":"progression of kidney disease. These include suppression of","text_display":" progression of kidney disease. These include suppression of","confidence":1,"confidence_rate":1},{"cnt":[[120,2118],[1106,2118],[1106,2163],[120,2163]],"region":{"top_left_x":120,"top_left_y":2118,"width":987,"height":46},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f67c265c233a4763b5cbd8886833e9a7","type":"text","conversion_output":true,"text":"endothelial activation, reduction of renal inflammation and","text_display":" endothelial activation, reduction of renal inflammation and","confidence":1,"confidence_rate":1},{"cnt":[[120,2161],[1171,2161],[1171,2211],[120,2211]],"region":{"top_left_x":120,"top_left_y":2161,"width":1051,"height":50},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"96ca4b315e08410ca12e06cf85479bb1","type":"text","conversion_output":true,"text":"oxidative stress, and modest blood pressure lowering (Figure","text_display":" oxidative stress, and modest blood pressure lowering (Figure","confidence":1,"confidence_rate":1},{"cnt":[[120,2209],[1210,2209],[1210,2254],[120,2254]],"region":{"top_left_x":120,"top_left_y":2208,"width":1090,"height":46},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cfe4fd72359a4621a0ef45caec968eea","type":"text","conversion_output":true,"text":"6). First, at least 7 human intervention studies suggest that \\(\\omega-3\\)","text_display":" 6). First, at least 7 human intervention studies suggest that \\(\\omega-3\\)","confidence":0.9960954189300537,"confidence_rate":0.9999456650338691},{"cnt":[[120,2252],[1210,2252],[1210,2297],[120,2297]],"region":{"top_left_x":120,"top_left_y":2251,"width":1090,"height":46},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5f0fd1f9f6984363826f463e907223d4","type":"text","conversion_output":true,"text":"FA improve vasodilation and/or decrease markers of endothelial","text_display":" FA improve vasodilation and/or decrease markers of endothelial","confidence":1,"confidence_rate":1},{"cnt":[[120,2290],[1158,2290],[1158,2342],[120,2342]],"region":{"top_left_x":120,"top_left_y":2290,"width":1039,"height":52},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8f1393fc0e4640c5ad0ed68d08ebae67","type":"text","conversion_output":true,"text":"cell activation. \\({ }^{114}\\) For example, in a cross-over trial among 23","text_display":" cell activation. \\({ }^{114}\\) For example, in a cross-over trial among 23","confidence":0.966796875,"confidence_rate":0.9995671851981457},{"cnt":[[120,2338],[1038,2338],[1038,2387],[120,2387]],"region":{"top_left_x":120,"top_left_y":2337,"width":918,"height":50},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5a2b5b768cb04dc58ee1ce470fea1ccd","type":"text","conversion_output":true,"text":"participants with type 2 diabetes, six weeks of \\(\\omega-3\\) FA","text_display":" participants with type 2 diabetes, six weeks of \\(\\omega-3\\) FA","confidence":0.9737377166748047,"confidence_rate":0.9995906484790308},{"cnt":[[120,2385],[1089,2385],[1089,2430],[120,2430]],"region":{"top_left_x":120,"top_left_y":2384,"width":970,"height":46},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ad012d530de948e696ef9e1b675e374a","type":"text","conversion_output":true,"text":"administration improved forearm blood flow responses to","text_display":" administration improved forearm blood flow responses to","confidence":1,"confidence_rate":1},{"cnt":[[120,2428],[1132,2428],[1132,2473],[120,2473]],"region":{"top_left_x":120,"top_left_y":2427,"width":1013,"height":46},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cc76d453bf35446aab4b3c63a5c35329","type":"text","conversion_output":true,"text":"acetylcholine, when compared to the vasodilator responses","text_display":" acetylcholine, when compared to the vasodilator responses","confidence":1,"confidence_rate":1},{"cnt":[[1244,1822],[2004,1822],[2004,2446],[1244,2446]],"region":{"top_left_x":1244,"top_left_y":1822,"width":760,"height":624},"line":53,"column":0,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"938fea71b556476385f52335d7efe0e5","type":"column","conversion_output":false,"children_ids":["691b1ca475d84135a066b985a7137c68","037c984326584defa10b211cc9a3cc09"],"text":"","text_display":""},{"cnt":[[1246,1824],[2000,1824],[2000,2348],[1246,2348]],"region":{"top_left_x":1246,"top_left_y":1824,"width":755,"height":525},"line":54,"column":1,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"691b1ca475d84135a066b985a7137c68","type":"diagram","conversion_output":true,"parent_id":"938fea71b556476385f52335d7efe0e5","selected_labels":["037c984326584defa10b211cc9a3cc09"],"text":"","text_display":"\n\n\\begin{figure}\n\\includegraphics[alt={},max width=\\textwidth]{https://cdn.mathpix.com/cropped/7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-08.jpg?height=525&width=755&top_left_y=1824&top_left_x=1246}\n\\captionsetup{labelformat=empty}\n\\caption{Figure 6. Mechanisms through which omega-3 fatty acids ( \\(\\omega-3\\) FA) may prevent diabetic kidney disease.}\n\\end{figure}"},{"cnt":[[1285,2350],[1989,2350],[1989,2443],[1285,2443]],"region":{"top_left_x":1284,"top_left_y":2350,"width":706,"height":93},"line":55,"column":1,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"037c984326584defa10b211cc9a3cc09","type":"figure_label","conversion_output":false,"parent_id":"938fea71b556476385f52335d7efe0e5","children_ids":["7f5b0038a06649ca968fb045685ac183","0a72095aef2e4a9d9b4450b03ab87766"],"text":"","text_display":""},{"cnt":[[1306,2359],[1983,2359],[1983,2400],[1306,2400]],"region":{"top_left_x":1306,"top_left_y":2358,"width":678,"height":42},"line":56,"column":1,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"7f5b0038a06649ca968fb045685ac183","type":"text","conversion_output":false,"parent_id":"037c984326584defa10b211cc9a3cc09","text":"Figure 6. Mechanisms through which omega-3 fatty","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[1293,2398],[1987,2398],[1987,2434],[1293,2434]],"region":{"top_left_x":1293,"top_left_y":2397,"width":695,"height":38},"line":57,"column":1,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"0a72095aef2e4a9d9b4450b03ab87766","type":"text","conversion_output":false,"parent_id":"037c984326584defa10b211cc9a3cc09","text":"acids ( \\(\\omega-3\\) FA) may prevent diabetic kidney disease.","text_display":"","confidence":0.7141260703701846,"confidence_rate":0.9944041195434714},{"cnt":[[120,2464],[1863,2464],[1863,2516],[120,2516]],"region":{"top_left_x":120,"top_left_y":2464,"width":1743,"height":52},"line":58,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"16fc4ccc8bd244be909ede3168dbff9e","type":"text","conversion_output":true,"text":"recorded at baseline or after olive oil administration. \\({ }^{118}\\) Another study reported that \\(\\omega\\)-3 FA significantly","text_display":"\nrecorded at baseline or after olive oil administration. \\({ }^{118}\\) Another study reported that \\(\\omega\\)-3 FA significantly","confidence":0.6531871841289103,"confidence_rate":0.9966521399439273},{"cnt":[[120,2509],[1895,2509],[1895,2563],[120,2563]],"region":{"top_left_x":120,"top_left_y":2509,"width":1775,"height":55},"line":59,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fc4cc855ae0644e4924925231c53b757","type":"text","conversion_output":true,"text":"reduced soluble cell adhesion molecules, particularly among persons with type 2 diabetes. \\({ }^{119}\\) Endothelial","text_display":" reduced soluble cell adhesion molecules, particularly among persons with type 2 diabetes. \\({ }^{119}\\) Endothelial","confidence":0.99658203125,"confidence_rate":0.9999721644252253},{"cnt":[[1977,2582],[2007,2582],[2007,2628],[1977,2628]],"region":{"top_left_x":1976,"top_left_y":2582,"width":31,"height":46},"line":60,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4e80fcff62914366817bc06d93199cff","type":"page_info","conversion_output":false,"text":"8","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-09","page":9,"lines":[{"cnt":[[120,125],[2000,125],[2000,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":1881,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f1732f8d64074a978897648e3f677249","type":"text","conversion_output":true,"text":"function regulates intraglomerular pressure, and the endothelium is a critical barrier to urinary albumin filtration.","text_display":"\nfunction regulates intraglomerular pressure, and the endothelium is a critical barrier to urinary albumin filtration.","confidence":1,"confidence_rate":1},{"cnt":[[120,172],[1949,172],[1949,217],[120,217]],"region":{"top_left_x":120,"top_left_y":171,"width":1829,"height":46},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c6f722a881724acba7b90e6f3259b7dd","type":"text","conversion_output":true,"text":"Second, at least 3 studies of persons with type 2 diabetes found that \\(\\omega-3\\) FA reduced measures of oxidative","text_display":" Second, at least 3 studies of persons with type 2 diabetes found that \\(\\omega-3\\) FA reduced measures of oxidative","confidence":0.9868226051330566,"confidence_rate":0.9998894645505172},{"cnt":[[120,211],[1983,211],[1983,260],[120,260]],"region":{"top_left_x":120,"top_left_y":210,"width":1864,"height":50},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"56182394699742b9929ef01ae91fd1ba","type":"text","conversion_output":true,"text":"stress, such as urine F2-isoprostane excretion. \\({ }^{120-122}\\) Oxidative stress is closely linked with tissue inflammation","text_display":" stress, such as urine F2-isoprostane excretion. \\({ }^{120-122}\\) Oxidative stress is closely linked with tissue inflammation","confidence":1,"confidence_rate":1},{"cnt":[[120,254],[1987,254],[1987,305],[120,305]],"region":{"top_left_x":120,"top_left_y":253,"width":1868,"height":53},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ece64df2860e4a78a5acaed6a6b6fb54","type":"text","conversion_output":true,"text":"(Section B2c) and may contribute to the pathogenesis of albuminuria and DKD progression. \\({ }^{25,88}\\) Third, \\(\\omega\\)-3 FA","text_display":" (Section B2c) and may contribute to the pathogenesis of albuminuria and DKD progression. \\({ }^{25,88}\\) Third, \\(\\omega\\)-3 FA","confidence":0.5321144335903227,"confidence_rate":0.9950446279224906},{"cnt":[[120,301],[1835,301],[1835,348],[120,348]],"region":{"top_left_x":120,"top_left_y":300,"width":1715,"height":49},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"662189ae84ef4287895fd8dcbb214315","type":"text","conversion_output":true,"text":"appear to have modest effects lowering systemic blood pressure, perhaps related to the mechanisms","text_display":" appear to have modest effects lowering systemic blood pressure, perhaps related to the mechanisms","confidence":1,"confidence_rate":1},{"cnt":[[120,339],[462,339],[462,389],[120,389]],"region":{"top_left_x":120,"top_left_y":339,"width":342,"height":50},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"23667ce63c1346bb9ed7adc8cd836113","type":"text","conversion_output":true,"text":"described above. \\({ }^{114}\\)","text_display":" described above. \\({ }^{114}\\)","confidence":0.99853515625,"confidence_rate":0.9999527134508668},{"cnt":[[120,408],[2002,408],[2002,455],[120,455]],"region":{"top_left_x":120,"top_left_y":408,"width":1883,"height":48},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cd11cf45702649ef8e41775d7fcb09ff","type":"text","conversion_output":true,"text":"I.c.3. \\(\\omega\\)-3 FA reduce albuminuria and tubulo-interstitial fibrosis in animal-experimental models. Effects of \\(\\omega-3\\)","text_display":"\nI.c.3. \\(\\omega\\)-3 FA reduce albuminuria and tubulo-interstitial fibrosis in animal-experimental models. Effects of \\(\\omega-3\\)","confidence":0.5635488380682135,"confidence_rate":0.9951922558902407},{"cnt":[[120,453],[1944,453],[1944,501],[120,501]],"region":{"top_left_x":120,"top_left_y":453,"width":1825,"height":48},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3e0059ab945a491ab41bd063d6508fe5","type":"text","conversion_output":true,"text":"FA have recently been studied in several animal models of kidney disease. In the diabetic KKay/Ta mouse,","text_display":" FA have recently been studied in several animal models of kidney disease. In the diabetic KKay/Ta mouse,","confidence":1,"confidence_rate":1},{"cnt":[[120,494],[1863,494],[1863,544],[120,544]],"region":{"top_left_x":120,"top_left_y":494,"width":1743,"height":50},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6cf1ac336a6749618cbac07319e20e02","type":"text","conversion_output":true,"text":"intraperitoneal EPA reduced mesangial expansion, albuminuria, and tubulo-interstitial fibrosis. \\({ }^{123}\\) It was","text_display":" intraperitoneal EPA reduced mesangial expansion, albuminuria, and tubulo-interstitial fibrosis. \\({ }^{123}\\) It was","confidence":1,"confidence_rate":1},{"cnt":[[120,541],[1998,541],[1998,589],[120,589]],"region":{"top_left_x":120,"top_left_y":541,"width":1879,"height":48},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ec0fd7dd60b24bedba252e847cecdbac","type":"text","conversion_output":true,"text":"postulated that these effects were mediated by suppression of monocyte chemoattractant protein-1 (MCP-1), a","text_display":" postulated that these effects were mediated by suppression of monocyte chemoattractant protein-1 (MCP-1), a","confidence":1,"confidence_rate":1},{"cnt":[[120,587],[1955,587],[1955,634],[120,634]],"region":{"top_left_x":120,"top_left_y":586,"width":1836,"height":48},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a2d32174f1be42aca60f55870b67afa5","type":"text","conversion_output":true,"text":"protein which regulates macrophage recruitment, is increased in experimental DKD, and was suppressed by","text_display":" protein which regulates macrophage recruitment, is increased in experimental DKD, and was suppressed by","confidence":1,"confidence_rate":1},{"cnt":[[120,632],[1927,632],[1927,677],[120,677]],"region":{"top_left_x":120,"top_left_y":631,"width":1808,"height":46},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"352ff34494e54b43a90a0bf32dbd0f91","type":"text","conversion_output":true,"text":"EPA administration. In the stretozotocin model of DKD, \\(\\omega-3\\) FA prevented the development of albuminuria","text_display":" EPA administration. In the stretozotocin model of DKD, \\(\\omega-3\\) FA prevented the development of albuminuria","confidence":0.9883153438568115,"confidence_rate":0.9998931560880783},{"cnt":[[120,675],[1996,675],[1996,724],[120,724]],"region":{"top_left_x":120,"top_left_y":674,"width":1876,"height":51},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"86ab16fff451471ea32a83faf38d0e77","type":"text","conversion_output":true,"text":"(urine albumin excretion approximately \\(10 mg / d\\), versus \\(95 mg /\\) day in untreated and \\(17 mg /\\) day in non-diabetic","text_display":" (urine albumin excretion approximately \\(10 mg / d\\), versus \\(95 mg /\\) day in untreated and \\(17 mg /\\) day in non-diabetic","confidence":0.917554444167763,"confidence_rate":0.9993532666573967},{"cnt":[[120,718],[1927,718],[1927,765],[120,765]],"region":{"top_left_x":120,"top_left_y":717,"width":1808,"height":48},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fe4ede839a66452085e93c10d1589e25","type":"text","conversion_output":true,"text":"control animals), reduced glomerulsclerosis, and downregulated MCP-1, interleukin-6, transforming growth","text_display":" control animals), reduced glomerulsclerosis, and downregulated MCP-1, interleukin-6, transforming growth","confidence":1,"confidence_rate":1},{"cnt":[[120,756],[1901,756],[1901,810],[120,810]],"region":{"top_left_x":120,"top_left_y":756,"width":1782,"height":54},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c359266dcd324bc0b6551104e2cbc272","type":"text","conversion_output":true,"text":"factor- \\(\\beta\\) (TGF- \\(\\beta\\) ), and collagen type I and type IV. \\({ }^{124}\\) In the \\(5 / 6\\) nephrectomy model of nondiabetic kidney","text_display":" factor- \\(\\beta\\) (TGF- \\(\\beta\\) ), and collagen type I and type IV. \\({ }^{124}\\) In the \\(5 / 6\\) nephrectomy model of nondiabetic kidney","confidence":0.9726946230512112,"confidence_rate":0.9997902864097776},{"cnt":[[120,804],[1904,804],[1904,853],[120,853]],"region":{"top_left_x":120,"top_left_y":803,"width":1784,"height":50},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5341e758afd347fa9aac1f6b77d840d3","type":"text","conversion_output":true,"text":"disease, \\(\\omega\\)-3 FA suppressed markers of renal inflammation, including MCP-1; downregulated tissue-level","text_display":" disease, \\(\\omega\\)-3 FA suppressed markers of renal inflammation, including MCP-1; downregulated tissue-level","confidence":0.9586464014137164,"confidence_rate":0.9996161374392655},{"cnt":[[120,844],[1919,844],[1919,896],[120,896]],"region":{"top_left_x":120,"top_left_y":844,"width":1799,"height":52},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"000468d3871940b89d1cbacc1395dd79","type":"text","conversion_output":true,"text":"NAD(P)H oxidase; and reduced expression of fibrotic markers including TGF- \\(\\beta\\). \\({ }^{125}\\) Together, these studies","text_display":" NAD(P)H oxidase; and reduced expression of fibrotic markers including TGF- \\(\\beta\\). \\({ }^{125}\\) Together, these studies","confidence":0.94677734375,"confidence_rate":0.9995590381319789},{"cnt":[[120,894],[1931,894],[1931,941],[120,941]],"region":{"top_left_x":120,"top_left_y":893,"width":1812,"height":49},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ee34b291593448268a7cb224be3caedf","type":"text","conversion_output":true,"text":"suggest that \\(\\omega-3\\) FA reduce kidney disease in animals by reducing renal oxidative stress and inflammation.","text_display":" suggest that \\(\\omega-3\\) FA reduce kidney disease in animals by reducing renal oxidative stress and inflammation.","confidence":0.9008967876434326,"confidence_rate":0.9990768460057932},{"cnt":[[120,958],[1949,958],[1949,1003],[120,1003]],"region":{"top_left_x":120,"top_left_y":958,"width":1829,"height":46},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9e826aa148f647b7a08178492024c6f1","type":"text","conversion_output":true,"text":"I.c.4. Epidemiologic studies of \\(\\omega-3\\) FA and kidney disease. Observational data suggest that effects of \\(\\omega-3\\)","text_display":"\nI.c.4. Epidemiologic studies of \\(\\omega-3\\) FA and kidney disease. Observational data suggest that effects of \\(\\omega-3\\)","confidence":0.8446102212787764,"confidence_rate":0.9984932787937443},{"cnt":[[120,1001],[1923,1001],[1923,1051],[120,1051]],"region":{"top_left_x":120,"top_left_y":1001,"width":1803,"height":50},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ec07048b1d084b198bdf8d861a8b83be","type":"text","conversion_output":true,"text":"FA on the diabetic kidney may have clinical relevance. A cross-sectional study of 22,384 individuals in the","text_display":" FA on the diabetic kidney may have clinical relevance. A cross-sectional study of 22,384 individuals in the","confidence":1,"confidence_rate":1},{"cnt":[[120,1044],[1989,1044],[1989,1094],[120,1094]],"region":{"top_left_x":120,"top_left_y":1044,"width":1870,"height":50},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b871a6a0c73c49b59713c32ed27616e1","type":"text","conversion_output":true,"text":"European Prospective Investigation of Cancer-Norfolk population cohort demonstrated that greater dietary fish","text_display":" European Prospective Investigation of Cancer-Norfolk population cohort demonstrated that greater dietary fish","confidence":0.99951171875,"confidence_rate":0.9999957157942815},{"cnt":[[120,1091],[1944,1091],[1944,1137],[120,1137]],"region":{"top_left_x":120,"top_left_y":1091,"width":1825,"height":46},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"48ba0f215c6d4a71aac7f43ff40089a6","type":"text","conversion_output":true,"text":"intake was associated with decreased risk of macroalbuminuria (urine ACR \\(\\geq 220 mg / g\\) ) among participants","text_display":" intake was associated with decreased risk of macroalbuminuria (urine ACR \\(\\geq 220 mg / g\\) ) among participants","confidence":1,"confidence_rate":1},{"cnt":[[120,1130],[1904,1130],[1904,1182],[120,1182]],"region":{"top_left_x":120,"top_left_y":1130,"width":1784,"height":52},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2c117ebb9fac40d8822be13140285c92","type":"text","conversion_output":true,"text":"with diabetes. \\({ }^{126}\\) In the InCHIANTI study, a population-based Tuscan cohort, higher baseline plasma total","text_display":" with diabetes. \\({ }^{126}\\) In the InCHIANTI study, a population-based Tuscan cohort, higher baseline plasma total","confidence":1,"confidence_rate":1},{"cnt":[[120,1177],[1938,1177],[1938,1227],[120,1227]],"region":{"top_left_x":120,"top_left_y":1177,"width":1818,"height":50},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"656ad5584cd64620827bb8bc4d09376e","type":"text","conversion_output":true,"text":"polyunsaturated fatty acids, \\(\\omega\\)-3 FA, and \\(\\omega\\)-6 FA were each strong independent predictors of slower loss of","text_display":" polyunsaturated fatty acids, \\(\\omega\\)-3 FA, and \\(\\omega\\)-6 FA were each strong independent predictors of slower loss of","confidence":0.48049268017422264,"confidence_rate":0.9938078669989818},{"cnt":[[120,1216],[1160,1216],[1160,1270],[120,1270]],"region":{"top_left_x":120,"top_left_y":1216,"width":1041,"height":54},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d7c2e26b8728443bb403db5887cd2f22","type":"text","conversion_output":true,"text":"creatinine clearance over 3 years of follow-up ( \\(P <0.0001\\) ). \\({ }^{127}\\)","text_display":" creatinine clearance over 3 years of follow-up ( \\(P <0.0001\\) ). \\({ }^{127}\\)","confidence":0.9888014663010836,"confidence_rate":0.9998659410180164},{"cnt":[[129,1285],[707,1285],[707,1334],[129,1334]],"region":{"top_left_x":128,"top_left_y":1284,"width":579,"height":51},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d49f029d056243fdb2ceaff525617521","type":"text","conversion_output":true,"text":"I.c.5. Clinical trials of w-3 FA for","text_display":"\nI.c.5. Clinical trials of w-3 FA for","confidence":0.265927376691252,"confidence_rate":0.9682105943645657},{"cnt":[[120,1332],[672,1332],[672,1377],[120,1377]],"region":{"top_left_x":120,"top_left_y":1332,"width":553,"height":46},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4944b1626a0c4f45b03f7338c950ab81","type":"text","conversion_output":true,"text":"the treatment of kidney disease.","text_display":" the treatment of kidney disease.","confidence":1,"confidence_rate":1},{"cnt":[[120,1375],[715,1375],[715,1416],[120,1416]],"region":{"top_left_x":120,"top_left_y":1375,"width":596,"height":41},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9c2e85383c224678b570312db5ddfabb","type":"text","conversion_output":true,"text":"\\(\\omega\\)-3 FA have been studied in small","text_display":" \\(\\omega\\)-3 FA have been studied in small","confidence":0.825953483581543,"confidence_rate":0.9949806177713165},{"cnt":[[120,1418],[668,1418],[668,1463],[120,1463]],"region":{"top_left_x":120,"top_left_y":1417,"width":549,"height":47},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e737f1689b18499aba1b9770261d9ddc","type":"text","conversion_output":true,"text":"clinical trials to treat established","text_display":" clinical trials to treat established","confidence":0.99853515625,"confidence_rate":0.9999642465493529},{"cnt":[[120,1461],[696,1461],[696,1508],[120,1508]],"region":{"top_left_x":120,"top_left_y":1460,"width":577,"height":49},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2dc85e6649b8403aa3617ee146b271c4","type":"text","conversion_output":true,"text":"DKD, IgA nephropathy, and other","text_display":" DKD, IgA nephropathy, and other","confidence":1,"confidence_rate":1},{"cnt":[[120,1508],[700,1508],[700,1553],[120,1553]],"region":{"top_left_x":120,"top_left_y":1508,"width":581,"height":46},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1d10a828317844c091c1a484dbe681b1","type":"text","conversion_output":true,"text":"glomerular diseases. Individually,","text_display":" glomerular diseases. Individually,","confidence":1,"confidence_rate":1},{"cnt":[[120,1551],[655,1551],[655,1596],[120,1596]],"region":{"top_left_x":120,"top_left_y":1551,"width":536,"height":46},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"28c06e7dad2948c694582bbd5c36924a","type":"text","conversion_output":true,"text":"these trials have not generated","text_display":" these trials have not generated","confidence":1,"confidence_rate":1},{"cnt":[[120,1594],[668,1594],[668,1639],[120,1639]],"region":{"top_left_x":120,"top_left_y":1594,"width":549,"height":46},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"37060f1dd8cd494289824538770292f9","type":"text","conversion_output":true,"text":"consistent findings. However, a","text_display":" consistent findings. However, a","confidence":1,"confidence_rate":1},{"cnt":[[120,1637],[703,1637],[703,1687],[120,1687]],"region":{"top_left_x":120,"top_left_y":1637,"width":583,"height":50},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1e21a02c74de428190e999ece67c5f0e","type":"text","conversion_output":true,"text":"recent meta-analysis of 17 clinical","text_display":" recent meta-analysis of 17 clinical","confidence":1,"confidence_rate":1},{"cnt":[[120,1680],[599,1680],[599,1729],[120,1729]],"region":{"top_left_x":120,"top_left_y":1680,"width":480,"height":50},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5b61cf6784b44d819ee71eb76e620a2e","type":"text","conversion_output":true,"text":"trials (626 total participants)","text_display":" trials (626 total participants)","confidence":1,"confidence_rate":1},{"cnt":[[120,1727],[690,1727],[690,1772],[120,1772]],"region":{"top_left_x":120,"top_left_y":1727,"width":570,"height":46},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4c4ae66a3ec548d286dbc58fbe0c4853","type":"text","conversion_output":true,"text":"reported that \\(\\omega\\)-3 FA significantly","text_display":" reported that \\(\\omega\\)-3 FA significantly","confidence":0.5273827468045056,"confidence_rate":0.9852304185965258},{"cnt":[[120,1766],[707,1766],[707,1811],[120,1811]],"region":{"top_left_x":120,"top_left_y":1766,"width":587,"height":46},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1073c4947db94829a8e79e2a8d9556bd","type":"text","conversion_output":true,"text":"reduced albuminuria. \\({ }^{128}\\) Effects on","text_display":" reduced albuminuria. \\({ }^{128}\\) Effects on","confidence":1,"confidence_rate":1},{"cnt":[[120,1813],[662,1813],[662,1858],[120,1858]],"region":{"top_left_x":120,"top_left_y":1813,"width":542,"height":46},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e1faba6a21804788a1128fe6ddef5d6f","type":"text","conversion_output":true,"text":"albuminuria in 7 clinical trials of","text_display":" albuminuria in 7 clinical trials of","confidence":1,"confidence_rate":1},{"cnt":[[120,1858],[587,1858],[587,1906],[120,1906]],"region":{"top_left_x":120,"top_left_y":1858,"width":467,"height":48},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f0b01d633d7242a599f2a8b2d433a706","type":"text","conversion_output":true,"text":"persons with diabetes ( 222","text_display":" persons with diabetes ( 222","confidence":0.85595703125,"confidence_rate":0.9949953041018957},{"cnt":[[120,1901],[690,1901],[690,1949],[120,1949]],"region":{"top_left_x":120,"top_left_y":1901,"width":570,"height":48},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e4b2c248e5794cb683047d739e873f0d","type":"text","conversion_output":true,"text":"participants) were consistent with","text_display":" participants) were consistent with","confidence":1,"confidence_rate":1},{"cnt":[[120,1946],[642,1946],[642,1987],[120,1987]],"region":{"top_left_x":120,"top_left_y":1946,"width":523,"height":42},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a462d5376af74b038602204cc46bf142","type":"text","conversion_output":true,"text":"the overall estimate of \\(\\omega-3 FA\\)","text_display":" the overall estimate of \\(\\omega-3 FA\\)","confidence":0.48693710938096046,"confidence_rate":0.9802090116504574},{"cnt":[[120,1985],[655,1985],[655,2035],[120,2035]],"region":{"top_left_x":120,"top_left_y":1985,"width":536,"height":50},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cbdf96c35e2e498a9749155c1ead582c","type":"text","conversion_output":true,"text":"effect (Figure 7). \\({ }^{129-135} 12\\) of 17","text_display":" effect (Figure 7). \\({ }^{129-135} 12\\) of 17","confidence":1,"confidence_rate":1},{"cnt":[[120,2032],[690,2032],[690,2082],[120,2082]],"region":{"top_left_x":120,"top_left_y":2032,"width":570,"height":50},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"400b828944dc43668d2566f402c50470","type":"text","conversion_output":true,"text":"clinical trials additionally reported","text_display":" clinical trials additionally reported","confidence":1,"confidence_rate":1},{"cnt":[[754,1304],[1993,1304],[1993,2055],[754,2055]],"region":{"top_left_x":754,"top_left_y":1304,"width":1239,"height":751},"line":44,"column":0,"font_size":29,"is_printed":true,"is_handwritten":false,"id":"cdd6b89784354bba834c4f8cb81e5748","type":"column","conversion_output":false,"children_ids":["75a7acc0549b4dc989012cafd7dc1f88","38be45d36a024758b253b9332ceb0883"],"text":"","text_display":""},{"cnt":[[758,1306],[1987,1306],[1987,1886],[758,1886]],"region":{"top_left_x":758,"top_left_y":1306,"width":1230,"height":581},"line":45,"column":1,"font_size":22,"is_printed":true,"is_handwritten":false,"id":"75a7acc0549b4dc989012cafd7dc1f88","type":"chart","conversion_output":true,"parent_id":"cdd6b89784354bba834c4f8cb81e5748","selected_labels":["38be45d36a024758b253b9332ceb0883"],"text":"","text_display":"\n\n\\begin{figure}\n\\includegraphics[alt={},max width=\\textwidth]{https://cdn.mathpix.com/cropped/7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-09.jpg?height=581&width=1230&top_left_y=1306&top_left_x=758}\n\\captionsetup{labelformat=empty}\n\\caption{Figure 7. Meta-analysis of clinical trials assessing effects of omega-3 fatty acids on albuminuria in Diabetes (\"Combined\") and all glomerular disease (\"Overall\"), from Miller et al (ref 128).}\n\\end{figure}","subtype":"bar"},{"cnt":[[756,1912],[1989,1912],[1989,2052],[756,2052]],"region":{"top_left_x":756,"top_left_y":1912,"width":1234,"height":140},"line":46,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"38be45d36a024758b253b9332ceb0883","type":"figure_label","conversion_output":false,"parent_id":"cdd6b89784354bba834c4f8cb81e5748","children_ids":["6d8fffda61eb484fa15cbeb7ea014e33","27d5a29438164fbbafc6cece51fee609","63b9da7b37bb4b21a11c10b47b5d8072"],"text":"","text_display":""},{"cnt":[[761,1916],[1983,1916],[1983,1962],[761,1962]],"region":{"top_left_x":760,"top_left_y":1916,"width":1224,"height":46},"line":47,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6d8fffda61eb484fa15cbeb7ea014e33","type":"text","conversion_output":false,"parent_id":"38be45d36a024758b253b9332ceb0883","text":"Figure 7. Meta-analysis of clinical trials assessing effects of omega-3 fatty acids","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[761,1959],[1979,1959],[1979,2004],[761,2004]],"region":{"top_left_x":760,"top_left_y":1959,"width":1219,"height":46},"line":48,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"27d5a29438164fbbafc6cece51fee609","type":"text","conversion_output":false,"parent_id":"38be45d36a024758b253b9332ceb0883","text":"on albuminuria in Diabetes (\"Combined\") and all glomerular disease (\"Overall\"),","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[761,2002],[1154,2002],[1154,2047],[761,2047]],"region":{"top_left_x":760,"top_left_y":2002,"width":394,"height":46},"line":49,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"63b9da7b37bb4b21a11c10b47b5d8072","type":"text","conversion_output":false,"parent_id":"38be45d36a024758b253b9332ceb0883","text":"from Miller et al (ref 128).","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[120,2075],[1962,2075],[1962,2125],[120,2125]],"region":{"top_left_x":120,"top_left_y":2075,"width":1842,"height":50},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cd888fc75c574c6bbfd925f3bf235dcc","type":"text","conversion_output":true,"text":"effects on GFR; in these, \\(\\omega-3\\) FA resulted in a preservation of GFR, relative to control groups, which was not","text_display":" effects on GFR; in these, \\(\\omega-3\\) FA resulted in a preservation of GFR, relative to control groups, which was not","confidence":0.9599609375,"confidence_rate":0.9996508072601671},{"cnt":[[120,2123],[1934,2123],[1934,2168],[120,2168]],"region":{"top_left_x":120,"top_left_y":2122,"width":1814,"height":46},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b0fcefadd9af4b5cb34606b6a93e8dfe","type":"text","conversion_output":true,"text":"statistically significant. Studies included in the meta-analysis were heterogenous with regard to population,","text_display":" statistically significant. Studies included in the meta-analysis were heterogenous with regard to population,","confidence":1,"confidence_rate":1},{"cnt":[[120,2166],[1886,2166],[1886,2211],[120,2211]],"region":{"top_left_x":120,"top_left_y":2165,"width":1767,"height":46},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5ac00c6c16fd4ff5a74acd853b1d0c13","type":"text","conversion_output":true,"text":"precise nature and dose of intervention, follow-up, and outcome ascertainment, such that results require","text_display":" precise nature and dose of intervention, follow-up, and outcome ascertainment, such that results require","confidence":1,"confidence_rate":1},{"cnt":[[120,2209],[1936,2209],[1936,2256],[120,2256]],"region":{"top_left_x":120,"top_left_y":2208,"width":1816,"height":48},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e3d6a1280afb4365a0f70ddca5022e51","type":"text","conversion_output":true,"text":"confirmation in adequately powered, high-quality clinical trials. No definitive large clinical trials of \\(\\omega-3\\) FA in","text_display":" confirmation in adequately powered, high-quality clinical trials. No definitive large clinical trials of \\(\\omega-3\\) FA in","confidence":0.9917128008106602,"confidence_rate":0.9999317914334679},{"cnt":[[120,2252],[1188,2252],[1188,2301],[120,2301]],"region":{"top_left_x":120,"top_left_y":2251,"width":1069,"height":50},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"341d0afbb77741ed98d1baafb0bbc0c1","type":"text","conversion_output":true,"text":"diabetic or other forms of kidney disease have been published.","text_display":" diabetic or other forms of kidney disease have been published.","confidence":1,"confidence_rate":1},{"cnt":[[120,2316],[1914,2316],[1914,2365],[120,2365]],"region":{"top_left_x":120,"top_left_y":2316,"width":1795,"height":50},"line":55,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"40e8a960ab6f4bafa7c39cb8ce142f3a","type":"text","conversion_output":true,"text":"I.d. Summary of background and current gaps in knowledge. DKD is highly prevalent, particularly","text_display":"\nI.d. Summary of background and current gaps in knowledge. DKD is highly prevalent, particularly","confidence":1,"confidence_rate":1},{"cnt":[[120,2363],[1792,2363],[1792,2408],[120,2408]],"region":{"top_left_x":120,"top_left_y":2363,"width":1672,"height":46},"line":56,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"562339b5a7b54573a15095f39f85050c","type":"text","conversion_output":true,"text":"among older adults, and leads to substantial morbidity and mortality due to progressive kidney and","text_display":" among older adults, and leads to substantial morbidity and mortality due to progressive kidney and","confidence":1,"confidence_rate":1},{"cnt":[[120,2406],[1897,2406],[1897,2451],[120,2451]],"region":{"top_left_x":120,"top_left_y":2406,"width":1778,"height":46},"line":57,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"eb20048396ee4d27a180d548babba60b","type":"text","conversion_output":true,"text":"cardiovascular disease. While tight glycemic control and RAAS inhibitors help prevent the incidence and","text_display":" cardiovascular disease. While tight glycemic control and RAAS inhibitors help prevent the incidence and","confidence":1,"confidence_rate":1},{"cnt":[[120,2449],[1897,2449],[1897,2494],[120,2494]],"region":{"top_left_x":120,"top_left_y":2449,"width":1778,"height":46},"line":58,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"03595da7bc3a438da221476373d1c3b1","type":"text","conversion_output":true,"text":"progression of DKD, rates of adverse renal and cardiovascular consequences remain unacceptably high.","text_display":" progression of DKD, rates of adverse renal and cardiovascular consequences remain unacceptably high.","confidence":1,"confidence_rate":1},{"cnt":[[120,2492],[1910,2492],[1910,2539],[120,2539]],"region":{"top_left_x":120,"top_left_y":2492,"width":1790,"height":48},"line":59,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bb0b0271347d4b43b5d693ed677a0f78","type":"text","conversion_output":true,"text":"Cholecalciferol and \\(\\omega-3\\) FA are promising interventions for the prevention and treatment of DKD, because","text_display":" Cholecalciferol and \\(\\omega-3\\) FA are promising interventions for the prevention and treatment of DKD, because","confidence":0.9009179493455476,"confidence_rate":0.9990604318354398},{"cnt":[[1972,2582],[2007,2582],[2007,2628],[1972,2628]],"region":{"top_left_x":1972,"top_left_y":2582,"width":35,"height":46},"line":60,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"236c7efd69df4bf4b617fcd85089635b","type":"page_info","conversion_output":false,"text":"9","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-10","page":10,"lines":[{"cnt":[[116,125],[1927,125],[1927,174],[116,174]],"region":{"top_left_x":116,"top_left_y":124,"width":1812,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"aa98fc9627de49c18b936be1d35a801c","type":"text","conversion_output":true,"text":"animal-experimental data suggest they have substantial reno-protective effects, early human data suggest","text_display":"\nanimal-experimental data suggest they have substantial reno-protective effects, early human data suggest","confidence":1,"confidence_rate":1},{"cnt":[[116,168],[1921,168],[1921,217],[116,217]],"region":{"top_left_x":116,"top_left_y":167,"width":1805,"height":50},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8b1edd3c4f3b4e3b8b541d0baa45e7d5","type":"text","conversion_output":true,"text":"these effects have clinical relevance, and each intervention is relatively accessible, inexpensive, and safe.","text_display":" these effects have clinical relevance, and each intervention is relatively accessible, inexpensive, and safe.","confidence":1,"confidence_rate":1},{"cnt":[[116,213],[1989,213],[1989,260],[116,260]],"region":{"top_left_x":116,"top_left_y":212,"width":1874,"height":48},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ab5e67d6e9654d1bb0fbfb274b10cf63","type":"text","conversion_output":true,"text":"Thus, it is possible that cholecalciferol and/or \\(\\omega-3\\) FA are appropriate for wide-spread use to prevent and treat","text_display":" Thus, it is possible that cholecalciferol and/or \\(\\omega-3\\) FA are appropriate for wide-spread use to prevent and treat","confidence":0.8334503173828125,"confidence_rate":0.9984829752988142},{"cnt":[[114,258],[1936,258],[1936,307],[114,307]],"region":{"top_left_x":113,"top_left_y":257,"width":1823,"height":51},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4a616217b4234b24ac9554f6989142bf","type":"text","conversion_output":true,"text":"DKD in the large and growing population of older persons with diabetes. This hypothesis requires rigorous","text_display":" DKD in the large and growing population of older persons with diabetes. This hypothesis requires rigorous","confidence":1,"confidence_rate":1},{"cnt":[[116,301],[767,301],[767,350],[116,350]],"region":{"top_left_x":116,"top_left_y":300,"width":651,"height":51},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1cc69367e249433493e0f56b750b9843","type":"text","conversion_output":true,"text":"testing in well-controlled clinical trials.","text_display":" testing in well-controlled clinical trials.","confidence":1,"confidence_rate":1},{"cnt":[[1955,2578],[2009,2578],[2009,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2578,"width":54,"height":50},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cdaf832325994608848ace3532191d3e","type":"page_info","conversion_output":false,"text":"10","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-11","page":11,"lines":[{"cnt":[[116,125],[475,125],[475,170],[116,170]],"region":{"top_left_x":116,"top_left_y":124,"width":359,"height":46},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e2f5d1afd2d44377adfd53adc728ecac","type":"section_header","conversion_output":false,"children_ids":["0c282a571e694a8d805c3921542f6f71"],"text":"","text_display":""},{"cnt":[[120,129],[473,129],[473,165],[120,165]],"region":{"top_left_x":120,"top_left_y":128,"width":353,"height":38},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0c282a571e694a8d805c3921542f6f71","type":"text","conversion_output":true,"parent_id":"e2f5d1afd2d44377adfd53adc728ecac","text":"II. SPECIFIC AIMS","text_display":"\n\n\\section*{II. SPECIFIC AIMS}","confidence":0.998046875,"confidence_rate":0.9999111387285874},{"cnt":[[185,191],[1979,191],[1979,238],[185,238]],"region":{"top_left_x":184,"top_left_y":191,"width":1795,"height":48},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5597095408ac411db2c867d195fbe9c0","type":"text","conversion_output":true,"text":"Diabetic kidney disease (DKD) is a common and morbid complication of diabetes mellitus. Preventing the","text_display":"\n\nDiabetic kidney disease (DKD) is a common and morbid complication of diabetes mellitus. Preventing the","confidence":1,"confidence_rate":1},{"cnt":[[120,236],[1981,236],[1981,281],[120,281]],"region":{"top_left_x":120,"top_left_y":236,"width":1861,"height":46},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"efb573465fbb44a7a7c88423c1dbfa62","type":"text","conversion_output":true,"text":"development and progression of DKD is a critical goal for improving long-term health outcomes of the growing","text_display":" development and progression of DKD is a critical goal for improving long-term health outcomes of the growing","confidence":1,"confidence_rate":1},{"cnt":[[120,279],[1921,279],[1921,324],[120,324]],"region":{"top_left_x":120,"top_left_y":279,"width":1801,"height":46},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0ede6c8082ed4ecea9ad0eb4373d1f61","type":"text","conversion_output":true,"text":"diabetes population and for reducing the overall burden of kidney disease in the United States. Therefore,","text_display":" diabetes population and for reducing the overall burden of kidney disease in the United States. Therefore,","confidence":1,"confidence_rate":1},{"cnt":[[120,322],[1931,322],[1931,367],[120,367]],"region":{"top_left_x":120,"top_left_y":322,"width":1812,"height":46},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2c2389102c584f3491e6c7c0bb783344","type":"text","conversion_output":true,"text":"there is an urgent need for additional, complementary interventions to prevent and treat DKD. This need is","text_display":" there is an urgent need for additional, complementary interventions to prevent and treat DKD. This need is","confidence":1,"confidence_rate":1},{"cnt":[[120,367],[2000,367],[2000,415],[120,415]],"region":{"top_left_x":120,"top_left_y":367,"width":1881,"height":48},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2ee9f22883114d91a5696b54de52490a","type":"text","conversion_output":true,"text":"greatest among older adults because diabetes and kidney disease are highly prevalent among older adults and","text_display":" greatest among older adults because diabetes and kidney disease are highly prevalent among older adults and","confidence":1,"confidence_rate":1},{"cnt":[[120,412],[1919,412],[1919,458],[120,458]],"region":{"top_left_x":120,"top_left_y":412,"width":1799,"height":46},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"841ffc3364dc4b29866ae598d77ce916","type":"text","conversion_output":true,"text":"kidney disease is among the strongest risk factors for mortality in this group. Vitamin D and omega- 3 fatty","text_display":" kidney disease is among the strongest risk factors for mortality in this group. Vitamin D and omega- 3 fatty","confidence":0.87060546875,"confidence_rate":0.9988061755183814},{"cnt":[[120,455],[1876,455],[1876,501],[120,501]],"region":{"top_left_x":120,"top_left_y":455,"width":1756,"height":46},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5d83a17ac2204e71a54418afe82167ab","type":"text","conversion_output":true,"text":"acids ( \\(\\omega-3\\) FA) are two of the most promising interventions for DKD prevention and treatment. Because","text_display":" acids ( \\(\\omega-3\\) FA) are two of the most promising interventions for DKD prevention and treatment. Because","confidence":0.9975595474243164,"confidence_rate":0.9999775834133297},{"cnt":[[120,498],[1979,498],[1979,544],[120,544]],"region":{"top_left_x":120,"top_left_y":498,"width":1859,"height":46},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6fc76ed2c9d14ca58986bdfb5fb29af3","type":"text","conversion_output":true,"text":"cholecalciferol and \\(\\omega-3\\) FA are relatively safe, inexpensive, and widely available, they may offer opportunity to","text_display":" cholecalciferol and \\(\\omega-3\\) FA are relatively safe, inexpensive, and widely available, they may offer opportunity to","confidence":0.9322266262024641,"confidence_rate":0.9994153432059792},{"cnt":[[120,544],[1940,544],[1940,589],[120,589]],"region":{"top_left_x":120,"top_left_y":543,"width":1821,"height":46},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4ee65b59dde141219240104e0ef4883d","type":"text","conversion_output":true,"text":"substantially reduce the burden of DKD in large populations. Prior to widespread implementation, however,","text_display":" substantially reduce the burden of DKD in large populations. Prior to widespread implementation, however,","confidence":1,"confidence_rate":1},{"cnt":[[120,589],[1996,589],[1996,632],[120,632]],"region":{"top_left_x":120,"top_left_y":588,"width":1876,"height":44},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2d65c4d8c2fe4509aedbf9326157c20e","type":"text","conversion_output":true,"text":"these hypothesized benefits should be rigorously tested in well-powered clinical trials. Therefore, among older","text_display":" these hypothesized benefits should be rigorously tested in well-powered clinical trials. Therefore, among older","confidence":1,"confidence_rate":1},{"cnt":[[120,632],[617,632],[617,672],[120,672]],"region":{"top_left_x":120,"top_left_y":631,"width":497,"height":42},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"89074b8f46c942329e7d369ddbc87c23","type":"text","conversion_output":true,"text":"adults with diabetes, we aim:","text_display":" adults with diabetes, we aim:","confidence":1,"confidence_rate":1},{"cnt":[[183,696],[1983,696],[1983,741],[183,741]],"region":{"top_left_x":182,"top_left_y":696,"width":1802,"height":46},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e37ea8d26a1d4b7a8be7a893845ae5e9","type":"text","conversion_output":true,"text":"SPECIFIC AIM 1: To test whether cholecalciferol (vitamin \\(D _{3}, 2000\\) IU per day) prevents the development","text_display":"\n\nSPECIFIC AIM 1: To test whether cholecalciferol (vitamin \\(D _{3}, 2000\\) IU per day) prevents the development","confidence":0.8120442376052628,"confidence_rate":0.9982519459277244},{"cnt":[[120,741],[958,741],[958,784],[120,784]],"region":{"top_left_x":120,"top_left_y":741,"width":839,"height":44},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1eef813704154637be8b5bdcca4c0609","type":"text","conversion_output":true,"text":"and progression of DKD, compared with placebo.","text_display":" and progression of DKD, compared with placebo.","confidence":0.99951171875,"confidence_rate":0.9999904235654993},{"cnt":[[183,804],[1691,804],[1691,849],[183,849]],"region":{"top_left_x":182,"top_left_y":803,"width":1509,"height":46},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b5b4cd4ce97945cc8e04dc92af2f1ee8","type":"text","conversion_output":true,"text":"Hypothesis 1a: Cholecalciferol slows progression of albuminuria over 4 years of therapy.","text_display":"\n\nHypothesis 1a: Cholecalciferol slows progression of albuminuria over 4 years of therapy.","confidence":0.9921910762786865,"confidence_rate":0.9999183411152145},{"cnt":[[183,868],[1482,868],[1482,915],[183,915]],"region":{"top_left_x":182,"top_left_y":867,"width":1301,"height":49},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6e0e411a8d4d416f956040714156661a","type":"text","conversion_output":true,"text":"Hypothesis 1b: Cholecalciferol reduces loss of GFR over 4 years of therapy.","text_display":"\nHypothesis 1b: Cholecalciferol reduces loss of GFR over 4 years of therapy.","confidence":0.9990236759185791,"confidence_rate":0.9999882313825493},{"cnt":[[183,935],[1996,935],[1996,982],[183,982]],"region":{"top_left_x":182,"top_left_y":934,"width":1814,"height":48},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"12a6f3a306aa44ab97eaee946ad031a6","type":"text","conversion_output":true,"text":"Hypothesis 1c: Beneficial effects of cholecalciferol are strongest among persons who at baseline have low","text_display":"\nHypothesis 1c: Beneficial effects of cholecalciferol are strongest among persons who at baseline have low","confidence":1,"confidence_rate":1},{"cnt":[[120,975],[1454,975],[1454,1025],[120,1025]],"region":{"top_left_x":120,"top_left_y":975,"width":1335,"height":50},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cd365398e1574e69a056250918e1b59a","type":"text","conversion_output":true,"text":"plasma 25-hydroxyvitamin D concentration, albuminuria, and/or impaired GFR.","text_display":" plasma 25-hydroxyvitamin D concentration, albuminuria, and/or impaired GFR.","confidence":0.99951171875,"confidence_rate":0.9999938950124091},{"cnt":[[180,1044],[1876,1044],[1876,1089],[180,1089]],"region":{"top_left_x":180,"top_left_y":1044,"width":1696,"height":46},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a161cc2e45e241ce8be1ceed02672389","type":"text","conversion_output":true,"text":"SPECIFIC AIM 2: To test whether marine omega-3 fatty acids ( \\(\\omega-3\\) FA, eicosapentaenoic acid plus","text_display":"\n\nSPECIFIC AIM 2: To test whether marine omega-3 fatty acids ( \\(\\omega-3\\) FA, eicosapentaenoic acid plus","confidence":0.9951210021972656,"confidence_rate":0.9999525162830285},{"cnt":[[120,1087],[1923,1087],[1923,1132],[120,1132]],"region":{"top_left_x":120,"top_left_y":1087,"width":1803,"height":46},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ebf21db4248b4d578ae9718030417b9d","type":"text","conversion_output":true,"text":"docosahexaenoic acid, 840 mg per day) prevent the development and progression of DKD, compared with","text_display":" docosahexaenoic acid, 840 mg per day) prevent the development and progression of DKD, compared with","confidence":0.98388671875,"confidence_rate":0.9998509788865969},{"cnt":[[120,1130],[271,1130],[271,1175],[120,1175]],"region":{"top_left_x":120,"top_left_y":1130,"width":151,"height":46},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3c5d6df15e074cf09a7d33333062fc6d","type":"text","conversion_output":true,"text":"placebo.","text_display":" placebo.","confidence":1,"confidence_rate":1},{"cnt":[[183,1195],[1644,1195],[1644,1242],[183,1242]],"region":{"top_left_x":182,"top_left_y":1194,"width":1462,"height":48},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"280c3245f2e54c5aace215697f8ca7b4","type":"text","conversion_output":true,"text":"Hypothesis 2a: \\(\\omega\\)-3 FA acids slow progression of albuminuria over 4 years of therapy.","text_display":"\n\nHypothesis 2a: \\(\\omega\\)-3 FA acids slow progression of albuminuria over 4 years of therapy.","confidence":0.6141155529767275,"confidence_rate":0.9949339989008975},{"cnt":[[183,1259],[1336,1259],[1336,1308],[183,1308]],"region":{"top_left_x":182,"top_left_y":1258,"width":1155,"height":51},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"873018f18daf4cffa4ce37c0824046a0","type":"text","conversion_output":true,"text":"Hypothesis 2b: \\(\\omega-3\\) FA reduce loss of GFR over 4 years of therapy.","text_display":"\nHypothesis 2b: \\(\\omega-3\\) FA reduce loss of GFR over 4 years of therapy.","confidence":0.8634013528258428,"confidence_rate":0.9980692921530322},{"cnt":[[185,1323],[1893,1323],[1893,1371],[185,1371]],"region":{"top_left_x":184,"top_left_y":1323,"width":1709,"height":48},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"089d308c1a50452a94b3c3c93ceb83f7","type":"text","conversion_output":true,"text":"Hypothesis 2c: Beneficial effects of \\(\\omega\\)-3 FA are strongest among persons with low baseline levels of","text_display":"\nHypothesis 2c: Beneficial effects of \\(\\omega\\)-3 FA are strongest among persons with low baseline levels of","confidence":0.5971850138157606,"confidence_rate":0.9952379643603837},{"cnt":[[120,1369],[1927,1369],[1927,1416],[120,1416]],"region":{"top_left_x":120,"top_left_y":1368,"width":1808,"height":48},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bc751a312aac4c188dafa5b33cc1e7e7","type":"text","conversion_output":true,"text":"plasma eicosapentaenoic acid and docosahexaenoic acid and/or high baseline levels of C-reactive protein.","text_display":" plasma eicosapentaenoic acid and docosahexaenoic acid and/or high baseline levels of C-reactive protein.","confidence":0.62255859375,"confidence_rate":0.9956615710564195},{"cnt":[[183,1433],[1923,1433],[1923,1480],[183,1480]],"region":{"top_left_x":182,"top_left_y":1433,"width":1741,"height":48},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f39be57fd1114e4a952621cf36dcc620","type":"text","conversion_output":true,"text":"To test these hypotheses effectively and efficiently, we propose an ancillary study to the Vitamin D and","text_display":"\n\nTo test these hypotheses effectively and efficiently, we propose an ancillary study to the Vitamin D and","confidence":1,"confidence_rate":1},{"cnt":[[120,1474],[1962,1474],[1962,1523],[120,1523]],"region":{"top_left_x":120,"top_left_y":1473,"width":1842,"height":51},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"dd2b97a2e3454074a3377277f70b2ee7","type":"text","conversion_output":true,"text":"Omega-3 Trial (VITAL). The parent VITAL trial will be a randomized, double-blind, placebo-controlled trial of","text_display":" Omega-3 Trial (VITAL). The parent VITAL trial will be a randomized, double-blind, placebo-controlled trial of","confidence":1,"confidence_rate":1},{"cnt":[[120,1521],[1938,1521],[1938,1566],[120,1566]],"region":{"top_left_x":120,"top_left_y":1521,"width":1818,"height":46},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8e3c3cf4743947fc9778d2893e3b0e90","type":"text","conversion_output":true,"text":"the benefits and risks of cholecalciferol and \\(\\omega-3\\) FA in the primary prevention of cardiovascular disease and","text_display":" the benefits and risks of cholecalciferol and \\(\\omega-3\\) FA in the primary prevention of cardiovascular disease and","confidence":0.8917664932723275,"confidence_rate":0.9990129791541545},{"cnt":[[120,1564],[1940,1564],[1940,1611],[120,1611]],"region":{"top_left_x":120,"top_left_y":1564,"width":1821,"height":48},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a0074778699f4ff88dbe45516077f44f","type":"text","conversion_output":true,"text":"cancer. Funded by the NIH (R01 CA138962), 20,000 participants (men ages \\(\\geq 60\\) years, women ages \\(\\geq 65\\)","text_display":" cancer. Funded by the NIH (R01 CA138962), 20,000 participants (men ages \\(\\geq 60\\) years, women ages \\(\\geq 65\\)","confidence":0.86328125,"confidence_rate":0.9986269739036393},{"cnt":[[120,1607],[1974,1607],[1974,1656],[120,1656]],"region":{"top_left_x":120,"top_left_y":1607,"width":1855,"height":50},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8f38dc513567409da66153186e4d89c9","type":"text","conversion_output":true,"text":"years) will be randomly assigned in a \\(2 \\times 2\\) factorial design to cholecalciferol 2000 IU daily versus placebo, and","text_display":" years) will be randomly assigned in a \\(2 \\times 2\\) factorial design to cholecalciferol 2000 IU daily versus placebo, and","confidence":0.99951171875,"confidence_rate":0.9999959967252418},{"cnt":[[120,1652],[1992,1652],[1992,1699],[120,1699]],"region":{"top_left_x":120,"top_left_y":1652,"width":1872,"height":48},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8b30f8d8a1e34fa5b54e4d93935d7dd7","type":"text","conversion_output":true,"text":"to eicosapentaenoic acid plus docosahexaenoic acid 840 mg daily versus placebo. Planned mean follow-up is","text_display":" to eicosapentaenoic acid plus docosahexaenoic acid 840 mg daily versus placebo. Planned mean follow-up is","confidence":1,"confidence_rate":1},{"cnt":[[120,1697],[1979,1697],[1979,1742],[120,1742]],"region":{"top_left_x":120,"top_left_y":1697,"width":1859,"height":46},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f88b9f7e578644dda9234a3620d9dbbb","type":"text","conversion_output":true,"text":"5 years. Leveraging the established infrastructure of VITAL, we propose to ascertain effects of cholecalciferol","text_display":" 5 years. Leveraging the established infrastructure of VITAL, we propose to ascertain effects of cholecalciferol","confidence":1,"confidence_rate":1},{"cnt":[[120,1740],[1998,1740],[1998,1788],[120,1788]],"region":{"top_left_x":120,"top_left_y":1740,"width":1879,"height":48},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"76872fad1f96442a938664d702578bb5","type":"text","conversion_output":true,"text":"and \\(\\omega\\) - 3 FA on albuminuria and GFR among 1,500 participants with diabetes at baseline. Following the simple","text_display":" and \\(\\omega\\) - 3 FA on albuminuria and GFR among 1,500 participants with diabetes at baseline. Following the simple","confidence":0.43364416348908474,"confidence_rate":0.993174783716957},{"cnt":[[120,1783],[1949,1783],[1949,1830],[120,1830]],"region":{"top_left_x":120,"top_left_y":1783,"width":1829,"height":48},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"62da9831d67d44f9acce06807cb8c5da","type":"text","conversion_output":true,"text":"and cost-efficient design of the parent VITAL trial, biospecimens will be collected locally and delivered to the","text_display":" and cost-efficient design of the parent VITAL trial, biospecimens will be collected locally and delivered to the","confidence":1,"confidence_rate":1},{"cnt":[[120,1828],[1992,1828],[1992,1876],[120,1876]],"region":{"top_left_x":120,"top_left_y":1828,"width":1872,"height":48},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"230c0ab2f5a94c2a8162b9783165e450","type":"text","conversion_output":true,"text":"VITAL central laboratory by mail. First morning voids will be collected at baseline and year 4 for measurement","text_display":" VITAL central laboratory by mail. First morning voids will be collected at baseline and year 4 for measurement","confidence":0.99853515625,"confidence_rate":0.999987577045958},{"cnt":[[120,1873],[1921,1873],[1921,1919],[120,1919]],"region":{"top_left_x":120,"top_left_y":1873,"width":1801,"height":46},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9057eb87ab1d4e7387abda0205efd8af","type":"text","conversion_output":true,"text":"of urine albumin-creatinine ratio. Blood samples will be collected simultaneously for measurement of GFR","text_display":" of urine albumin-creatinine ratio. Blood samples will be collected simultaneously for measurement of GFR","confidence":1,"confidence_rate":1},{"cnt":[[120,1916],[1966,1916],[1966,1962],[120,1962]],"region":{"top_left_x":120,"top_left_y":1916,"width":1846,"height":46},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3ddb9c72285a4d5ca6fa0c9cdf820f88","type":"text","conversion_output":true,"text":"(using plasma creatinine and cystatin C), 25-hydroxyvitamin D, eicosapentaenoic acid plus docosahexaenoic","text_display":" (using plasma creatinine and cystatin C), 25-hydroxyvitamin D, eicosapentaenoic acid plus docosahexaenoic","confidence":0.994140625,"confidence_rate":0.9999465777134849},{"cnt":[[120,1959],[900,1959],[900,2004],[120,2004]],"region":{"top_left_x":120,"top_left_y":1959,"width":781,"height":46},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"220b4af61fff42329c974b3291f0bb84","type":"text","conversion_output":true,"text":"acid, C -reactive protein, and hemoglobin A1c.","text_display":" acid, C -reactive protein, and hemoglobin A1c.","confidence":0.995610237121582,"confidence_rate":0.9999228200631285},{"cnt":[[183,2024],[1921,2024],[1921,2071],[183,2071]],"region":{"top_left_x":182,"top_left_y":2023,"width":1739,"height":49},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"714791b0229649ab85c621a5e4b2e377","type":"text","conversion_output":true,"text":"This VITAL Diabetes ancillary study is designed to determine whether cholecalciferol and \\(\\omega-3\\) FA have","text_display":"\n\nThis VITAL Diabetes ancillary study is designed to determine whether cholecalciferol and \\(\\omega-3\\) FA have","confidence":0.9931671619415283,"confidence_rate":0.9999365178596985},{"cnt":[[120,2069],[1962,2069],[1962,2116],[120,2116]],"region":{"top_left_x":120,"top_left_y":2068,"width":1842,"height":49},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"62b05e26247b41819fe7efd390179aff","type":"text","conversion_output":true,"text":"causal and clinically relevant effects on the development of DKD. Null results of the studies proposed herein","text_display":" causal and clinically relevant effects on the development of DKD. Null results of the studies proposed herein","confidence":0.9990234375,"confidence_rate":0.9999914295135003},{"cnt":[[120,2114],[1996,2114],[1996,2159],[120,2159]],"region":{"top_left_x":120,"top_left_y":2114,"width":1876,"height":46},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"71adf140bfc34986b27021e559a85d9f","type":"text","conversion_output":true,"text":"would suggest that salutary effects of vitamin D and/or ω-3 FA observed in animal-experimental studies do not","text_display":" would suggest that salutary effects of vitamin D and/or ω-3 FA observed in animal-experimental studies do not","confidence":0.506828784942627,"confidence_rate":0.9940564870535923},{"cnt":[[120,2157],[1884,2157],[1884,2202],[120,2202]],"region":{"top_left_x":120,"top_left_y":2157,"width":1765,"height":46},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3236025af51f44c582c1ed72692e92bc","type":"text","conversion_output":true,"text":"translate to meaningful clinical benefits in early DKD. Positive results would support wide-spread use of","text_display":" translate to meaningful clinical benefits in early DKD. Positive results would support wide-spread use of","confidence":1,"confidence_rate":1},{"cnt":[[120,2200],[1869,2200],[1869,2247],[120,2247]],"region":{"top_left_x":120,"top_left_y":2200,"width":1750,"height":48},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"71bbcb52665849a2b460ff294d0e0212","type":"text","conversion_output":true,"text":"cholecalciferol and/or \\(\\omega\\)-3 FA interventions among the growing and high-risk population of persons with","text_display":" cholecalciferol and/or \\(\\omega\\)-3 FA interventions among the growing and high-risk population of persons with","confidence":0.7783692236957904,"confidence_rate":0.9977452998366175},{"cnt":[[120,2245],[281,2245],[281,2288],[120,2288]],"region":{"top_left_x":120,"top_left_y":2245,"width":162,"height":44},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4633c9ddfeee4bc1890abe4579ab85e3","type":"text","conversion_output":true,"text":"diabetes.","text_display":" diabetes.","confidence":1,"confidence_rate":1},{"cnt":[[1955,2582],[2007,2582],[2007,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2582,"width":52,"height":46},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5a56741be9ff4cdd8b676b6d9f0d7844","type":"page_info","conversion_output":false,"text":"11","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-12","page":12,"lines":[{"cnt":[[114,118],[2008,118],[2008,2567],[114,2567]],"region":{"top_left_x":114,"top_left_y":118,"width":1894,"height":2449},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a92f5f0f198a4a508d8aa4f2ee08b525","type":"column","conversion_output":false,"children_ids":["bd9630093cf242e4918491d732f2984f","d4daf40abe7f4acc879e6b29c532766d","b669bdf5f75943cb95813dfda722c4f8","ac8d03c5206d4afab4e655f3f7353914","11870cc48ed444e7a1200b898c12d55f","d290b5a5b0c1486cb0a20ed3c2591c92","a8de856fa1b04fbc9abcd3ece6289316","e5b9667a8a904d049dd451cfbd986aa2","b1fae93605f749e48e592487e4e316f2","f310556698134f71a443574e16303e39","e0a98d905dab488a8f8df11ca3bfd49e","53ae73096c1348b6bb5ba5b041e1f3aa","f8a3fcb7de0a4b409a886ffe6e6a0625","3ca29bb9a996414ab81ba9a8125f27c4","e9fe5e9aa9244abbb64ec867605c6dc7","2f6e4339bec947df88efb1ac14ca5e0f","ebb5840075b849d0818bedf56e7968d4","a3aa61e00ad040b5ba4a5d3eacfee346","5e9cd04248dd4a20ac9d2fb84b0b91ef","90db189426854cbcb0e838735e8316a4","9c3ff1895ee44db9b759ffb184a72768","532d34172074459dac84e74c702635f4","c8c9687b1824471bbf8726de65384117","a5a3ff2f25114486b8d544da74b56999","ebaffa7c061446a4aea20fd1a4a118d0","b66ab6507e5f46fca6460d12cbb1f6c3","41e0e608b80c476e82235dc20da7689e","e914a1c3e9d74f4a97729f3b56264b45","8b60af3920dd472189009bd879f079a8","f396d85c0c964107a58684777ddd2dba","2d24f16e8d7f40fdbcb9121c71fe1212","507de6237b454b42b3f9f021e53656ce","a27904e3044045f093ce0cc9f5b794d6","1cf6a8e3d5394548b0b8281e6df013b7","69a057ce8d3546febab8734dc6799a52","4246682da225472390b82d59bbc2c95b","779d8510e5534e1eb6558b02a113d809","87d71b03e8114975908dfd258946b09c","d09b4025d7304d079a4fd3f3c15e6735","9a0d080a130f4c61aadb86e9f2d5cbdc","05f8cdb0c8664fcdaa18cce2299bfc8e","271075cc1be94db0b1a0db285111b845","cb53ccadea82493cb33eb5277708590f","17eca2ad4eaf4280b8ebc2f517ad5ca1","faf85d8a96f3470aa668a8f09f750690","cba15832f3b3416890c2518c438c4130","bbd17b6deaff40a7bc64cac48bcde191","655839feb2544a6dbff6c0800caeda86","fa05bab958a04da198b5931a49055f9b","7dd58528fd234aceae51df0896498ddf","2d483c97575341c9b6432448550a5c4b","bfb5fce36d1847b29a6acd8d32e2cf88","21801106ca6c491186953ad468925d09","2dede66998ef4077980e2c96e50109b0","c125dac481364b4eb6de2aa4c8042eec"],"text":"","text_display":""},{"cnt":[[116,120],[509,120],[509,178],[116,178]],"region":{"top_left_x":116,"top_left_y":120,"width":394,"height":59},"line":2,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bd9630093cf242e4918491d732f2984f","type":"section_header","conversion_output":false,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","children_ids":["b84e47d7cc3143519c8d73a1ce6aea6a"],"text":"","text_display":""},{"cnt":[[120,125],[505,125],[505,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":385,"height":51},"line":3,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b84e47d7cc3143519c8d73a1ce6aea6a","type":"text","conversion_output":true,"parent_id":"bd9630093cf242e4918491d732f2984f","text":"III. Study Population","text_display":"\n\n\\section*{III. Study Population}","confidence":1,"confidence_rate":1},{"cnt":[[120,191],[870,191],[870,236],[120,236]],"region":{"top_left_x":120,"top_left_y":191,"width":751,"height":46},"line":4,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d4daf40abe7f4acc879e6b29c532766d","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"III.a. Parent VITAL study population. The","text_display":"\nIII.a. Parent VITAL study population. The","confidence":1,"confidence_rate":1},{"cnt":[[120,236],[857,236],[857,281],[120,281]],"region":{"top_left_x":120,"top_left_y":236,"width":738,"height":46},"line":5,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b669bdf5f75943cb95813dfda722c4f8","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"study described herein is an ancillary study","text_display":" study described herein is an ancillary study","confidence":1,"confidence_rate":1},{"cnt":[[120,279],[855,279],[855,324],[120,324]],"region":{"top_left_x":120,"top_left_y":279,"width":736,"height":46},"line":6,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ac8d03c5206d4afab4e655f3f7353914","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"to the NIH-funded VITAL study. Therefore,","text_display":" to the NIH-funded VITAL study. Therefore,","confidence":1,"confidence_rate":1},{"cnt":[[120,322],[879,322],[879,367],[120,367]],"region":{"top_left_x":120,"top_left_y":322,"width":759,"height":46},"line":7,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"11870cc48ed444e7a1200b898c12d55f","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"all participants in our ancillary study must be","text_display":" all participants in our ancillary study must be","confidence":1,"confidence_rate":1},{"cnt":[[120,367],[806,367],[806,415],[120,415]],"region":{"top_left_x":120,"top_left_y":367,"width":686,"height":48},"line":8,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d290b5a5b0c1486cb0a20ed3c2591c92","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"existing participants in the parent VITAL","text_display":" existing participants in the parent VITAL","confidence":1,"confidence_rate":1},{"cnt":[[120,412],[776,412],[776,458],[120,458]],"region":{"top_left_x":120,"top_left_y":412,"width":656,"height":46},"line":9,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a8de856fa1b04fbc9abcd3ece6289316","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"study. The parent VITAL study will be","text_display":" study. The parent VITAL study will be","confidence":1,"confidence_rate":1},{"cnt":[[120,455],[883,455],[883,501],[120,501]],"region":{"top_left_x":120,"top_left_y":455,"width":764,"height":46},"line":10,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e5b9667a8a904d049dd451cfbd986aa2","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"conducted among 20,000 apparently healthy","text_display":" conducted among 20,000 apparently healthy","confidence":0.99609375,"confidence_rate":0.9999149188517554},{"cnt":[[120,498],[750,498],[750,544],[120,544]],"region":{"top_left_x":120,"top_left_y":498,"width":630,"height":46},"line":11,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b1fae93605f749e48e592487e4e316f2","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"participants. The study population is","text_display":" participants. The study population is","confidence":1,"confidence_rate":1},{"cnt":[[120,590],[120,541],[887,544],[887,593]],"region":{"top_left_x":120,"top_left_y":541,"width":768,"height":52},"line":12,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f310556698134f71a443574e16303e39","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"restricted to older individuals (men ages \\(\\geq 60\\)","text_display":" restricted to older individuals (men ages \\(\\geq 60\\)","confidence":1,"confidence_rate":1},{"cnt":[[120,589],[827,589],[827,634],[120,634]],"region":{"top_left_x":120,"top_left_y":588,"width":708,"height":46},"line":13,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e0a98d905dab488a8f8df11ca3bfd49e","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"years, women ages \\(\\geq 65\\) years), because","text_display":" years, women ages \\(\\geq 65\\) years), because","confidence":1,"confidence_rate":1},{"cnt":[[120,632],[810,632],[810,677],[120,677]],"region":{"top_left_x":120,"top_left_y":631,"width":690,"height":46},"line":14,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"53ae73096c1348b6bb5ba5b041e1f3aa","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"rates of chronic disease (including CVD,","text_display":" rates of chronic disease (including CVD,","confidence":1,"confidence_rate":1},{"cnt":[[120,675],[761,675],[761,724],[120,724]],"region":{"top_left_x":120,"top_left_y":674,"width":641,"height":51},"line":15,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f8a3fcb7de0a4b409a886ffe6e6a0625","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"cancer, and kidney disease) increase","text_display":" cancer, and kidney disease) increase","confidence":1,"confidence_rate":1},{"cnt":[[120,718],[836,718],[836,767],[120,767]],"region":{"top_left_x":120,"top_left_y":717,"width":716,"height":50},"line":16,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3ca29bb9a996414ab81ba9a8125f27c4","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"substantially with age. VITAL will exclude","text_display":" substantially with age. VITAL will exclude","confidence":1,"confidence_rate":1},{"cnt":[[120,763],[797,763],[797,810],[120,810]],"region":{"top_left_x":120,"top_left_y":762,"width":678,"height":48},"line":17,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e9fe5e9aa9244abbb64ec867605c6dc7","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"persons with clinically apparent CVD or","text_display":" persons with clinically apparent CVD or","confidence":1,"confidence_rate":1},{"cnt":[[120,808],[870,808],[870,853],[120,853]],"region":{"top_left_x":120,"top_left_y":807,"width":751,"height":46},"line":18,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2f6e4339bec947df88efb1ac14ca5e0f","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"cancer (except non-melanoma skin cancer),","text_display":" cancer (except non-melanoma skin cancer),","confidence":1,"confidence_rate":1},{"cnt":[[120,851],[889,851],[889,896],[120,896]],"region":{"top_left_x":120,"top_left_y":850,"width":770,"height":46},"line":19,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ebb5840075b849d0818bedf56e7968d4","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"because it is a trial for the primary prevention","text_display":" because it is a trial for the primary prevention","confidence":1,"confidence_rate":1},{"cnt":[[120,894],[866,894],[866,939],[120,939]],"region":{"top_left_x":120,"top_left_y":893,"width":746,"height":46},"line":20,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a3aa61e00ad040b5ba4a5d3eacfee346","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"of these conditions. Other eligibility criteria,","text_display":" of these conditions. Other eligibility criteria,","confidence":1,"confidence_rate":1},{"cnt":[[120,937],[836,937],[836,986],[120,986]],"region":{"top_left_x":120,"top_left_y":936,"width":716,"height":51},"line":21,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5e9cd04248dd4a20ac9d2fb84b0b91ef","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"which focus largely on safety, are listed in","text_display":" which focus largely on safety, are listed in","confidence":1,"confidence_rate":1},{"cnt":[[120,984],[728,984],[728,1029],[120,1029]],"region":{"top_left_x":120,"top_left_y":983,"width":609,"height":47},"line":22,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"90db189426854cbcb0e838735e8316a4","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"Table 1. VITAL will oversample for","text_display":"\nTable 1. VITAL will oversample for","confidence":1,"confidence_rate":1},{"cnt":[[120,1027],[698,1027],[698,1072],[120,1072]],"region":{"top_left_x":120,"top_left_y":1026,"width":579,"height":47},"line":23,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9c3ff1895ee44db9b759ffb184a72768","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"participants of black and Hispanic","text_display":" participants of black and Hispanic","confidence":1,"confidence_rate":1},{"cnt":[[120,1070],[363,1070],[363,1119],[120,1119]],"region":{"top_left_x":120,"top_left_y":1069,"width":244,"height":51},"line":24,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"532d34172074459dac84e74c702635f4","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"race/ethnicity.","text_display":" race/ethnicity.","confidence":1,"confidence_rate":1},{"cnt":[[180,1134],[780,1134],[780,1182],[180,1182]],"region":{"top_left_x":180,"top_left_y":1134,"width":600,"height":48},"line":25,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c8c9687b1824471bbf8726de65384117","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"The VITAL study population will be","text_display":"\n\nThe VITAL study population will be","confidence":1,"confidence_rate":1},{"cnt":[[120,1177],[862,1177],[862,1227],[120,1227]],"region":{"top_left_x":120,"top_left_y":1177,"width":742,"height":50},"line":26,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a5a3ff2f25114486b8d544da74b56999","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"recruited entirely by mail. A master mailing","text_display":" recruited entirely by mail. A master mailing","confidence":1,"confidence_rate":1},{"cnt":[[120,1225],[771,1225],[771,1270],[120,1270]],"region":{"top_left_x":120,"top_left_y":1224,"width":652,"height":46},"line":27,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ebaffa7c061446a4aea20fd1a4a118d0","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"tape containing 1.2 million names and","text_display":" tape containing 1.2 million names and","confidence":1,"confidence_rate":1},{"cnt":[[120,1268],[862,1268],[862,1313],[120,1313]],"region":{"top_left_x":120,"top_left_y":1267,"width":742,"height":46},"line":28,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b66ab6507e5f46fca6460d12cbb1f6c3","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"addresses will be assembled by Listmart, a","text_display":" addresses will be assembled by Listmart, a","confidence":1,"confidence_rate":1},{"cnt":[[120,1311],[829,1311],[829,1360],[120,1360]],"region":{"top_left_x":120,"top_left_y":1310,"width":710,"height":50},"line":29,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"41e0e608b80c476e82235dc20da7689e","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"list broker with access to all commercially","text_display":" list broker with access to all commercially","confidence":1,"confidence_rate":1},{"cnt":[[120,1354],[810,1354],[810,1401],[120,1401]],"region":{"top_left_x":120,"top_left_y":1353,"width":690,"height":48},"line":30,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e914a1c3e9d74f4a97729f3b56264b45","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"available U.S. mailing lists. This master","text_display":" available U.S. mailing lists. This master","confidence":1,"confidence_rate":1},{"cnt":[[120,1396],[870,1396],[870,1446],[120,1446]],"region":{"top_left_x":120,"top_left_y":1396,"width":751,"height":50},"line":31,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8b60af3920dd472189009bd879f079a8","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"mailing tape will be compiled from the same","text_display":" mailing tape will be compiled from the same","confidence":1,"confidence_rate":1},{"cnt":[[116,1439],[1931,1439],[1931,1489],[116,1489]],"region":{"top_left_x":116,"top_left_y":1439,"width":1816,"height":50},"line":32,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f396d85c0c964107a58684777ddd2dba","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"age-selected source tapes as the VITAL pilot study (i.e., licensed health professionals, other professionals,","text_display":" age-selected source tapes as the VITAL pilot study (i.e., licensed health professionals, other professionals,","confidence":1,"confidence_rate":1},{"cnt":[[116,1485],[1824,1485],[1824,1532],[116,1532]],"region":{"top_left_x":116,"top_left_y":1484,"width":1709,"height":48},"line":33,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2d24f16e8d7f40fdbcb9121c71fe1212","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"AARP members, and Essence subscribers), as well as subscription lists of magazines that appeal to","text_display":" AARP members, and Essence subscribers), as well as subscription lists of magazines that appeal to","confidence":0.99853515625,"confidence_rate":0.9999856283612877},{"cnt":[[116,1530],[2004,1530],[2004,1579],[116,1579]],"region":{"top_left_x":116,"top_left_y":1529,"width":1889,"height":51},"line":34,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"507de6237b454b42b3f9f021e53656ce","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"professionals and college-educated individuals (e.g., National Geographic and Time) and a subset of Listmart's","text_display":" professionals and college-educated individuals (e.g., National Geographic and Time) and a subset of Listmart's","confidence":0.9985356330871582,"confidence_rate":0.9999872571234004},{"cnt":[[116,1573],[1983,1573],[1983,1622],[116,1622]],"region":{"top_left_x":116,"top_left_y":1572,"width":1868,"height":51},"line":35,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a27904e3044045f093ce0cc9f5b794d6","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"executive database that includes black business professionals. Each of the 1.2 million persons on the master","text_display":" executive database that includes black business professionals. Each of the 1.2 million persons on the master","confidence":1,"confidence_rate":1},{"cnt":[[116,1618],[1863,1618],[1863,1665],[116,1665]],"region":{"top_left_x":116,"top_left_y":1617,"width":1747,"height":49},"line":36,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1cf6a8e3d5394548b0b8281e6df013b7","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"mailing tape will be mailed a letter explaining the rationale for VITAL, an informed consent form, a brief","text_display":" mailing tape will be mailed a letter explaining the rationale for VITAL, an informed consent form, a brief","confidence":0.9990234375,"confidence_rate":0.9999911978797494},{"cnt":[[116,1661],[1962,1661],[1962,1708],[116,1708]],"region":{"top_left_x":116,"top_left_y":1660,"width":1846,"height":49},"line":37,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"69a057ce8d3546febab8734dc6799a52","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"questionnaire, and a self-addressed, pre-paid envelope for returning study forms. The letter will outline what","text_display":" questionnaire, and a self-addressed, pre-paid envelope for returning study forms. The letter will outline what","confidence":1,"confidence_rate":1},{"cnt":[[116,1706],[1927,1706],[1927,1755],[116,1755]],"region":{"top_left_x":116,"top_left_y":1705,"width":1812,"height":51},"line":38,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4246682da225472390b82d59bbc2c95b","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"participation would entail and provide sources for further information on relevant scientific issues. Persons","text_display":" participation would entail and provide sources for further information on relevant scientific issues. Persons","confidence":1,"confidence_rate":1},{"cnt":[[116,1749],[1949,1749],[1949,1798],[116,1798]],"region":{"top_left_x":116,"top_left_y":1748,"width":1833,"height":51},"line":39,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"779d8510e5534e1eb6558b02a113d809","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"identified as black with a high degree of certainty (e.g., Essence subscribers) will receive a special invitation","text_display":" identified as black with a high degree of certainty (e.g., Essence subscribers) will receive a special invitation","confidence":1,"confidence_rate":1},{"cnt":[[116,1794],[1972,1794],[1972,1841],[116,1841]],"region":{"top_left_x":116,"top_left_y":1793,"width":1857,"height":49},"line":40,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"87d71b03e8114975908dfd258946b09c","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"letter emphasizing that blacks are at higher risk for vitamin D deficiency, as well as heart disease, stroke, and","text_display":" letter emphasizing that blacks are at higher risk for vitamin D deficiency, as well as heart disease, stroke, and","confidence":0.916015625,"confidence_rate":0.9992568706931058},{"cnt":[[116,1839],[1987,1839],[1987,1884],[116,1884]],"region":{"top_left_x":116,"top_left_y":1839,"width":1872,"height":46},"line":41,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d09b4025d7304d079a4fd3f3c15e6735","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"certain cancers. The initial questionnaire will focus only on VITAL eligibility criteria, containing items related to","text_display":" certain cancers. The initial questionnaire will focus only on VITAL eligibility criteria, containing items related to","confidence":1,"confidence_rate":1},{"cnt":[[116,1882],[1989,1882],[1989,1931],[116,1931]],"region":{"top_left_x":116,"top_left_y":1882,"width":1874,"height":50},"line":42,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9a0d080a130f4c61aadb86e9f2d5cbdc","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"demographics, specific medical history (including diabetes), relevant allergies, and dietary intakes of vitamin \\(D\\)","text_display":" demographics, specific medical history (including diabetes), relevant allergies, and dietary intakes of vitamin \\(D\\)","confidence":0.5655384063720703,"confidence_rate":0.9951402481036239},{"cnt":[[116,1925],[1929,1925],[1929,1974],[116,1974]],"region":{"top_left_x":116,"top_left_y":1925,"width":1814,"height":50},"line":43,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"05f8cdb0c8664fcdaa18cce2299bfc8e","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"and fish, as well as contact information. Based on the completed pilot mailing, it is anticipated that roughly","text_display":" and fish, as well as contact information. Based on the completed pilot mailing, it is anticipated that roughly","confidence":1,"confidence_rate":1},{"cnt":[[116,1968],[1747,1968],[1747,2017],[116,2017]],"region":{"top_left_x":116,"top_left_y":1967,"width":1631,"height":51},"line":44,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"271075cc1be94db0b1a0db285111b845","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"40,000 individuals ( \\(25 \\%\\) minority race/ethnicity) will be willing and eligible for the placebo run-in.","text_display":" 40,000 individuals ( \\(25 \\%\\) minority race/ethnicity) will be willing and eligible for the placebo run-in.","confidence":0.987845801344065,"confidence_rate":0.9998878167065136},{"cnt":[[116,2032],[1944,2032],[1944,2082],[116,2082]],"region":{"top_left_x":116,"top_left_y":2032,"width":1829,"height":50},"line":45,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cb53ccadea82493cb33eb5277708590f","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"III.b. VITAL Diabetes ancillary study population. Eligibility criteria specific to this proposed ancillary study","text_display":"\nIII.b. VITAL Diabetes ancillary study population. Eligibility criteria specific to this proposed ancillary study","confidence":1,"confidence_rate":1},{"cnt":[[116,2075],[1940,2075],[1940,2125],[116,2125]],"region":{"top_left_x":116,"top_left_y":2075,"width":1825,"height":50},"line":46,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"17eca2ad4eaf4280b8ebc2f517ad5ca1","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"are listed along with parent VITAL trial eligibility criteria in Table 1. We aim to recruit a diabetes sub-cohort","text_display":" are listed along with parent VITAL trial eligibility criteria in Table 1. We aim to recruit a diabetes sub-cohort","confidence":1,"confidence_rate":1},{"cnt":[[116,2123],[1983,2123],[1983,2168],[116,2168]],"region":{"top_left_x":116,"top_left_y":2122,"width":1868,"height":46},"line":47,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"faf85d8a96f3470aa668a8f09f750690","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"with prevalent diagnosed type 2 diabetes. Persons with known diabetes are at high risk of DKD and comprise","text_display":" with prevalent diagnosed type 2 diabetes. Persons with known diabetes are at high risk of DKD and comprise","confidence":1,"confidence_rate":1},{"cnt":[[116,2166],[1987,2166],[1987,2213],[116,2213]],"region":{"top_left_x":116,"top_left_y":2165,"width":1872,"height":48},"line":48,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cba15832f3b3416890c2518c438c4130","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"a targetable population for clinical intervention. For the purpose of this VITAL Diabetes ancillary study, we will","text_display":" a targetable population for clinical intervention. For the purpose of this VITAL Diabetes ancillary study, we will","confidence":1,"confidence_rate":1},{"cnt":[[116,2209],[1893,2209],[1893,2258],[116,2258]],"region":{"top_left_x":116,"top_left_y":2208,"width":1777,"height":51},"line":49,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bbd17b6deaff40a7bc64cac48bcde191","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"define diabetes as a self-reported physician diagnosis of diabetes. Specificities of self-reported diabetes","text_display":" define diabetes as a self-reported physician diagnosis of diabetes. Specificities of self-reported diabetes","confidence":1,"confidence_rate":1},{"cnt":[[116,2247],[1871,2247],[1871,2301],[116,2301]],"region":{"top_left_x":116,"top_left_y":2247,"width":1756,"height":54},"line":50,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"655839feb2544a6dbff6c0800caeda86","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"diagnosis were \\(97.5 \\%\\) and \\(98.9 \\%\\) in the WHS and NHS, respectively, using self-report alone. \\({ }^{136}\\) We will","text_display":" diagnosis were \\(97.5 \\%\\) and \\(98.9 \\%\\) in the WHS and NHS, respectively, using self-report alone. \\({ }^{136}\\) We will","confidence":1,"confidence_rate":1},{"cnt":[[116,2299],[1835,2299],[1835,2346],[116,2346]],"region":{"top_left_x":116,"top_left_y":2298,"width":1719,"height":49},"line":51,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fa05bab958a04da198b5931a49055f9b","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"exclude (a) persons who report a diagnosis of diabetes only during pregnancy (presumed gestational","text_display":" exclude (a) persons who report a diagnosis of diabetes only during pregnancy (presumed gestational","confidence":1,"confidence_rate":1},{"cnt":[[116,2342],[1936,2342],[1936,2391],[116,2391]],"region":{"top_left_x":116,"top_left_y":2341,"width":1820,"height":51},"line":52,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7dd58528fd234aceae51df0896498ddf","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"diabetes), and (b) persons who report diabetes diagnosis prior to age 30 and first treated with insulin (likely","text_display":" diabetes), and (b) persons who report diabetes diagnosis prior to age 30 and first treated with insulin (likely","confidence":1,"confidence_rate":1},{"cnt":[[116,2385],[1858,2385],[1858,2434],[116,2434]],"region":{"top_left_x":116,"top_left_y":2384,"width":1743,"height":51},"line":53,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2d483c97575341c9b6432448550a5c4b","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"type 1 diabetes). Persons who are likely to have type 1 diabetes will be excluded because DKD in this","text_display":" type 1 diabetes). Persons who are likely to have type 1 diabetes will be excluded because DKD in this","confidence":1,"confidence_rate":1},{"cnt":[[116,2430],[1865,2430],[1865,2477],[116,2477]],"region":{"top_left_x":116,"top_left_y":2429,"width":1749,"height":49},"line":54,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bfb5fce36d1847b29a6acd8d32e2cf88","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"population generally develops prior to older age among susceptible individuals, thus leading to disease","text_display":" population generally develops prior to older age among susceptible individuals, thus leading to disease","confidence":1,"confidence_rate":1},{"cnt":[[116,2471],[1910,2471],[1910,2520],[116,2520]],"region":{"top_left_x":116,"top_left_y":2470,"width":1794,"height":51},"line":55,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"21801106ca6c491186953ad468925d09","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"heterogeneity compared with the much larger proportion of participants with type 2 diabetes. To focus on","text_display":" heterogeneity compared with the much larger proportion of participants with type 2 diabetes. To focus on","confidence":1,"confidence_rate":1},{"cnt":[[116,2516],[1919,2516],[1919,2563],[116,2563]],"region":{"top_left_x":116,"top_left_y":2515,"width":1803,"height":49},"line":56,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2dede66998ef4077980e2c96e50109b0","type":"text","conversion_output":true,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","text":"DKD, we will also exclude (a) participants who report a physician diagnosis of kidney disease caused by a","text_display":" DKD, we will also exclude (a) participants who report a physician diagnosis of kidney disease caused by a","confidence":0.88720703125,"confidence_rate":0.9989126196472713},{"cnt":[[934,148],[2010,148],[2010,1419],[934,1419]],"region":{"top_left_x":934,"top_left_y":148,"width":1076,"height":1271},"line":57,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c125dac481364b4eb6de2aa4c8042eec","type":"column","conversion_output":false,"parent_id":"a92f5f0f198a4a508d8aa4f2ee08b525","children_ids":["4e34291ad3a14a9e95db4d20fa41f71a","c77bf991bea8428f95db62c6b8bd3828","fd00cfdb601c42a38a0c2c19c8999b4a","aaec9953806f46ea84cf0f09a7c44aee","aea4be17a0f3449ea1a3f9e9413e740c","b033e05158014e64b157503aa7a9e40a","69b9944ddca9447294b9022ca8951110","6a7cc13693b54a26a365d2b961547993","ce1af813dc124e4ea0bde086bc92643d","d86854537cc04e8588fae78a9c8d41da","66c4fa95fa3645b2b832ecd0a3e2a444","1b48fdbd176644cda16ed4a8a393cf92","8177e8506a1a43e59704b7fe85e7dc39","9474362a6c4d440893352ca012c732fd","2952e62aed4e404884aa578dd7ce1b6f","429e99c9629c422f9818104a21de84af","5f70c00db5014433afbe145bc7461131","a2f3bdd1992c40bfae7fee0115cbce25","3b982a4569614be5b514c4d80c12f3a8","489a2316f06046bb8d525ee004cf769c","2f66caa445494bf8a6f7414dcc2623ce","ecc81560a6bd4ba485c1afc0f3c9bf60","3b633640cab74d01b92e2fa88fcd76cd","ee5abb1676ec4481a619694409df51a0","b95cc0881a044ebc9b001a0801ca17df","2aebb95f6c2a44b09ce6a2ff9d57aa97"],"text":"","text_display":""},{"cnt":[[937,150],[1424,150],[1424,200],[937,200]],"region":{"top_left_x":936,"top_left_y":150,"width":489,"height":50},"line":58,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4e34291ad3a14a9e95db4d20fa41f71a","type":"figure_label","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"Table 1. Eligibility criteria","text_display":"\n\nTable 1. Eligibility criteria","confidence":1,"confidence_rate":1},{"cnt":[[937,234],[1265,234],[1265,294],[937,294]],"region":{"top_left_x":936,"top_left_y":234,"width":330,"height":61},"line":59,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c77bf991bea8428f95db62c6b8bd3828","type":"section_header","conversion_output":false,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","children_ids":["f0ea37d350ae4367b4cc347dd6df21fa"],"text":"","text_display":""},{"cnt":[[941,241],[1261,241],[1261,288],[941,288]],"region":{"top_left_x":941,"top_left_y":240,"width":321,"height":48},"line":60,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f0ea37d350ae4367b4cc347dd6df21fa","type":"text","conversion_output":true,"parent_id":"c77bf991bea8428f95db62c6b8bd3828","text":"Inclusion criteria","text_display":"\n\n\\section*{Inclusion criteria}","confidence":1,"confidence_rate":1},{"cnt":[[941,284],[1738,284],[1738,335],[941,335]],"region":{"top_left_x":941,"top_left_y":283,"width":798,"height":53},"line":61,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fd00cfdb601c42a38a0c2c19c8999b4a","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* Age \\(\\geq 60\\) years (men) or \\(\\geq 65\\) years (women)","text_display":"\n* Age \\(\\geq 60\\) years (men) or \\(\\geq 65\\) years (women)","confidence":0.8971506542479801,"confidence_rate":0.9979543315099365},{"cnt":[[941,331],[1854,331],[1854,380],[941,380]],"region":{"top_left_x":941,"top_left_y":330,"width":914,"height":51},"line":62,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"aaec9953806f46ea84cf0f09a7c44aee","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* High school education or higher (for questionnaires)","text_display":"\n* High school education or higher (for questionnaires)","confidence":0.9990234375,"confidence_rate":0.9999834401430849},{"cnt":[[941,374],[1888,374],[1888,423],[941,423]],"region":{"top_left_x":941,"top_left_y":373,"width":948,"height":51},"line":63,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"aea4be17a0f3449ea1a3f9e9413e740c","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* Willing to limit nonstudy vitamin D intake to \\(\\leq 800 IU / d\\)","text_display":"\n* Willing to limit nonstudy vitamin D intake to \\(\\leq 800 IU / d\\)","confidence":0.496174581348896,"confidence_rate":0.9894375807758244},{"cnt":[[941,417],[1729,417],[1729,466],[941,466]],"region":{"top_left_x":941,"top_left_y":416,"width":789,"height":51},"line":64,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b033e05158014e64b157503aa7a9e40a","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"*Willing to limit calcium intake to \\(\\leq 1200 mg / d\\)","text_display":"\n*Willing to limit calcium intake to \\(\\leq 1200 mg / d\\)","confidence":0.9630610942840576,"confidence_rate":0.9993158990570561},{"cnt":[[941,464],[1601,464],[1601,509],[941,509]],"region":{"top_left_x":941,"top_left_y":464,"width":660,"height":46},"line":65,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"69b9944ddca9447294b9022ca8951110","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"*Willing to forego fish oil supplements","text_display":"\n*Willing to forego fish oil supplements","confidence":0.8173828125,"confidence_rate":0.9954275824055071},{"cnt":[[941,507],[1876,507],[1876,556],[941,556]],"region":{"top_left_x":941,"top_left_y":507,"width":935,"height":50},"line":66,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6a7cc13693b54a26a365d2b961547993","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* Adherence to placebo run-in study medication > 67\\%","text_display":"\n* Adherence to placebo run-in study medication > 67\\%","confidence":0.9834777470678091,"confidence_rate":0.999707757313416},{"cnt":[[941,550],[1497,550],[1497,599],[941,599]],"region":{"top_left_x":941,"top_left_y":550,"width":557,"height":50},"line":67,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ce1af813dc124e4ea0bde086bc92643d","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"Self-reported history of diabetes","text_display":"\n\nSelf-reported history of diabetes","confidence":1,"confidence_rate":1},{"cnt":[[941,595],[1936,595],[1936,642],[941,642]],"region":{"top_left_x":941,"top_left_y":595,"width":995,"height":48},"line":68,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d86854537cc04e8588fae78a9c8d41da","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"Blood and urine specimens returned during placebo run-in","text_display":"\nBlood and urine specimens returned during placebo run-in","confidence":1,"confidence_rate":1},{"cnt":[[937,655],[1278,655],[1278,707],[937,707]],"region":{"top_left_x":936,"top_left_y":655,"width":343,"height":52},"line":69,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"66c4fa95fa3645b2b832ecd0a3e2a444","type":"section_header","conversion_output":false,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","children_ids":["6e0fa34b58bf4df9adfabde73266c9e2"],"text":"","text_display":""},{"cnt":[[941,657],[1270,657],[1270,703],[941,703]],"region":{"top_left_x":941,"top_left_y":657,"width":329,"height":46},"line":70,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6e0fa34b58bf4df9adfabde73266c9e2","type":"text","conversion_output":true,"parent_id":"66c4fa95fa3645b2b832ecd0a3e2a444","text":"Exclusion criteria","text_display":"\n\n\\section*{Exclusion criteria}","confidence":1,"confidence_rate":1},{"cnt":[[941,700],[1962,700],[1962,750],[941,750]],"region":{"top_left_x":941,"top_left_y":700,"width":1021,"height":50},"line":71,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1b48fdbd176644cda16ed4a8a393cf92","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* Known CVD: MI, stroke, TIA, angina pectoris, CABG, PCI","text_display":"\n* Known CVD: MI, stroke, TIA, angina pectoris, CABG, PCI","confidence":0.9765737056732178,"confidence_rate":0.9996114680870345},{"cnt":[[941,748],[1871,748],[1871,795],[941,795]],"region":{"top_left_x":941,"top_left_y":747,"width":931,"height":48},"line":72,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8177e8506a1a43e59704b7fe85e7dc39","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* History of cancer, except non-melanoma skin cancer","text_display":"\n* History of cancer, except non-melanoma skin cancer","confidence":1,"confidence_rate":1},{"cnt":[[941,791],[1386,791],[1386,840],[941,840]],"region":{"top_left_x":941,"top_left_y":790,"width":445,"height":51},"line":73,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9474362a6c4d440893352ca012c732fd","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* History of kidney stones","text_display":"\n* History of kidney stones","confidence":1,"confidence_rate":1},{"cnt":[[941,834],[1390,834],[1390,883],[941,883]],"region":{"top_left_x":941,"top_left_y":833,"width":450,"height":51},"line":74,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2952e62aed4e404884aa578dd7ce1b6f","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* Kidney failure or dialysis","text_display":"\n* Kidney failure or dialysis","confidence":0.9990234375,"confidence_rate":0.9999703931762353},{"cnt":[[941,881],[1231,881],[1231,930],[941,930]],"region":{"top_left_x":941,"top_left_y":880,"width":291,"height":51},"line":75,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"429e99c9629c422f9818104a21de84af","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* Hypercalcemia","text_display":"\n* Hypercalcemia","confidence":1,"confidence_rate":1},{"cnt":[[941,924],[1482,924],[1482,973],[941,973]],"region":{"top_left_x":941,"top_left_y":923,"width":542,"height":51},"line":76,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5f70c00db5014433afbe145bc7461131","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* Hypo- or hyperparathyroidism","text_display":"\n* Hypo- or hyperparathyroidism","confidence":1,"confidence_rate":1},{"cnt":[[941,967],[1321,967],[1321,1012],[941,1012]],"region":{"top_left_x":941,"top_left_y":966,"width":381,"height":46},"line":77,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a2f3bdd1992c40bfae7fee0115cbce25","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* Cirrhosis of the liver","text_display":"\n* Cirrhosis of the liver","confidence":0.9990234375,"confidence_rate":0.9999663095451973},{"cnt":[[941,1010],[1854,1010],[1854,1059],[941,1059]],"region":{"top_left_x":941,"top_left_y":1009,"width":914,"height":51},"line":78,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3b982a4569614be5b514c4d80c12f3a8","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* Granulomatous diseases (sarcoidosis, tuberculosis)","text_display":"\n* Granulomatous diseases (sarcoidosis, tuberculosis)","confidence":0.9878129959106445,"confidence_rate":0.9997849025307574},{"cnt":[[941,1053],[1467,1053],[1467,1102],[941,1102]],"region":{"top_left_x":941,"top_left_y":1052,"width":527,"height":51},"line":79,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"489a2316f06046bb8d525ee004cf769c","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* Fish allergy (for EPA + DHA)","text_display":"\n* Fish allergy (for EPA + DHA)","confidence":0.9931724045891315,"confidence_rate":0.9998042760113387},{"cnt":[[941,1096],[1846,1096],[1846,1145],[941,1145]],"region":{"top_left_x":941,"top_left_y":1095,"width":905,"height":51},"line":80,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2f66caa445494bf8a6f7414dcc2623ce","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* Other serious illnesses which preclude participation","text_display":"\n* Other serious illnesses which preclude participation","confidence":1,"confidence_rate":1},{"cnt":[[941,1143],[1708,1143],[1708,1192],[941,1192]],"region":{"top_left_x":941,"top_left_y":1142,"width":768,"height":51},"line":81,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ecc81560a6bd4ba485c1afc0f3c9bf60","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"Diagnosis of diabetes only during pregnancy","text_display":" Diagnosis of diabetes only during pregnancy","confidence":1,"confidence_rate":1},{"cnt":[[941,1186],[2007,1186],[2007,1235],[941,1235]],"region":{"top_left_x":941,"top_left_y":1185,"width":1066,"height":51},"line":82,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3b633640cab74d01b92e2fa88fcd76cd","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"Diabetes diagnosis prior to age 30 and first treated with insulin","text_display":" Diabetes diagnosis prior to age 30 and first treated with insulin","confidence":1,"confidence_rate":1},{"cnt":[[941,1229],[1826,1229],[1826,1278],[941,1278]],"region":{"top_left_x":941,"top_left_y":1228,"width":886,"height":51},"line":83,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ee5abb1676ec4481a619694409df51a0","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"Known cause of kidney disease other than diabetes","text_display":" Known cause of kidney disease other than diabetes","confidence":1,"confidence_rate":1},{"cnt":[[941,1274],[1250,1274],[1250,1326],[941,1326]],"region":{"top_left_x":941,"top_left_y":1274,"width":310,"height":52},"line":84,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b95cc0881a044ebc9b001a0801ca17df","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"Kidney transplant","text_display":" Kidney transplant","confidence":1,"confidence_rate":1},{"cnt":[[941,1362],[1590,1362],[1590,1416],[941,1416]],"region":{"top_left_x":941,"top_left_y":1362,"width":649,"height":54},"line":85,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2aebb95f6c2a44b09ce6a2ff9d57aa97","type":"text","conversion_output":true,"parent_id":"c125dac481364b4eb6de2aa4c8042eec","text":"* Parent VITAL study eligibility criteria","text_display":"\n* Parent VITAL study eligibility criteria","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-13","page":13,"lines":[{"cnt":[[120,125],[1558,125],[1558,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":1438,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c422c1fa66aa4dba9370230ec049ac60","type":"text","conversion_output":true,"text":"condition other than diabetes, and (b) participants who have had a kidney transplant.","text_display":"\ncondition other than diabetes, and (b) participants who have had a kidney transplant.","confidence":1,"confidence_rate":1},{"cnt":[[120,189],[1914,189],[1914,238],[120,238]],"region":{"top_left_x":120,"top_left_y":189,"width":1795,"height":50},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"48c049a4e15b446c89e8eb65c9ea2fb9","type":"text","conversion_output":true,"text":"III.c. Recruitment of the VITAL Diabetes ancillary study. To conduct the VITAL Diabetes ancillary study","text_display":"\nIII.c. Recruitment of the VITAL Diabetes ancillary study. To conduct the VITAL Diabetes ancillary study","confidence":0.9970703125,"confidence_rate":0.9999728338186853},{"cnt":[[120,234],[2000,234],[2000,281],[120,281]],"region":{"top_left_x":120,"top_left_y":234,"width":1881,"height":48},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9c22144a22fa447c8f425c9dc4aec7ca","type":"text","conversion_output":true,"text":"outlined in this application, we will identify, recruit, and study a sub-cohort of \\(1,500 VITAL\\) participants with pre-","text_display":" outlined in this application, we will identify, recruit, and study a sub-cohort of \\(1,500 VITAL\\) participants with pre","confidence":0.9946351032704115,"confidence_rate":0.9999576438933675},{"cnt":[[120,279],[1972,279],[1972,324],[120,324]],"region":{"top_left_x":120,"top_left_y":279,"width":1853,"height":46},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0ba4c6e1397e48b28d04c33a25947f8c","type":"text","conversion_output":true,"text":"existing diabetes at baseline. The VITAL Diabetes ancillary study sub-cohort will be recruited during the 3 - to","text_display":"existing diabetes at baseline. The VITAL Diabetes ancillary study sub-cohort will be recruited during the 3 - to","confidence":0.9975595474243164,"confidence_rate":0.9999796382461874},{"cnt":[[120,322],[1987,322],[1987,370],[120,370]],"region":{"top_left_x":120,"top_left_y":322,"width":1868,"height":48},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"144841c5b26e448b8dfb47356b86989a","type":"text","conversion_output":true,"text":"6 -month placebo run-in phase of the parent VITAL trial. VITAL will utilize a \\(3-6\\) month placebo run-in phase to","text_display":" 6 -month placebo run-in phase of the parent VITAL trial. VITAL will utilize a \\(3-6\\) month placebo run-in phase to","confidence":0.7203636169433594,"confidence_rate":0.9972242056702956},{"cnt":[[120,365],[1979,365],[1979,415],[120,415]],"region":{"top_left_x":120,"top_left_y":365,"width":1859,"height":50},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0f011aeaa0794b958083fe5565c40b87","type":"text","conversion_output":true,"text":"maximize the proportion of randomized participants who adhere to study medications. Maximizing adherence","text_display":" maximize the proportion of randomized participants who adhere to study medications. Maximizing adherence","confidence":1,"confidence_rate":1},{"cnt":[[120,408],[2002,408],[2002,458],[120,458]],"region":{"top_left_x":120,"top_left_y":408,"width":1883,"height":50},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7617ea28a0794ece8a847cee234b3671","type":"text","conversion_output":true,"text":"increases the power of the study, because study outcomes will be analyzed according to treatment assignment","text_display":" increases the power of the study, because study outcomes will be analyzed according to treatment assignment","confidence":1,"confidence_rate":1},{"cnt":[[120,449],[1983,449],[1983,501],[120,501]],"region":{"top_left_x":120,"top_left_y":449,"width":1864,"height":52},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"469393fcb16f49bd8dfd4d2be6b83c92","type":"text","conversion_output":true,"text":"(intention to treat). \\({ }^{137}\\) During the run-in phase, all participants will be asked to take placebo cholecalciferol and","text_display":" (intention to treat). \\({ }^{137}\\) During the run-in phase, all participants will be asked to take placebo cholecalciferol and","confidence":0.99951171875,"confidence_rate":0.9999963000030714},{"cnt":[[120,498],[1835,498],[1835,546],[120,546]],"region":{"top_left_x":120,"top_left_y":498,"width":1715,"height":48},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e5764ce7967541629c1953ba39cfe6cd","type":"text","conversion_output":true,"text":"placebo \\(\\omega\\)-3 FA. Participants will receive a follow-up questionnaire reevaluating eligibility criteria and","text_display":" placebo \\(\\omega\\)-3 FA. Participants will receive a follow-up questionnaire reevaluating eligibility criteria and","confidence":0.6995120644569397,"confidence_rate":0.9968700643026484},{"cnt":[[120,541],[1899,541],[1899,591],[120,591]],"region":{"top_left_x":120,"top_left_y":541,"width":1780,"height":50},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4c8ec13ac78d4423939c59cb5c9525a2","type":"text","conversion_output":true,"text":"assessing willingness to continue in the trial, pill adherence, and potential adverse effects. Parent VITAL","text_display":" assessing willingness to continue in the trial, pill adherence, and potential adverse effects. Parent VITAL","confidence":1,"confidence_rate":1},{"cnt":[[120,587],[1906,587],[1906,634],[120,634]],"region":{"top_left_x":120,"top_left_y":586,"width":1786,"height":48},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7b2b9a75088a4062a2b1c1e65e3cbefa","type":"text","conversion_output":true,"text":"investigators estimate that, of the 40,000 initially willing and eligible individuals enrolled in the run-in, \\(50 \\%\\)","text_display":" investigators estimate that, of the 40,000 initially willing and eligible individuals enrolled in the run-in, \\(50 \\%\\)","confidence":0.99658203125,"confidence_rate":0.9999714685457833},{"cnt":[[120,629],[1884,629],[1884,677],[120,677]],"region":{"top_left_x":120,"top_left_y":629,"width":1765,"height":48},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3f7371c5388349ac82a05ea184a7c653","type":"text","conversion_output":true,"text":"( \\(n =20,000\\) ) will be adherent and remain willing and eligible for randomization. The placebo run-in phase","text_display":" ( \\(n =20,000\\) ) will be adherent and remain willing and eligible for randomization. The placebo run-in phase","confidence":0.71533203125,"confidence_rate":0.9971161622657625},{"cnt":[[120,675],[1326,675],[1326,724],[120,724]],"region":{"top_left_x":120,"top_left_y":674,"width":1206,"height":51},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ebaa2ad5a2df4ada81ce728eb37fe6d3","type":"text","conversion_output":true,"text":"provides a critical window of opportunity for ancillary study recruitment.","text_display":" provides a critical window of opportunity for ancillary study recruitment.","confidence":1,"confidence_rate":1},{"cnt":[[183,739],[1824,739],[1824,786],[183,786]],"region":{"top_left_x":182,"top_left_y":739,"width":1643,"height":48},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"adcd931e7d8e4487bc1878c14e2d0442","type":"text","conversion_output":true,"text":"Persons willing to participate in the parent VITAL trial will return a screening medical history form","text_display":"\n\nPersons willing to participate in the parent VITAL trial will return a screening medical history form","confidence":1,"confidence_rate":1},{"cnt":[[120,782],[1938,782],[1938,831],[120,831]],"region":{"top_left_x":120,"top_left_y":782,"width":1818,"height":50},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e7aa1c7fea534665a8523768594ea4eb","type":"text","conversion_output":true,"text":"concurrent with their parent VITAL trial consent form. Those who respond \"YES\" to the question \"Have you","text_display":" concurrent with their parent VITAL trial consent form. Those who respond \"YES\" to the question \"Have you","confidence":1,"confidence_rate":1},{"cnt":[[120,827],[1927,827],[1927,874],[120,874]],"region":{"top_left_x":120,"top_left_y":827,"width":1808,"height":48},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c83cabf742b64071b463d87103a65a50","type":"text","conversion_output":true,"text":"EVER been diagnosed as having diabetes?\" and who indicate \"YES\" or \"MAYBE\" to the question \"Are you","text_display":" EVER been diagnosed as having diabetes?\" and who indicate \"YES\" or \"MAYBE\" to the question \"Are you","confidence":1,"confidence_rate":1},{"cnt":[[116,870],[1992,870],[1992,917],[116,917]],"region":{"top_left_x":116,"top_left_y":870,"width":1876,"height":48},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ad0216eecf6d40fdaa9e7a92dad73606","type":"text","conversion_output":true,"text":"willing to give a blood sample\" (in addition to meeting initial parent VITAL trial eligibility criteria) will be targeted","text_display":" willing to give a blood sample\" (in addition to meeting initial parent VITAL trial eligibility criteria) will be targeted","confidence":1,"confidence_rate":1},{"cnt":[[116,915],[1996,915],[1996,965],[116,965]],"region":{"top_left_x":116,"top_left_y":915,"width":1880,"height":50},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"482656bdffbd4d56ae368b3df9c05150","type":"text","conversion_output":true,"text":"for VITAL Diabetes ancillary study recruitment. With their placebo run-in materials, we will send these persons","text_display":" for VITAL Diabetes ancillary study recruitment. With their placebo run-in materials, we will send these persons","confidence":1,"confidence_rate":1},{"cnt":[[116,958],[896,958],[896,1008],[116,1008]],"region":{"top_left_x":116,"top_left_y":958,"width":780,"height":50},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fbdf8b113dc841c5a1941a9fa96dfd89","type":"text","conversion_output":true,"text":"a DKD ancillary study packet, which includes:","text_display":" a DKD ancillary study packet, which includes:","confidence":1,"confidence_rate":1},{"cnt":[[180,1025],[1343,1025],[1343,1076],[180,1076]],"region":{"top_left_x":180,"top_left_y":1024,"width":1163,"height":53},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1a328e7a7cd84a39906348a40d7ed284","type":"text","conversion_output":true,"text":"- Letter explaining the rationale for the VITAL DKD ancillary study,","text_display":"\n- Letter explaining the rationale for the VITAL DKD ancillary study,","confidence":1,"confidence_rate":1},{"cnt":[[185,1072],[988,1072],[988,1119],[185,1119]],"region":{"top_left_x":184,"top_left_y":1072,"width":805,"height":48},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"219d348a7eb941eaac8672f61f5fea1f","type":"text","conversion_output":true,"text":"- DKD ancillary study informed consent form,","text_display":"\n- DKD ancillary study informed consent form,","confidence":1,"confidence_rate":1},{"cnt":[[185,1117],[838,1117],[838,1167],[185,1167]],"region":{"top_left_x":184,"top_left_y":1117,"width":654,"height":50},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"356d992f5859441fb271d49c18893977","type":"text","conversion_output":true,"text":"- DKD ancillary study questionnaire,","text_display":"\n- DKD ancillary study questionnaire,","confidence":1,"confidence_rate":1},{"cnt":[[183,1164],[651,1164],[651,1210],[183,1210]],"region":{"top_left_x":182,"top_left_y":1164,"width":469,"height":46},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"492aaa3cc1964c9e8270c1fdb59e7f4c","type":"text","conversion_output":true,"text":"- Urine collection kit, and","text_display":"\n- Urine collection kit, and","confidence":1,"confidence_rate":1},{"cnt":[[183,1212],[1360,1212],[1360,1261],[183,1261]],"region":{"top_left_x":182,"top_left_y":1211,"width":1178,"height":51},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0b0646838c7b4168addb1d643267e184","type":"text","conversion_output":true,"text":"- Self-addressed, pre-paid FedEx box for returning study materials.","text_display":"\n- Self-addressed, pre-paid FedEx box for returning study materials.","confidence":1,"confidence_rate":1},{"cnt":[[120,1276],[1953,1276],[1953,1326],[120,1326]],"region":{"top_left_x":120,"top_left_y":1276,"width":1833,"height":50},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4bf3004c99514df1aa91bc57d435b636","type":"text","conversion_output":true,"text":"The VITAL Diabetes ancillary study letter will outline what participation in the VITAL Diabetes ancillary study","text_display":"\n\nThe VITAL Diabetes ancillary study letter will outline what participation in the VITAL Diabetes ancillary study","confidence":1,"confidence_rate":1},{"cnt":[[120,1319],[1927,1319],[1927,1369],[120,1369]],"region":{"top_left_x":120,"top_left_y":1319,"width":1808,"height":50},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"39c2fad2490b4737bf09188cec274c0a","type":"text","conversion_output":true,"text":"would entail and will provide sources for further information on relevant scientific issues. It will explain that","text_display":" would entail and will provide sources for further information on relevant scientific issues. It will explain that","confidence":1,"confidence_rate":1},{"cnt":[[120,1366],[1923,1366],[1923,1412],[120,1412]],"region":{"top_left_x":120,"top_left_y":1366,"width":1803,"height":46},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"37f663248bd34e258b7078c2b8ef865e","type":"text","conversion_output":true,"text":"participation in the ancillary study is optional and that it will not affect participation in the parent VITAL trial.","text_display":" participation in the ancillary study is optional and that it will not affect participation in the parent VITAL trial.","confidence":1,"confidence_rate":1},{"cnt":[[120,1405],[1989,1405],[1989,1454],[120,1454]],"region":{"top_left_x":120,"top_left_y":1405,"width":1870,"height":50},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5c6ae91cfc7142eb9dad2b73f87b937c","type":"text","conversion_output":true,"text":"The VITAL Diabetes ancillary study questionnaire will include items which clarify the self-reported diagnosis of","text_display":" The VITAL Diabetes ancillary study questionnaire will include items which clarify the self-reported diagnosis of","confidence":1,"confidence_rate":1},{"cnt":[[120,1452],[1931,1452],[1931,1500],[120,1500]],"region":{"top_left_x":120,"top_left_y":1452,"width":1812,"height":48},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1d2ce53f358940f3bed74b7b407e2d4a","type":"text","conversion_output":true,"text":"diabetes and further define diabetes and kidney disease history. All persons will have the option to decline","text_display":" diabetes and further define diabetes and kidney disease history. All persons will have the option to decline","confidence":1,"confidence_rate":1},{"cnt":[[120,1495],[1996,1495],[1996,1545],[120,1545]],"region":{"top_left_x":120,"top_left_y":1495,"width":1876,"height":50},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"afb3486ed452482c8bc7f2b7591b0f84","type":"text","conversion_output":true,"text":"VITAL Diabetes ancillary study participation by checking a single box on their initial contact letter and returning","text_display":" VITAL Diabetes ancillary study participation by checking a single box on their initial contact letter and returning","confidence":1,"confidence_rate":1},{"cnt":[[120,1540],[1996,1540],[1996,1588],[120,1588]],"region":{"top_left_x":120,"top_left_y":1540,"width":1876,"height":48},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b0990df220274865b4a5543517d540f9","type":"text","conversion_output":true,"text":"this by mail to the VITAL coordinating center, or by calling the toll-free VITAL telephone number. Persons who","text_display":" this by mail to the VITAL coordinating center, or by calling the toll-free VITAL telephone number. Persons who","confidence":0.99951171875,"confidence_rate":0.9999957530481652},{"cnt":[[120,1586],[1957,1586],[1957,1635],[120,1635]],"region":{"top_left_x":120,"top_left_y":1585,"width":1838,"height":50},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e38b9b52b6c34927818d0d9dd4901e3f","type":"text","conversion_output":true,"text":"do not respond to the first mailing of VITAL Diabetes ancillary study materials will be sent a reminder mailing","text_display":" do not respond to the first mailing of VITAL Diabetes ancillary study materials will be sent a reminder mailing","confidence":1,"confidence_rate":1},{"cnt":[[120,1629],[655,1629],[655,1678],[120,1678]],"region":{"top_left_x":120,"top_left_y":1628,"width":536,"height":50},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"88dba1983a294bf0ab80efaf952a0d38","type":"text","conversion_output":true,"text":"and/or contacted by telephone.","text_display":" and/or contacted by telephone.","confidence":1,"confidence_rate":1},{"cnt":[[180,1693],[1974,1693],[1974,1742],[180,1742]],"region":{"top_left_x":180,"top_left_y":1692,"width":1795,"height":51},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"26b5b257078444558e215c12c0a6040b","type":"text","conversion_output":true,"text":"Recent NHANES estimates suggest that \\(15-18 \\%\\) of the US population in the VITAL study age range have","text_display":"\n\nRecent NHANES estimates suggest that \\(15-18 \\%\\) of the US population in the VITAL study age range have","confidence":0.5613670349121094,"confidence_rate":0.9945678236167821},{"cnt":[[120,1732],[1901,1732],[1901,1785],[120,1785]],"region":{"top_left_x":120,"top_left_y":1731,"width":1782,"height":55},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bd8920f0094d4f5c8cceeb012197a13d","type":"text","conversion_output":true,"text":"been diagnosed with diabetes, not including \\(13 \\%\\) with undiagnosed diabetes. \\({ }^{5}\\) Based on VITAL recruiting","text_display":" been diagnosed with diabetes, not including \\(13 \\%\\) with undiagnosed diabetes. \\({ }^{5}\\) Based on VITAL recruiting","confidence":0.99951171875,"confidence_rate":0.9999959300041316},{"cnt":[[120,1779],[1867,1779],[1867,1828],[120,1828]],"region":{"top_left_x":120,"top_left_y":1778,"width":1747,"height":51},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b6315066d133476283626d6024386879","type":"text","conversion_output":true,"text":"strategies and selective response to mailings, it is possible that the VITAL population will be somewhat","text_display":" strategies and selective response to mailings, it is possible that the VITAL population will be somewhat","confidence":1,"confidence_rate":1},{"cnt":[[120,1824],[1824,1824],[1824,1871],[120,1871]],"region":{"top_left_x":120,"top_left_y":1824,"width":1705,"height":48},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8670d25aa9f1412c8f557dbc7a7e7aec","type":"text","conversion_output":true,"text":"healthier than the general US population. This may have competing effects on the number of VITAL","text_display":" healthier than the general US population. This may have competing effects on the number of VITAL","confidence":1,"confidence_rate":1},{"cnt":[[120,1867],[1927,1867],[1927,1916],[120,1916]],"region":{"top_left_x":120,"top_left_y":1866,"width":1808,"height":51},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c333577354cd439c949bc027d78aea2a","type":"text","conversion_output":true,"text":"participants with diagnosed diabetes, with a lower prevalence of diabetes overall but a higher proportion of","text_display":" participants with diagnosed diabetes, with a lower prevalence of diabetes overall but a higher proportion of","confidence":1,"confidence_rate":1},{"cnt":[[120,1912],[1818,1912],[1818,1962],[120,1962]],"region":{"top_left_x":120,"top_left_y":1912,"width":1698,"height":50},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e06539496c7540f58e00daf4d54691d8","type":"text","conversion_output":true,"text":"diabetes being diagnosed. Accordingly, of the 20,000 participants who will be enrolled in VITAL, we","text_display":" diabetes being diagnosed. Accordingly, of the 20,000 participants who will be enrolled in VITAL, we","confidence":1,"confidence_rate":1},{"cnt":[[120,1955],[1880,1955],[1880,2004],[120,2004]],"region":{"top_left_x":120,"top_left_y":1955,"width":1760,"height":50},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e91c4b86675745e7b982a4eedeb18ce9","type":"text","conversion_output":true,"text":"conservatively estimate that 3,000 participants will have prevalent diagnosed diabetes. VITAL Diabetes","text_display":" conservatively estimate that 3,000 participants will have prevalent diagnosed diabetes. VITAL Diabetes","confidence":1,"confidence_rate":1},{"cnt":[[120,2002],[1863,2002],[1863,2047],[120,2047]],"region":{"top_left_x":120,"top_left_y":2002,"width":1743,"height":46},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7c269e38791e4c7c9a51ec3a03c3befb","type":"text","conversion_output":true,"text":"ancillary study participant burden is modest compared with parent VITAL trial activities (including study","text_display":" ancillary study participant burden is modest compared with parent VITAL trial activities (including study","confidence":1,"confidence_rate":1},{"cnt":[[120,2045],[1854,2045],[1854,2090],[120,2090]],"region":{"top_left_x":120,"top_left_y":2045,"width":1735,"height":46},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bb5d1b489cf74869b1962b2e6e6ab774","type":"text","conversion_output":true,"text":"interventions), and VITAL participants with diabetes may be further motivated to contribute to scientific","text_display":" interventions), and VITAL participants with diabetes may be further motivated to contribute to scientific","confidence":1,"confidence_rate":1},{"cnt":[[120,2088],[1981,2088],[1981,2136],[120,2136]],"region":{"top_left_x":120,"top_left_y":2088,"width":1861,"height":48},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"589a37434433475a81d3e30d9ad406ff","type":"text","conversion_output":true,"text":"advancement in a disease with which they have personal experience. Thus, we anticipate that the majority of","text_display":" advancement in a disease with which they have personal experience. Thus, we anticipate that the majority of","confidence":1,"confidence_rate":1},{"cnt":[[120,2131],[1936,2131],[1936,2181],[120,2181]],"region":{"top_left_x":120,"top_left_y":2131,"width":1816,"height":50},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"82bed90b1df54a19b5511023cbdf696b","type":"text","conversion_output":true,"text":"VITAL participants with diabetes will consent to VITAL Diabetes ancillary study participation, allowing quick","text_display":" VITAL participants with diabetes will consent to VITAL Diabetes ancillary study participation, allowing quick","confidence":1,"confidence_rate":1},{"cnt":[[120,2176],[1592,2176],[1592,2224],[120,2224]],"region":{"top_left_x":120,"top_left_y":2176,"width":1472,"height":48},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a5e6a64234ca4d2eb2f8a3f73383ecc9","type":"text","conversion_output":true,"text":"and successful recruitment of the VITAL Diabetes ancillary study population ( \\(n =1,500\\) ).","text_display":" and successful recruitment of the VITAL Diabetes ancillary study population ( \\(n =1,500\\) ).","confidence":0.90185546875,"confidence_rate":0.9989570996942722},{"cnt":[[1955,2580],[2007,2580],[2007,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2580,"width":52,"height":48},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"584212f5ba3e4143a53d2f2a374081af","type":"page_info","conversion_output":false,"text":"13","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-14","page":14,"lines":[{"cnt":[[116,125],[599,125],[599,174],[116,174]],"region":{"top_left_x":116,"top_left_y":124,"width":484,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e14c619bb54a4268ad0e2bb9a840111e","type":"section_header","conversion_output":false,"children_ids":["2edf6299f7274428b48fded39325e33f"],"text":"","text_display":""},{"cnt":[[120,129],[595,129],[595,174],[120,174]],"region":{"top_left_x":120,"top_left_y":128,"width":476,"height":47},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2edf6299f7274428b48fded39325e33f","type":"text","conversion_output":true,"parent_id":"e14c619bb54a4268ad0e2bb9a840111e","text":"IV. Subject enrollment","text_display":"\n\n\\section*{IV. Subject enrollment}","confidence":1,"confidence_rate":1},{"cnt":[[122,193],[1914,193],[1914,238],[122,238]],"region":{"top_left_x":122,"top_left_y":193,"width":1793,"height":46},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e6c48154760b419fae6c0c3ecf5fe9dc","type":"text","conversion_output":true,"text":"IV.a. Methods of Enrollment. All potential participants who return a valid VITAL Diabetes ancillary study","text_display":"\nIV.a. Methods of Enrollment. All potential participants who return a valid VITAL Diabetes ancillary study","confidence":1,"confidence_rate":1},{"cnt":[[122,236],[1983,236],[1983,281],[122,281]],"region":{"top_left_x":122,"top_left_y":236,"width":1862,"height":46},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bc54c08354384dc98294f88c5dd5e070","type":"text","conversion_output":true,"text":"consent form will be evaluated for enrollment in the VITAL Diabetes ancillary study. First, in collaboration with","text_display":" consent form will be evaluated for enrollment in the VITAL Diabetes ancillary study. First, in collaboration with","confidence":1,"confidence_rate":1},{"cnt":[[122,279],[1992,279],[1992,324],[122,324]],"region":{"top_left_x":122,"top_left_y":279,"width":1870,"height":46},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8b858c1e97a94d5badb8b578d245ecb1","type":"text","conversion_output":true,"text":"study staff for the parent VITAL study, we will assess whether each potential participant qualifies for the parent","text_display":" study staff for the parent VITAL study, we will assess whether each potential participant qualifies for the parent","confidence":1,"confidence_rate":1},{"cnt":[[122,322],[1863,322],[1863,367],[122,367]],"region":{"top_left_x":122,"top_left_y":322,"width":1741,"height":46},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8f82e96e7e84458da1d613606d098107","type":"text","conversion_output":true,"text":"trial. Second, we will screen responses to the initial diabetes questionnaire using computer algorithms,","text_display":" trial. Second, we will screen responses to the initial diabetes questionnaire using computer algorithms,","confidence":1,"confidence_rate":1},{"cnt":[[122,370],[1966,370],[1966,410],[122,410]],"region":{"top_left_x":122,"top_left_y":369,"width":1844,"height":42},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9bcc145bb09b40ceb1acb56a3417810a","type":"text","conversion_output":true,"text":"excluding potential participants who report a diagnosis of diabetes only during pregnancy, diabetes diagnosis","text_display":" excluding potential participants who report a diagnosis of diabetes only during pregnancy, diabetes diagnosis","confidence":1,"confidence_rate":1},{"cnt":[[122,412],[1811,412],[1811,455],[122,455]],"region":{"top_left_x":122,"top_left_y":412,"width":1690,"height":44},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0c08f30fee2f4b30a66fa10424d2ab1b","type":"text","conversion_output":true,"text":"prior to age 30 and first treated with insulin, a known cause of kidney disease other than diabetes of","text_display":" prior to age 30 and first treated with insulin, a known cause of kidney disease other than diabetes of","confidence":1,"confidence_rate":1},{"cnt":[[125,455],[1852,455],[1852,501],[125,501]],"region":{"top_left_x":124,"top_left_y":455,"width":1728,"height":46},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"afb2ee9dbf724b288d78ae66606bcd3c","type":"text","conversion_output":true,"text":"hypertension, or kidney transplantation. Follow-up telephone calls will be used to clarify incomplete or","text_display":" hypertension, or kidney transplantation. Follow-up telephone calls will be used to clarify incomplete or","confidence":1,"confidence_rate":1},{"cnt":[[125,501],[1951,501],[1951,544],[125,544]],"region":{"top_left_x":124,"top_left_y":500,"width":1827,"height":44},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8833ddb4b751490cbb77911bcf3a96d2","type":"text","conversion_output":true,"text":"inconsistent responses. Finally, we will include only participants who during the placebo run-in period return","text_display":" inconsistent responses. Finally, we will include only participants who during the placebo run-in period return","confidence":1,"confidence_rate":1},{"cnt":[[125,544],[2000,544],[2000,587],[125,587]],"region":{"top_left_x":124,"top_left_y":543,"width":1877,"height":44},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8729e94032884aa8979429ab60002fd4","type":"text","conversion_output":true,"text":"samples of both blood (for the parent VITAL trial) and urine (for this VITAL Diabetes ancillary study). Follow-up","text_display":" samples of both blood (for the parent VITAL trial) and urine (for this VITAL Diabetes ancillary study). Follow-up","confidence":1,"confidence_rate":1},{"cnt":[[125,589],[1981,589],[1981,632],[125,632]],"region":{"top_left_x":124,"top_left_y":588,"width":1857,"height":44},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bde087269ef34846b8fc99fe2ae0c524","type":"text","conversion_output":true,"text":"telephone calls will be used to remind potential participants to complete blood and urine collections, if needed.","text_display":" telephone calls will be used to remind potential participants to complete blood and urine collections, if needed.","confidence":1,"confidence_rate":1},{"cnt":[[125,632],[1953,632],[1953,677],[125,677]],"region":{"top_left_x":124,"top_left_y":631,"width":1829,"height":46},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e69e3fb1753c4567bde62b28978f7563","type":"text","conversion_output":true,"text":"The first 1,500 VITAL participants who meet these VITAL Diabetes ancillary study eligibility criteria (Table 1)","text_display":" The first 1,500 VITAL participants who meet these VITAL Diabetes ancillary study eligibility criteria (Table 1)","confidence":0.989750862121582,"confidence_rate":0.9999134321342187},{"cnt":[[122,675],[1919,675],[1919,720],[122,720]],"region":{"top_left_x":122,"top_left_y":674,"width":1797,"height":46},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e50dea053fd74e4ba34d4b6819be47c4","type":"text","conversion_output":true,"text":"will be fully enrolled in the VITAL Diabetes ancillary study. Persons who meet eligibility criteria only for the","text_display":" will be fully enrolled in the VITAL Diabetes ancillary study. Persons who meet eligibility criteria only for the","confidence":1,"confidence_rate":1},{"cnt":[[125,718],[1025,718],[1025,763],[125,763]],"region":{"top_left_x":124,"top_left_y":717,"width":901,"height":46},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4b47d687828443a0ba3325b242f35ac8","type":"text","conversion_output":true,"text":"parent VITAL trial will continue in the parent trial only.","text_display":" parent VITAL trial will continue in the parent trial only.","confidence":1,"confidence_rate":1},{"cnt":[[125,782],[1970,782],[1970,827],[125,827]],"region":{"top_left_x":124,"top_left_y":782,"width":1847,"height":46},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f8acff2399e14f39b105befa02d1dab0","type":"text","conversion_output":true,"text":"IV.b. Informed Consent. A VITAL Diabetes consent form will be mailed to each potential participant as part","text_display":"\nIV.b. Informed Consent. A VITAL Diabetes consent form will be mailed to each potential participant as part","confidence":1,"confidence_rate":1},{"cnt":[[125,829],[1843,829],[1843,870],[125,870]],"region":{"top_left_x":124,"top_left_y":829,"width":1720,"height":42},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"25d9553f20d14cf6903b2bf5edc55caf","type":"text","conversion_output":true,"text":"of their initial VITAL Diabetes ancillary study packet. All persons will have the option to decline VITAL","text_display":" of their initial VITAL Diabetes ancillary study packet. All persons will have the option to decline VITAL","confidence":1,"confidence_rate":1},{"cnt":[[125,872],[1996,872],[1996,915],[125,915]],"region":{"top_left_x":124,"top_left_y":872,"width":1872,"height":44},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1cbd75d9946c4def8775f8ec330cdd32","type":"text","conversion_output":true,"text":"Diabetes ancillary study participation by checking a single box on their initial contact letter and returning this by","text_display":" Diabetes ancillary study participation by checking a single box on their initial contact letter and returning this by","confidence":1,"confidence_rate":1},{"cnt":[[125,915],[1949,915],[1949,960],[125,960]],"region":{"top_left_x":124,"top_left_y":915,"width":1825,"height":46},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"70682aac27684f3d83089a66f91267ad","type":"text","conversion_output":true,"text":"mail to the VITAL coordinating center, or by calling the toll-free VITAL telephone number. The initial contact","text_display":" mail to the VITAL coordinating center, or by calling the toll-free VITAL telephone number. The initial contact","confidence":0.998046875,"confidence_rate":0.9999829998415843},{"cnt":[[125,958],[1996,958],[1996,1003],[125,1003]],"region":{"top_left_x":124,"top_left_y":958,"width":1872,"height":46},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"eff831d63466453896a355d9c96be0d4","type":"text","conversion_output":true,"text":"letter and consent form will encourage participants to ask questions or address concerns by calling the toll-free","text_display":" letter and consent form will encourage participants to ask questions or address concerns by calling the toll-free","confidence":1,"confidence_rate":1},{"cnt":[[125,1003],[1906,1003],[1906,1046],[125,1046]],"region":{"top_left_x":124,"top_left_y":1003,"width":1782,"height":44},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c8a50621d60549b6b8fe548de4488836","type":"text","conversion_output":true,"text":"VITAL telephone number to speak with study staff in person. Willing potential participants will return their","text_display":" VITAL telephone number to speak with study staff in person. Willing potential participants will return their","confidence":1,"confidence_rate":1},{"cnt":[[125,1048],[1878,1048],[1878,1091],[125,1091]],"region":{"top_left_x":124,"top_left_y":1048,"width":1754,"height":44},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e9a5c13817924fe7afca8eb6d99ca12f","type":"text","conversion_output":true,"text":"consent forms to the VITAL coordinating center by mail. Study staff will contact potential participants by","text_display":" consent forms to the VITAL coordinating center by mail. Study staff will contact potential participants by","confidence":0.99951171875,"confidence_rate":0.9999956000051925},{"cnt":[[125,1091],[1068,1091],[1068,1137],[125,1137]],"region":{"top_left_x":124,"top_left_y":1091,"width":944,"height":46},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bf7b9bde07494830a4551fb7150d1658","type":"text","conversion_output":true,"text":"telephone to clarify ambiguous or invalid consent forms.","text_display":" telephone to clarify ambiguous or invalid consent forms.","confidence":1,"confidence_rate":1},{"cnt":[[125,1156],[1938,1156],[1938,1201],[125,1201]],"region":{"top_left_x":124,"top_left_y":1155,"width":1814,"height":46},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f3a192e675f94ed8a907acbaad35c121","type":"text","conversion_output":true,"text":"IV.c. Treatment Assignment. Upon enrollment in the VITAL Diabetes ancillary study and/or parent VITAL","text_display":"\nIV.c. Treatment Assignment. Upon enrollment in the VITAL Diabetes ancillary study and/or parent VITAL","confidence":1,"confidence_rate":1},{"cnt":[[122,1199],[2000,1199],[2000,1244],[122,1244]],"region":{"top_left_x":122,"top_left_y":1198,"width":1879,"height":46},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1428a5dcc601472399dab102197abc43","type":"text","conversion_output":true,"text":"trial, participants will be randomly assigned to vitamin D and omega-3 fatty acid treatment groups by the parent","text_display":" trial, participants will be randomly assigned to vitamin D and omega-3 fatty acid treatment groups by the parent","confidence":0.8292083740234375,"confidence_rate":0.9984005642274294},{"cnt":[[122,1246],[1867,1246],[1867,1287],[122,1287]],"region":{"top_left_x":122,"top_left_y":1246,"width":1745,"height":41},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"52c2767e25224054b7798c2e7695c7da","type":"text","conversion_output":true,"text":"VITAL trial. Assignment to treatment groups will be accomplished using a computer-generated table of","text_display":" VITAL trial. Assignment to treatment groups will be accomplished using a computer-generated table of","confidence":1,"confidence_rate":1},{"cnt":[[122,1289],[1871,1289],[1871,1330],[122,1330]],"region":{"top_left_x":122,"top_left_y":1289,"width":1750,"height":41},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b90f5b88c33944f8a094160a47015bd9","type":"text","conversion_output":true,"text":"random numbers, stratified by 5 -year age group. Within each age group, treatment assignments will be","text_display":" random numbers, stratified by 5 -year age group. Within each age group, treatment assignments will be","confidence":0.99462890625,"confidence_rate":0.9999505923221353},{"cnt":[[125,1332],[1867,1332],[1867,1377],[125,1377]],"region":{"top_left_x":124,"top_left_y":1332,"width":1743,"height":46},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7ea597fbc4d244b590c1108bc6e25b89","type":"text","conversion_output":true,"text":"generated in blocks of eight individuals, with two individuals in each of the four treatment combinations:","text_display":" generated in blocks of eight individuals, with two individuals in each of the four treatment combinations:","confidence":1,"confidence_rate":1},{"cnt":[[125,1375],[1682,1375],[1682,1420],[125,1420]],"region":{"top_left_x":124,"top_left_y":1375,"width":1559,"height":46},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0bfa85a3eff24c78b4ba6218cc529f2e","type":"text","conversion_output":true,"text":"cholecalciferol \\(+\\omega-3\\) FA, cholecalciferol + placebo, placebo \\(+\\omega-3\\) FA, or placebo + placebo.","text_display":" cholecalciferol \\(+\\omega-3\\) FA, cholecalciferol + placebo, placebo \\(+\\omega-3\\) FA, or placebo + placebo.","confidence":0.6734278250840942,"confidence_rate":0.9963117300940163},{"cnt":[[1959,2582],[2007,2582],[2007,2628],[1959,2628]],"region":{"top_left_x":1959,"top_left_y":2582,"width":48,"height":46},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c7a349cd15b24b61b2bd2304546ca022","type":"page_info","conversion_output":false,"text":"14","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-15","page":15,"lines":[{"cnt":[[116,125],[582,125],[582,176],[116,176]],"region":{"top_left_x":116,"top_left_y":124,"width":467,"height":53},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8ab9e2ddaad64a328e36689a3293d467","type":"section_header","conversion_output":false,"children_ids":["87681ea4c1ff42a292d3cb9da9f4cc0b"],"text":"","text_display":""},{"cnt":[[120,129],[578,129],[578,174],[120,174]],"region":{"top_left_x":120,"top_left_y":128,"width":458,"height":47},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"87681ea4c1ff42a292d3cb9da9f4cc0b","type":"text","conversion_output":true,"parent_id":"8ab9e2ddaad64a328e36689a3293d467","text":"V. Study Procedures","text_display":"\n\n\\section*{V. Study Procedures}","confidence":1,"confidence_rate":1},{"cnt":[[125,193],[1923,193],[1923,236],[125,236]],"region":{"top_left_x":124,"top_left_y":193,"width":1799,"height":44},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5cd70224232b4351b50c80efe4d006c1","type":"text","conversion_output":true,"text":"V.a. Approach to Data Collection. We will to collect all study data via mail, including questionnaires and","text_display":"\nV.a. Approach to Data Collection. We will to collect all study data via mail, including questionnaires and","confidence":0.99951171875,"confidence_rate":0.9999956000051925},{"cnt":[[125,236],[1992,236],[1992,281],[125,281]],"region":{"top_left_x":124,"top_left_y":236,"width":1868,"height":46},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"63a777aeff3445618fae1fe3d1bbac62","type":"text","conversion_output":true,"text":"urine and blood samples. The BWH Division of Preventive Medicine research group has extensive experience","text_display":" urine and blood samples. The BWH Division of Preventive Medicine research group has extensive experience","confidence":1,"confidence_rate":1},{"cnt":[[125,279],[1955,279],[1955,324],[125,324]],"region":{"top_left_x":124,"top_left_y":279,"width":1832,"height":46},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e054000a86764d608acaa01d5f0d10ea","type":"text","conversion_output":true,"text":"collecting and analyzing questionnaires and collecting, processing, and storing biospecimens using the mail-","text_display":" collecting and analyzing questionnaires and collecting, processing, and storing biospecimens using the mail","confidence":1,"confidence_rate":1},{"cnt":[[125,322],[1987,322],[1987,367],[125,367]],"region":{"top_left_x":124,"top_left_y":322,"width":1864,"height":46},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"489a812ea599450381021b4ae3f0865d","type":"text","conversion_output":true,"text":"based collection procedures to be used in this study. We will utilize these established, standardized protocols,","text_display":"based collection procedures to be used in this study. We will utilize these established, standardized protocols,","confidence":1,"confidence_rate":1},{"cnt":[[125,370],[780,370],[780,410],[125,410]],"region":{"top_left_x":124,"top_left_y":369,"width":656,"height":42},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"978a164fbb104aeeab598e7280a4bb6c","type":"text","conversion_output":true,"text":"described below, for all data collection.","text_display":" described below, for all data collection.","confidence":1,"confidence_rate":1},{"cnt":[[125,477],[125,432],[1983,434],[1983,479]],"region":{"top_left_x":124,"top_left_y":431,"width":1860,"height":49},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1181ba5b3ce740a784feb6ae3804dc2b","type":"text","conversion_output":true,"text":"V.b. Questionnaire Data. All participants will be asked to complete diabetes questionnaires at baseline and","text_display":"\nV.b. Questionnaire Data. All participants will be asked to complete diabetes questionnaires at baseline and","confidence":1,"confidence_rate":1},{"cnt":[[125,477],[1992,477],[1992,522],[125,522]],"region":{"top_left_x":124,"top_left_y":476,"width":1868,"height":47},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9ebcf3122a914ab989a96d2f3f2600c6","type":"text","conversion_output":true,"text":"after 4 years of study participation. Questionnaires will address diabetes diagnosis, diabetes history, history of","text_display":" after 4 years of study participation. Questionnaires will address diabetes diagnosis, diabetes history, history of","confidence":1,"confidence_rate":1},{"cnt":[[125,520],[1403,520],[1403,565],[125,565]],"region":{"top_left_x":124,"top_left_y":519,"width":1279,"height":47},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"38508ba70e30415d9240a5ab3e8b4fc0","type":"text","conversion_output":true,"text":"kidney disease, and medication use related to diabetes and kidney disease.","text_display":" kidney disease, and medication use related to diabetes and kidney disease.","confidence":1,"confidence_rate":1},{"cnt":[[125,584],[1893,584],[1893,629],[125,629]],"region":{"top_left_x":124,"top_left_y":584,"width":1769,"height":46},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cbb10cf6ca6041fea15f55767e25a4bd","type":"text","conversion_output":true,"text":"V.c. Urine Collection. Each participant will be sent a standardized urine collection kit at baseline (pre-","text_display":"\nV.c. Urine Collection. Each participant will be sent a standardized urine collection kit at baseline (pre","confidence":0.9912109375,"confidence_rate":0.9999204724046169},{"cnt":[[125,629],[1867,629],[1867,672],[125,672]],"region":{"top_left_x":124,"top_left_y":629,"width":1743,"height":44},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d1f37ebf2ce24e1a82a1b6073fa6725e","type":"text","conversion_output":true,"text":"randomization) and again after 4 years of study participation. The kit will include instructions for proper","text_display":"randomization) and again after 4 years of study participation. The kit will include instructions for proper","confidence":1,"confidence_rate":1},{"cnt":[[125,675],[1904,675],[1904,718],[125,718]],"region":{"top_left_x":124,"top_left_y":674,"width":1780,"height":44},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1da1e89836af4056bbe3223e2b40f0b7","type":"text","conversion_output":true,"text":"collection of a clean-catch first morning void; a urine cup; a plastic single-use pipette; two \\(5- mL\\) screw-top","text_display":" collection of a clean-catch first morning void; a urine cup; a plastic single-use pipette; two \\(5- mL\\) screw-top","confidence":0.9716796875,"confidence_rate":0.9997606197523509},{"cnt":[[125,718],[1974,718],[1974,763],[125,763]],"region":{"top_left_x":124,"top_left_y":717,"width":1851,"height":46},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c7bf0049ce8543cf812cf7ed26020e13","type":"text","conversion_output":true,"text":"cryovials; a gel-filled freezer pack; and an overnight courier air bill. Participants will be instructed to fill each 5","text_display":" cryovials; a gel-filled freezer pack; and an overnight courier air bill. Participants will be instructed to fill each 5","confidence":1,"confidence_rate":1},{"cnt":[[125,763],[1962,763],[1962,806],[125,806]],"region":{"top_left_x":124,"top_left_y":762,"width":1838,"height":44},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"da9b34dde0db4a46820e823bf1769117","type":"text","conversion_output":true,"text":"mL cryovial with urine using the pipette, to securely close each cryovial, and to immediately mail both vials to","text_display":" mL cryovial with urine using the pipette, to securely close each cryovial, and to immediately mail both vials to","confidence":1,"confidence_rate":1},{"cnt":[[125,804],[1983,804],[1983,849],[125,849]],"region":{"top_left_x":124,"top_left_y":803,"width":1860,"height":46},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8be9102a4d1b47d5a106646004f3debf","type":"text","conversion_output":true,"text":"the VITAL laboratory at the BWH Division of Preventive Medicine in the freezer packs provided. Upon receipt,","text_display":" the VITAL laboratory at the BWH Division of Preventive Medicine in the freezer packs provided. Upon receipt,","confidence":1,"confidence_rate":1},{"cnt":[[125,851],[1803,851],[1803,892],[125,892]],"region":{"top_left_x":124,"top_left_y":850,"width":1679,"height":42},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"50ce3559aeb94f638986b55143b2bda3","type":"text","conversion_output":true,"text":"any precipitate in the urine will be removed by centrifugation, and the urine will be aliquoted without","text_display":" any precipitate in the urine will be removed by centrifugation, and the urine will be aliquoted without","confidence":1,"confidence_rate":1},{"cnt":[[125,894],[1841,894],[1841,937],[125,937]],"region":{"top_left_x":124,"top_left_y":893,"width":1718,"height":44},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"da7f2d95e8494cd1a072cbb36367b40c","type":"text","conversion_output":true,"text":"preservative into six \\(2- ml\\) Nunc vials. Urine samples will be thawed for measurements of albumin and","text_display":" preservative into six \\(2- ml\\) Nunc vials. Urine samples will be thawed for measurements of albumin and","confidence":0.9917092323303223,"confidence_rate":0.9999243180709909},{"cnt":[[125,937],[303,937],[303,973],[125,973]],"region":{"top_left_x":124,"top_left_y":936,"width":179,"height":38},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"15fa8235bd144d6a8657fd65ad3de5a4","type":"text","conversion_output":true,"text":"creatinine.","text_display":" creatinine.","confidence":1,"confidence_rate":1},{"cnt":[[125,1001],[1985,1001],[1985,1046],[125,1046]],"region":{"top_left_x":124,"top_left_y":1001,"width":1862,"height":46},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"49fe13b2832c4d1b98dc82d9ca623eee","type":"text","conversion_output":true,"text":"V.d. Blood Collection. Each participant will be sent a standardized blood collection kit after 4 years of study","text_display":"\nV.d. Blood Collection. Each participant will be sent a standardized blood collection kit after 4 years of study","confidence":0.99853515625,"confidence_rate":0.9999876814398867},{"cnt":[[125,1044],[1970,1044],[1970,1089],[125,1089]],"region":{"top_left_x":124,"top_left_y":1044,"width":1847,"height":46},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5a8ca18ef185436d81b8cd76bafbe33a","type":"text","conversion_output":true,"text":"participation. This kit will be identical to the blood collection kit used by the parent VITAL trial for collection of","text_display":" participation. This kit will be identical to the blood collection kit used by the parent VITAL trial for collection of","confidence":0.994140625,"confidence_rate":0.9999522238365287},{"cnt":[[125,1091],[1910,1091],[1910,1132],[125,1132]],"region":{"top_left_x":124,"top_left_y":1091,"width":1786,"height":42},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d35a3beae6834347bca4ffa2165c8e94","type":"text","conversion_output":true,"text":"baseline (pre-randomization) blood samples. (Baseline blood samples will be collected only by the parent","text_display":" baseline (pre-randomization) blood samples. (Baseline blood samples will be collected only by the parent","confidence":0.9985356330871582,"confidence_rate":0.999986555685367},{"cnt":[[125,1134],[1985,1134],[1985,1177],[125,1177]],"region":{"top_left_x":124,"top_left_y":1134,"width":1862,"height":44},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a494ef5ffe7041ee8a1aed05f29b6116","type":"text","conversion_output":true,"text":"VITAL trial under the parent VITAL trial IRB approval and with separate informed consent. These samples will","text_display":" VITAL trial under the parent VITAL trial IRB approval and with separate informed consent. These samples will","confidence":1,"confidence_rate":1},{"cnt":[[125,1177],[1983,1177],[1983,1222],[125,1222]],"region":{"top_left_x":124,"top_left_y":1177,"width":1860,"height":46},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b76b3bfce73c4b8c836d6d629e359df9","type":"text","conversion_output":true,"text":"be made available for use in the VITAL Diabetes ancillary study.) The kit will include supplies and instructions","text_display":" be made available for use in the VITAL Diabetes ancillary study.) The kit will include supplies and instructions","confidence":1,"confidence_rate":1},{"cnt":[[122,1222],[1966,1222],[1966,1265],[122,1265]],"region":{"top_left_x":122,"top_left_y":1222,"width":1844,"height":44},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cf2a5956db784fc3b541b08271bc53be","type":"text","conversion_output":true,"text":"for having blood drawn into two EDTA tubes, one heparin tube, and one citrate tube; a gel-filled freezer pack;","text_display":" for having blood drawn into two EDTA tubes, one heparin tube, and one citrate tube; a gel-filled freezer pack;","confidence":1,"confidence_rate":1},{"cnt":[[125,1265],[1962,1265],[1962,1308],[125,1308]],"region":{"top_left_x":124,"top_left_y":1265,"width":1838,"height":44},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"295522f26c9640d9a312568a9eea3f33","type":"text","conversion_output":true,"text":"and an overnight courier air bill. We anticipate that most participants will have their blood drawn by their own","text_display":" and an overnight courier air bill. We anticipate that most participants will have their blood drawn by their own","confidence":0.99951171875,"confidence_rate":0.999995825645481},{"cnt":[[125,1311],[1985,1311],[1985,1351],[125,1351]],"region":{"top_left_x":124,"top_left_y":1310,"width":1862,"height":42},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7b90976684014c65a743ec91b337564a","type":"text","conversion_output":true,"text":"healthcare providers or in another healthcare or blood-drawing facility. Participants will be instructed to record","text_display":" healthcare providers or in another healthcare or blood-drawing facility. Participants will be instructed to record","confidence":1,"confidence_rate":1},{"cnt":[[125,1354],[1893,1354],[1893,1396],[125,1396]],"region":{"top_left_x":124,"top_left_y":1353,"width":1769,"height":44},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4f21c9929ab94239851d1debf92db97d","type":"text","conversion_output":true,"text":"the time of venipuncture and the time of their last meal. They will be instructed to immediately send their","text_display":" the time of venipuncture and the time of their last meal. They will be instructed to immediately send their","confidence":1,"confidence_rate":1},{"cnt":[[125,1396],[1867,1396],[1867,1439],[125,1439]],"region":{"top_left_x":124,"top_left_y":1396,"width":1743,"height":44},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0cbf661793b045609b9b6d5bb1a58768","type":"text","conversion_output":true,"text":"sample to the VITAL laboratory at the BWH Division of Preventive Medicine in the freezer packs. Upon","text_display":" sample to the VITAL laboratory at the BWH Division of Preventive Medicine in the freezer packs. Upon","confidence":1,"confidence_rate":1},{"cnt":[[125,1442],[1861,1442],[1861,1485],[125,1485]],"region":{"top_left_x":124,"top_left_y":1441,"width":1737,"height":44},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2f212511862444c09bcfc9042dd54b19","type":"text","conversion_output":true,"text":"receipt, samples will be processed using the same protocols as the parent VITAL trial, in order to avoid","text_display":" receipt, samples will be processed using the same protocols as the parent VITAL trial, in order to avoid","confidence":1,"confidence_rate":1},{"cnt":[[125,1487],[1944,1487],[1944,1528],[125,1528]],"region":{"top_left_x":124,"top_left_y":1486,"width":1821,"height":42},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"de9fc634bd5b4e71b016a1e44f5eb47b","type":"text","conversion_output":true,"text":"laboratory errors. Blood samples will be centrifuged to separate plasma and red blood cells, each aliquoted","text_display":" laboratory errors. Blood samples will be centrifuged to separate plasma and red blood cells, each aliquoted","confidence":1,"confidence_rate":1},{"cnt":[[125,1530],[1921,1530],[1921,1571],[125,1571]],"region":{"top_left_x":124,"top_left_y":1529,"width":1797,"height":42},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9133365563624ab5bacf6bccc0f1d5f3","type":"text","conversion_output":true,"text":"into \\(2- ml\\) Nunc vials. EDTA-plasma samples will be thawed for measurements of creatinine, cystatin C, C-","text_display":" into \\(2- ml\\) Nunc vials. EDTA-plasma samples will be thawed for measurements of creatinine, cystatin C, C","confidence":0.9709603973627168,"confidence_rate":0.9997415281733114},{"cnt":[[125,1573],[1987,1573],[1987,1618],[125,1618]],"region":{"top_left_x":124,"top_left_y":1572,"width":1864,"height":46},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e9c9e722a6c6450d972e1fd2b78dd5a9","type":"text","conversion_output":true,"text":"reactive protein, 25 -hydroxyvitamin D, and eicosapentaenoic acid and docosahexaenoic acid. Red blood cells","text_display":"reactive protein, 25 -hydroxyvitamin D, and eicosapentaenoic acid and docosahexaenoic acid. Red blood cells","confidence":0.83740234375,"confidence_rate":0.9984581409612947},{"cnt":[[122,1618],[1003,1618],[1003,1661],[122,1661]],"region":{"top_left_x":122,"top_left_y":1617,"width":882,"height":44},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"101503995b514caba00e1a4fac4794c8","type":"text","conversion_output":true,"text":"will be thawed for measurement of hemoglobin A1c.","text_display":" will be thawed for measurement of hemoglobin A1c.","confidence":1,"confidence_rate":1},{"cnt":[[125,1680],[1940,1680],[1940,1725],[125,1725]],"region":{"top_left_x":124,"top_left_y":1680,"width":1817,"height":46},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"40d4339e6f4343fea0820a7885cc60a6","type":"text","conversion_output":true,"text":"V.e. Interventions. All interventions will be provided by the parent VITAL trial and are included in the IRB","text_display":"\nV.e. Interventions. All interventions will be provided by the parent VITAL trial and are included in the IRB","confidence":0.9990236759185791,"confidence_rate":0.9999913557807578},{"cnt":[[125,1727],[1549,1727],[1549,1768],[125,1768]],"region":{"top_left_x":124,"top_left_y":1727,"width":1426,"height":42},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8971cde50a574dd3963b8053edd6f87c","type":"text","conversion_output":true,"text":"application for the parent VITAL trial. For completeness, these are described below.","text_display":" application for the parent VITAL trial. For completeness, these are described below.","confidence":0.99951171875,"confidence_rate":0.9999945123690109},{"cnt":[[125,1792],[1893,1792],[1893,1833],[125,1833]],"region":{"top_left_x":124,"top_left_y":1791,"width":1769,"height":42},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d34bff82e7d44d3aaf52d338e05944d2","type":"text","conversion_output":true,"text":"V.e.1. Cholecalciferol intervention. Active cholecalciferol (vitamin \\(D _{3}\\) ) and matching inert placebo will be","text_display":"\nV.e.1. Cholecalciferol intervention. Active cholecalciferol (vitamin \\(D _{3}\\) ) and matching inert placebo will be","confidence":0.9970724578015506,"confidence_rate":0.9999767317323609},{"cnt":[[125,1835],[1983,1835],[1983,1878],[125,1878]],"region":{"top_left_x":124,"top_left_y":1834,"width":1860,"height":44},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5fe8b6ca4f514ecbae2ad6a16c04b394","type":"text","conversion_output":true,"text":"provided by Pharmavite LLC. Cholecalciferol is recommended by many experts as the optimal form of vitamin","text_display":" provided by Pharmavite LLC. Cholecalciferol is recommended by many experts as the optimal form of vitamin","confidence":0.99853515625,"confidence_rate":0.9999866735644114},{"cnt":[[125,1878],[1953,1878],[1953,1921],[125,1921]],"region":{"top_left_x":124,"top_left_y":1877,"width":1829,"height":44},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5f4d8c6144774b49bd0a40686999b3f6","type":"text","conversion_output":true,"text":"D supplementation based on its known dose-response effects on \\(25( OH )\\) D concentration, documented long-","text_display":" D supplementation based on its known dose-response effects on \\(25( OH )\\) D concentration, documented long","confidence":0.6073164939880371,"confidence_rate":0.995596403884446},{"cnt":[[125,1916],[1979,1916],[1979,1966],[125,1966]],"region":{"top_left_x":124,"top_left_y":1916,"width":1855,"height":50},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1a143ccbfbaf4590b8b12afee7b37323","type":"text","conversion_output":true,"text":"term safety, and proven benefits in fracture reduction when used with calcium in the setting of osteoporosis. \\({ }^{61,}\\)","text_display":"term safety, and proven benefits in fracture reduction when used with calcium in the setting of osteoporosis. \\({ }^{61,}","confidence":0.99658203125,"confidence_rate":0.9999723889025679},{"cnt":[[125,1959],[1966,1959],[1966,2009],[125,2009]],"region":{"top_left_x":124,"top_left_y":1959,"width":1842,"height":50},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"932cbe4231cf41abbe4fc8fafeaa17bc","type":"text","conversion_output":true,"text":"\\({ }^{62,138}\\) Each active cholecalciferol study pill will contain \\(2000 IU (40 \\mu g)\\) cholecalciferol. This dose was chosen","text_display":" { }^{62,138}\\) Each active cholecalciferol study pill will contain \\(2000 IU (40 \\mu g)\\) cholecalciferol. This dose was chosen","confidence":0.6019078591034666,"confidence_rate":0.9960724547399038},{"cnt":[[122,2011],[1921,2011],[1921,2052],[122,2052]],"region":{"top_left_x":122,"top_left_y":2010,"width":1799,"height":42},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"588705a3d2b44026857064c524890504","type":"text","conversion_output":true,"text":"to maximize the separation in 25-hydroxyvitamin D concentration attained between treatment groups while","text_display":" to maximize the separation in 25-hydroxyvitamin D concentration attained between treatment groups while","confidence":0.53466796875,"confidence_rate":0.994219463228006},{"cnt":[[125,2054],[1949,2054],[1949,2099],[125,2099]],"region":{"top_left_x":124,"top_left_y":2053,"width":1825,"height":47},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5049aeb62bd84f3a93b7e3e25657fcd7","type":"text","conversion_output":true,"text":"maintaining safety. Specifically, cholecalciferol 2000 IU daily is conservatively anticipated to raise mean 25-","text_display":" maintaining safety. Specifically, cholecalciferol 2000 IU daily is conservatively anticipated to raise mean 25","confidence":0.9815254211425781,"confidence_rate":0.9998433117281256},{"cnt":[[125,2099],[1981,2099],[1981,2142],[125,2142]],"region":{"top_left_x":124,"top_left_y":2099,"width":1857,"height":43},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e85185a2502543c884aeeb63e3b1a48b","type":"text","conversion_output":true,"text":"hydroxyvitamin D concentration by approximately \\(16 ng / mL\\), while maintaining total daily cholecalciferol intake","text_display":"hydroxyvitamin D concentration by approximately \\(16 ng / mL\\), while maintaining total daily cholecalciferol intake","confidence":0.99951171875,"confidence_rate":0.9999960612940623},{"cnt":[[125,2142],[1897,2142],[1897,2185],[125,2185]],"region":{"top_left_x":124,"top_left_y":2141,"width":1774,"height":44},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"016ebdf597a440cc81b61fdc2d514d2e","type":"text","conversion_output":true,"text":"at or below the no-observed-adverse-effect level (NOAEL) specified by the Institute of Medicine, and well","text_display":" at or below the no-observed-adverse-effect level (NOAEL) specified by the Institute of Medicine, and well","confidence":1,"confidence_rate":1},{"cnt":[[125,2187],[1846,2187],[1846,2228],[125,2228]],"region":{"top_left_x":124,"top_left_y":2187,"width":1722,"height":41},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"aecd1d167ee64b728b24b064c2ac95a4","type":"text","conversion_output":true,"text":"below the 4000 IU NOAEL specified by the European Commission Scientific Committee on Food, with","text_display":" below the 4000 IU NOAEL specified by the European Commission Scientific Committee on Food, with","confidence":0.99951171875,"confidence_rate":0.9999952582588333},{"cnt":[[125,2224],[2000,2224],[2000,2273],[125,2273]],"region":{"top_left_x":124,"top_left_y":2223,"width":1877,"height":51},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ea2797d2acf34a5694a181d6b305ec64","type":"text","conversion_output":true,"text":"allowance for nonstudy use up to \\(800 IU / d .{ }^{62,138-140}\\) Study medications will be dispensed in calendar packs, with","text_display":" allowance for nonstudy use up to \\(800 IU / d .{ }^{62,138-140}\\) Study medications will be dispensed in calendar packs, with","confidence":0.6444195709191263,"confidence_rate":0.9966767066968119},{"cnt":[[125,2273],[1893,2273],[1893,2316],[125,2316]],"region":{"top_left_x":124,"top_left_y":2273,"width":1769,"height":44},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0fe098a328b84c50a1c0ac4a43077627","type":"text","conversion_output":true,"text":"participants asked to take one pill (cholecalciferol or placebo) each day. Participants will be instructed to","text_display":" participants asked to take one pill (cholecalciferol or placebo) each day. Participants will be instructed to","confidence":1,"confidence_rate":1},{"cnt":[[125,2316],[1931,2316],[1931,2361],[125,2361]],"region":{"top_left_x":124,"top_left_y":2316,"width":1808,"height":46},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"90194ddda9fa4dbbbbf3b12fc42897f8","type":"text","conversion_output":true,"text":"discontinue their study pills if, during follow-up, they receive a diagnosis of kidney stones or hypercalcemia.","text_display":" discontinue their study pills if, during follow-up, they receive a diagnosis of kidney stones or hypercalcemia.","confidence":0.9990234375,"confidence_rate":0.9999915772798866},{"cnt":[[125,2380],[1970,2380],[1970,2426],[125,2426]],"region":{"top_left_x":124,"top_left_y":2380,"width":1847,"height":46},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5103333f7b8142d9af77e861d4f0df58","type":"text","conversion_output":true,"text":"V.e.2. Omega-3 fatty acid intervention. Active fish oil ( 1000 mg capsule containing 840 mg EPA + DHA) and","text_display":"\nV.e.2. Omega-3 fatty acid intervention. Active fish oil ( 1000 mg capsule containing 840 mg EPA + DHA) and","confidence":0.723548453682497,"confidence_rate":0.9973292936579724},{"cnt":[[125,2428],[1953,2428],[1953,2469],[125,2469]],"region":{"top_left_x":124,"top_left_y":2427,"width":1829,"height":42},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b6347b7ceba84cd58599aea89906d171","type":"text","conversion_output":true,"text":"matching inert placebo will be provided by Pronova BioPharma ASA of Norway. Each active soft-gel capsule","text_display":" matching inert placebo will be provided by Pronova BioPharma ASA of Norway. Each active soft-gel capsule","confidence":1,"confidence_rate":1},{"cnt":[[122,2471],[1966,2471],[1966,2514],[122,2514]],"region":{"top_left_x":122,"top_left_y":2470,"width":1844,"height":44},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"dd0563b173b3405495297fc4c9f8d965","type":"text","conversion_output":true,"text":"will contain a total EPA+DHA dose of \\(840 mg / d\\), the highest dose of EPA + DHA currently available in a 1000","text_display":" will contain a total EPA+DHA dose of \\(840 mg / d\\), the highest dose of EPA + DHA currently available in a 1000","confidence":0.9712690813466907,"confidence_rate":0.9997550574712277},{"cnt":[[125,2514],[1987,2514],[1987,2559],[125,2559]],"region":{"top_left_x":124,"top_left_y":2513,"width":1864,"height":46},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c2f23b9ec2134bd5b5538415b89484af","type":"text","conversion_output":true,"text":"mg capsule. We believe that this dose provides the best balance of feasibility, efficacy and safety. We seek to","text_display":" mg capsule. We believe that this dose provides the best balance of feasibility, efficacy and safety. We seek to","confidence":0.998535871389322,"confidence_rate":0.9999875831152738},{"cnt":[[1959,2582],[2007,2582],[2007,2628],[1959,2628]],"region":{"top_left_x":1959,"top_left_y":2582,"width":48,"height":46},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"676fc4abe2194cb68126a063b7787d71","type":"page_info","conversion_output":false,"text":"15","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-16","page":16,"lines":[{"cnt":[[120,125],[1936,125],[1936,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":1816,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8bb89b62dbd44df8a97d3a9893e7f4fa","type":"text","conversion_output":true,"text":"obtain a large-enough difference in omega-3 fatty acid status between the treatment and placebo groups to","text_display":"\nobtain a large-enough difference in omega-3 fatty acid status between the treatment and placebo groups to","confidence":0.9873046875,"confidence_rate":0.9998838559581599},{"cnt":[[120,172],[1955,172],[1955,217],[120,217]],"region":{"top_left_x":120,"top_left_y":171,"width":1836,"height":46},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0cb905db48864f73b7f9773e3a2b58e1","type":"text","conversion_output":true,"text":"detect health benefits, and there appear to be few safety issues associated with this dose. Health authorities","text_display":" detect health benefits, and there appear to be few safety issues associated with this dose. Health authorities","confidence":1,"confidence_rate":1},{"cnt":[[120,211],[1824,211],[1824,260],[120,260]],"region":{"top_left_x":120,"top_left_y":210,"width":1705,"height":50},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"01a94d7d630545ee97530510dcd92833","type":"text","conversion_output":true,"text":"recommend 400 mg to \\(1 g / d\\) for cardioprotection. \\({ }^{141}\\) A total dose of \\(840 mg / d\\) was used in the GISSI-","text_display":" recommend 400 mg to \\(1 g / d\\) for cardioprotection. \\({ }^{141}\\) A total dose of \\(840 mg / d\\) was used in the GISSI","confidence":0.9474135756258875,"confidence_rate":0.9995999351639868},{"cnt":[[120,258],[1936,258],[1936,305],[120,305]],"region":{"top_left_x":120,"top_left_y":257,"width":1816,"height":49},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d0c52a07d658452b9f6ef4e781fd7942","type":"text","conversion_output":true,"text":"Prevenzione Trial (EPA to DHA ratio, 1:2) and AREDS 2 (EPA to DHA ratio, 2:1), while a dose of \\(1.8 g / d\\) of","text_display":"Prevenzione Trial (EPA to DHA ratio, 1:2) and AREDS 2 (EPA to DHA ratio, 2:1), while a dose of \\(1.8 g / d\\) of","confidence":0.9980475902557373,"confidence_rate":0.9999838487405106},{"cnt":[[120,301],[1970,301],[1970,350],[120,350]],"region":{"top_left_x":120,"top_left_y":300,"width":1851,"height":51},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"07a648e8266147f09caffda20211dfe4","type":"text","conversion_output":true,"text":"EPA was used in JELIS. For this trial, we have selected a total dose of omega-3 fatty acids recommended by","text_display":" EPA was used in JELIS. For this trial, we have selected a total dose of omega-3 fatty acids recommended by","confidence":0.6954610347747803,"confidence_rate":0.9967334522738145},{"cnt":[[120,346],[1893,346],[1893,393],[120,393]],"region":{"top_left_x":120,"top_left_y":345,"width":1773,"height":49},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"de137958c6e54e5684bf1a2e3e68c294","type":"text","conversion_output":true,"text":"the American Heart Association for cardioprotection and demonstrated to be beneficial in one secondary","text_display":" the American Heart Association for cardioprotection and demonstrated to be beneficial in one secondary","confidence":1,"confidence_rate":1},{"cnt":[[120,385],[1949,385],[1949,436],[120,436]],"region":{"top_left_x":120,"top_left_y":384,"width":1829,"height":53},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b551d28bce0a4de0903e32a133c4a515","type":"text","conversion_output":true,"text":"prevention population with minimal side effects. \\({ }^{142}\\) Because the optimal ratio of EPA to DHA is unknown, we","text_display":" prevention population with minimal side effects. \\({ }^{142}\\) Because the optimal ratio of EPA to DHA is unknown, we","confidence":1,"confidence_rate":1},{"cnt":[[120,434],[1985,434],[1985,479],[120,479]],"region":{"top_left_x":120,"top_left_y":433,"width":1866,"height":47},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3920506e24314a048b595c1e27422d3f","type":"text","conversion_output":true,"text":"have selected a 40:30 ratio of EPA to DHA. The ratio of omega-3 to omega-6 fatty acid intake is between 1:10","text_display":" have selected a 40:30 ratio of EPA to DHA. The ratio of omega-3 to omega-6 fatty acid intake is between 1:10","confidence":0.9936652099713683,"confidence_rate":0.999943763174685},{"cnt":[[120,477],[1957,477],[1957,524],[120,524]],"region":{"top_left_x":120,"top_left_y":476,"width":1838,"height":49},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cee94aaec20d44f6bde44f49ed4cd43f","type":"text","conversion_output":true,"text":"and 1:20 in most Western countries, including the U.S., whereas the optimal ratio for disease prevention has","text_display":" and 1:20 in most Western countries, including the U.S., whereas the optimal ratio for disease prevention has","confidence":0.916015625,"confidence_rate":0.999224001626721},{"cnt":[[120,520],[1815,520],[1815,569],[120,569]],"region":{"top_left_x":120,"top_left_y":519,"width":1696,"height":51},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d70b3154ea63473dbbe820ad5724ca68","type":"text","conversion_output":true,"text":"been hypothesized to be closer to \\(1: 1\\) or \\(1: 2\\), although this is controversial. Indeed, there is growing","text_display":" been hypothesized to be closer to \\(1: 1\\) or \\(1: 2\\), although this is controversial. Indeed, there is growing","confidence":0.8028304576873779,"confidence_rate":0.9980754357265932},{"cnt":[[120,563],[1897,563],[1897,612],[120,612]],"region":{"top_left_x":120,"top_left_y":562,"width":1778,"height":51},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a0a91fdc4b124d5eadce3130e36532a3","type":"text","conversion_output":true,"text":"consensus that the absolute intake of omega- 3 is a more important predictor of health than is the ratio of","text_display":" consensus that the absolute intake of omega- 3 is a more important predictor of health than is the ratio of","confidence":0.8740234375,"confidence_rate":0.9988298322475968},{"cnt":[[120,610],[1970,610],[1970,655],[120,655]],"region":{"top_left_x":120,"top_left_y":610,"width":1851,"height":46},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"99ffbba145794749829655a80c9690a8","type":"text","conversion_output":true,"text":"omega-3 to omega-6 intake, at least for cardiovascular outcomes. However, given that the average intake of","text_display":" omega-3 to omega-6 intake, at least for cardiovascular outcomes. However, given that the average intake of","confidence":0.9765737056732178,"confidence_rate":0.9997864637744143},{"cnt":[[120,653],[1955,653],[1955,700],[120,700]],"region":{"top_left_x":120,"top_left_y":653,"width":1836,"height":48},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c818f08da3a14418a0e79b493dc4fc28","type":"text","conversion_output":true,"text":"EPA+DHA is \\(100-200 mg / d\\) among U.S. adults, the proposed intervention of \\(840 mg / d\\) would be expected to","text_display":" EPA+DHA is \\(100-200 mg / d\\) among U.S. adults, the proposed intervention of \\(840 mg / d\\) would be expected to","confidence":0.9941432476043701,"confidence_rate":0.9999518538604503},{"cnt":[[120,696],[1923,696],[1923,746],[120,746]],"region":{"top_left_x":120,"top_left_y":696,"width":1803,"height":50},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"10bdf57292634cdcaf004628e48c14d4","type":"text","conversion_output":true,"text":"increase the average participant's omega- 3 intake by a factor of 4 to 8 . Assuming no concurrent change in","text_display":" increase the average participant's omega- 3 intake by a factor of 4 to 8 . Assuming no concurrent change in","confidence":0.9858527183532715,"confidence_rate":0.9998822523178967},{"cnt":[[120,741],[1934,741],[1934,788],[120,788]],"region":{"top_left_x":120,"top_left_y":741,"width":1814,"height":48},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"548b7018c3f845f2a9e582c0d85fd958","type":"text","conversion_output":true,"text":"omega-6 intake, the proposed omega-3 dose would thus have the effect of achieving the purported optimal","text_display":" omega-6 intake, the proposed omega-3 dose would thus have the effect of achieving the purported optimal","confidence":0.9345703125,"confidence_rate":0.9993736368571003},{"cnt":[[120,786],[1695,786],[1695,831],[120,831]],"region":{"top_left_x":120,"top_left_y":786,"width":1576,"height":46},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cede98b1f83848779a71890b418ae7f7","type":"text","conversion_output":true,"text":"omega-3 to omega-6 ratio and providing intakes associated with benefits in previous studies.","text_display":" omega-3 to omega-6 ratio and providing intakes associated with benefits in previous studies.","confidence":0.99951171875,"confidence_rate":0.9999949649559944},{"cnt":[[180,849],[1979,849],[1979,898],[180,898]],"region":{"top_left_x":180,"top_left_y":848,"width":1799,"height":51},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"84a535aee8944a18b019d6935348d070","type":"text","conversion_output":true,"text":"As with vitamin D, potential side effects of omega-3 fatty acids are rare. They include gastrointestinal (GI)","text_display":"\n\nAs with vitamin D, potential side effects of omega-3 fatty acids are rare. They include gastrointestinal (GI)","confidence":0.9805040191859007,"confidence_rate":0.9998273084722372},{"cnt":[[120,894],[1871,894],[1871,941],[120,941]],"region":{"top_left_x":120,"top_left_y":893,"width":1752,"height":49},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"245749293de8432496c13c927e4ce139","type":"text","conversion_output":true,"text":"symptoms (stomach upset or pain, nausea, constipation, diarrhea), bleeding (any GI bleed, GI bleeding","text_display":" symptoms (stomach upset or pain, nausea, constipation, diarrhea), bleeding (any GI bleed, GI bleeding","confidence":0.9853813648223877,"confidence_rate":0.9998610800244865},{"cnt":[[120,937],[1970,937],[1970,986],[120,986]],"region":{"top_left_x":120,"top_left_y":936,"width":1851,"height":51},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e71809e6ed484b22ac4d7a71ee75b4d0","type":"text","conversion_output":true,"text":"requiring transfusion, hematuria, easy bruising, epistaxis), skin rash, colds or upper respiratory tract infection,","text_display":" requiring transfusion, hematuria, easy bruising, epistaxis), skin rash, colds or upper respiratory tract infection,","confidence":1,"confidence_rate":1},{"cnt":[[120,982],[1944,982],[1944,1029],[120,1029]],"region":{"top_left_x":120,"top_left_y":981,"width":1825,"height":49},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9d39c73b694a421ab5f5ef6361d8cfca","type":"text","conversion_output":true,"text":"flu-like symptoms, bad taste in mouth, and physician diagnosis of atrial fibrillation or other irregular rhythms.","text_display":" flu-like symptoms, bad taste in mouth, and physician diagnosis of atrial fibrillation or other irregular rhythms.","confidence":1,"confidence_rate":1},{"cnt":[[120,1025],[1927,1025],[1927,1072],[120,1072]],"region":{"top_left_x":120,"top_left_y":1024,"width":1808,"height":49},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"41a0ce92d13d492bacbb4b5e570054e6","type":"text","conversion_output":true,"text":"The FDA has concluded that marine omega- 3 fatty acid doses of up to \\(3 g / d\\) are \"Generally Recognized as","text_display":" The FDA has concluded that marine omega- 3 fatty acid doses of up to \\(3 g / d\\) are \"Generally Recognized as","confidence":0.85009765625,"confidence_rate":0.9986361909483404},{"cnt":[[120,1070],[1919,1070],[1919,1117],[120,1117]],"region":{"top_left_x":120,"top_left_y":1069,"width":1799,"height":49},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5718e2f66b5d44998b73bdc9751513b6","type":"text","conversion_output":true,"text":"Safe.\" The AHA also has concluded that these risks are very low or low at doses of up to \\(1 g / d\\) and low to","text_display":" Safe.\" The AHA also has concluded that these risks are very low or low at doses of up to \\(1 g / d\\) and low to","confidence":1,"confidence_rate":1},{"cnt":[[120,1113],[1931,1113],[1931,1162],[120,1162]],"region":{"top_left_x":120,"top_left_y":1112,"width":1812,"height":51},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4cad2fe3dd9a4beb882feb1370974dab","type":"text","conversion_output":true,"text":"moderate at doses of \\(1-3 g / d\\). Because they undergo an extensive purification process, high-quality fish oil","text_display":" moderate at doses of \\(1-3 g / d\\). Because they undergo an extensive purification process, high-quality fish oil","confidence":0.99853515625,"confidence_rate":0.9999878850512172},{"cnt":[[120,1158],[1916,1158],[1916,1205],[120,1205]],"region":{"top_left_x":120,"top_left_y":1158,"width":1797,"height":48},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7005945d7af54be2be8cf488343f3488","type":"text","conversion_output":true,"text":"supplements are free of environmental toxins (e.g., methylmercury, polychlorinated biphenyls [PCBs], and","text_display":" supplements are free of environmental toxins (e.g., methylmercury, polychlorinated biphenyls [PCBs], and","confidence":0.99951171875,"confidence_rate":0.9999955192715237},{"cnt":[[120,1199],[1405,1199],[1405,1248],[120,1248]],"region":{"top_left_x":120,"top_left_y":1198,"width":1286,"height":51},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8d22131dc320416ea759b8ee8df37924","type":"text","conversion_output":true,"text":"dioxins) found in some fish. The \\(\\omega-3\\) FA supplement contains no vitamin D.","text_display":" dioxins) found in some fish. The \\(\\omega-3\\) FA supplement contains no vitamin D.","confidence":0.5838329994136053,"confidence_rate":0.9933783132607795},{"cnt":[[1955,2580],[2009,2580],[2009,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2580,"width":54,"height":48},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d3dd2abf247e41f48895c178cf7da304","type":"page_info","conversion_output":false,"text":"16","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-17","page":17,"lines":[{"cnt":[[116,125],[501,125],[501,176],[116,176]],"region":{"top_left_x":116,"top_left_y":124,"width":385,"height":53},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"36001190d66c491fa07e59c3f250757a","type":"section_header","conversion_output":false,"children_ids":["c070f92187024cf6b8ba5f3e18188353"],"text":"","text_display":""},{"cnt":[[120,129],[501,129],[501,174],[120,174]],"region":{"top_left_x":120,"top_left_y":128,"width":381,"height":47},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c070f92187024cf6b8ba5f3e18188353","type":"text","conversion_output":true,"parent_id":"36001190d66c491fa07e59c3f250757a","text":"VI. Analysis plan","text_display":"\n\n\\section*{VI. Analysis plan}","confidence":1,"confidence_rate":1},{"cnt":[[122,193],[1846,193],[1846,238],[122,238]],"region":{"top_left_x":122,"top_left_y":193,"width":1724,"height":46},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9c17b4a334814393ab2ece4f8706ad9a","type":"text","conversion_output":true,"text":"VI.a. Descriptive analyses. We will describe creation of the VITAL diabetes sub-cohort according to","text_display":"\nVI.a. Descriptive analyses. We will describe creation of the VITAL diabetes sub-cohort according to","confidence":1,"confidence_rate":1},{"cnt":[[122,236],[1929,236],[1929,281],[122,281]],"region":{"top_left_x":122,"top_left_y":236,"width":1808,"height":46},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2b7cd514f244467fa687d68d6eb6561d","type":"text","conversion_output":true,"text":"CONSORT guidelines, including numbers of participants who consent to VITAL participation; self-identify a","text_display":" CONSORT guidelines, including numbers of participants who consent to VITAL participation; self-identify a","confidence":1,"confidence_rate":1},{"cnt":[[120,279],[1951,279],[1951,324],[120,324]],"region":{"top_left_x":120,"top_left_y":279,"width":1831,"height":46},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"422ae7b5004e45ad9e3a97ac9f6458bb","type":"text","conversion_output":true,"text":"diagnosis of diabetes; consent to participation in the DKD ancillary study; complete baseline urine and blood","text_display":" diagnosis of diabetes; consent to participation in the DKD ancillary study; complete baseline urine and blood","confidence":1,"confidence_rate":1},{"cnt":[[122,322],[1992,322],[1992,367],[122,367]],"region":{"top_left_x":122,"top_left_y":322,"width":1870,"height":46},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ecdb98b4626a4f9097c6f8a998be06ef","type":"text","conversion_output":true,"text":"collections; and complete year 4 urine and/or blood collections. We will document reasons that participants do","text_display":" collections; and complete year 4 urine and/or blood collections. We will document reasons that participants do","confidence":1,"confidence_rate":1},{"cnt":[[120,367],[1992,367],[1992,412],[120,412]],"region":{"top_left_x":120,"top_left_y":367,"width":1872,"height":46},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9171fd5db9054001a8fdab3752fc0489","type":"text","conversion_output":true,"text":"not complete the proposed studies, e.g. death, withdrawal of consent, or loss to follow-up. Among participants","text_display":" not complete the proposed studies, e.g. death, withdrawal of consent, or loss to follow-up. Among participants","confidence":1,"confidence_rate":1},{"cnt":[[120,412],[1931,412],[1931,458],[120,458]],"region":{"top_left_x":120,"top_left_y":412,"width":1812,"height":46},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"654df2ad228f4943a7f40565b37d5502","type":"text","conversion_output":true,"text":"recruited into the DKD ancillary study, we will compare baseline characteristics of those who do and do not","text_display":" recruited into the DKD ancillary study, we will compare baseline characteristics of those who do and do not","confidence":1,"confidence_rate":1},{"cnt":[[120,455],[1949,455],[1949,501],[120,501]],"region":{"top_left_x":120,"top_left_y":455,"width":1829,"height":46},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4eba00ec86594a37a8845a0ee936a0b8","type":"text","conversion_output":true,"text":"complete year 4 biospecimen collections in order to assess the potential impact of loss to follow-up. Among","text_display":" complete year 4 biospecimen collections in order to assess the potential impact of loss to follow-up. Among","confidence":0.99755859375,"confidence_rate":0.9999787446490132},{"cnt":[[120,501],[1803,501],[1803,544],[120,544]],"region":{"top_left_x":120,"top_left_y":500,"width":1683,"height":44},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"46d3c542f79f469581b224c1fc075b0f","type":"text","conversion_output":true,"text":"participants who complete year 4 biospecimens, we will describe by treatment assignment baseline","text_display":" participants who complete year 4 biospecimens, we will describe by treatment assignment baseline","confidence":0.99951171875,"confidence_rate":0.9999953038523912},{"cnt":[[120,544],[1515,544],[1515,589],[120,589]],"region":{"top_left_x":120,"top_left_y":543,"width":1395,"height":46},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8f31e723506c4b70a54318c14e8198e8","type":"text","conversion_output":true,"text":"characteristics and changes in clinical characteristics over the course of the study.","text_display":" characteristics and changes in clinical characteristics over the course of the study.","confidence":1,"confidence_rate":1},{"cnt":[[122,608],[1970,608],[1970,655],[122,655]],"region":{"top_left_x":122,"top_left_y":608,"width":1849,"height":48},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6cc57a0c7e4642a38072fc7ca05148e9","type":"text","conversion_output":true,"text":"VI.b. Primary study outcome. The primary outcome of this study is change in urine albumin-creatinine ratio","text_display":"\nVI.b. Primary study outcome. The primary outcome of this study is change in urine albumin-creatinine ratio","confidence":1,"confidence_rate":1},{"cnt":[[122,653],[1949,653],[1949,698],[122,698]],"region":{"top_left_x":122,"top_left_y":653,"width":1827,"height":46},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"acdde595c54f4ea2ab3b619c6f0dcd00","type":"text","conversion_output":true,"text":"(ACR) from baseline to year 4 , analyzed as a continuous variable. We will examine percent change in urine","text_display":" (ACR) from baseline to year 4 , analyzed as a continuous variable. We will examine percent change in urine","confidence":0.5078125,"confidence_rate":0.9940733952322185},{"cnt":[[120,696],[1897,696],[1897,741],[120,741]],"region":{"top_left_x":120,"top_left_y":696,"width":1778,"height":46},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9605df2db09d4c6ebcc290e6a7de78f8","type":"text","conversion_output":true,"text":"ACR, because relative increases in urine ACR have been roughly linearly associated with adverse health","text_display":" ACR, because relative increases in urine ACR have been roughly linearly associated with adverse health","confidence":1,"confidence_rate":1},{"cnt":[[120,741],[1996,741],[1996,784],[120,784]],"region":{"top_left_x":120,"top_left_y":741,"width":1876,"height":44},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a54992d6aa1847559151a16b331b4896","type":"text","conversion_output":true,"text":"parameters and outcomes in the published literature, and because the distribution of urine ACR and its change","text_display":" parameters and outcomes in the published literature, and because the distribution of urine ACR and its change","confidence":1,"confidence_rate":1},{"cnt":[[120,778],[1983,778],[1983,827],[120,827]],"region":{"top_left_x":120,"top_left_y":777,"width":1864,"height":51},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"634b7796fc1542f894d9ef7d7e7bd959","type":"text","conversion_output":true,"text":"over time are normalized by log transformation. \\({ }^{21,38,143,144}\\) Percent change in urine ACR will be calculated and","text_display":" over time are normalized by log transformation. \\({ }^{21,38,143,144}\\) Percent change in urine ACR will be calculated and","confidence":0.9883010317571461,"confidence_rate":0.9999073433509325},{"cnt":[[120,827],[1946,827],[1946,872],[120,872]],"region":{"top_left_x":120,"top_left_y":827,"width":1827,"height":46},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2f9a31a173a84bdaade37a0d764bb30f","type":"text","conversion_output":true,"text":"summarized by treatment group as \\(\\left[\\left(A C R_{4}-A C R_{0}\\right) / A C R_{0}\\right]\\), where \\(ACR _{4}\\) represents urine ACR at follow-up","text_display":" summarized by treatment group as \\(\\left[\\left(A C R_{4}-A C R_{0}\\right) / A C R_{0}\\right]\\), where \\(ACR _{4}\\) represents urine ACR at follow-up","confidence":0.5330057582108028,"confidence_rate":0.9955156345599664},{"cnt":[[120,872],[1021,872],[1021,917],[120,917]],"region":{"top_left_x":120,"top_left_y":872,"width":901,"height":46},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"dd06df5be6e24aeaa74b20a73a56be5a","type":"text","conversion_output":true,"text":"(year 4) and \\(ACR _{0}\\) represents urine ACR at baseline.","text_display":" (year 4) and \\(ACR _{0}\\) represents urine ACR at baseline.","confidence":0.7825762014107701,"confidence_rate":0.9967364838258822},{"cnt":[[122,937],[1858,937],[1858,982],[122,982]],"region":{"top_left_x":122,"top_left_y":936,"width":1737,"height":46},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"104723c3b95240c3929f9d215e533055","type":"text","conversion_output":true,"text":"VI.c. Secondary study outcomes. As a secondary dichotomous outcome, we will examine change in","text_display":"\nVI.c. Secondary study outcomes. As a secondary dichotomous outcome, we will examine change in","confidence":0.9960978019516915,"confidence_rate":0.9999601045561738},{"cnt":[[120,980],[1996,980],[1996,1025],[120,1025]],"region":{"top_left_x":120,"top_left_y":979,"width":1876,"height":46},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f01b3fe5361c4cb78bd8f4ed65ae765e","type":"text","conversion_output":true,"text":"estimated glomerular filtration rate (eGFR) from baseline to year 4, analyzed as a continuous variable. We will","text_display":" estimated glomerular filtration rate (eGFR) from baseline to year 4, analyzed as a continuous variable. We will","confidence":1,"confidence_rate":1},{"cnt":[[120,1070],[120,1023],[1910,1025],[1910,1072]],"region":{"top_left_x":120,"top_left_y":1022,"width":1791,"height":51},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8833b37aa71145828c14858cbc0fb7ed","type":"text","conversion_output":true,"text":"measure plasma concentrations of both creatinine and cystatin C to estimate GFR using the most precise","text_display":" measure plasma concentrations of both creatinine and cystatin C to estimate GFR using the most precise","confidence":0.99951171875,"confidence_rate":0.9999954355197808},{"cnt":[[120,1068],[1998,1068],[1998,1113],[120,1113]],"region":{"top_left_x":120,"top_left_y":1067,"width":1879,"height":46},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"89f26209e54b476fa0b86c48b119c4f0","type":"text","conversion_output":true,"text":"serologic methods available. Specifically, data from multiple community-based studies have been combined to","text_display":" serologic methods available. Specifically, data from multiple community-based studies have been combined to","confidence":1,"confidence_rate":1},{"cnt":[[120,1113],[1966,1113],[1966,1158],[120,1158]],"region":{"top_left_x":120,"top_left_y":1112,"width":1846,"height":47},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d8b565b4e84643dab88fba3c32cb00a3","type":"text","conversion_output":true,"text":"create and validate an equation which calculates estimated GFR from serum creatinine and cystatin C, along","text_display":" create and validate an equation which calculates estimated GFR from serum creatinine and cystatin C, along","confidence":0.99951171875,"confidence_rate":0.9999956000051925},{"cnt":[[120,1147],[645,1147],[645,1201],[120,1201]],"region":{"top_left_x":120,"top_left_y":1147,"width":525,"height":54},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"af1aca620df047b4836621f4751b3549","type":"text","conversion_output":true,"text":"with demographic variables. \\({ }^{145}\\)","text_display":" with demographic variables. \\({ }^{145}\\)","confidence":1,"confidence_rate":1},{"cnt":[[245,1212],[1944,1212],[1944,1274],[245,1274]],"region":{"top_left_x":244,"top_left_y":1211,"width":1701,"height":64},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6257fd6eed034d569815a2594f716fd5","type":"text","conversion_output":true,"text":"Equation 1: Estimated GFR \\(=177.6 \\times SCr ^{-0.65} \\times CysC ^{-0.57} \\times\\) age \\({ }^{-0.20} \\times\\) ( 0.82 if female) x ( 1.11 if black)","text_display":"\n\nEquation 1: Estimated GFR \\(=177.6 \\times SCr ^{-0.65} \\times CysC ^{-0.57} \\times\\) age \\({ }^{-0.20} \\times\\) ( 0.82 if female) x ( 1.11 if black)","confidence":0.08717251045807488,"confidence_rate":0.9836495608246401},{"cnt":[[120,1289],[1919,1289],[1919,1334],[120,1334]],"region":{"top_left_x":120,"top_left_y":1289,"width":1799,"height":46},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2b32f813a8064aa6a1ae118c7503c535","type":"text","conversion_output":true,"text":"where SCr is serum creatinine ( \\(mg / dL\\) ) and CysC is cystatin \\(C ( mg / L )\\). GFR estimated using this equation","text_display":"\nwhere SCr is serum creatinine ( \\(mg / dL\\) ) and CysC is cystatin \\(C ( mg / L )\\). GFR estimated using this equation","confidence":0.9543690036450986,"confidence_rate":0.9996711464359757},{"cnt":[[120,1332],[1852,1332],[1852,1377],[120,1377]],"region":{"top_left_x":120,"top_left_y":1332,"width":1732,"height":46},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4cbd77a9bf124e8eaef91059e981839b","type":"text","conversion_output":true,"text":"captures 89\\% of variation in GFR measured using radionucleotide methods. In addition, use of serum","text_display":" captures 89\\% of variation in GFR measured using radionucleotide methods. In addition, use of serum","confidence":0.99462890625,"confidence_rate":0.9999477142802217},{"cnt":[[120,1377],[1888,1377],[1888,1422],[120,1422]],"region":{"top_left_x":120,"top_left_y":1377,"width":1769,"height":46},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"10633e5e76e24196958800c726203b9e","type":"text","conversion_output":true,"text":"creatinine and serum cystatin C in combination to estimate GFR offers important theoretical advantages.","text_display":" creatinine and serum cystatin C in combination to estimate GFR offers important theoretical advantages.","confidence":0.99951171875,"confidence_rate":0.9999954777833909},{"cnt":[[120,1422],[2000,1422],[2000,1467],[120,1467]],"region":{"top_left_x":120,"top_left_y":1422,"width":1881,"height":46},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"781f0714428746b496ad8a4e04b55967","type":"text","conversion_output":true,"text":"Serum cystatin C concentration appears to be more sensitive to mild decrements in kidney function than serum","text_display":" Serum cystatin C concentration appears to be more sensitive to mild decrements in kidney function than serum","confidence":0.9951193332672119,"confidence_rate":0.999956703449862},{"cnt":[[120,1461],[1987,1461],[1987,1510],[120,1510]],"region":{"top_left_x":120,"top_left_y":1460,"width":1868,"height":51},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"78f7d64ab8764d3da1a549455e01dc3f","type":"text","conversion_output":true,"text":"creatinine, such that inclusion of cystatin C may aid detection of changes in GFR within the \"normal\" range. \\({ }^{146-}\\)","text_display":" creatinine, such that inclusion of cystatin C may aid detection of changes in GFR within the \"normal\" range. \\({ }^{146-}","confidence":0.9946362947812304,"confidence_rate":0.9999566288314421},{"cnt":[[120,1504],[1841,1504],[1841,1553],[120,1553]],"region":{"top_left_x":120,"top_left_y":1503,"width":1722,"height":51},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b31e8a40f7fb4b0b8b8039605153a8fb","type":"text","conversion_output":true,"text":"\\({ }^{148}\\) However, some reports suggest that serum cystatin C concentration may be affected by systemic","text_display":" { }^{148}\\) However, some reports suggest that serum cystatin C concentration may be affected by systemic","confidence":0.8308918476104736,"confidence_rate":0.9983762702053501},{"cnt":[[120,1549],[1992,1549],[1992,1601],[120,1601]],"region":{"top_left_x":120,"top_left_y":1549,"width":1872,"height":52},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3313478854b3497fbbfb2585f50defad","type":"text","conversion_output":true,"text":"inflammation. \\({ }^{149,150}\\) This influence may be moderated by combination with creatinine. We will examine change","text_display":" inflammation. \\({ }^{149,150}\\) This influence may be moderated by combination with creatinine. We will examine change","confidence":0.99951171875,"confidence_rate":0.9999960292721264},{"cnt":[[120,1596],[1979,1596],[1979,1644],[120,1644]],"region":{"top_left_x":120,"top_left_y":1596,"width":1859,"height":48},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2588032ece404d118ee2ae5a2128c5db","type":"text","conversion_output":true,"text":"in eGFR without transformation, because absolute differences in eGFR have been roughly linearly associated","text_display":" in eGFR without transformation, because absolute differences in eGFR have been roughly linearly associated","confidence":1,"confidence_rate":1},{"cnt":[[120,1641],[2004,1641],[2004,1687],[120,1687]],"region":{"top_left_x":120,"top_left_y":1641,"width":1885,"height":46},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4441cc62057740d0aa67002be97e52a3","type":"text","conversion_output":true,"text":"with adverse health parameters and outcomes in the published literature, and because the distribution of eGFR","text_display":" with adverse health parameters and outcomes in the published literature, and because the distribution of eGFR","confidence":1,"confidence_rate":1},{"cnt":[[120,1680],[1910,1680],[1910,1729],[120,1729]],"region":{"top_left_x":120,"top_left_y":1680,"width":1790,"height":50},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c19c31b094204be7a57bedc09f3154b3","type":"text","conversion_output":true,"text":"and its change over time is roughly normal. \\({ }^{18,34,37}\\) Change in eGFR will be calculated and summarized by","text_display":" and its change over time is roughly normal. \\({ }^{18,34,37}\\) Change in eGFR will be calculated and summarized by","confidence":0.994140625,"confidence_rate":0.9999506179547201},{"cnt":[[120,1727],[765,1727],[765,1777],[120,1777]],"region":{"top_left_x":120,"top_left_y":1727,"width":645,"height":50},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"910019b91ee347a198b9d753bc8995ef","type":"text","conversion_output":true,"text":"treatment group as \\(\\left[e G F R_{4}-e G F R_{0}\\right]\\).","text_display":" treatment group as \\(\\left[e G F R_{4}-e G F R_{0}\\right]\\).","confidence":0.97607421875,"confidence_rate":0.9995676532805938},{"cnt":[[180,1792],[1867,1792],[1867,1841],[180,1841]],"region":{"top_left_x":180,"top_left_y":1791,"width":1687,"height":51},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"61fcfa1085bc4b71954e91cb0c860155","type":"text","conversion_output":true,"text":"As an additional secondary outcomes, we will examine the proportion of participants who develop a","text_display":"\n\nAs an additional secondary outcomes, we will examine the proportion of participants who develop a","confidence":1,"confidence_rate":1},{"cnt":[[120,1835],[1919,1835],[1919,1884],[120,1884]],"region":{"top_left_x":120,"top_left_y":1834,"width":1799,"height":51},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"03a5339230d84381892a08cc0ab35009","type":"text","conversion_output":true,"text":"composite outcome of albuminuria progression ( \\(100 \\%\\) increase in urine ACR and a year 4 urine ACR \\(\\geq 30\\)","text_display":" composite outcome of albuminuria progression ( \\(100 \\%\\) increase in urine ACR and a year 4 urine ACR \\(\\geq 30","confidence":1,"confidence_rate":1},{"cnt":[[120,1882],[2000,1882],[2000,1927],[120,1927]],"region":{"top_left_x":120,"top_left_y":1882,"width":1881,"height":46},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8e18e890aa8244e8a67792862d54a205","type":"text","conversion_output":true,"text":"\\(mg / g\\) ), rapid loss of eGFR (loss of eGFR \\(\\geq 12 mL / min\\) over the 4 -year interval), ESRD (maintenance dialysis or","text_display":" mg / g\\) ), rapid loss of eGFR (loss of eGFR \\(\\geq 12 mL / min\\) over the 4 -year interval), ESRD (maintenance dialysis or","confidence":0.5692678856430575,"confidence_rate":0.9956754995832203},{"cnt":[[120,1925],[1893,1925],[1893,1970],[120,1970]],"region":{"top_left_x":120,"top_left_y":1925,"width":1773,"height":46},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8328302d7a42467cb7005f50370150fd","type":"text","conversion_output":true,"text":"kidney transplant verified by medical records review), and/or death. This composite outcome serves two","text_display":" kidney transplant verified by medical records review), and/or death. This composite outcome serves two","confidence":1,"confidence_rate":1},{"cnt":[[120,1968],[1964,1968],[1964,2015],[120,2015]],"region":{"top_left_x":120,"top_left_y":1967,"width":1844,"height":49},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a264dfa229444e2d81007decb49cbc8e","type":"text","conversion_output":true,"text":"purposes. First, it addresses large changes in DKD which have particularly high clinical impact. Second, the","text_display":" purposes. First, it addresses large changes in DKD which have particularly high clinical impact. Second, the","confidence":1,"confidence_rate":1},{"cnt":[[120,2013],[1944,2013],[1944,2058],[120,2058]],"region":{"top_left_x":120,"top_left_y":2013,"width":1825,"height":46},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"144963cf0bd541a0b98f6b108904a133","type":"text","conversion_output":true,"text":"composite outcome reduces the potential impact of competing risks that preclude assessment of urine ACR","text_display":" composite outcome reduces the potential impact of competing risks that preclude assessment of urine ACR","confidence":1,"confidence_rate":1},{"cnt":[[120,2056],[1901,2056],[1901,2103],[120,2103]],"region":{"top_left_x":120,"top_left_y":2056,"width":1782,"height":48},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9fd8b37c3cd34540a4c43df98d2b88d4","type":"text","conversion_output":true,"text":"and/or eGFR at follow-up. Accounting for competing risks will be particularly important if the incidence of","text_display":" and/or eGFR at follow-up. Accounting for competing risks will be particularly important if the incidence of","confidence":1,"confidence_rate":1},{"cnt":[[120,2101],[1876,2101],[1876,2146],[120,2146]],"region":{"top_left_x":120,"top_left_y":2101,"width":1756,"height":46},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c258971b76c048dc98afc6fe13db1d50","type":"text","conversion_output":true,"text":"ESRD and/or death differs by treatment assignment. The composite endpoint is scientifically important,","text_display":" ESRD and/or death differs by treatment assignment. The composite endpoint is scientifically important,","confidence":0.99951171875,"confidence_rate":0.9999954355197808},{"cnt":[[120,2144],[1850,2144],[1850,2191],[120,2191]],"region":{"top_left_x":120,"top_left_y":2144,"width":1730,"height":48},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"02602a8adf9445d3b440de4852ec65eb","type":"text","conversion_output":true,"text":"because each component is a clinically relevant diabetes outcome and progression of DKD is strongly","text_display":" because each component is a clinically relevant diabetes outcome and progression of DKD is strongly","confidence":1,"confidence_rate":1},{"cnt":[[120,2187],[1897,2187],[1897,2237],[120,2237]],"region":{"top_left_x":120,"top_left_y":2187,"width":1778,"height":50},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0e13c63782704257a8077be1caee8862","type":"text","conversion_output":true,"text":"associated with ESRD and death. A \\(100 \\%\\) increase in urine ACR is generally considered to have clinical","text_display":" associated with ESRD and death. A \\(100 \\%\\) increase in urine ACR is generally considered to have clinical","confidence":1,"confidence_rate":1},{"cnt":[[120,2230],[1949,2230],[1949,2279],[120,2279]],"region":{"top_left_x":120,"top_left_y":2230,"width":1829,"height":50},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4e637b5be22a4f2d866bbe0f8cfa303b","type":"text","conversion_output":true,"text":"relevance, and additional inclusion of a threshold ( \\(30 mg / g\\) ) will reduce the potential impact of measurement","text_display":" relevance, and additional inclusion of a threshold ( \\(30 mg / g\\) ) will reduce the potential impact of measurement","confidence":1,"confidence_rate":1},{"cnt":[[120,2275],[1901,2275],[1901,2322],[120,2322]],"region":{"top_left_x":120,"top_left_y":2275,"width":1782,"height":48},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ff057705b71442ffae639987373cdebc","type":"text","conversion_output":true,"text":"error among persons with \"normal\" levels of albuminuria near the limits of assay reliability. Loss of eGFR","text_display":" error among persons with \"normal\" levels of albuminuria near the limits of assay reliability. Loss of eGFR","confidence":1,"confidence_rate":1},{"cnt":[[120,2320],[1893,2320],[1893,2365],[120,2365]],"region":{"top_left_x":120,"top_left_y":2320,"width":1773,"height":46},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d68db5de60204aa8bb5ca16687ad04dd","type":"text","conversion_output":true,"text":"exceeding \\(12 mL / min\\) over the 4-year interval ( \\(3 mL / min /\\) year) has been associated with increased risk of","text_display":" exceeding \\(12 mL / min\\) over the 4-year interval ( \\(3 mL / min /\\) year) has been associated with increased risk of","confidence":0.4500436681806086,"confidence_rate":0.9936834413208734},{"cnt":[[120,2359],[1128,2359],[1128,2408],[120,2408]],"region":{"top_left_x":120,"top_left_y":2358,"width":1008,"height":51},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ed93b49189a7419594298fc354afb281","type":"text","conversion_output":true,"text":"mortality among older adults with and without diabetes. \\({ }^{34,37}\\)","text_display":" mortality among older adults with and without diabetes. \\({ }^{34,37}\\)","confidence":1,"confidence_rate":1},{"cnt":[[122,2428],[1895,2428],[1895,2477],[122,2477]],"region":{"top_left_x":122,"top_left_y":2427,"width":1773,"height":51},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c63619ef570f4746b9d7b44b0a50f35a","type":"text","conversion_output":true,"text":"VI.d. Interaction of cholecalciferol and \\(\\omega-3\\) FA. We will assess for interaction of the study interventions","text_display":"\nVI.d. Interaction of cholecalciferol and \\(\\omega-3\\) FA. We will assess for interaction of the study interventions","confidence":0.9820418342037206,"confidence_rate":0.9998410532429101},{"cnt":[[122,2471],[1882,2471],[1882,2520],[122,2520]],"region":{"top_left_x":122,"top_left_y":2470,"width":1761,"height":51},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"52ac2f93919143449a1c93cb5492a388","type":"text","conversion_output":true,"text":"(vitamin D and \\(\\omega-3\\) FA) for each of the primary and secondary study outcomes. First, we will assess for","text_display":" (vitamin D and \\(\\omega-3\\) FA) for each of the primary and secondary study outcomes. First, we will assess for","confidence":0.8694559298455715,"confidence_rate":0.9987291025391535},{"cnt":[[120,2518],[1923,2518],[1923,2563],[120,2563]],"region":{"top_left_x":120,"top_left_y":2517,"width":1803,"height":47},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3f7d8fa042ea4386a5b789cd5dcf2ac6","type":"text","conversion_output":true,"text":"interaction on the additive scale. Differences in each study outcome comparing the treatment group which","text_display":" interaction on the additive scale. Differences in each study outcome comparing the treatment group which","confidence":1,"confidence_rate":1},{"cnt":[[1959,2582],[2007,2582],[2007,2628],[1959,2628]],"region":{"top_left_x":1959,"top_left_y":2582,"width":48,"height":46},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6d141a8e2e4c464cb0c833460d30dba8","type":"page_info","conversion_output":false,"text":"17","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-18","page":18,"lines":[{"cnt":[[120,125],[1921,125],[1921,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":1801,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"48a3ce14a2e14e3fbb778cb3bd2f028a","type":"text","conversion_output":true,"text":"receives both active study medications (vitamin \\(D +\\omega-3 FA\\) ) to the treatment group which receives neither","text_display":"\nreceives both active study medications (vitamin \\(D +\\omega-3 FA\\) ) to the treatment group which receives neither","confidence":0.6157118124371852,"confidence_rate":0.9958634827984132},{"cnt":[[120,172],[1996,172],[1996,217],[120,217]],"region":{"top_left_x":120,"top_left_y":171,"width":1876,"height":46},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"345613e2784b420fa1f415caaaca8201","type":"text","conversion_output":true,"text":"(placebo + placebo) will be compared to the sum of differences comparing treatment groups receiving only one","text_display":" (placebo + placebo) will be compared to the sum of differences comparing treatment groups receiving only one","confidence":0.6227941513061523,"confidence_rate":0.9958181557095063},{"cnt":[[120,215],[1987,215],[1987,260],[120,260]],"region":{"top_left_x":120,"top_left_y":214,"width":1868,"height":46},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"849c2c979fa14f1aa60ac83b591b8d04","type":"text","conversion_output":true,"text":"medication (vitamin \\(D +\\) placebo, or placebo \\(+\\omega-3 FA\\) ) to the treatment group which receives neither (placebo","text_display":" medication (vitamin \\(D +\\) placebo, or placebo \\(+\\omega-3 FA\\) ) to the treatment group which receives neither (placebo","confidence":0.5286281150559944,"confidence_rate":0.994830723271438},{"cnt":[[120,258],[1983,258],[1983,305],[120,305]],"region":{"top_left_x":120,"top_left_y":257,"width":1864,"height":49},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4414699e4eba455bb96d57d37000f5c8","type":"text","conversion_output":true,"text":"+ placebo). Interaction on the additive scale exists if the former difference differs significantly from the sum of","text_display":" + placebo). Interaction on the additive scale exists if the former difference differs significantly from the sum of","confidence":0.86865234375,"confidence_rate":0.9988272523858179},{"cnt":[[120,296],[1927,296],[1927,350],[120,350]],"region":{"top_left_x":120,"top_left_y":296,"width":1808,"height":55},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e53088c41098451aa8cfd99fd73b463f","type":"text","conversion_output":true,"text":"the latter two differences. \\({ }^{151}\\) Second, we will assess for interaction on the multiplicative scale by testing the","text_display":" the latter two differences. \\({ }^{151}\\) Second, we will assess for interaction on the multiplicative scale by testing the","confidence":0.9975595474243164,"confidence_rate":0.999980910843654},{"cnt":[[116,346],[1646,346],[1646,393],[116,393]],"region":{"top_left_x":116,"top_left_y":345,"width":1530,"height":49},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9cc1d2187ebc4aa3b4aae57166b6f2c4","type":"text","conversion_output":true,"text":"joint effect of assigned treatment on each study outcome using ANCOVA. For urine ACR:","text_display":" joint effect of assigned treatment on each study outcome using ANCOVA. For urine ACR:","confidence":1,"confidence_rate":1},{"cnt":[[241,404],[1962,404],[1962,462],[241,462]],"region":{"top_left_x":240,"top_left_y":403,"width":1722,"height":59},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"423aa571c0e04546846bda95c6941b2a","type":"math","conversion_output":true,"text":"\\[\n\\text { Equation 2: } \\log \\left(A C R_{4}\\right)=\\beta_{0}+\\beta_{1} \\log \\left(A C R_{0}\\right)+\\beta_{2}(\\text { vitamin } D)+\\beta_{3}(\\omega-3 \\text { FA })+\\beta_{4}(\\text { vitamin } D+\\omega-3 \\text { FA })+e\n\\]","text_display":"\n\\[\n\\text { Equation 2: } \\log \\left(A C R_{4}\\right)=\\beta_{0}+\\beta_{1} \\log \\left(A C R_{0}\\right)+\\beta_{2}(\\text { vitamin } D)+\\beta_{3}(\\omega-3 \\text { FA })+\\beta_{4}(\\text { vitamin } D+\\omega-3 \\text { FA })+e\n\\]","confidence":0.9242935180664062,"confidence_rate":0.9995049930121359},{"cnt":[[116,475],[1884,475],[1884,522],[116,522]],"region":{"top_left_x":116,"top_left_y":474,"width":1769,"height":49},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5d19abae1b6847668d5680e9a235b966","type":"text","conversion_output":true,"text":"where \\(\\log \\left(A C R_{4}\\right)\\) represents the natural log of urine ACR at follow-up (year 4), \\(\\log \\left(A C R_{0}\\right)\\) represents the","text_display":"\nwhere \\(\\log \\left(A C R_{4}\\right)\\) represents the natural log of urine ACR at follow-up (year 4), \\(\\log \\left(A C R_{0}\\right)\\) represents the","confidence":0.44433741599109067,"confidence_rate":0.9939647702407046},{"cnt":[[120,520],[1992,520],[1992,565],[120,565]],"region":{"top_left_x":120,"top_left_y":519,"width":1872,"height":47},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1e34f44f9a394ef78f19bb9c254f848e","type":"text","conversion_output":true,"text":"natural log of urine ACR at baseline, (vitamin D) is active vitamin D treatment assignment (yes/no), ( \\(\\omega-3\\) FA) is","text_display":" natural log of urine ACR at baseline, (vitamin D) is active vitamin D treatment assignment (yes/no), ( \\(\\omega-3\\) FA) is","confidence":0.9397548856213689,"confidence_rate":0.9994866095349726},{"cnt":[[120,563],[1970,563],[1970,610],[120,610]],"region":{"top_left_x":120,"top_left_y":562,"width":1851,"height":49},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f3a3bf61c46b4e61a04f581be207a88b","type":"text","conversion_output":true,"text":"active \\(\\omega-3\\) FA treatment assignment (yes/no), and (vitamin \\(D+\\omega-3\\) FA) is an interaction indicator variable for","text_display":" active \\(\\omega-3\\) FA treatment assignment (yes/no), and (vitamin \\(D+\\omega-3\\) FA) is an interaction indicator variable for","confidence":0.46349926158820076,"confidence_rate":0.993559063533465},{"cnt":[[120,608],[1985,608],[1985,655],[120,655]],"region":{"top_left_x":120,"top_left_y":608,"width":1866,"height":48},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"56afc895a76c4f0b85640f0e1baf712a","type":"text","conversion_output":true,"text":"assignment to both active vitamin D and active \\(\\omega-3\\) FA. A p value \\(<0.05\\) for \\(\\beta_{4}\\) will be interpreted as evidence","text_display":" assignment to both active vitamin D and active \\(\\omega-3\\) FA. A p value \\(<0.05\\) for \\(\\beta_{4}\\) will be interpreted as evidence","confidence":0.641070476786733,"confidence_rate":0.9965857198025748},{"cnt":[[120,653],[801,653],[801,698],[120,698]],"region":{"top_left_x":120,"top_left_y":653,"width":682,"height":46},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ab16b328abbb4e0ea7bb1f6f5a7a9605","type":"text","conversion_output":true,"text":"of interaction on the multiplicative scale.","text_display":" of interaction on the multiplicative scale.","confidence":0.99951171875,"confidence_rate":0.999989825041388},{"cnt":[[183,715],[1936,715],[1936,763],[183,763]],"region":{"top_left_x":182,"top_left_y":715,"width":1754,"height":48},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b94e6c24382641b7bb18ff421f93e92d","type":"text","conversion_output":true,"text":"If we observe evidence of interaction on either the additive or relative scale for either study outcome, all","text_display":"\n\nIf we observe evidence of interaction on either the additive or relative scale for either study outcome, all","confidence":1,"confidence_rate":1},{"cnt":[[120,761],[1944,761],[1944,806],[120,806]],"region":{"top_left_x":120,"top_left_y":760,"width":1825,"height":46},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"96f551b52d6841d4a39da02becc7df34","type":"text","conversion_output":true,"text":"analyses of that outcome will separately compare each of the 3 treatment groups which include at least one","text_display":" analyses of that outcome will separately compare each of the 3 treatment groups which include at least one","confidence":0.99951171875,"confidence_rate":0.9999957157942815},{"cnt":[[120,804],[1974,804],[1974,849],[120,849]],"region":{"top_left_x":120,"top_left_y":803,"width":1855,"height":46},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"083e0166eb4e4d219f30495fa441889b","type":"text","conversion_output":true,"text":"active study medication (i.e. cholecacliferol + placebo, placebo \\(+\\omega-3\\) FA, and cholecalciferol \\(+\\omega-3\\) FA) to the","text_display":" active study medication (i.e. cholecacliferol + placebo, placebo \\(+\\omega-3\\) FA, and cholecalciferol \\(+\\omega-3\\) FA) to the","confidence":0.5073109711977075,"confidence_rate":0.9944978664087851},{"cnt":[[120,846],[1901,846],[1901,896],[120,896]],"region":{"top_left_x":120,"top_left_y":846,"width":1782,"height":50},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"876d1a2d0bac42e7ab515aa6601b7670","type":"text","conversion_output":true,"text":"treatment group which receives (placebo + placebo). In contrast, if there is no evidence of interaction, as","text_display":" treatment group which receives (placebo + placebo). In contrast, if there is no evidence of interaction, as","confidence":0.67578125,"confidence_rate":0.9965071334965709},{"cnt":[[120,889],[1996,889],[1996,939],[120,939]],"region":{"top_left_x":120,"top_left_y":889,"width":1876,"height":50},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"49a2477a3ce74af5b71cb1bb433af43d","type":"text","conversion_output":true,"text":"hypothesized, all participants assigned to any active vitamin \\(D\\) (i.e. vitamin \\(D+\\) placebo or vitamin \\(D+\\omega-3\\) FA)","text_display":" hypothesized, all participants assigned to any active vitamin \\(D\\) (i.e. vitamin \\(D+\\) placebo or vitamin \\(D+\\omega-3\\) FA)","confidence":0.43023425698713313,"confidence_rate":0.9931663390269393},{"cnt":[[120,937],[1972,937],[1972,982],[120,982]],"region":{"top_left_x":120,"top_left_y":936,"width":1853,"height":46},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b9da9211c59f4a3996a69dfc14768a38","type":"text","conversion_output":true,"text":"will be compared to all participants assigned to no vitamin D (i.e. placebo + placebo or placebo \\(+\\omega-3 FA\\) ). In","text_display":" will be compared to all participants assigned to no vitamin D (i.e. placebo + placebo or placebo \\(+\\omega-3 FA\\) ). In","confidence":0.9321091187429046,"confidence_rate":0.9994551454565267},{"cnt":[[120,980],[1888,980],[1888,1025],[120,1025]],"region":{"top_left_x":120,"top_left_y":979,"width":1769,"height":46},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a70a2a03f92842028abc79f5028bd48c","type":"text","conversion_output":true,"text":"parallel, participants assigned to any active \\(\\omega-3\\) FA (i.e. placebo \\(+\\omega-3\\) FA or vitamin D \\(+\\omega-3\\) FA) will be","text_display":" parallel, participants assigned to any active \\(\\omega-3\\) FA (i.e. placebo \\(+\\omega-3\\) FA or vitamin D \\(+\\omega-3\\) FA) will be","confidence":0.7328079092328763,"confidence_rate":0.997368961565363},{"cnt":[[120,1023],[1800,1023],[1800,1072],[120,1072]],"region":{"top_left_x":120,"top_left_y":1022,"width":1681,"height":51},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"93a2bc4e3c0b49c4964ed9c7dff56def","type":"text","conversion_output":true,"text":"compared to all participants assigned to no w-3 FA (i.e. placebo + placebo or vitamin D + placebo).","text_display":" compared to all participants assigned to no w-3 FA (i.e. placebo + placebo or vitamin D + placebo).","confidence":0.4724026224002996,"confidence_rate":0.9928151312091817},{"cnt":[[122,1087],[1910,1087],[1910,1137],[122,1137]],"region":{"top_left_x":122,"top_left_y":1087,"width":1788,"height":50},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"21c4103fb99c4281a5b69c2f0ed339fb","type":"text","conversion_output":true,"text":"VI.e. Hypothesis testing. Change in urine ACR and eGFR are continuous variables which will be tested","text_display":"\nVI.e. Hypothesis testing. Change in urine ACR and eGFR are continuous variables which will be tested","confidence":0.998046875,"confidence_rate":0.9999813807939509},{"cnt":[[120,1130],[1962,1130],[1962,1179],[120,1179]],"region":{"top_left_x":120,"top_left_y":1130,"width":1842,"height":50},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3e188435c6c346b88855a4bc745629b8","type":"text","conversion_output":true,"text":"using ANCOVA. To test the effect of vitamin D on percent change in urine ACR in the absence of interaction","text_display":" using ANCOVA. To test the effect of vitamin D on percent change in urine ACR in the absence of interaction","confidence":1,"confidence_rate":1},{"cnt":[[120,1177],[926,1177],[926,1222],[120,1222]],"region":{"top_left_x":120,"top_left_y":1177,"width":806,"height":46},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"02d444590e4b4af383c3e332b129af78","type":"text","conversion_output":true,"text":"with \\(\\omega-3 FA\\), we will test the following equation:","text_display":" with \\(\\omega-3 FA\\), we will test the following equation:","confidence":0.9892807006835938,"confidence_rate":0.999820396715671},{"cnt":[[183,1240],[1235,1240],[1235,1291],[183,1291]],"region":{"top_left_x":182,"top_left_y":1239,"width":1054,"height":53},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7423b428f2d94e83a9c291510e48d6a4","type":"text","conversion_output":true,"text":"Equation 3: \\(\\log \\left(A C R_{4}\\right)=\\beta_{0}+\\beta_{1} \\log \\left(A C R_{0}\\right)+\\beta_{2}(v i t a m i n ~ D)+e\\)","text_display":"\n\nEquation 3: \\(\\log \\left(A C R_{4}\\right)=\\beta_{0}+\\beta_{1} \\log \\left(A C R_{0}\\right)+\\beta_{2}(v i t a m i n ~ D)+e\\)","confidence":0.23213571056542523,"confidence_rate":0.9850567635153337},{"cnt":[[116,1302],[1880,1302],[1880,1351],[116,1351]],"region":{"top_left_x":116,"top_left_y":1301,"width":1764,"height":51},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"61c7adafc47842cd9fb121c709657f2e","type":"text","conversion_output":true,"text":"where \\(\\left[\\exp \\left(\\beta_{2}\\right)-1\\right]\\) represents the relative difference in percent change in albuminuria comparing active","text_display":"\nwhere \\(\\left[\\exp \\left(\\beta_{2}\\right)-1\\right]\\) represents the relative difference in percent change in albuminuria comparing active","confidence":0.99951171875,"confidence_rate":0.9999959300041316},{"cnt":[[120,1349],[1798,1349],[1798,1394],[120,1394]],"region":{"top_left_x":120,"top_left_y":1349,"width":1679,"height":46},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"deffbe8788134d169aec076de814cc9c","type":"text","conversion_output":true,"text":"vitamin \\(D _{3}\\) to placebo, and the corresponding \\(95 \\%\\) confidence interval and p -value reflect statistical","text_display":" vitamin \\(D _{3}\\) to placebo, and the corresponding \\(95 \\%\\) confidence interval and p -value reflect statistical","confidence":0.646749212872237,"confidence_rate":0.9966011277648056},{"cnt":[[120,1392],[1884,1392],[1884,1439],[120,1439]],"region":{"top_left_x":120,"top_left_y":1392,"width":1765,"height":48},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5ca841fd635f4f6abd71d74673ab6f0d","type":"text","conversion_output":true,"text":"significance of the treatment effect. To test the effect of vitamin D on change in eGFR in the absence of","text_display":" significance of the treatment effect. To test the effect of vitamin D on change in eGFR in the absence of","confidence":0.99267578125,"confidence_rate":0.9999331733918059},{"cnt":[[120,1437],[1113,1437],[1113,1485],[120,1485]],"region":{"top_left_x":120,"top_left_y":1437,"width":993,"height":48},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f5fc90aa0451419d9c1446d6a24d9d32","type":"text","conversion_output":true,"text":"interaction with \\(\\omega-3 FA\\), we will test the following equation:","text_display":" interaction with \\(\\omega-3 FA\\), we will test the following equation:","confidence":0.99365234375,"confidence_rate":0.999911561018142},{"cnt":[[183,1500],[1124,1500],[1124,1549],[183,1549]],"region":{"top_left_x":182,"top_left_y":1499,"width":942,"height":51},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"289f0b20190b4aa7abd9d39f1408311c","type":"text","conversion_output":true,"text":"Equation 4: \\(e G F R_{4}=\\beta_{0}+\\beta_{1} e G F R_{0}+\\beta_{2}(\\) vitamin \\(D)+e\\)","text_display":"\n\nEquation 4: \\(e G F R_{4}=\\beta_{0}+\\beta_{1} e G F R_{0}+\\beta_{2}(\\) vitamin \\(D)+e\\)","confidence":0.6080495781880018,"confidence_rate":0.9942979411313327},{"cnt":[[116,1566],[1936,1566],[1936,1613],[116,1613]],"region":{"top_left_x":116,"top_left_y":1566,"width":1820,"height":48},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7cbe912e1a8d407b9b02ffe2ef9af947","type":"text","conversion_output":true,"text":"where \\(\\beta_{2}\\) represents the difference in eGFR comparing active vitamin \\(D _{3}\\) to placebo, and the corresponding","text_display":"\nwhere \\(\\beta_{2}\\) represents the difference in eGFR comparing active vitamin \\(D _{3}\\) to placebo, and the corresponding","confidence":0.8363666534423828,"confidence_rate":0.9986472174925651},{"cnt":[[116,1611],[1953,1611],[1953,1656],[116,1656]],"region":{"top_left_x":116,"top_left_y":1611,"width":1837,"height":46},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"20dd70134d3e4aaa9da830fb17b97a28","type":"text","conversion_output":true,"text":"\\(95 \\%\\) confidence interval and \\(p\\)-value reflect statistical significance of the treatment effect. Parallel equations","text_display":" \\(95 \\%\\) confidence interval and \\(p\\)-value reflect statistical significance of the treatment effect. Parallel equations","confidence":0.8898785949321564,"confidence_rate":0.9990282205192274},{"cnt":[[116,1654],[1953,1654],[1953,1699],[116,1699]],"region":{"top_left_x":116,"top_left_y":1654,"width":1837,"height":46},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f29bbde3862845858bb8afb5559f6f19","type":"text","conversion_output":true,"text":"will be used to test effects of \\(\\omega-3\\) FA on changes in albuminuria and eGFR in the absence of interaction with","text_display":" will be used to test effects of \\(\\omega-3\\) FA on changes in albuminuria and eGFR in the absence of interaction with","confidence":0.9980480668600649,"confidence_rate":0.9999831566880222},{"cnt":[[118,1697],[1893,1697],[1893,1745],[118,1745]],"region":{"top_left_x":118,"top_left_y":1697,"width":1775,"height":48},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e4801fc10bcb4341bd4272fad5857911","type":"text","conversion_output":true,"text":"vitamin \\(D _{3}\\). An alpha level of 0.05 will be taken to represent statistical significance, without correction for","text_display":" vitamin \\(D _{3}\\). An alpha level of 0.05 will be taken to represent statistical significance, without correction for","confidence":0.96142578125,"confidence_rate":0.9997020299509844},{"cnt":[[118,1742],[1914,1742],[1914,1790],[118,1790]],"region":{"top_left_x":118,"top_left_y":1742,"width":1797,"height":48},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5b1c8845b6be4a4fbdbf74586b4113a2","type":"text","conversion_output":true,"text":"multiple comparisons. We will examine the distributions of change in urine ACR and eGFR and substitute","text_display":" multiple comparisons. We will examine the distributions of change in urine ACR and eGFR and substitute","confidence":1,"confidence_rate":1},{"cnt":[[118,1781],[1869,1781],[1869,1833],[118,1833]],"region":{"top_left_x":118,"top_left_y":1781,"width":1752,"height":52},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"93d46401982345cf920c97e20383a259","type":"text","conversion_output":true,"text":"rank-sum comparisons if indicated. \\({ }^{152}\\) We will test differences in proportions of participants attaining the","text_display":" rank-sum comparisons if indicated. \\({ }^{152}\\) We will test differences in proportions of participants attaining the","confidence":1,"confidence_rate":1},{"cnt":[[116,1826],[1008,1826],[1008,1878],[116,1878]],"region":{"top_left_x":116,"top_left_y":1826,"width":892,"height":52},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ce555a526db5453888357b8b0f9974e3","type":"text","conversion_output":true,"text":"composite dichotomous outcome using the chi \\({ }^{2}\\) test.","text_display":" composite dichotomous outcome using the chi \\({ }^{2}\\) test.","confidence":1,"confidence_rate":1},{"cnt":[[180,1895],[1996,1895],[1996,1944],[180,1944]],"region":{"top_left_x":180,"top_left_y":1894,"width":1816,"height":51},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"00fac4e450ae4136995db34f63a66b22","type":"text","conversion_output":true,"text":"Analyses will be performed in accordance with the intent-to-treat principle. For analyses of change in urine","text_display":"\n\nAnalyses will be performed in accordance with the intent-to-treat principle. For analyses of change in urine","confidence":1,"confidence_rate":1},{"cnt":[[116,1938],[1985,1938],[1985,1987],[116,1987]],"region":{"top_left_x":116,"top_left_y":1937,"width":1870,"height":51},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3a6f022688ca43e7b04714e8d175e9f9","type":"text","conversion_output":true,"text":"ACR and eGFR as continuous variables, only participants who complete study measurements at baseline and","text_display":" ACR and eGFR as continuous variables, only participants who complete study measurements at baseline and","confidence":1,"confidence_rate":1},{"cnt":[[116,1983],[1949,1983],[1949,2030],[116,2030]],"region":{"top_left_x":116,"top_left_y":1983,"width":1833,"height":48},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7272cf85d55d478896299bc5e2a7f666","type":"text","conversion_output":true,"text":"year 4 will be included in analyses (complete case analysis). Maximum effort will be made to ensure that all","text_display":" year 4 will be included in analyses (complete case analysis). Maximum effort will be made to ensure that all","confidence":1,"confidence_rate":1},{"cnt":[[116,2028],[1815,2028],[1815,2073],[116,2073]],"region":{"top_left_x":116,"top_left_y":2028,"width":1700,"height":46},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b281a248a9da4d12bdfa4ea3e68184a9","type":"text","conversion_output":true,"text":"possible participants supply follow-up biospecimens, and all available participants will be included in","text_display":" possible participants supply follow-up biospecimens, and all available participants will be included in","confidence":1,"confidence_rate":1},{"cnt":[[116,2071],[1981,2071],[1981,2116],[116,2116]],"region":{"top_left_x":116,"top_left_y":2071,"width":1865,"height":46},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"938c82defda549e395159fadde6291f8","type":"text","conversion_output":true,"text":"continuous outcome analyses regardless of adherence to study medications. The relatively large sample size","text_display":" continuous outcome analyses regardless of adherence to study medications. The relatively large sample size","confidence":0.99951171875,"confidence_rate":0.9999956000051925},{"cnt":[[116,2114],[1936,2114],[1936,2159],[116,2159]],"region":{"top_left_x":116,"top_left_y":2114,"width":1820,"height":46},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a8beb53b8e674a6c9f437a0f25e9d18d","type":"text","conversion_output":true,"text":"makes it likely that few or no substantial differences in baseline characteristics will be present. In the event","text_display":" makes it likely that few or no substantial differences in baseline characteristics will be present. In the event","confidence":1,"confidence_rate":1},{"cnt":[[116,2157],[1946,2157],[1946,2204],[116,2204]],"region":{"top_left_x":116,"top_left_y":2157,"width":1831,"height":48},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7b5b02220dcd4153a8a02468617df2cf","type":"text","conversion_output":true,"text":"that any baseline characteristics are not balanced between treatment groups, however, secondary analyses","text_display":" that any baseline characteristics are not balanced between treatment groups, however, secondary analyses","confidence":1,"confidence_rate":1},{"cnt":[[116,2202],[1992,2202],[1992,2249],[116,2249]],"region":{"top_left_x":116,"top_left_y":2202,"width":1876,"height":48},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"95287d45c91741fda3ef608a7b1873f4","type":"text","conversion_output":true,"text":"will add to the ANCOVA model additional terms for such baseline characteristics. If we observe differences by","text_display":" will add to the ANCOVA model additional terms for such baseline characteristics. If we observe differences by","confidence":1,"confidence_rate":1},{"cnt":[[116,2247],[1876,2247],[1876,2292],[116,2292]],"region":{"top_left_x":116,"top_left_y":2247,"width":1760,"height":46},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ce152c653eac4ee693a80b32185b6b75","type":"text","conversion_output":true,"text":"treatment group in medication use (e.g. glucose-lowering or antihypertensive medications) or laboratory","text_display":" treatment group in medication use (e.g. glucose-lowering or antihypertensive medications) or laboratory","confidence":1,"confidence_rate":1},{"cnt":[[116,2290],[1972,2290],[1972,2340],[116,2340]],"region":{"top_left_x":116,"top_left_y":2290,"width":1857,"height":50},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ea1af484d1bb406eb5146e91e016949e","type":"text","conversion_output":true,"text":"covariates (e.g. hemoglobin A1c, CRP) over follow-up, we will explore whether such differences may mediate","text_display":" covariates (e.g. hemoglobin A1c, CRP) over follow-up, we will explore whether such differences may mediate","confidence":1,"confidence_rate":1},{"cnt":[[116,2333],[1835,2333],[1835,2383],[116,2383]],"region":{"top_left_x":116,"top_left_y":2333,"width":1719,"height":50},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"eca2a93598a441608722456cde56fe56","type":"text","conversion_output":true,"text":"or obscure effects of study interventions on study outcomes by including additional covariate(s) in the","text_display":" or obscure effects of study interventions on study outcomes by including additional covariate(s) in the","confidence":1,"confidence_rate":1},{"cnt":[[116,2378],[1775,2378],[1775,2426],[116,2426]],"region":{"top_left_x":116,"top_left_y":2378,"width":1659,"height":48},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f446994148c546d38da789fba1af4f11","type":"text","conversion_output":true,"text":"ANCOVA model to assess change in \\(\\beta_{2}\\) (treatment effect) toward or away from zero, respectively.","text_display":" ANCOVA model to assess change in \\(\\beta_{2}\\) (treatment effect) toward or away from zero, respectively.","confidence":1,"confidence_rate":1},{"cnt":[[120,2443],[1953,2443],[1953,2490],[120,2490]],"region":{"top_left_x":120,"top_left_y":2442,"width":1833,"height":49},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2674caff0ca24719a6c697738c14443e","type":"text","conversion_output":true,"text":"VI.f. Subgroup analyses. For the vitamin D intervention, prespecified subgroup analyses will be based on","text_display":"\nVI.f. Subgroup analyses. For the vitamin D intervention, prespecified subgroup analyses will be based on","confidence":1,"confidence_rate":1},{"cnt":[[116,2488],[1846,2488],[1846,2533],[116,2533]],"region":{"top_left_x":116,"top_left_y":2487,"width":1730,"height":47},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"88aed8fc56e94076b931f0d3583de148","type":"text","conversion_output":true,"text":"baseline plasma \\(25( OH ) D\\) concentration, baseline urine ACR, baseline eGFR, and race/ethnicity. We","text_display":" baseline plasma \\(25( OH ) D\\) concentration, baseline urine ACR, baseline eGFR, and race/ethnicity. We","confidence":0.9921996551565826,"confidence_rate":0.9999288122915143},{"cnt":[[116,2531],[1798,2531],[1798,2580],[116,2580]],"region":{"top_left_x":116,"top_left_y":2530,"width":1683,"height":51},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9a0990ce8a074957b31593beb3ffe4c3","type":"text","conversion_output":true,"text":"hypothesize that beneficial effects of cholecalciferol on urine ACR and eGFR will be greater among","text_display":" hypothesize that beneficial effects of cholecalciferol on urine ACR and eGFR will be greater among","confidence":1,"confidence_rate":1},{"cnt":[[1955,2582],[2007,2582],[2007,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2582,"width":52,"height":46},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5dd65a1b69cb4b6295f26b3a898319de","type":"page_info","conversion_output":false,"text":"18","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-19","page":19,"lines":[{"cnt":[[120,125],[1955,125],[1955,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":1836,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"911f678e3d5c415587bd57c688e43b2c","type":"text","conversion_output":true,"text":"participants who at baseline (a) have low levels of plasma \\(25( OH ) D\\), because vitamin D insufficiency may be","text_display":"\nparticipants who at baseline (a) have low levels of plasma \\(25( OH ) D\\), because vitamin D insufficiency may be","confidence":0.8818005240473193,"confidence_rate":0.9990100225421555},{"cnt":[[120,168],[1931,168],[1931,217],[120,217]],"region":{"top_left_x":120,"top_left_y":167,"width":1812,"height":50},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"11b55780c8374c2aa90d45135366f7bd","type":"text","conversion_output":true,"text":"particularly detrimental below a threshold vitamin D level; (b) have urine ACR \\(\\geq 30 mg / g\\) and/or eGFR \\(<60\\)","text_display":" particularly detrimental below a threshold vitamin D level; (b) have urine ACR \\(\\geq 30 mg / g\\) and/or eGFR \\(<60","confidence":0.99951171875,"confidence_rate":0.9999957530481652},{"cnt":[[120,208],[1944,208],[1944,260],[120,260]],"region":{"top_left_x":120,"top_left_y":208,"width":1825,"height":52},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"31a085afad56482fbe7c6817829dfa90","type":"text","conversion_output":true,"text":"\\(mL / min / m ^{2}\\), because persons with DKD may be particularly dependent on adequate \\(25( OH )\\) D availability for","text_display":" mL / min / m ^{2}\\), because persons with DKD may be particularly dependent on adequate \\(25( OH )\\) D availability for","confidence":0.98046875,"confidence_rate":0.99984828454574},{"cnt":[[120,258],[1944,258],[1944,305],[120,305]],"region":{"top_left_x":120,"top_left_y":257,"width":1825,"height":49},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"62f5651929d4403eac2caffea89bf648","type":"text","conversion_output":true,"text":"renal synthesis of 1,25dihydroxyvitamin D; and/or (c) are non-Caucasian, i.e. differences in albuminuria and","text_display":" renal synthesis of 1,25dihydroxyvitamin D; and/or (c) are non-Caucasian, i.e. differences in albuminuria and","confidence":0.99512362270616,"confidence_rate":0.9999567415939427},{"cnt":[[120,301],[1852,301],[1852,350],[120,350]],"region":{"top_left_x":120,"top_left_y":300,"width":1732,"height":51},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"858695e137004c0ab0893c2685fd31b4","type":"text","conversion_output":true,"text":"eGFR by race/ethnicity will narrow with vitamin D treatment. For the \\(\\omega-3\\) FA intervention, prespecified","text_display":" eGFR by race/ethnicity will narrow with vitamin D treatment. For the \\(\\omega-3\\) FA intervention, prespecified","confidence":0.9554313347734933,"confidence_rate":0.9995856096922983},{"cnt":[[120,344],[1944,344],[1944,393],[120,393]],"region":{"top_left_x":120,"top_left_y":343,"width":1825,"height":51},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"edb001eaef314c89976c9ac5a4038fc1","type":"text","conversion_output":true,"text":"subgroup analyses will be based on baseline levels of EPA+DHA and CRP. We hypothesize that beneficial","text_display":" subgroup analyses will be based on baseline levels of EPA+DHA and CRP. We hypothesize that beneficial","confidence":1,"confidence_rate":1},{"cnt":[[120,389],[1923,389],[1923,436],[120,436]],"region":{"top_left_x":120,"top_left_y":388,"width":1803,"height":49},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5e86f99dde174d8488cc18cf534f7a1d","type":"text","conversion_output":true,"text":"effects of \\(\\omega-3\\) FA on urine ACR and eGFR will be greater among participants who at baseline have (a) low","text_display":" effects of \\(\\omega-3\\) FA on urine ACR and eGFR will be greater among participants who at baseline have (a) low","confidence":0.9970729344058782,"confidence_rate":0.9999735917196197},{"cnt":[[120,434],[1818,434],[1818,479],[120,479]],"region":{"top_left_x":120,"top_left_y":433,"width":1698,"height":47},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"dab3c733c07c43cb8692a85db3832a25","type":"text","conversion_output":true,"text":"levels of EPA+DHA, because \\(\\omega-3\\) FA insufficiency may be particularly detrimental below a threshold","text_display":" levels of EPA+DHA, because \\(\\omega-3\\) FA insufficiency may be particularly detrimental below a threshold","confidence":0.7457294464111328,"confidence_rate":0.9972096866864535},{"cnt":[[120,477],[1953,477],[1953,524],[120,524]],"region":{"top_left_x":120,"top_left_y":476,"width":1833,"height":49},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d4bc2dd1e1e14210b527fba0dddca2ef","type":"text","conversion_output":true,"text":"EPA+DHA level; and/or (b) high levels of CRP, because inflammation at baseline will provide opportunity for","text_display":" EPA+DHA level; and/or (b) high levels of CRP, because inflammation at baseline will provide opportunity for","confidence":1,"confidence_rate":1},{"cnt":[[120,520],[1858,520],[1858,569],[120,569]],"region":{"top_left_x":120,"top_left_y":519,"width":1739,"height":51},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"21441cec70de447fa74ac3997721fcee","type":"text","conversion_output":true,"text":"anti-inflammatory actions of \\(\\omega-3\\) FA. Effect modification will be tested by including interaction terms of","text_display":" anti-inflammatory actions of \\(\\omega-3\\) FA. Effect modification will be tested by including interaction terms of","confidence":0.9858855575276243,"confidence_rate":0.999874211464855},{"cnt":[[120,565],[1407,565],[1407,612],[120,612]],"region":{"top_left_x":120,"top_left_y":565,"width":1288,"height":48},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3bb9d7c5cca646278c9b037d79a9a5fc","type":"text","conversion_output":true,"text":"treatment assignment with subgroup in ANCOVA models (Equations 3 \\& 4).","text_display":" treatment assignment with subgroup in ANCOVA models (Equations 3 \\& 4).","confidence":1,"confidence_rate":1},{"cnt":[[122,627],[1972,627],[1972,677],[122,677]],"region":{"top_left_x":122,"top_left_y":627,"width":1851,"height":50},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e658fc8095cd4719bc697840a075fd74","type":"text","conversion_output":true,"text":"VI.g. Exploratory adherence and efficacy analyses. All primary analyses will be performed according to the","text_display":"\nVI.g. Exploratory adherence and efficacy analyses. All primary analyses will be performed according to the","confidence":1,"confidence_rate":1},{"cnt":[[120,675],[1927,675],[1927,724],[120,724]],"region":{"top_left_x":120,"top_left_y":674,"width":1808,"height":51},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a486e30caa7444e1ad9b17bf4417da57","type":"text","conversion_output":true,"text":"intent-to-treat principle. We plan secondary, exploratory analyses for the following limited purposes: (a) to","text_display":" intent-to-treat principle. We plan secondary, exploratory analyses for the following limited purposes: (a) to","confidence":1,"confidence_rate":1},{"cnt":[[120,718],[1880,718],[1880,767],[120,767]],"region":{"top_left_x":120,"top_left_y":717,"width":1760,"height":50},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5e6393463a3c41488aeeb82e9a4bc98d","type":"text","conversion_output":true,"text":"evaluate whether null findings, if observed, are robust (i.e. not readily attributable to defects in the study","text_display":" evaluate whether null findings, if observed, are robust (i.e. not readily attributable to defects in the study","confidence":1,"confidence_rate":1},{"cnt":[[120,761],[1888,761],[1888,810],[120,810]],"region":{"top_left_x":120,"top_left_y":760,"width":1769,"height":50},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"83d66372fee54c9f9e204ebb6aecb733","type":"text","conversion_output":true,"text":"interventions or their administration); and/or (b) to more comprehensively evaluate the potential range of","text_display":" interventions or their administration); and/or (b) to more comprehensively evaluate the potential range of","confidence":0.99951171875,"confidence_rate":0.9999956000051925},{"cnt":[[120,804],[1931,804],[1931,853],[120,853]],"region":{"top_left_x":120,"top_left_y":803,"width":1812,"height":50},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f93a7775b3c84fcaaaf40fb895b0d745","type":"text","conversion_output":true,"text":"treatment effects, if treatment effects are observed. We understand and acknowledge that these analyses,","text_display":" treatment effects, if treatment effects are observed. We understand and acknowledge that these analyses,","confidence":1,"confidence_rate":1},{"cnt":[[120,851],[2000,851],[2000,896],[120,896]],"region":{"top_left_x":120,"top_left_y":850,"width":1881,"height":46},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f0fdcbf9b54f48e5aecc038f758374ad","type":"text","conversion_output":true,"text":"which are based on data collected after randomization, may introduce bias into study results. We will therefore","text_display":" which are based on data collected after randomization, may introduce bias into study results. We will therefore","confidence":1,"confidence_rate":1},{"cnt":[[120,894],[1987,894],[1987,941],[120,941]],"region":{"top_left_x":120,"top_left_y":893,"width":1868,"height":49},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2329e97865f4464086892a24e652a3ec","type":"text","conversion_output":true,"text":"use great caution to limit their interpretation. To conduct these efficacy-based explorations, we will first repeat","text_display":" use great caution to limit their interpretation. To conduct these efficacy-based explorations, we will first repeat","confidence":1,"confidence_rate":1},{"cnt":[[120,937],[1966,937],[1966,984],[120,984]],"region":{"top_left_x":120,"top_left_y":936,"width":1846,"height":48},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"65fd923679c54a029ffa6819eaa03ac0","type":"text","conversion_output":true,"text":"analyses among the subset of participants who report adherence to \\(\\geq 80 \\%\\) of study medications. In addition,","text_display":" analyses among the subset of participants who report adherence to \\(\\geq 80 \\%\\) of study medications. In addition,","confidence":1,"confidence_rate":1},{"cnt":[[120,982],[1970,980],[1970,1029],[120,1031]],"region":{"top_left_x":120,"top_left_y":979,"width":1851,"height":53},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"503ffcef8ff44f0188628bdd71f17c3d","type":"text","conversion_output":true,"text":"we will assess whether changes in \\(25( OH ) D\\) and EPA+DHA levels are associated with changes in urine ACR","text_display":" we will assess whether changes in \\(25( OH ) D\\) and EPA+DHA levels are associated with changes in urine ACR","confidence":0.8132339274712361,"confidence_rate":0.9982039064130647},{"cnt":[[120,1025],[1974,1025],[1974,1072],[120,1072]],"region":{"top_left_x":120,"top_left_y":1024,"width":1855,"height":49},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"94690feefaba4543936c3e656f25ba67","type":"text","conversion_output":true,"text":"and eGFR. For the latter analyses, change in \\(25( OH ) D\\) concentrations or change in EPA+DHA concentration","text_display":" and eGFR. For the latter analyses, change in \\(25( OH ) D\\) concentrations or change in EPA+DHA concentration","confidence":0.8953068373600843,"confidence_rate":0.9990471027053979},{"cnt":[[120,1070],[1437,1070],[1437,1119],[120,1119]],"region":{"top_left_x":120,"top_left_y":1069,"width":1318,"height":51},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b6847b1dc0c9404cb56c41eae59ee75c","type":"text","conversion_output":true,"text":"(continuous variables) will replace treatment assignment in ANCOVA models.","text_display":" (continuous variables) will replace treatment assignment in ANCOVA models.","confidence":1,"confidence_rate":1},{"cnt":[[122,1130],[1876,1130],[1876,1182],[122,1182]],"region":{"top_left_x":122,"top_left_y":1130,"width":1754,"height":52},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a0c6a1f09f3b4be5af7259f34c53f463","type":"text","conversion_output":true,"text":"VI.h. Power. The following assumptions are made for power calculations: (1) independent and equal","text_display":"\nVI.h. Power. The following assumptions are made for power calculations: (1) independent and equal","confidence":0.9960966110229492,"confidence_rate":0.9999616573323281},{"cnt":[[120,1177],[1985,1177],[1985,1227],[120,1227]],"region":{"top_left_x":120,"top_left_y":1177,"width":1866,"height":50},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"69cdd83a136549289f3847120448ead6","type":"text","conversion_output":true,"text":"allocation of participants to each treatment; (2) variation in urine ACR as observed in the Multi-Ethnic Study of","text_display":" allocation of participants to each treatment; (2) variation in urine ACR as observed in the Multi-Ethnic Study of","confidence":1,"confidence_rate":1},{"cnt":[[120,1222],[1944,1222],[1944,1270],[120,1270]],"region":{"top_left_x":120,"top_left_y":1222,"width":1825,"height":48},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"079b30bb6161475ba1481b760bbf8fba","type":"text","conversion_output":true,"text":"Atherosclerosis (MESA), including follow-up log(ACR) mean 3.085 , standard deviation 1.59 , and correlation","text_display":" Atherosclerosis (MESA), including follow-up log(ACR) mean 3.085 , standard deviation 1.59 , and correlation","confidence":0.5677348247263581,"confidence_rate":0.995214024815856},{"cnt":[[120,1265],[1919,1265],[1919,1313],[120,1313]],"region":{"top_left_x":120,"top_left_y":1265,"width":1799,"height":48},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2104ad6ad8764cf385b044966cf6f980","type":"text","conversion_output":true,"text":"with baseline 0.78; (3) variation in eGFR as observed in the Cardiovascular Health Study (CHS), including","text_display":" with baseline 0.78; (3) variation in eGFR as observed in the Cardiovascular Health Study (CHS), including","confidence":0.96044921875,"confidence_rate":0.9996332112128208},{"cnt":[[120,1306],[1979,1306],[1979,1356],[120,1356]],"region":{"top_left_x":120,"top_left_y":1306,"width":1859,"height":50},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"41fa07d038d643dbbbad3b686abe5e9a","type":"text","conversion_output":true,"text":"follow-up eGFR mean \\(70 mL / \\min / 1.73 m^{2}\\), standard deviation \\(25 mL / \\min / 1.73 m^{2}\\); and correlation with baseline","text_display":" follow-up eGFR mean \\(70 mL / \\min / 1.73 m^{2}\\), standard deviation \\(25 mL / \\min / 1.73 m^{2}\\); and correlation with baseline","confidence":0.5468963168095797,"confidence_rate":0.9959030004359622},{"cnt":[[120,1354],[1919,1354],[1919,1401],[120,1401]],"region":{"top_left_x":120,"top_left_y":1353,"width":1799,"height":48},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5c7306f650f84aee994a74319b288af5","type":"text","conversion_output":true,"text":"0.834 ; and (4) \\(20 \\%\\) loss to follow-up. These assumptions are conservative, in that we anticipate follow-up","text_display":" 0.834 ; and (4) \\(20 \\%\\) loss to follow-up. These assumptions are conservative, in that we anticipate follow-up","confidence":0.8201237798180157,"confidence_rate":0.9982466716303889},{"cnt":[[120,1396],[1944,1396],[1944,1446],[120,1446]],"region":{"top_left_x":120,"top_left_y":1396,"width":1825,"height":50},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bea8efcdb51d4329941f88493722fc94","type":"text","conversion_output":true,"text":"greater than \\(80 \\%\\) using planned participant recruiting and retention techniques, and that we will collect first-","text_display":" greater than \\(80 \\%\\) using planned participant recruiting and retention techniques, and that we will collect first","confidence":1,"confidence_rate":1},{"cnt":[[120,1439],[1897,1439],[1897,1489],[120,1489]],"region":{"top_left_x":120,"top_left_y":1439,"width":1778,"height":50},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"986f775d198244bcb6f7fd7d35d11ae7","type":"text","conversion_output":true,"text":"morning voids which yield lower intra-individual variation in urine ACR than the random voids collected in","text_display":"morning voids which yield lower intra-individual variation in urine ACR than the random voids collected in","confidence":1,"confidence_rate":1},{"cnt":[[120,1480],[1949,1480],[1949,1532],[120,1532]],"region":{"top_left_x":120,"top_left_y":1480,"width":1829,"height":52},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5bb0716a4d394b3ab164e514fa789535","type":"text","conversion_output":true,"text":"MESA. \\({ }^{153}\\) Statistical confidence is tested using ANCOVA (Equations 3 \\& 4), with a significance level of 0.05.","text_display":" MESA. \\({ }^{153}\\) Statistical confidence is tested using ANCOVA (Equations 3 \\& 4), with a significance level of 0.05.","confidence":0.9800510108470917,"confidence_rate":0.9998400869399378},{"cnt":[[180,1549],[1936,1549],[1936,1596],[180,1596]],"region":{"top_left_x":180,"top_left_y":1549,"width":1756,"height":48},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"42fee09051d541598bfd827df319978c","type":"text","conversion_output":true,"text":"Applying these assumptions, 1,500 enrolled participants (1,200 returning for follow-up) will provide \\(90 \\%\\)","text_display":"\n\nApplying these assumptions, 1,500 enrolled participants (1,200 returning for follow-up) will provide \\(90 \\%\\)","confidence":0.4851227458566427,"confidence_rate":0.993504490899513},{"cnt":[[120,1594],[1747,1594],[1747,1641],[120,1641]],"region":{"top_left_x":120,"top_left_y":1594,"width":1627,"height":48},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"238493298500415bb53f5c5223e8ba11","type":"text","conversion_output":true,"text":"power to detect observed differences by treatment group of \\(17 \\%\\) in follow-up urine ACR and 2.6","text_display":" power to detect observed differences by treatment group of \\(17 \\%\\) in follow-up urine ACR and 2.6","confidence":0.9511814117431641,"confidence_rate":0.9994996204746306},{"cnt":[[120,1633],[1957,1633],[1957,1687],[120,1687]],"region":{"top_left_x":120,"top_left_y":1632,"width":1838,"height":55},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cf60aef022ff4751a43db8dc2d2c543a","type":"text","conversion_output":true,"text":"\\(mL / min / 1.73 m^{2}\\) in follow-up eGFR. These differences are modest compared with observed changes in urine","text_display":" \\(mL / min / 1.73 m^{2}\\) in follow-up eGFR. These differences are modest compared with observed changes in urine","confidence":1,"confidence_rate":1},{"cnt":[[118,1680],[1764,1680],[1764,1729],[118,1729]],"region":{"top_left_x":118,"top_left_y":1680,"width":1646,"height":50},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ccb9e437dd9044f4ac532d5f15385dc9","type":"text","conversion_output":true,"text":"ACR and eGFR over time in comparable MESA and CHS participants, similar to the difference in","text_display":" ACR and eGFR over time in comparable MESA and CHS participants, similar to the difference in","confidence":1,"confidence_rate":1},{"cnt":[[120,1747],[539,1747],[539,1794],[120,1794]],"region":{"top_left_x":120,"top_left_y":1746,"width":420,"height":48},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ab7aff7970b04d36a9b1142eebaac36b","type":"text","conversion_output":true,"text":"eGFR expected with the","text_display":"\neGFR expected with the","confidence":1,"confidence_rate":1},{"cnt":[[120,1792],[683,1792],[683,1833],[120,1833]],"region":{"top_left_x":120,"top_left_y":1791,"width":564,"height":42},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1f1062bf822948418da7fcb35975050f","type":"text","conversion_output":true,"text":"cholecalcierol intervention based","text_display":" cholecalcierol intervention based","confidence":1,"confidence_rate":1},{"cnt":[[120,1835],[668,1835],[668,1882],[120,1882]],"region":{"top_left_x":120,"top_left_y":1834,"width":549,"height":49},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2436c978e7de49c6aac3cab68ca2b4a5","type":"text","conversion_output":true,"text":"on observational \\(25( OH ) D\\) data,","text_display":" on observational \\(25( OH ) D\\) data,","confidence":0.9556165757919644,"confidence_rate":0.9989687476127651},{"cnt":[[120,1878],[651,1878],[651,1927],[120,1927]],"region":{"top_left_x":120,"top_left_y":1877,"width":531,"height":51},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7943c38c32a445579fe2d9f2df610979","type":"text","conversion_output":true,"text":"and substantially more modest","text_display":" and substantially more modest","confidence":1,"confidence_rate":1},{"cnt":[[120,1921],[707,1921],[707,1970],[120,1970]],"region":{"top_left_x":120,"top_left_y":1920,"width":587,"height":51},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d72049906a2040a980d47c1268c713d9","type":"text","conversion_output":true,"text":"than the point estimate for change","text_display":" than the point estimate for change","confidence":1,"confidence_rate":1},{"cnt":[[120,1968],[621,1968],[621,2009],[120,2009]],"region":{"top_left_x":120,"top_left_y":1967,"width":501,"height":42},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"78b43612a3ea407693f7e8e4a421238b","type":"text","conversion_output":true,"text":"in urine ACR observed in our","text_display":" in urine ACR observed in our","confidence":1,"confidence_rate":1},{"cnt":[[120,2007],[556,2007],[556,2052],[120,2052]],"region":{"top_left_x":120,"top_left_y":2006,"width":437,"height":46},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e07e6ae32d2f401ea9ef21c1bd929ea1","type":"text","conversion_output":true,"text":"short-term cholecalciferol","text_display":" short-term cholecalciferol","confidence":1,"confidence_rate":1},{"cnt":[[120,2054],[629,2054],[629,2099],[120,2099]],"region":{"top_left_x":120,"top_left_y":2053,"width":510,"height":47},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8d92e47a975b49d6ab33ce75469f9623","type":"text","conversion_output":true,"text":"intervention study. Powers to","text_display":" intervention study. Powers to","confidence":1,"confidence_rate":1},{"cnt":[[120,2097],[696,2097],[696,2142],[120,2142]],"region":{"top_left_x":120,"top_left_y":2096,"width":577,"height":46},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cbcd83b3c2db497ba371755dd4cbcbc4","type":"text","conversion_output":true,"text":"detect other observed differences","text_display":" detect other observed differences","confidence":1,"confidence_rate":1},{"cnt":[[120,2142],[610,2142],[610,2189],[120,2189]],"region":{"top_left_x":120,"top_left_y":2141,"width":491,"height":49},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f873e218d2e541e9b079ddfc434e1eee","type":"text","conversion_output":true,"text":"in the co-primary continuous","text_display":" in the co-primary continuous","confidence":1,"confidence_rate":1},{"cnt":[[120,2187],[720,2187],[720,2228],[120,2228]],"region":{"top_left_x":120,"top_left_y":2187,"width":600,"height":41},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"70de40aac0534795989d85a10561343d","type":"text","conversion_output":true,"text":"outcomes are shown in Table 2. It","text_display":" outcomes are shown in Table 2. It","confidence":1,"confidence_rate":1},{"cnt":[[120,2230],[724,2230],[724,2277],[120,2277]],"region":{"top_left_x":120,"top_left_y":2230,"width":605,"height":48},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"20d7ef7fa025403d89f0585e2ee5c27f","type":"text","conversion_output":true,"text":"is likely that an observed treatment","text_display":" is likely that an observed treatment","confidence":1,"confidence_rate":1},{"cnt":[[120,2273],[679,2273],[679,2322],[120,2322]],"region":{"top_left_x":120,"top_left_y":2273,"width":559,"height":50},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"946dfe021c1544e6b512bce0be334a71","type":"text","conversion_output":true,"text":"effect, if present, will be due to a","text_display":" effect, if present, will be due to a","confidence":1,"confidence_rate":1},{"cnt":[[120,2316],[621,2316],[621,2365],[120,2365]],"region":{"top_left_x":120,"top_left_y":2316,"width":501,"height":50},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9b2efe56379c45acb29f5599561d3dc6","type":"text","conversion_output":true,"text":"larger effect among adherent","text_display":" larger effect among adherent","confidence":1,"confidence_rate":1},{"cnt":[[742,1769],[2030,1769],[2030,2348],[742,2348]],"region":{"top_left_x":742,"top_left_y":1769,"width":1288,"height":579},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"83f595a0b41447c89b9694bf31c86576","type":"column","conversion_output":false,"children_ids":["8ba5859c828c499d904d71d656d8a075","bbda18aa71de41d8a83b7a24619e49a5"],"text":"","text_display":""},{"cnt":[[767,1772],[2004,1772],[2004,1824],[767,1824]],"region":{"top_left_x":766,"top_left_y":1772,"width":1239,"height":53},"line":51,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8ba5859c828c499d904d71d656d8a075","type":"figure_label","conversion_output":false,"parent_id":"83f595a0b41447c89b9694bf31c86576","text":"Table 2. Study power for co-primary study outcomes, by effect size","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[746,1830],[2026,1830],[2026,2344],[746,2344]],"region":{"top_left_x":745,"top_left_y":1830,"width":1281,"height":514},"line":52,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bbda18aa71de41d8a83b7a24619e49a5","type":"table","conversion_output":true,"parent_id":"83f595a0b41447c89b9694bf31c86576","children_ids":["137520b1635f41c1b8c715cb9c00eedc","dc17c2efa4e6456aa95a89531d8bea35","6aec786927a44eb09842349caaa1adeb","71faf9bc984448ec803ef564d448346f","a59295d7982546768ac7f3bed3210ef5","5b5d2bbe3060479586c49164fe7b4bba","6b226beb49e9408ca9c90292ab2df232","e62bce0dc0c84637a1990960beef3bb3","f6466db96281479ab4f1e8750cd50ba5","d7123794ff34447d8306b86c0b21c437","81cb60940bbd43009b8b0df5a736023f","890ce44f0d8641a3bd944570e70b97b8","562bf8b492f04caaa3e3e50a30fad58f","d866f78e305548cabad9e59a38468916","17dcaa6681c146d782d760fb72671f8b","bf62dbc1984c43c6a53ab3b05510391b","120294c546a74db498026e824bb95fc0","f4581a63a248411891ed8cae2d60e0ad","a652dbaf0079479abba4adf2cf1c1666","8001fadfd6a64db9aaa4be6e2833a321","66d32116e41f40bc9e4cf630f63af285","f3b3c6d5503349cc9b09babd559da9e6","f992021f02fb480dbb91746fdf750b70","70b140d966184242ac28f5af81f1cbaa","799bea2ca19d49718fb1ad9efe86aa01","2074a1c603f5404890913de0e7fd5019","3b009cc4045941148d6b6cadc20dda0d","79efcf8404664a82b9e5720b21d59065","da76990ff8ef4974a086db672a4e0f1b","75bc2e2880fa46b49a39f6842f55edc4","08ba48d04ee04aa1899b319fb0b63827","3f363f8ee972407483dd26e3c8930a30","cfed3167f2054e2bb5062b8f20c11121","c05a00f3dc0849de950feba9676e0d14","87ff06ff1eb74f2ab7fbf4eac6e5083e","737d2929d0914301a9ebded5a3a73ee3","f4d51642a5e64ceea5e3eee7d769e2fa","ec061d3d8eff405886c8087354eb68b1","c2a108756a0d411294678c36e48a1175","b20487040cc0435881dc4f5a07e19a89","f2bf7c8f38f047bb86fb92f0869be152","ac8803b2605945fcb0c7c30a2ecf0104","a0d42a0515674ae09a1cc8a65dc52108","4a01e7ef322d4654b7ad7221cab32116"],"selected_labels":["8ba5859c828c499d904d71d656d8a075"],"text":"\\begin{tabular}{|l|l|l|l|}\n\\hline \\multicolumn{2}{|c|}{Urine ACR} & \\multicolumn{2}{|c|}{Estimated GFR} \\\\\n\\hline \\% Difference & Power & Difference ( \\(mL / \\min / 1 . 7 3 m ^{ 2 }\\) ) & Power \\\\\n\\hline 15\\% & 81\\% & 2.0 & 71\\% \\\\\n\\hline 17\\% & 90\\% & 2.2 & 79\\% \\\\\n\\hline 19\\% & 96\\% & 2.4 & 85\\% \\\\\n\\hline 21\\% & 98\\% & 2.6 & 90\\% \\\\\n\\hline 23\\% & >99\\% & 2.8 & 94\\% \\\\\n\\hline 25\\% & >99\\% & 3.0 & 97\\% \\\\\n\\hline \\multicolumn{4}{|l|}{Differences are assessed after four years total follow-up (not per year)} \\\\\n\\hline\n\\end{tabular}","text_display":"\n\n\\begin{table}\n\\captionsetup{labelformat=empty}\n\\caption{Table 2. Study power for co-primary study outcomes, by effect size}\n\\begin{tabular}{|l|l|l|l|}\n\\hline \\multicolumn{2}{|c|}{Urine ACR} & \\multicolumn{2}{|c|}{Estimated GFR} \\\\\n\\hline \\% Difference & Power & Difference ( \\(mL / \\min / 1 . 7 3 m ^{ 2 }\\) ) & Power \\\\\n\\hline 15\\% & 81\\% & 2.0 & 71\\% \\\\\n\\hline 17\\% & 90\\% & 2.2 & 79\\% \\\\\n\\hline 19\\% & 96\\% & 2.4 & 85\\% \\\\\n\\hline 21\\% & 98\\% & 2.6 & 90\\% \\\\\n\\hline 23\\% & >99\\% & 2.8 & 94\\% \\\\\n\\hline 25\\% & >99\\% & 3.0 & 97\\% \\\\\n\\hline \\multicolumn{4}{|l|}{Differences are assessed after four years total follow-up (not per year)} \\\\\n\\hline\n\\end{tabular}\n\\end{table}","confidence":0.28719837779397944,"confidence_rate":0.9991902098168148},{"cnt":[[767,1830],[1040,1830],[1040,2346],[767,2346]],"region":{"top_left_x":766,"top_left_y":1830,"width":274,"height":516},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"137520b1635f41c1b8c715cb9c00eedc","type":"table_column","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"","text_display":""},{"cnt":[[1078,1830],[1217,1830],[1217,2346],[1078,2346]],"region":{"top_left_x":1077,"top_left_y":1830,"width":141,"height":516},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"dc17c2efa4e6456aa95a89531d8bea35","type":"table_column","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"","text_display":""},{"cnt":[[1277,1830],[1806,1830],[1806,2346],[1277,2346]],"region":{"top_left_x":1277,"top_left_y":1830,"width":530,"height":516},"line":55,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6aec786927a44eb09842349caaa1adeb","type":"table_column","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"","text_display":""},{"cnt":[[1864,1830],[2000,1830],[2000,2346],[1864,2346]],"region":{"top_left_x":1863,"top_left_y":1830,"width":138,"height":516},"line":56,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"71faf9bc984448ec803ef564d448346f","type":"table_column","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"","text_display":""},{"cnt":[[745,1907],[745,1857],[2027,1860],[2027,1910]],"region":{"top_left_x":744,"top_left_y":1856,"width":1284,"height":54},"line":57,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a59295d7982546768ac7f3bed3210ef5","type":"table_row","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"","text_display":""},{"cnt":[[745,1923],[2027,1923],[2027,1977],[745,1977]],"region":{"top_left_x":745,"top_left_y":1922,"width":1283,"height":56},"line":58,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5b5d2bbe3060479586c49164fe7b4bba","type":"table_row","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"","text_display":""},{"cnt":[[745,1991],[2025,1991],[2025,2040],[745,2040]],"region":{"top_left_x":745,"top_left_y":1990,"width":1280,"height":51},"line":59,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6b226beb49e9408ca9c90292ab2df232","type":"table_row","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"","text_display":""},{"cnt":[[745,2037],[2025,2037],[2025,2084],[745,2084]],"region":{"top_left_x":745,"top_left_y":2037,"width":1280,"height":47},"line":60,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e62bce0dc0c84637a1990960beef3bb3","type":"table_row","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"","text_display":""},{"cnt":[[745,2084],[2025,2080],[2025,2128],[745,2131]],"region":{"top_left_x":744,"top_left_y":2080,"width":1281,"height":52},"line":61,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f6466db96281479ab4f1e8750cd50ba5","type":"table_row","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"","text_display":""},{"cnt":[[745,2125],[2025,2125],[2025,2174],[745,2174]],"region":{"top_left_x":745,"top_left_y":2124,"width":1280,"height":50},"line":62,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d7123794ff34447d8306b86c0b21c437","type":"table_row","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"","text_display":""},{"cnt":[[745,2168],[2027,2168],[2027,2217],[745,2217]],"region":{"top_left_x":745,"top_left_y":2168,"width":1283,"height":50},"line":63,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"81cb60940bbd43009b8b0df5a736023f","type":"table_row","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"","text_display":""},{"cnt":[[745,2212],[2027,2212],[2027,2264],[745,2264]],"region":{"top_left_x":745,"top_left_y":2211,"width":1283,"height":53},"line":64,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"890ce44f0d8641a3bd944570e70b97b8","type":"table_row","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"","text_display":""},{"cnt":[[745,2280],[2027,2280],[2027,2340],[745,2340]],"region":{"top_left_x":745,"top_left_y":2280,"width":1283,"height":61},"line":65,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"562bf8b492f04caaa3e3e50a30fad58f","type":"table_row","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"","text_display":""},{"cnt":[[772,1857],[1220,1857],[1220,1909],[772,1909]],"region":{"top_left_x":772,"top_left_y":1857,"width":448,"height":53},"line":66,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d866f78e305548cabad9e59a38468916","type":"table_spanning_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","children_ids":["e98593e3d9534561886e6f0c15581ff9"],"text":"","text_display":"Urine ACR","cell_row":0,"cell_column":0,"cell_row_span":1,"cell_col_span":2},{"cnt":[[898,1863],[1097,1863],[1097,1904],[898,1904]],"region":{"top_left_x":897,"top_left_y":1862,"width":200,"height":42},"line":67,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e98593e3d9534561886e6f0c15581ff9","type":"simple_cell","conversion_output":false,"parent_id":"d866f78e305548cabad9e59a38468916","text":"Urine ACR","text_display":"Urine ACR","cell_row":0,"cell_column":0,"cell_row_span":1,"cell_col_span":2,"confidence":1,"confidence_rate":1},{"cnt":[[1291,1857],[2000,1857],[2000,1909],[1291,1909]],"region":{"top_left_x":1290,"top_left_y":1857,"width":711,"height":53},"line":68,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"17dcaa6681c146d782d760fb72671f8b","type":"table_spanning_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","children_ids":["49d6997f8b6e4c609bcb0d919f0875e7"],"text":"","text_display":"Estimated GFR","cell_row":0,"cell_column":2,"cell_row_span":1,"cell_col_span":2},{"cnt":[[1487,1863],[1774,1863],[1774,1904],[1487,1904]],"region":{"top_left_x":1487,"top_left_y":1862,"width":287,"height":42},"line":69,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"49d6997f8b6e4c609bcb0d919f0875e7","type":"simple_cell","conversion_output":false,"parent_id":"17dcaa6681c146d782d760fb72671f8b","text":"Estimated GFR","text_display":"Estimated GFR","cell_row":0,"cell_column":2,"cell_row_span":1,"cell_col_span":2,"confidence":1,"confidence_rate":1},{"cnt":[[789,1928],[1031,1928],[1031,1972],[789,1972]],"region":{"top_left_x":788,"top_left_y":1928,"width":244,"height":44},"line":70,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bf62dbc1984c43c6a53ab3b05510391b","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"\\% Difference","text_display":"\\% Difference","cell_row":1,"cell_column":0,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1089,1928],[1214,1928],[1214,1972],[1089,1972]],"region":{"top_left_x":1088,"top_left_y":1928,"width":127,"height":44},"line":71,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"120294c546a74db498026e824bb95fc0","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"Power","text_display":"Power","cell_row":1,"cell_column":1,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1291,1925],[1790,1925],[1790,1977],[1291,1977]],"region":{"top_left_x":1290,"top_left_y":1925,"width":500,"height":53},"line":72,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f4581a63a248411891ed8cae2d60e0ad","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"Difference ( \\(mL / \\min / 1 . 7 3 m ^{ 2 }\\) )","text_display":"Difference ( \\(mL / \\min / 1 . 7 3 m ^{ 2 }\\) )","cell_row":1,"cell_column":2,"cell_row_span":1,"cell_col_span":1,"confidence":0.28719837779397944,"confidence_rate":0.9775720213264648},{"cnt":[[1872,1928],[1997,1928],[1997,1975],[1872,1975]],"region":{"top_left_x":1871,"top_left_y":1928,"width":127,"height":47},"line":73,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a652dbaf0079479abba4adf2cf1c1666","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"Power","text_display":"Power","cell_row":1,"cell_column":3,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[868,1999],[952,1999],[952,2043],[868,2043]],"region":{"top_left_x":867,"top_left_y":1999,"width":86,"height":44},"line":74,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8001fadfd6a64db9aaa4be6e2833a321","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"15\\%","text_display":"15\\%","cell_row":2,"cell_column":0,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1105,1999],[1192,1999],[1192,2043],[1105,2043]],"region":{"top_left_x":1105,"top_left_y":1999,"width":88,"height":44},"line":75,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"66d32116e41f40bc9e4cf630f63af285","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"81\\%","text_display":"81\\%","cell_row":2,"cell_column":1,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1512,1988],[1574,1988],[1574,2040],[1512,2040]],"region":{"top_left_x":1511,"top_left_y":1988,"width":64,"height":53},"line":76,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f3b3c6d5503349cc9b09babd559da9e6","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"2.0","text_display":"2.0","cell_row":2,"cell_column":2,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1891,1999],[1975,1999],[1975,2043],[1891,2043]],"region":{"top_left_x":1890,"top_left_y":1999,"width":86,"height":44},"line":77,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f992021f02fb480dbb91746fdf750b70","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"71\\%","text_display":"71\\%","cell_row":2,"cell_column":3,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[868,2043],[952,2043],[952,2086],[868,2086]],"region":{"top_left_x":867,"top_left_y":2042,"width":86,"height":45},"line":78,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"70b140d966184242ac28f5af81f1cbaa","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"17\\%","text_display":"17\\%","cell_row":3,"cell_column":0,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1108,2043],[1195,2043],[1195,2086],[1108,2086]],"region":{"top_left_x":1107,"top_left_y":2042,"width":89,"height":45},"line":79,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"799bea2ca19d49718fb1ad9efe86aa01","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"90\\%","text_display":"90\\%","cell_row":3,"cell_column":1,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1512,2035],[1574,2035],[1574,2086],[1512,2086]],"region":{"top_left_x":1511,"top_left_y":2034,"width":64,"height":53},"line":80,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2074a1c603f5404890913de0e7fd5019","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"2.2","text_display":"2.2","cell_row":3,"cell_column":2,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1891,2043],[1975,2043],[1975,2086],[1891,2086]],"region":{"top_left_x":1890,"top_left_y":2042,"width":86,"height":45},"line":81,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3b009cc4045941148d6b6cadc20dda0d","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"79\\%","text_display":"79\\%","cell_row":3,"cell_column":3,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[871,2086],[952,2086],[952,2130],[871,2130]],"region":{"top_left_x":870,"top_left_y":2086,"width":83,"height":45},"line":82,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"79efcf8404664a82b9e5720b21d59065","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"19\\%","text_display":"19\\%","cell_row":4,"cell_column":0,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1108,2086],[1192,2086],[1192,2130],[1108,2130]],"region":{"top_left_x":1107,"top_left_y":2086,"width":86,"height":45},"line":83,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"da76990ff8ef4974a086db672a4e0f1b","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"96\\%","text_display":"96\\%","cell_row":4,"cell_column":1,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1512,2081],[1574,2081],[1574,2130],[1512,2130]],"region":{"top_left_x":1511,"top_left_y":2081,"width":64,"height":50},"line":84,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"75bc2e2880fa46b49a39f6842f55edc4","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"2.4","text_display":"2.4","cell_row":4,"cell_column":2,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1891,2086],[1975,2086],[1975,2130],[1891,2130]],"region":{"top_left_x":1890,"top_left_y":2086,"width":86,"height":45},"line":85,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"08ba48d04ee04aa1899b319fb0b63827","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"85\\%","text_display":"85\\%","cell_row":4,"cell_column":3,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[865,2130],[952,2130],[952,2174],[865,2174]],"region":{"top_left_x":865,"top_left_y":2130,"width":88,"height":44},"line":86,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3f363f8ee972407483dd26e3c8930a30","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"21\\%","text_display":"21\\%","cell_row":5,"cell_column":0,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1111,2130],[1195,2130],[1195,2174],[1111,2174]],"region":{"top_left_x":1110,"top_left_y":2130,"width":86,"height":44},"line":87,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cfed3167f2054e2bb5062b8f20c11121","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"98\\%","text_display":"98\\%","cell_row":5,"cell_column":1,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1512,2125],[1574,2125],[1574,2174],[1512,2174]],"region":{"top_left_x":1511,"top_left_y":2124,"width":64,"height":50},"line":88,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c05a00f3dc0849de950feba9676e0d14","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"2.6","text_display":"2.6","cell_row":5,"cell_column":2,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1891,2130],[1978,2130],[1978,2174],[1891,2174]],"region":{"top_left_x":1890,"top_left_y":2130,"width":89,"height":44},"line":89,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"87ff06ff1eb74f2ab7fbf4eac6e5083e","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"90\\%","text_display":"90\\%","cell_row":5,"cell_column":3,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[865,2174],[952,2174],[952,2217],[865,2217]],"region":{"top_left_x":865,"top_left_y":2173,"width":88,"height":45},"line":90,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"737d2929d0914301a9ebded5a3a73ee3","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"23\\%","text_display":"23\\%","cell_row":6,"cell_column":0,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1097,2174],[1203,2174],[1203,2217],[1097,2217]],"region":{"top_left_x":1096,"top_left_y":2173,"width":108,"height":45},"line":91,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f4d51642a5e64ceea5e3eee7d769e2fa","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":">99\\%","text_display":">99\\%","cell_row":6,"cell_column":1,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1512,2171],[1574,2171],[1574,2217],[1512,2217]],"region":{"top_left_x":1511,"top_left_y":2171,"width":64,"height":47},"line":92,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ec061d3d8eff405886c8087354eb68b1","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"2.8","text_display":"2.8","cell_row":6,"cell_column":2,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1891,2174],[1973,2174],[1973,2217],[1891,2217]],"region":{"top_left_x":1890,"top_left_y":2173,"width":83,"height":45},"line":93,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c2a108756a0d411294678c36e48a1175","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"94\\%","text_display":"94\\%","cell_row":6,"cell_column":3,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[865,2217],[952,2217],[952,2261],[865,2261]],"region":{"top_left_x":865,"top_left_y":2217,"width":88,"height":45},"line":94,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b20487040cc0435881dc4f5a07e19a89","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"25\\%","text_display":"25\\%","cell_row":7,"cell_column":0,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1097,2217],[1203,2217],[1203,2261],[1097,2261]],"region":{"top_left_x":1096,"top_left_y":2217,"width":108,"height":45},"line":95,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f2bf7c8f38f047bb86fb92f0869be152","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":">99\\%","text_display":">99\\%","cell_row":7,"cell_column":1,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1514,2215],[1574,2215],[1574,2261],[1514,2261]],"region":{"top_left_x":1514,"top_left_y":2214,"width":61,"height":48},"line":96,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ac8803b2605945fcb0c7c30a2ecf0104","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"3.0","text_display":"3.0","cell_row":7,"cell_column":2,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[1891,2217],[1973,2217],[1973,2261],[1891,2261]],"region":{"top_left_x":1890,"top_left_y":2217,"width":83,"height":45},"line":97,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a0d42a0515674ae09a1cc8a65dc52108","type":"simple_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","text":"97\\%","text_display":"97\\%","cell_row":7,"cell_column":3,"cell_row_span":1,"cell_col_span":1,"confidence":1,"confidence_rate":1},{"cnt":[[767,2283],[2000,2283],[2000,2340],[767,2340]],"region":{"top_left_x":766,"top_left_y":2282,"width":1235,"height":59},"line":98,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4a01e7ef322d4654b7ad7221cab32116","type":"table_spanning_cell","conversion_output":false,"parent_id":"bbda18aa71de41d8a83b7a24619e49a5","children_ids":["d81ec3b957b04f50b19456c4cf08368b"],"text":"","text_display":"Differences are assessed after four years total follow-up (not per year)","cell_row":8,"cell_column":0,"cell_row_span":1,"cell_col_span":4},{"cnt":[[770,2286],[1962,2286],[1962,2335],[770,2335]],"region":{"top_left_x":769,"top_left_y":2285,"width":1193,"height":50},"line":99,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d81ec3b957b04f50b19456c4cf08368b","type":"simple_cell","conversion_output":false,"parent_id":"4a01e7ef322d4654b7ad7221cab32116","text":"Differences are assessed after four years total follow-up (not per year)","text_display":"Differences are assessed after four years total follow-up (not per year)","cell_row":8,"cell_column":0,"cell_row_span":1,"cell_col_span":4,"confidence":1,"confidence_rate":1},{"cnt":[[120,2361],[2004,2361],[2004,2408],[120,2408]],"region":{"top_left_x":120,"top_left_y":2361,"width":1885,"height":48},"line":100,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"506fff95c81c4acca81d6c0308007a2c","type":"text","conversion_output":true,"text":"participants \"diluted\" by little or no effect among nonadherent participants. If adherence to study medications is","text_display":"\nparticipants \"diluted\" by little or no effect among nonadherent participants. If adherence to study medications is","confidence":0.99853515625,"confidence_rate":0.9999876814398867},{"cnt":[[120,2400],[1946,2400],[1946,2451],[120,2451]],"region":{"top_left_x":120,"top_left_y":2399,"width":1827,"height":53},"line":101,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9e7bb1b91a68423d923cae99cd1403f1","type":"text","conversion_output":true,"text":"\\(80 \\%\\) in each treatment group, observed differences in urine ACR and eGFR of \\(17 \\%\\) and \\(2.6 mL / min / 1.73 m^{2}\\)","text_display":" \\(80 \\%\\) in each treatment group, observed differences in urine ACR and eGFR of \\(17 \\%\\) and \\(2.6 mL / min / 1.73 m^{2}\\)","confidence":0.9980475902557373,"confidence_rate":0.9999838487405106},{"cnt":[[120,2445],[1914,2445],[1914,2496],[120,2496]],"region":{"top_left_x":120,"top_left_y":2444,"width":1795,"height":53},"line":102,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"84a776772fbc469fbde4498899cb68ae","type":"text","conversion_output":true,"text":"correspond to differences of \\(21 \\%\\) and \\(3.2 mL / min / 1.73 m^{2}\\), respectively, among adherent participants. \\({ }^{154} A\\)","text_display":" correspond to differences of \\(21 \\%\\) and \\(3.2 mL / min / 1.73 m^{2}\\), respectively, among adherent participants. \\({ }^{154} A\\)","confidence":1,"confidence_rate":1},{"cnt":[[120,2492],[1979,2492],[1979,2542],[120,2542]],"region":{"top_left_x":120,"top_left_y":2492,"width":1859,"height":50},"line":103,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f05a10aac41b461ba0d78ab8f0136b4a","type":"text","conversion_output":true,"text":"decrease in loss to follow-up to \\(10 \\%\\) ( 1,350 participants returning for follow-up) will increase power to \\(93 \\%\\) for","text_display":" decrease in loss to follow-up to \\(10 \\%\\) ( 1,350 participants returning for follow-up) will increase power to \\(93 \\%\\) for","confidence":0.911536175691765,"confidence_rate":0.9992709430757801},{"cnt":[[1955,2582],[2007,2582],[2007,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2582,"width":52,"height":46},"line":104,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"14b50cbcd85342ce8bfd4eff5add308f","type":"page_info","conversion_output":false,"text":"19","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-20","page":20,"lines":[{"cnt":[[116,120],[1884,120],[1884,174],[116,174]],"region":{"top_left_x":116,"top_left_y":120,"width":1769,"height":55},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4274c98295174f8ab0e8fee53c14a012","type":"text","conversion_output":true,"text":"the detection of differences by treatment group of \\(17 \\%\\) in follow-up urine ACR and \\(2.6 mL / min / 1.73 m^{2}\\) in","text_display":"\nthe detection of differences by treatment group of \\(17 \\%\\) in follow-up urine ACR and \\(2.6 mL / min / 1.73 m^{2}\\) in","confidence":0.98828125,"confidence_rate":0.9999079108361546},{"cnt":[[116,168],[1949,168],[1949,217],[116,217]],"region":{"top_left_x":116,"top_left_y":167,"width":1833,"height":50},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6562e48ea5c4427e985295e459bc837f","type":"text","conversion_output":true,"text":"follow-up eGFR, while an increase in loss to follow-up to \\(30 \\%\\) ( 1,050 participants returning for follow-up) will","text_display":" follow-up eGFR, while an increase in loss to follow-up to \\(30 \\%\\) ( 1,050 participants returning for follow-up) will","confidence":0.8578997772065691,"confidence_rate":0.9987546947677943},{"cnt":[[116,215],[1876,215],[1876,262],[116,262]],"region":{"top_left_x":116,"top_left_y":214,"width":1760,"height":49},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e01f794ffb8e4acbb7437050358d736b","type":"text","conversion_output":true,"text":"decrease power to \\(86 \\%\\) for the detection of these differences. If interaction of the study interventions is","text_display":" decrease power to \\(86 \\%\\) for the detection of these differences. If interaction of the study interventions is","confidence":0.99853515625,"confidence_rate":0.9999871411556362},{"cnt":[[116,258],[1747,258],[1747,305],[116,305]],"region":{"top_left_x":116,"top_left_y":257,"width":1631,"height":49},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4f2c8fa3cba24c39b4edea30a439bef1","type":"text","conversion_output":true,"text":"present, requiring separate testing of each treatment combination against the group assigned to","text_display":" present, requiring separate testing of each treatment combination against the group assigned to","confidence":1,"confidence_rate":1},{"cnt":[[116,301],[1936,301],[1936,350],[116,350]],"region":{"top_left_x":116,"top_left_y":300,"width":1820,"height":51},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"52f77b12cd8b455d9a31d747e3abab32","type":"text","conversion_output":true,"text":"(placebo+placebo), we will have \\(80 \\%\\) power to detect differences in follow-up urine ACR and eGFR of \\(20 \\%\\)","text_display":" (placebo+placebo), we will have \\(80 \\%\\) power to detect differences in follow-up urine ACR and eGFR of \\(20 \\%\\)","confidence":0.951195478439331,"confidence_rate":0.9995410623427431},{"cnt":[[116,339],[1962,339],[1962,393],[116,393]],"region":{"top_left_x":116,"top_left_y":339,"width":1846,"height":55},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d2830d6fa7a84947acd553a011357ccb","type":"text","conversion_output":true,"text":"and \\(3.2 mL / min / 1.73 m^{2}\\), respectively, comparing any one treatment combination (e.g. active cholecalciferol +","text_display":" and \\(3.2 mL / min / 1.73 m^{2}\\), respectively, comparing any one treatment combination (e.g. active cholecalciferol +","confidence":0.8874034881591797,"confidence_rate":0.9990885415142022},{"cnt":[[116,389],[776,389],[776,436],[116,436]],"region":{"top_left_x":116,"top_left_y":388,"width":660,"height":49},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b90c1d440e5e417dbda1329ece5c090c","type":"text","conversion_output":true,"text":"active \\(\\omega-3\\) FA) to (placebo + placebo).","text_display":" active \\(\\omega-3\\) FA) to (placebo + placebo).","confidence":0.6026565553166847,"confidence_rate":0.9897183679395007},{"cnt":[[180,451],[2000,451],[2000,501],[180,501]],"region":{"top_left_x":180,"top_left_y":451,"width":1821,"height":50},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2018082b17874a0c9a83fe35d9317e37","type":"text","conversion_output":true,"text":"Power for the secondary composite outcome is shown in Figure 11, given an enrolled sample size of 1,500","text_display":"\n\nPower for the secondary composite outcome is shown in Figure 11, given an enrolled sample size of 1,500","confidence":0.9990234375,"confidence_rate":0.9999908688300274},{"cnt":[[116,498],[1910,498],[1910,546],[116,546]],"region":{"top_left_x":116,"top_left_y":498,"width":1794,"height":48},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4c6f1f31147a416b989358dbbc3c7ca3","type":"text","conversion_output":true,"text":"participants and other assumptions listed above (including 20\\% loss to follow-up). Power depends on the","text_display":" participants and other assumptions listed above (including 20\\% loss to follow-up). Power depends on the","confidence":0.9423828125,"confidence_rate":0.9994506721926455},{"cnt":[[116,541],[1983,541],[1983,591],[116,591]],"region":{"top_left_x":116,"top_left_y":541,"width":1868,"height":50},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5ad1181bfb8d4694ad134a1a4685a40f","type":"text","conversion_output":true,"text":"observed 4 -year incidence of the composite outcome. Based on observational data from MESA and CHS, we","text_display":" observed 4 -year incidence of the composite outcome. Based on observational data from MESA and CHS, we","confidence":0.984375,"confidence_rate":0.9998568433663604},{"cnt":[[116,587],[1884,587],[1884,634],[116,634]],"region":{"top_left_x":116,"top_left_y":586,"width":1769,"height":48},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"66a5bd4fe1a04943a325e811b23ea54e","type":"text","conversion_output":true,"text":"expect the incidences of albuminuria progression and rapid loss of eGFR to be approximately \\(17 \\%\\) each","text_display":" expect the incidences of albuminuria progression and rapid loss of eGFR to be approximately \\(17 \\%\\) each","confidence":0.9990234375,"confidence_rate":0.9999909533775151},{"cnt":[[116,627],[1923,627],[1923,677],[116,677]],"region":{"top_left_x":116,"top_left_y":627,"width":1807,"height":50},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ca8911ea0cd84d55b1025942b29d4d51","type":"text","conversion_output":true,"text":"(Section C1), the 4 -year cumulative incidence of ESRD to be \\(<1 \\%\\), and the 4 -year cumulative incidence of","text_display":" (Section C1), the 4 -year cumulative incidence of ESRD to be \\(<1 \\%\\), and the 4 -year cumulative incidence of","confidence":0.916015625,"confidence_rate":0.9992692516551044},{"cnt":[[116,675],[1972,675],[1972,724],[116,724]],"region":{"top_left_x":116,"top_left_y":674,"width":1857,"height":51},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"196ee1cddd534165b61e5d3239083552","type":"text","conversion_output":true,"text":"death to be \\(\\sim 4.6 \\%\\) (cumulative incidence during the first 4 years of observation for CHS participants with self-","text_display":" death to be \\(\\sim 4.6 \\%\\) (cumulative incidence during the first 4 years of observation for CHS participants with self","confidence":0.99853515625,"confidence_rate":0.9999879843534795},{"cnt":[[116,718],[1914,718],[1914,767],[116,767]],"region":{"top_left_x":116,"top_left_y":717,"width":1799,"height":50},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9a729af7a9894fb1baf0d69efd00452a","type":"text","conversion_output":true,"text":"reported diabetes), for groups assigned to placebo. The joint cumulative incidence of these outcomes will","text_display":"reported diabetes), for groups assigned to placebo. The joint cumulative incidence of these outcomes will","confidence":1,"confidence_rate":1},{"cnt":[[116,761],[1992,761],[1992,810],[116,810]],"region":{"top_left_x":116,"top_left_y":760,"width":1876,"height":50},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a334beae00554b388587457c4115804a","type":"text","conversion_output":true,"text":"likely be at least \\(20-30 \\%\\), yielding \\(80 \\%\\) power to detect observed relative risks of \\(0.69-0.76\\) (or lower) and \\(90 \\%\\)","text_display":" likely be at least \\(20-30 \\%\\), yielding \\(80 \\%\\) power to detect observed relative risks of \\(0.69-0.76\\) (or lower) and \\(90 \\%\\)","confidence":0.9965848922729492,"confidence_rate":0.9999726327543434},{"cnt":[[116,804],[999,804],[999,853],[116,853]],"region":{"top_left_x":116,"top_left_y":803,"width":884,"height":50},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"eb74247bd13340e0a20a30d443bb2676","type":"text","conversion_output":true,"text":"power to detect observed relative risks of \\(0.65-0.73\\)","text_display":" power to detect observed relative risks of \\(0.65-0.73\\)","confidence":0.80810546875,"confidence_rate":0.9962025376245094},{"cnt":[[116,851],[939,851],[939,898],[116,898]],"region":{"top_left_x":116,"top_left_y":850,"width":823,"height":49},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2bda41272d4043738b8a7f6697da9c62","type":"text","conversion_output":true,"text":"(or lower). A higher cumulative incidence of the","text_display":" (or lower). A higher cumulative incidence of the","confidence":1,"confidence_rate":1},{"cnt":[[116,894],[1010,894],[1010,939],[116,939]],"region":{"top_left_x":116,"top_left_y":893,"width":894,"height":46},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"45a460b5ca554765bc336a63b66ef8f2","type":"text","conversion_output":true,"text":"composite outcome would allow detection of relative","text_display":" composite outcome would allow detection of relative","confidence":1,"confidence_rate":1},{"cnt":[[116,937],[406,937],[406,982],[116,982]],"region":{"top_left_x":116,"top_left_y":936,"width":291,"height":46},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2eaf862987b44a97acb78ff9eba6f011","type":"text","conversion_output":true,"text":"risks closer to 1.","text_display":" risks closer to 1.","confidence":1,"confidence_rate":1},{"cnt":[[180,1001],[857,1001],[857,1051],[180,1051]],"region":{"top_left_x":180,"top_left_y":1001,"width":678,"height":50},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3447d25e8cec44e6b0595030cf4ffd5f","type":"text","conversion_output":true,"text":"It is important to acknowledge that both","text_display":"\n\nIt is important to acknowledge that both","confidence":1,"confidence_rate":1},{"cnt":[[116,1044],[941,1044],[941,1094],[116,1094]],"region":{"top_left_x":116,"top_left_y":1044,"width":826,"height":50},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d484610f4a42490ea80295d79cb76b9b","type":"text","conversion_output":true,"text":"albuminuria and eGFR have substantial biologic","text_display":" albuminuria and eGFR have substantial biologic","confidence":1,"confidence_rate":1},{"cnt":[[116,1091],[1038,1091],[1038,1137],[116,1137]],"region":{"top_left_x":116,"top_left_y":1091,"width":922,"height":46},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"245e74a7e4704c4cbf5419e3029199ae","type":"text","conversion_output":true,"text":"variation over time, such that single measurements of","text_display":" variation over time, such that single measurements of","confidence":1,"confidence_rate":1},{"cnt":[[116,1134],[973,1134],[973,1182],[116,1182]],"region":{"top_left_x":116,"top_left_y":1134,"width":858,"height":48},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fb740ab769f2409fb87c8aa5f536f25c","type":"text","conversion_output":true,"text":"albuminuria and eGFR at baseline and year 4 can","text_display":" albuminuria and eGFR at baseline and year 4 can","confidence":1,"confidence_rate":1},{"cnt":[[116,1177],[943,1177],[943,1227],[116,1227]],"region":{"top_left_x":116,"top_left_y":1177,"width":828,"height":50},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ec511ddd75314751a63ea13eb05214fa","type":"text","conversion_output":true,"text":"lead to substantial misclassification of change in","text_display":" lead to substantial misclassification of change in","confidence":1,"confidence_rate":1},{"cnt":[[116,1222],[982,1222],[982,1270],[116,1270]],"region":{"top_left_x":116,"top_left_y":1222,"width":866,"height":48},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"afb2b85c56df4181b80764e9f40f53dd","type":"text","conversion_output":true,"text":"these outcomes (\"noise\"). This misclassification is","text_display":" these outcomes (\"noise\"). This misclassification is","confidence":1,"confidence_rate":1},{"cnt":[[116,1268],[967,1268],[967,1313],[116,1313]],"region":{"top_left_x":116,"top_left_y":1267,"width":851,"height":46},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8c6ee5463ff8472aaa6006ccc961ce2e","type":"text","conversion_output":true,"text":"unlikely to be biased by treatment assignment, so","text_display":" unlikely to be biased by treatment assignment, so","confidence":1,"confidence_rate":1},{"cnt":[[116,1311],[990,1311],[990,1356],[116,1356]],"region":{"top_left_x":116,"top_left_y":1310,"width":875,"height":46},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"86512866d7054ec88f2c112f5762bc99","type":"text","conversion_output":true,"text":"that it will bias results toward the null and decrease","text_display":" that it will bias results toward the null and decrease","confidence":1,"confidence_rate":1},{"cnt":[[116,1354],[988,1354],[988,1403],[116,1403]],"region":{"top_left_x":116,"top_left_y":1353,"width":873,"height":50},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7838a4d2361847babda230342c6db8ee","type":"text","conversion_output":true,"text":"power to detect effects of study interventions. Our","text_display":" power to detect effects of study interventions. Our","confidence":0.99951171875,"confidence_rate":0.9999912786005654},{"cnt":[[116,1401],[862,1401],[862,1446],[116,1446]],"region":{"top_left_x":116,"top_left_y":1400,"width":746,"height":46},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9d35a30bbbee443d8fa91abefcbe4bc2","type":"text","conversion_output":true,"text":"power calculations are based on real-world","text_display":" power calculations are based on real-world","confidence":1,"confidence_rate":1},{"cnt":[[116,1444],[1016,1444],[1016,1489],[116,1489]],"region":{"top_left_x":116,"top_left_y":1443,"width":901,"height":46},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"36be9c7f5e5144a3bfa2ff68b08e916d","type":"text","conversion_output":true,"text":"distributions of albuminuria, eGFR, and their change","text_display":" distributions of albuminuria, eGFR, and their change","confidence":1,"confidence_rate":1},{"cnt":[[116,1487],[1012,1487],[1012,1532],[116,1532]],"region":{"top_left_x":116,"top_left_y":1486,"width":896,"height":46},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b2db335ed84d44b38bdb1108c0d2758f","type":"text","conversion_output":true,"text":"over time. Thus, our power calculations account for","text_display":" over time. Thus, our power calculations account for","confidence":1,"confidence_rate":1},{"cnt":[[116,1530],[883,1530],[883,1575],[116,1575]],"region":{"top_left_x":116,"top_left_y":1529,"width":768,"height":46},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"82e21342bf42479789ea89ed93360dad","type":"text","conversion_output":true,"text":"known variability in study outcomes, with the","text_display":" known variability in study outcomes, with the","confidence":1,"confidence_rate":1},{"cnt":[[116,1573],[909,1573],[909,1620],[116,1620]],"region":{"top_left_x":116,"top_left_y":1572,"width":793,"height":48},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9b203cec4d8448fcb9f76e57b0f86c17","type":"text","conversion_output":true,"text":"relatively large proposed sample size of 1,500","text_display":" relatively large proposed sample size of 1,500","confidence":0.98046875,"confidence_rate":0.9996133197732576},{"cnt":[[116,1616],[1010,1616],[1010,1665],[116,1665]],"region":{"top_left_x":116,"top_left_y":1615,"width":894,"height":51},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ecdabf2f17a64f91b582d68cd677469d","type":"text","conversion_output":true,"text":"participants essentially overcoming misclassification","text_display":" participants essentially overcoming misclassification","confidence":1,"confidence_rate":1},{"cnt":[[116,1663],[982,1663],[982,1708],[116,1708]],"region":{"top_left_x":116,"top_left_y":1662,"width":866,"height":47},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"131e2cd9b88e406fbbf1481333ac8d07","type":"text","conversion_output":true,"text":"to permit detection of relatively modest changes in","text_display":" to permit detection of relatively modest changes in","confidence":1,"confidence_rate":1},{"cnt":[[116,1706],[836,1706],[836,1755],[116,1755]],"region":{"top_left_x":116,"top_left_y":1705,"width":720,"height":51},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"718b6cf9befb44fc8147e0dd519a5c36","type":"text","conversion_output":true,"text":"study outcomes with high levels of power.","text_display":" study outcomes with high levels of power.","confidence":1,"confidence_rate":1},{"cnt":[[1071,861],[1959,861],[1959,1797],[1071,1797]],"region":{"top_left_x":1071,"top_left_y":861,"width":888,"height":936},"line":37,"column":0,"font_size":31,"is_printed":true,"is_handwritten":false,"id":"71980cfc0210487ba7b5c363bb045d6c","type":"column","conversion_output":false,"children_ids":["78503649069546f298ad653d08102306","f95ab67cc9d14d0694174583fabc7bd5"],"text":"","text_display":""},{"cnt":[[1073,1662],[1075,863],[1953,866],[1951,1664]],"region":{"top_left_x":1073,"top_left_y":863,"width":881,"height":802},"line":38,"column":1,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"78503649069546f298ad653d08102306","type":"chart","conversion_output":true,"parent_id":"71980cfc0210487ba7b5c363bb045d6c","selected_labels":["f95ab67cc9d14d0694174583fabc7bd5"],"text":"","text_display":"\n\n\\begin{figure}\n\\includegraphics[alt={},max width=\\textwidth]{https://cdn.mathpix.com/cropped/7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-20.jpg?height=802&width=881&top_left_y=863&top_left_x=1073}\n\\captionsetup{labelformat=empty}\n\\caption{Figure 11. Power for dichotomous outcomes by relative risk (upper limit) and cumulative incidence.}\n\\end{figure}","subtype":"line"},{"cnt":[[1079,1689],[1955,1689],[1955,1794],[1079,1794]],"region":{"top_left_x":1078,"top_left_y":1688,"width":878,"height":106},"line":39,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f95ab67cc9d14d0694174583fabc7bd5","type":"figure_label","conversion_output":false,"parent_id":"71980cfc0210487ba7b5c363bb045d6c","children_ids":["473881857bdd437cb65b3f707bb6ce7f","4428ca1102004f8d87c721cc33c7f717"],"text":"","text_display":""},{"cnt":[[1087,1693],[1897,1693],[1897,1742],[1087,1742]],"region":{"top_left_x":1087,"top_left_y":1692,"width":811,"height":51},"line":40,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"473881857bdd437cb65b3f707bb6ce7f","type":"text","conversion_output":false,"parent_id":"f95ab67cc9d14d0694174583fabc7bd5","text":"Figure 11. Power for dichotomous outcomes by","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[1085,1740],[1949,1740],[1949,1790],[1085,1790]],"region":{"top_left_x":1084,"top_left_y":1740,"width":865,"height":50},"line":41,"column":1,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4428ca1102004f8d87c721cc33c7f717","type":"text","conversion_output":false,"parent_id":"f95ab67cc9d14d0694174583fabc7bd5","text":"relative risk (upper limit) and cumulative incidence.","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[1953,2582],[2007,2582],[2007,2628],[1953,2628]],"region":{"top_left_x":1952,"top_left_y":2582,"width":55,"height":46},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3b8cef2d04f944508bcb5a62d8175754","type":"page_info","conversion_output":false,"text":"20","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-21","page":21,"lines":[{"cnt":[[116,125],[668,125],[668,170],[116,170]],"region":{"top_left_x":116,"top_left_y":124,"width":553,"height":46},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"af1e13f8176f49ba9c35402077c8d46b","type":"section_header","conversion_output":false,"children_ids":["a3ac4a686c1a42b1a41952b678d8051d"],"text":"","text_display":""},{"cnt":[[120,129],[664,129],[664,165],[120,165]],"region":{"top_left_x":120,"top_left_y":128,"width":544,"height":38},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a3ac4a686c1a42b1a41952b678d8051d","type":"text","conversion_output":true,"parent_id":"af1e13f8176f49ba9c35402077c8d46b","text":"VII. Risks and Discomforts","text_display":"\n\n\\section*{VII. Risks and Discomforts}","confidence":1,"confidence_rate":1},{"cnt":[[125,193],[1781,193],[1781,236],[125,236]],"region":{"top_left_x":124,"top_left_y":193,"width":1658,"height":44},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7e83ee7db8dd4cd999abac3b767145b6","type":"text","conversion_output":true,"text":"VII.a. Potential adverse effects of study interventions. The main risks of this study arise from the","text_display":"\nVII.a. Potential adverse effects of study interventions. The main risks of this study arise from the","confidence":0.998046875,"confidence_rate":0.9999813807939509},{"cnt":[[122,236],[1936,236],[1936,279],[122,279]],"region":{"top_left_x":122,"top_left_y":236,"width":1814,"height":44},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"549758dc475e48f7b0ad66f1aa070f5e","type":"text","conversion_output":true,"text":"interventions of the parent VITAL trial, not the VITAL Diabetes ancillary study described herein. The parent","text_display":" interventions of the parent VITAL trial, not the VITAL Diabetes ancillary study described herein. The parent","confidence":1,"confidence_rate":1},{"cnt":[[122,279],[2002,279],[2002,324],[122,324]],"region":{"top_left_x":122,"top_left_y":279,"width":1881,"height":46},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6990dc42bb2f4a62b9e8848b153b8caf","type":"text","conversion_output":true,"text":"VITAL trial will test a dose of \\(2000 IU (40 \\mu g)\\) per day of vitamin \\(D _{3}\\) (cholecalciferol) and \\(840 mg / d\\) of EPA+DHA","text_display":" VITAL trial will test a dose of \\(2000 IU (40 \\mu g)\\) per day of vitamin \\(D _{3}\\) (cholecalciferol) and \\(840 mg / d\\) of EPA+DHA","confidence":0.6102538099803123,"confidence_rate":0.9965522486150084},{"cnt":[[122,322],[1996,322],[1996,367],[122,367]],"region":{"top_left_x":122,"top_left_y":322,"width":1874,"height":46},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0267c1ad4a4748af84d48c0e83e2004e","type":"text","conversion_output":true,"text":"in VITAL. We believe that these doses provide the best balance of efficacy and safety, based on careful review","text_display":" in VITAL. We believe that these doses provide the best balance of efficacy and safety, based on careful review","confidence":1,"confidence_rate":1},{"cnt":[[122,370],[1964,370],[1964,410],[122,410]],"region":{"top_left_x":122,"top_left_y":369,"width":1842,"height":42},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4fba9227131947fcb389f7291f278bff","type":"text","conversion_output":true,"text":"of the literature and extensive consultation with numerous nutritional experts. We seek to obtain an adequate","text_display":" of the literature and extensive consultation with numerous nutritional experts. We seek to obtain an adequate","confidence":1,"confidence_rate":1},{"cnt":[[122,412],[1884,412],[1884,455],[122,455]],"region":{"top_left_x":122,"top_left_y":412,"width":1763,"height":44},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ef9f0b554c2449a9af25964c15b11461","type":"text","conversion_output":true,"text":"difference in vitamin D and EPA+DHA levels between the treatment and placebo groups to detect health","text_display":" difference in vitamin D and EPA+DHA levels between the treatment and placebo groups to detect health","confidence":1,"confidence_rate":1},{"cnt":[[122,455],[1936,455],[1936,501],[122,501]],"region":{"top_left_x":122,"top_left_y":455,"width":1814,"height":46},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"edcd767c186341318bc732e3eb6fd379","type":"text","conversion_output":true,"text":"benefits, and there appear to be few safety issues associated with these doses. For vitamin D, the selected","text_display":" benefits, and there appear to be few safety issues associated with these doses. For vitamin D, the selected","confidence":0.850658655166626,"confidence_rate":0.9985568963738877},{"cnt":[[120,498],[1966,498],[1966,544],[120,544]],"region":{"top_left_x":120,"top_left_y":498,"width":1846,"height":46},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"dd3e5466b8db49e5b2197bc19415545d","type":"text","conversion_output":true,"text":"dose is lower than the tolerable upper intake level (UL) for vitamin \\(D _{3}(50 \\mu g\\), or 2000 IU \\()\\) set by the Food and","text_display":" dose is lower than the tolerable upper intake level (UL) for vitamin \\(D _{3}(50 \\mu g\\), or 2000 IU \\()\\) set by the Food and","confidence":0.9620095051852604,"confidence_rate":0.9997152541675325},{"cnt":[[122,544],[1989,544],[1989,587],[122,587]],"region":{"top_left_x":122,"top_left_y":543,"width":1868,"height":44},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d3af38171aff418faf0866ab9cfa3461","type":"text","conversion_output":true,"text":"Nutrition Board of the Institute of Medicine (IOM) and the European Commission Scientific Committee on Food","text_display":" Nutrition Board of the Institute of Medicine (IOM) and the European Commission Scientific Committee on Food","confidence":1,"confidence_rate":1},{"cnt":[[125,589],[1931,589],[1931,632],[125,632]],"region":{"top_left_x":124,"top_left_y":588,"width":1808,"height":44},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"60176e01bd7143c8a54fe31c334dd175","type":"text","conversion_output":true,"text":"(EC SCF). Also, because we will exclude from the trial persons who report supplemental vitamin D intakes","text_display":" (EC SCF). Also, because we will exclude from the trial persons who report supplemental vitamin D intakes","confidence":0.98876953125,"confidence_rate":0.9998963906282001},{"cnt":[[125,632],[1970,632],[1970,677],[125,677]],"region":{"top_left_x":124,"top_left_y":631,"width":1847,"height":46},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5938d62416d84eb1a8d815ed8cd39a0f","type":"text","conversion_output":true,"text":"\\(>800 IU / d\\), the selected dose ensures that no participants will be taking a supplemental vitamin D dose above","text_display":" \\(>800 IU / d\\), the selected dose ensures that no participants will be taking a supplemental vitamin D dose above","confidence":0.6362522250351503,"confidence_rate":0.9961754660105319},{"cnt":[[125,675],[1910,675],[1910,720],[125,720]],"region":{"top_left_x":124,"top_left_y":674,"width":1786,"height":46},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bec11938afa3444baf3b30a90f8c62b7","type":"text","conversion_output":true,"text":"2800 IU, which is well below the 4000 IU NOAEL specified by the EC SCF. To further ensure participants'","text_display":" 2800 IU, which is well below the 4000 IU NOAEL specified by the EC SCF. To further ensure participants'","confidence":0.9951229095458984,"confidence_rate":0.9999555553306881},{"cnt":[[122,718],[1893,718],[1893,763],[122,763]],"region":{"top_left_x":122,"top_left_y":717,"width":1771,"height":46},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"26a58d6f13eb4a79bae6ae67ba0b5559","type":"text","conversion_output":true,"text":"safety, we will exclude from the trial persons with a history of kidney stones, hypercalcemia, renal failure,","text_display":" safety, we will exclude from the trial persons with a history of kidney stones, hypercalcemia, renal failure,","confidence":0.9936552047729492,"confidence_rate":0.9999441681464885},{"cnt":[[125,765],[1962,765],[1962,806],[125,806]],"region":{"top_left_x":124,"top_left_y":764,"width":1838,"height":42},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bf3a54c28e0c4b52a5940e5c56679c29","type":"text","conversion_output":true,"text":"cirrhosis, or sarcoidosis or other granulomatous disease, and will obtain calcium and PTH levels in a random","text_display":" cirrhosis, or sarcoidosis or other granulomatous disease, and will obtain calcium and PTH levels in a random","confidence":1,"confidence_rate":1},{"cnt":[[122,808],[1938,808],[1938,853],[122,853]],"region":{"top_left_x":122,"top_left_y":807,"width":1816,"height":46},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fc4128e2f3984ea8b218316733ff3a01","type":"text","conversion_output":true,"text":"subsample of participants. For fish oil, there are no specific exclusions necessary except for those currently","text_display":" subsample of participants. For fish oil, there are no specific exclusions necessary except for those currently","confidence":1,"confidence_rate":1},{"cnt":[[122,851],[1227,851],[1227,896],[122,896]],"region":{"top_left_x":122,"top_left_y":850,"width":1105,"height":46},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"21993e28893a401b94da4cd86e87e8dd","type":"text","conversion_output":true,"text":"taking the supplement and unwilling to forego use during the trial.","text_display":" taking the supplement and unwilling to forego use during the trial.","confidence":1,"confidence_rate":1},{"cnt":[[185,915],[1921,915],[1921,960],[185,960]],"region":{"top_left_x":184,"top_left_y":915,"width":1737,"height":46},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f2a36899b733488d91c3e7a45f710a4e","type":"text","conversion_output":true,"text":"Potential side effects of the study agents will be assessed on each follow-up questionnaire. For fish oil,","text_display":"\n\nPotential side effects of the study agents will be assessed on each follow-up questionnaire. For fish oil,","confidence":0.99951171875,"confidence_rate":0.9999956000051925},{"cnt":[[122,958],[1867,958],[1867,1003],[122,1003]],"region":{"top_left_x":122,"top_left_y":958,"width":1745,"height":46},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"81fe60468ffc4c0498115b579d504a45","type":"text","conversion_output":true,"text":"these side effects include gastrointestinal (GI) upset (presence or absence of symptoms of peptic ulcer,","text_display":" these side effects include gastrointestinal (GI) upset (presence or absence of symptoms of peptic ulcer,","confidence":0.9834063053131104,"confidence_rate":0.9998464988258438},{"cnt":[[122,1005],[1927,1005],[1927,1046],[122,1046]],"region":{"top_left_x":122,"top_left_y":1005,"width":1806,"height":42},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"13d088439e4946fa8be46879fcdc01b0","type":"text","conversion_output":true,"text":"nausea, constipation, diarrhea); bleeding (any GI bleed, GI bleeding requiring transfusion, hematuria, easy","text_display":" nausea, constipation, diarrhea); bleeding (any GI bleed, GI bleeding requiring transfusion, hematuria, easy","confidence":1,"confidence_rate":1},{"cnt":[[122,1048],[1955,1048],[1955,1091],[122,1091]],"region":{"top_left_x":122,"top_left_y":1048,"width":1834,"height":44},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"53af310840394303a60f351165f74ed1","type":"text","conversion_output":true,"text":"bruising, epistaxis); skin eruptions; and physician diagnosis of atrial fibrillation or other irregular rhythms. For","text_display":" bruising, epistaxis); skin eruptions; and physician diagnosis of atrial fibrillation or other irregular rhythms. For","confidence":1,"confidence_rate":1},{"cnt":[[122,1091],[1962,1091],[1962,1137],[122,1137]],"region":{"top_left_x":122,"top_left_y":1091,"width":1840,"height":46},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3445f4c5cf264007b7f3df0a8e3378e3","type":"text","conversion_output":true,"text":"vitamin D, these side effects include GI symptoms as listed above, and physician diagnosis of hypercalcemia","text_display":" vitamin D, these side effects include GI symptoms as listed above, and physician diagnosis of hypercalcemia","confidence":0.9625228518166296,"confidence_rate":0.9996590093027359},{"cnt":[[120,1137],[1938,1137],[1938,1179],[120,1179]],"region":{"top_left_x":120,"top_left_y":1136,"width":1818,"height":44},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2e9654a9406742d1b4f69d7243703149","type":"text","conversion_output":true,"text":"or kidney stones. Participants who self-report one of the parent VITAL trial study endpoints will be asked to","text_display":" or kidney stones. Participants who self-report one of the parent VITAL trial study endpoints will be asked to","confidence":1,"confidence_rate":1},{"cnt":[[122,1179],[1897,1179],[1897,1222],[122,1222]],"region":{"top_left_x":122,"top_left_y":1179,"width":1776,"height":44},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"35dc4dd27b80486bb3809981a9f27133","type":"text","conversion_output":true,"text":"sign a medical release form authorizing VITAL staff to obtain hospital/physician records. VITAL Diabetes","text_display":" sign a medical release form authorizing VITAL staff to obtain hospital/physician records. VITAL Diabetes","confidence":1,"confidence_rate":1},{"cnt":[[122,1225],[1974,1225],[1974,1268],[122,1268]],"region":{"top_left_x":122,"top_left_y":1224,"width":1853,"height":44},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6171666a8779454090b995212a918596","type":"text","conversion_output":true,"text":"ancillary study participants who report a kidney biopsy prior to or during VITAL participation will also be asked","text_display":" ancillary study participants who report a kidney biopsy prior to or during VITAL participation will also be asked","confidence":1,"confidence_rate":1},{"cnt":[[122,1268],[1904,1268],[1904,1313],[122,1313]],"region":{"top_left_x":122,"top_left_y":1267,"width":1782,"height":46},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"399c97d7b71f4d8ba2f644355f5263c4","type":"text","conversion_output":true,"text":"to sign a medical release form authorizing VITAL staff to obtain hospital/physician records. The Data and","text_display":" to sign a medical release form authorizing VITAL staff to obtain hospital/physician records. The Data and","confidence":1,"confidence_rate":1},{"cnt":[[122,1311],[1981,1311],[1981,1356],[122,1356]],"region":{"top_left_x":122,"top_left_y":1310,"width":1859,"height":46},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5b8b5150993c43b4b6ef833d1c2e8b45","type":"text","conversion_output":true,"text":"Safety Monitoring Board will compare the incidence of potential side effects in the active v. placebo groups for","text_display":" Safety Monitoring Board will compare the incidence of potential side effects in the active v. placebo groups for","confidence":0.7428150177001953,"confidence_rate":0.9974621298513103},{"cnt":[[122,1354],[1867,1354],[1867,1399],[122,1399]],"region":{"top_left_x":122,"top_left_y":1353,"width":1745,"height":46},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"91bd0290034947479c6d2a17e66ba68e","type":"text","conversion_output":true,"text":"each agent, including the incidence of kidney stones with vitamin D assignment and the incidence of GI","text_display":" each agent, including the incidence of kidney stones with vitamin D assignment and the incidence of GI","confidence":0.879856480518356,"confidence_rate":0.9988876063418184},{"cnt":[[120,1401],[1280,1401],[1280,1446],[120,1446]],"region":{"top_left_x":120,"top_left_y":1400,"width":1161,"height":46},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9fa28596edec4680ab99a681aa366d6e","type":"text","conversion_output":true,"text":"symptoms, skin abnormalities, and bleeding with fish oil assignment.","text_display":" symptoms, skin abnormalities, and bleeding with fish oil assignment.","confidence":1,"confidence_rate":1},{"cnt":[[125,1463],[1882,1463],[1882,1506],[125,1506]],"region":{"top_left_x":124,"top_left_y":1463,"width":1759,"height":44},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4df978324d9c48f29801f5d04048ac2e","type":"text","conversion_output":true,"text":"VII.b. Psychosocial risks. There is also the possibility of social/psychological risk that could result from","text_display":"\nVII.b. Psychosocial risks. There is also the possibility of social/psychological risk that could result from","confidence":1,"confidence_rate":1},{"cnt":[[125,1508],[1929,1508],[1929,1551],[125,1551]],"region":{"top_left_x":124,"top_left_y":1508,"width":1806,"height":44},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"357d2886769b45aeaa123a8d4555fd96","type":"text","conversion_output":true,"text":"inadvertent disclosure of confidential information from the questionnaires or blood tests. However, we have","text_display":" inadvertent disclosure of confidential information from the questionnaires or blood tests. However, we have","confidence":1,"confidence_rate":1},{"cnt":[[125,1551],[1996,1551],[1996,1596],[125,1596]],"region":{"top_left_x":124,"top_left_y":1551,"width":1872,"height":46},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"05c43f1bd38b44189bd3500d792293c1","type":"text","conversion_output":true,"text":"many safeguards in place to avoid this possibility, and the experienced team leading the parent VITAL trial has","text_display":" many safeguards in place to avoid this possibility, and the experienced team leading the parent VITAL trial has","confidence":1,"confidence_rate":1},{"cnt":[[125,1594],[1854,1594],[1854,1639],[125,1639]],"region":{"top_left_x":124,"top_left_y":1594,"width":1731,"height":46},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"82f084905f544c7791c850e273bb3c29","type":"text","conversion_output":true,"text":"never had an inadvertent breach of confidentiality in prior trials. Each name on the mailing tape will be","text_display":" never had an inadvertent breach of confidentiality in prior trials. Each name on the mailing tape will be","confidence":1,"confidence_rate":1},{"cnt":[[125,1641],[1906,1641],[1906,1682],[125,1682]],"region":{"top_left_x":124,"top_left_y":1641,"width":1782,"height":42},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3afe3052394e4675b7dce4414ba82731","type":"text","conversion_output":true,"text":"assigned a study identification number and sent a package containing: a letter explaining the rationale for","text_display":" assigned a study identification number and sent a package containing: a letter explaining the rationale for","confidence":1,"confidence_rate":1},{"cnt":[[122,1684],[1955,1684],[1955,1727],[122,1727]],"region":{"top_left_x":122,"top_left_y":1684,"width":1834,"height":44},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"57bc649866d44653b5f5e07fdbae0ad7","type":"text","conversion_output":true,"text":"VITAL and what participation would entail; an informed consent form; and a brief questionnaire with items on","text_display":" VITAL and what participation would entail; an informed consent form; and a brief questionnaire with items on","confidence":1,"confidence_rate":1},{"cnt":[[122,1727],[1996,1727],[1996,1772],[122,1772]],"region":{"top_left_x":122,"top_left_y":1727,"width":1874,"height":46},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"677ce7fb100f4846815f54d68f027e7e","type":"text","conversion_output":true,"text":"demographics; medical history; current use of supplements containing vitamin D or fish oil; current use of other","text_display":" demographics; medical history; current use of supplements containing vitamin D or fish oil; current use of other","confidence":1,"confidence_rate":1},{"cnt":[[122,1772],[1910,1772],[1910,1815],[122,1815]],"region":{"top_left_x":122,"top_left_y":1772,"width":1788,"height":44},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c92064c7fd7e4fefb96cb008c755cc3d","type":"text","conversion_output":true,"text":"supplements or medications; dietary intake of vitamin D and consumption of fish; cancer and vascular risk","text_display":" supplements or medications; dietary intake of vitamin D and consumption of fish; cancer and vascular risk","confidence":0.99853515625,"confidence_rate":0.9999866735644114},{"cnt":[[122,1815],[1910,1815],[1910,1858],[122,1858]],"region":{"top_left_x":122,"top_left_y":1815,"width":1788,"height":44},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b03d59eacb6b471791571048e02cfdbd","type":"text","conversion_output":true,"text":"factors; and potential effect modifiers. Those who are initially willing and eligible will be entered into the 3 -","text_display":" factors; and potential effect modifiers. Those who are initially willing and eligible will be entered into the 3 ","confidence":0.6513671875,"confidence_rate":0.996492381202523},{"cnt":[[125,1861],[1944,1861],[1944,1904],[125,1904]],"region":{"top_left_x":124,"top_left_y":1860,"width":1821,"height":44},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d1c11c6ed2ee47a0b46acfa9803ccd4f","type":"text","conversion_output":true,"text":"month run-in phase. Those who remain willing and eligible, and who are compliant with pill-taking during the","text_display":"month run-in phase. Those who remain willing and eligible, and who are compliant with pill-taking during the","confidence":1,"confidence_rate":1},{"cnt":[[125,1904],[1938,1904],[1938,1946],[125,1946]],"region":{"top_left_x":124,"top_left_y":1903,"width":1814,"height":44},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f9e8222a8db54f788e1d3ba7afd0da4e","type":"text","conversion_output":true,"text":"run-in phase, will be randomized into the parent VITAL trial. Participants who are additionally eligible for the","text_display":" run-in phase, will be randomized into the parent VITAL trial. Participants who are additionally eligible for the","confidence":1,"confidence_rate":1},{"cnt":[[122,1946],[1796,1946],[1796,1992],[122,1992]],"region":{"top_left_x":122,"top_left_y":1946,"width":1675,"height":46},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"89fd0dffd3e04e2480faab0bf1b03c8e","type":"text","conversion_output":true,"text":"VITAL Diabetes ancillary study proposed herein will be additionally entered into this ancillary study.","text_display":" VITAL Diabetes ancillary study proposed herein will be additionally entered into this ancillary study.","confidence":1,"confidence_rate":1},{"cnt":[[185,2013],[1919,2013],[1919,2056],[185,2056]],"region":{"top_left_x":184,"top_left_y":2013,"width":1735,"height":44},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"868e8f6fcf5a4cbe92713eadabce9ddf","type":"text","conversion_output":true,"text":"The potential risk of disclosure of confidential information is guarded against by maintaining completed","text_display":"\n\nThe potential risk of disclosure of confidential information is guarded against by maintaining completed","confidence":0.99951171875,"confidence_rate":0.9999955192715237},{"cnt":[[122,2056],[1921,2056],[1921,2099],[122,2099]],"region":{"top_left_x":122,"top_left_y":2056,"width":1799,"height":44},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"199042df269044a2b533dbf2779b6e83","type":"text","conversion_output":true,"text":"questionnaires and blood test results in locked files accessible by authorized personnel only. In these files,","text_display":" questionnaires and blood test results in locked files accessible by authorized personnel only. In these files,","confidence":1,"confidence_rate":1},{"cnt":[[122,2101],[1865,2101],[1865,2142],[122,2142]],"region":{"top_left_x":122,"top_left_y":2101,"width":1743,"height":41},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f223c482e68c48498d9b38ead5110303","type":"text","conversion_output":true,"text":"participants are identified only by study ID. Subject identifiers are stored in separate computer files with","text_display":" participants are identified only by study ID. Subject identifiers are stored in separate computer files with","confidence":1,"confidence_rate":1},{"cnt":[[125,2144],[1974,2144],[1974,2189],[125,2189]],"region":{"top_left_x":124,"top_left_y":2144,"width":1851,"height":46},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"22b9895f4269448b90b8be2be8971dd5","type":"text","conversion_output":true,"text":"password protection, and results will be presented only in the aggregate. In addition, employees involved with","text_display":" password protection, and results will be presented only in the aggregate. In addition, employees involved with","confidence":1,"confidence_rate":1},{"cnt":[[122,2187],[1949,2187],[1949,2232],[122,2232]],"region":{"top_left_x":122,"top_left_y":2187,"width":1827,"height":46},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4c99b156cab04a0b8006e6ac6937be52","type":"text","conversion_output":true,"text":"the proposed study will be asked to sign a form agreeing not to disclose any information to which they might","text_display":" the proposed study will be asked to sign a form agreeing not to disclose any information to which they might","confidence":1,"confidence_rate":1},{"cnt":[[125,2230],[1981,2230],[1981,2275],[125,2275]],"region":{"top_left_x":124,"top_left_y":2230,"width":1857,"height":46},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e304c1c7f584419bb6076371d9f3f4c7","type":"text","conversion_output":true,"text":"have access, regardless of their personal perception about its confidentiality. Each employee of the study with","text_display":" have access, regardless of their personal perception about its confidentiality. Each employee of the study with","confidence":1,"confidence_rate":1},{"cnt":[[125,2275],[1858,2275],[1858,2318],[125,2318]],"region":{"top_left_x":124,"top_left_y":2275,"width":1735,"height":44},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c2dadd883e3248f5ac3bc82a54b19f88","type":"text","conversion_output":true,"text":"human subject contact participates in an institutional (Brigham and Women's Hospital) human subjects","text_display":" human subject contact participates in an institutional (Brigham and Women's Hospital) human subjects","confidence":1,"confidence_rate":1},{"cnt":[[125,2320],[1985,2320],[1985,2363],[125,2363]],"region":{"top_left_x":124,"top_left_y":2320,"width":1862,"height":44},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"39f192ada0b747b987e2dbe3b7a517e9","type":"text","conversion_output":true,"text":"educational program, which consists of reviewing regulatory and informational documents pertaining to human","text_display":" educational program, which consists of reviewing regulatory and informational documents pertaining to human","confidence":1,"confidence_rate":1},{"cnt":[[125,2363],[2000,2363],[2000,2408],[125,2408]],"region":{"top_left_x":124,"top_left_y":2363,"width":1877,"height":46},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1cb9e462b257453298222f883617b858","type":"text","conversion_output":true,"text":"subjects research; passing a test on ethical principles and regulations governing human subjects research; and","text_display":" subjects research; passing a test on ethical principles and regulations governing human subjects research; and","confidence":1,"confidence_rate":1},{"cnt":[[125,2408],[1876,2408],[1876,2451],[125,2451]],"region":{"top_left_x":124,"top_left_y":2408,"width":1752,"height":44},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ef52b12b917c4c79a54eb20189ddeec5","type":"text","conversion_output":true,"text":"signing a statement of commitment to the protection of human subjects. Finally, all such employees are","text_display":" signing a statement of commitment to the protection of human subjects. Finally, all such employees are","confidence":1,"confidence_rate":1},{"cnt":[[125,2449],[806,2449],[806,2494],[125,2494]],"region":{"top_left_x":124,"top_left_y":2449,"width":682,"height":46},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3e6057c6d7f0409ebe14483185f15a7d","type":"text","conversion_output":true,"text":"required to participate in HIPAA training.","text_display":" required to participate in HIPAA training.","confidence":1,"confidence_rate":1},{"cnt":[[1955,2582],[2007,2582],[2007,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2582,"width":52,"height":46},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c6f8aaf8551c4043b8464955a4f54b88","type":"page_info","conversion_output":false,"text":"21","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-22","page":22,"lines":[{"cnt":[[116,125],[578,125],[578,170],[116,170]],"region":{"top_left_x":116,"top_left_y":124,"width":462,"height":46},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"27a4030bcc0041ceaa5c7cbd81c7e1a1","type":"section_header","conversion_output":false,"children_ids":["534ded1edb5c4db4b4f26d4d68088aba"],"text":"","text_display":""},{"cnt":[[120,129],[574,129],[574,165],[120,165]],"region":{"top_left_x":120,"top_left_y":128,"width":454,"height":38},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"534ded1edb5c4db4b4f26d4d68088aba","type":"text","conversion_output":true,"parent_id":"27a4030bcc0041ceaa5c7cbd81c7e1a1","text":"VIII. Potential Benefits","text_display":"\n\n\\section*{VIII. Potential Benefits}","confidence":0.99853515625,"confidence_rate":0.9999494523919701},{"cnt":[[125,193],[1979,193],[1979,236],[125,236]],"region":{"top_left_x":124,"top_left_y":193,"width":1855,"height":44},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b70514c64527403bbf4e11b230029e1e","type":"text","conversion_output":true,"text":"VIII.a. Potential Benefits to Participants. For the majority of participants, there will be few direct benefits from","text_display":"\nVIII.a. Potential Benefits to Participants. For the majority of participants, there will be few direct benefits from","confidence":1,"confidence_rate":1},{"cnt":[[122,236],[1992,236],[1992,281],[122,281]],"region":{"top_left_x":122,"top_left_y":236,"width":1870,"height":46},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fa113f34d28b45eaad538d08c8e37c3f","type":"text","conversion_output":true,"text":"participating in this primary prevention study other than the awareness of being involved in a large endeavor to","text_display":" participating in this primary prevention study other than the awareness of being involved in a large endeavor to","confidence":0.99951171875,"confidence_rate":0.999995825645481},{"cnt":[[125,279],[1940,279],[1940,324],[125,324]],"region":{"top_left_x":124,"top_left_y":279,"width":1817,"height":46},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0f686f35e4b747d9906dc19eb857ac8d","type":"text","conversion_output":true,"text":"answer relevant and timely questions regarding the possible benefit of vitamin D and fish oil. During the trial","text_display":" answer relevant and timely questions regarding the possible benefit of vitamin D and fish oil. During the trial","confidence":0.998046875,"confidence_rate":0.9999831463934391},{"cnt":[[125,322],[1949,322],[1949,367],[125,367]],"region":{"top_left_x":124,"top_left_y":322,"width":1825,"height":46},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1cfb477c579c44e4bddcf0f3a8f06038","type":"text","conversion_output":true,"text":"itself, we will receive inquiries from the participants regarding both specific and general health concerns. We","text_display":" itself, we will receive inquiries from the participants regarding both specific and general health concerns. We","confidence":1,"confidence_rate":1},{"cnt":[[125,370],[1979,370],[1979,410],[125,410]],"region":{"top_left_x":124,"top_left_y":369,"width":1855,"height":42},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ce42096859f34b1fa00be5e8417b0445","type":"text","conversion_output":true,"text":"will respond to each of those questions, primarily directing participants to published sources or recommending","text_display":" will respond to each of those questions, primarily directing participants to published sources or recommending","confidence":1,"confidence_rate":1},{"cnt":[[125,412],[1472,412],[1472,455],[125,455]],"region":{"top_left_x":124,"top_left_y":412,"width":1348,"height":44},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2527b1b0e07942ea819e70d6023a29d6","type":"text","conversion_output":true,"text":"that they see their local health provider who is familiar with their medical history.","text_display":" that they see their local health provider who is familiar with their medical history.","confidence":1,"confidence_rate":1},{"cnt":[[125,477],[1893,477],[1893,522],[125,522]],"region":{"top_left_x":124,"top_left_y":476,"width":1769,"height":47},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2522ab2d5a374e44b13fd6bc9a1c4b5d","type":"text","conversion_output":true,"text":"VIII.b. Potential Benefits to Society. The potential benefits to society relate to the increasing use of both","text_display":"\nVIII.b. Potential Benefits to Society. The potential benefits to society relate to the increasing use of both","confidence":1,"confidence_rate":1},{"cnt":[[122,520],[1897,520],[1897,565],[122,565]],"region":{"top_left_x":122,"top_left_y":519,"width":1776,"height":47},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"696f30d13d4d4c8c9ced6eb61adebaf0","type":"text","conversion_output":true,"text":"vitamin D and fish oil, with data not yet clearly indicating efficacy in the general population with respect to","text_display":" vitamin D and fish oil, with data not yet clearly indicating efficacy in the general population with respect to","confidence":0.9951171875,"confidence_rate":0.9999578045766594},{"cnt":[[125,565],[1927,565],[1927,608],[125,608]],"region":{"top_left_x":124,"top_left_y":565,"width":1804,"height":44},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f1c5d30d49944305ab53920b8bc1aeaf","type":"text","conversion_output":true,"text":"prevention of cancer and CVD (parent VITAL trial outcomes) or with respect to albuminuria and glomerular","text_display":" prevention of cancer and CVD (parent VITAL trial outcomes) or with respect to albuminuria and glomerular","confidence":1,"confidence_rate":1},{"cnt":[[122,610],[1987,610],[1987,653],[122,653]],"region":{"top_left_x":122,"top_left_y":610,"width":1866,"height":44},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8b44d84e43884a748d9023a6263e7fb2","type":"text","conversion_output":true,"text":"filtration rate (VITAL Diabetes ancillary study outcomes). Such data will help guide individual decisions, clinical","text_display":" filtration rate (VITAL Diabetes ancillary study outcomes). Such data will help guide individual decisions, clinical","confidence":1,"confidence_rate":1},{"cnt":[[122,653],[930,653],[930,698],[122,698]],"region":{"top_left_x":122,"top_left_y":653,"width":809,"height":46},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a58103df82204d88a18707b1e7cdc52d","type":"text","conversion_output":true,"text":"recommendations, and public health guidelines.","text_display":" recommendations, and public health guidelines.","confidence":1,"confidence_rate":1},{"cnt":[[1955,2582],[2007,2582],[2007,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2582,"width":52,"height":46},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e5d7695d8b194e4ab27d73d2476c9341","type":"page_info","conversion_output":false,"text":"22","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-23","page":23,"lines":[{"cnt":[[116,122],[879,122],[879,176],[116,176]],"region":{"top_left_x":116,"top_left_y":122,"width":763,"height":55},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a809c0034bff4413a9458662dda13d75","type":"section_header","conversion_output":false,"children_ids":["dc835c62e35d4d08a84396e043fc2864"],"text":"","text_display":""},{"cnt":[[120,125],[874,125],[874,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":755,"height":51},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"dc835c62e35d4d08a84396e043fc2864","type":"text","conversion_output":true,"parent_id":"a809c0034bff4413a9458662dda13d75","text":"IX. Monitoring and Quality Assurance","text_display":"\n\n\\section*{IX. Monitoring and Quality Assurance}","confidence":1,"confidence_rate":1},{"cnt":[[180,191],[1992,191],[1992,238],[180,238]],"region":{"top_left_x":180,"top_left_y":191,"width":1812,"height":48},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1a7a50dcbac7428eaa5f01a14f8d2a6c","type":"text","conversion_output":true,"text":"An independent Data and Safety Monitoring Board (DSMB) has been assembled for the parent VITAL trial,","text_display":"\n\nAn independent Data and Safety Monitoring Board (DSMB) has been assembled for the parent VITAL trial,","confidence":0.99951171875,"confidence_rate":0.9999953924587458},{"cnt":[[120,236],[1927,236],[1927,281],[120,281]],"region":{"top_left_x":120,"top_left_y":236,"width":1808,"height":46},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c7baa044f6ba41128ccc68341f4a812d","type":"text","conversion_output":true,"text":"consisting of experts in clinical trials, epidemiology, biostatistics, relevant clinical areas of cancer and CVD,","text_display":" consisting of experts in clinical trials, epidemiology, biostatistics, relevant clinical areas of cancer and CVD,","confidence":1,"confidence_rate":1},{"cnt":[[120,279],[1970,279],[1970,324],[120,324]],"region":{"top_left_x":120,"top_left_y":279,"width":1851,"height":46},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2865aaaf7e58478585eafaeb481b808a","type":"text","conversion_output":true,"text":"and NIH representatives. The DSMB will annually examine the progress of the trial and the unblinded data on","text_display":" and NIH representatives. The DSMB will annually examine the progress of the trial and the unblinded data on","confidence":1,"confidence_rate":1},{"cnt":[[120,322],[1957,322],[1957,367],[120,367]],"region":{"top_left_x":120,"top_left_y":322,"width":1838,"height":46},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a67bbbcf860744ca841136edd9731372","type":"text","conversion_output":true,"text":"study endpoints and possible adverse effects to recommend continuation, alteration of study design, or early","text_display":" study endpoints and possible adverse effects to recommend continuation, alteration of study design, or early","confidence":1,"confidence_rate":1},{"cnt":[[120,361],[1996,361],[1996,415],[120,415]],"region":{"top_left_x":120,"top_left_y":360,"width":1876,"height":55},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4f399502c02c41cb839b702d69175ff3","type":"text","conversion_output":true,"text":"termination, as appropriate. Interim trial results will be assessed with the Haybittle-Peto rule, \\({ }^{155,156}\\) adjusting for","text_display":" termination, as appropriate. Interim trial results will be assessed with the Haybittle-Peto rule, \\({ }^{155,156}\\) adjusting for","confidence":0.692596435546875,"confidence_rate":0.9972626504557616},{"cnt":[[120,410],[1949,410],[1949,458],[120,458]],"region":{"top_left_x":120,"top_left_y":410,"width":1829,"height":48},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"35348b051b5144a399db0897f36fbf1a","type":"text","conversion_output":true,"text":"multiple looks. In this method, interim results are compared to a z -score of 3 standard deviations ( \\(p =0.0027\\) )","text_display":" multiple looks. In this method, interim results are compared to a z -score of 3 standard deviations ( \\(p =0.0027\\) )","confidence":0.6037116050720215,"confidence_rate":0.996184127272987},{"cnt":[[120,455],[1940,455],[1940,501],[120,501]],"region":{"top_left_x":120,"top_left_y":455,"width":1821,"height":46},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"def1ae559f0b490aa7dbd462e557c239","type":"text","conversion_output":true,"text":"throughout the trial. The final results may then be interpreted as having close to nominal significance levels.","text_display":" throughout the trial. The final results may then be interpreted as having close to nominal significance levels.","confidence":1,"confidence_rate":1},{"cnt":[[120,498],[1841,498],[1841,544],[120,544]],"region":{"top_left_x":120,"top_left_y":498,"width":1722,"height":46},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7ea4ac5429c8417e88e8872c81f86d7e","type":"text","conversion_output":true,"text":"This rule appropriately requires very strong evidence for early stopping, is more conservative than the","text_display":" This rule appropriately requires very strong evidence for early stopping, is more conservative than the","confidence":1,"confidence_rate":1},{"cnt":[[120,537],[1828,537],[1828,587],[120,587]],"region":{"top_left_x":120,"top_left_y":537,"width":1709,"height":50},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a38b27bb8dcc4e67b20ef8164e97bcbd","type":"text","conversion_output":true,"text":"Pocock \\({ }^{157}\\) and O'Brien-Fleming \\({ }^{158}\\) rules and the alpha-spending function, \\({ }^{159}\\) and can be conducted at","text_display":" Pocock \\({ }^{157}\\) and O'Brien-Fleming \\({ }^{158}\\) rules and the alpha-spending function, \\({ }^{159}\\) and can be conducted at","confidence":1,"confidence_rate":1},{"cnt":[[120,580],[1111,580],[1111,634],[120,634]],"region":{"top_left_x":120,"top_left_y":580,"width":991,"height":54},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"50836c2f6eee45a1a5607c42027b345e","type":"text","conversion_output":true,"text":"convenient times without inducing statistical complexity. \\({ }^{160}\\)","text_display":" convenient times without inducing statistical complexity. \\({ }^{160}\\)","confidence":1,"confidence_rate":1},{"cnt":[[180,653],[1996,653],[1996,698],[180,698]],"region":{"top_left_x":180,"top_left_y":653,"width":1816,"height":46},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"89124a93ac9d4998accf3565369a1450","type":"text","conversion_output":true,"text":"While these rules are intended for the primary endpoints, the goal of VITAL is to assess the overall balance","text_display":"\n\nWhile these rules are intended for the primary endpoints, the goal of VITAL is to assess the overall balance","confidence":1,"confidence_rate":1},{"cnt":[[120,696],[1953,696],[1953,741],[120,741]],"region":{"top_left_x":120,"top_left_y":696,"width":1833,"height":46},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6c1d6174eb894010928debfbe67348f9","type":"text","conversion_output":true,"text":"of benefits and risks of the two agents in the primary prevention of cancer and CVD. Thus, consideration will","text_display":" of benefits and risks of the two agents in the primary prevention of cancer and CVD. Thus, consideration will","confidence":1,"confidence_rate":1},{"cnt":[[120,739],[2000,739],[2000,784],[120,784]],"region":{"top_left_x":120,"top_left_y":739,"width":1881,"height":46},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"da147ccc021a4634bcd72da0dfb07c08","type":"text","conversion_output":true,"text":"also be given to the secondary endpoints that are needed in the interpretation of overall results. In addition, the","text_display":" also be given to the secondary endpoints that are needed in the interpretation of overall results. In addition, the","confidence":0.99951171875,"confidence_rate":0.9999959300041316},{"cnt":[[120,782],[1923,782],[1923,827],[120,827]],"region":{"top_left_x":120,"top_left_y":782,"width":1803,"height":46},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d816ad46a5a04cb1b8e8033c3f4e7066","type":"text","conversion_output":true,"text":"monitoring rules will serve solely as guidelines in decisions regarding continuation or stopping of treatment","text_display":" monitoring rules will serve solely as guidelines in decisions regarding continuation or stopping of treatment","confidence":1,"confidence_rate":1},{"cnt":[[120,827],[1955,827],[1955,872],[120,872]],"region":{"top_left_x":120,"top_left_y":827,"width":1836,"height":46},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9f49aa2269b140a0b7352516e706be53","type":"text","conversion_output":true,"text":"arms. All decisions must be made after examining the totality of evidence, including other trial data, on these","text_display":" arms. All decisions must be made after examining the totality of evidence, including other trial data, on these","confidence":1,"confidence_rate":1},{"cnt":[[120,872],[251,872],[251,917],[120,917]],"region":{"top_left_x":120,"top_left_y":872,"width":132,"height":46},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0ff5774fb2094fee904e495e3fd4ace8","type":"text","conversion_output":true,"text":"agents.","text_display":" agents.","confidence":1,"confidence_rate":1},{"cnt":[[1955,2582],[2007,2582],[2007,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2582,"width":52,"height":46},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b271919478334636a4483ba614292334","type":"page_info","conversion_output":false,"text":"23","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-24","page":24,"lines":[{"cnt":[[116,125],[460,125],[460,170],[116,170]],"region":{"top_left_x":116,"top_left_y":124,"width":344,"height":46},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"263f32c2cd104e9280d1f96a0f8f26e1","type":"section_header","conversion_output":false,"children_ids":["f3ccb2c473014b3da0a6b4110af774e0"],"text":"","text_display":""},{"cnt":[[120,129],[458,129],[458,165],[120,165]],"region":{"top_left_x":120,"top_left_y":128,"width":338,"height":38},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f3ccb2c473014b3da0a6b4110af774e0","type":"text","conversion_output":true,"parent_id":"263f32c2cd104e9280d1f96a0f8f26e1","text":"X. References","text_display":"\n\n\\section*{X. References}","confidence":1,"confidence_rate":1},{"cnt":[[122,193],[1807,193],[1807,236],[122,236]],"region":{"top_left_x":122,"top_left_y":193,"width":1685,"height":44},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3450a56609be47a2a272a318f984cd85","type":"text","conversion_output":true,"text":"1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and","text_display":"\n1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and","confidence":0.969794511795044,"confidence_rate":0.9997022669192837},{"cnt":[[247,236],[1321,236],[1321,281],[247,281]],"region":{"top_left_x":247,"top_left_y":236,"width":1075,"height":46},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f888dd04c96e4222a34404b9e55a6536","type":"text","conversion_output":true,"text":"stratification. Am J Kidney Dis. Feb 2002;39(2 Suppl 1):S1-266.","text_display":" stratification. Am J Kidney Dis. Feb 2002;39(2 Suppl 1):S1-266.","confidence":0.95607590675354,"confidence_rate":0.99933965975722},{"cnt":[[122,279],[1968,279],[1968,318],[122,318]],"region":{"top_left_x":122,"top_left_y":279,"width":1846,"height":39},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"591e626d91c242188c4b008e49fa13ad","type":"text","conversion_output":true,"text":"2. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic","text_display":"\n2. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic","confidence":0.9191389964328209,"confidence_rate":0.9991972945254558},{"cnt":[[249,322],[1405,322],[1405,367],[249,367]],"region":{"top_left_x":249,"top_left_y":322,"width":1157,"height":46},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"53583a9e90f146fe8b0e312f2b08ce2d","type":"text","conversion_output":true,"text":"Kidney Disease. Am J Kidney Dis. Feb 2007;49(2 Suppl 2):S12-154.","text_display":" Kidney Disease. Am J Kidney Dis. Feb 2007;49(2 Suppl 2):S12-154.","confidence":0.9941432476043701,"confidence_rate":0.9999148736172141},{"cnt":[[125,370],[1964,370],[1964,410],[125,410]],"region":{"top_left_x":124,"top_left_y":369,"width":1840,"height":42},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"068403b1a565403190e9c1862f1164e7","type":"text","conversion_output":true,"text":"3. U.S. Renal Data System, USRDS 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the","text_display":"\n3. U.S. Renal Data System, USRDS 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the","confidence":1,"confidence_rate":1},{"cnt":[[249,412],[1923,412],[1923,455],[249,455]],"region":{"top_left_x":249,"top_left_y":412,"width":1674,"height":44},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5c881d83084148c5ace44b6a703c56d5","type":"text","conversion_output":true,"text":"United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney","text_display":" United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney","confidence":0.9990234375,"confidence_rate":0.9999907826873115},{"cnt":[[249,455],[786,455],[786,496],[249,496]],"region":{"top_left_x":249,"top_left_y":455,"width":538,"height":42},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ec55ba8eb2e5408c8ec914e1bb648900","type":"text","conversion_output":true,"text":"Diseases, Bethesda, MD. 2008.","text_display":" Diseases, Bethesda, MD. 2008.","confidence":1,"confidence_rate":1},{"cnt":[[122,501],[1781,501],[1781,544],[122,544]],"region":{"top_left_x":122,"top_left_y":500,"width":1660,"height":44},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8769e54424574050b2e51a98f664ccc0","type":"text","conversion_output":true,"text":"4. Standards of medical care in diabetes--2009. Diabetes Care. Jan 2009;32 Suppl 1:S13-61.","text_display":"\n4. Standards of medical care in diabetes--2009. Diabetes Care. Jan 2009;32 Suppl 1:S13-61.","confidence":0.99951171875,"confidence_rate":0.9999948589553403},{"cnt":[[125,544],[1987,544],[1987,587],[125,587]],"region":{"top_left_x":124,"top_left_y":543,"width":1864,"height":44},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"23ab8ab153d74db5a116815b3ec90122","type":"text","conversion_output":true,"text":"5. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population","text_display":"\n5. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population","confidence":1,"confidence_rate":1},{"cnt":[[249,589],[1450,589],[1450,629],[249,629]],"region":{"top_left_x":249,"top_left_y":588,"width":1202,"height":42},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7de28f514213424eab1309ffe00b4cb8","type":"text","conversion_output":true,"text":"in 1988-1994 and 2005-2006. Diabetes Care. Feb 2009;32(2):287-294.","text_display":" in 1988-1994 and 2005-2006. Diabetes Care. Feb 2009;32(2):287-294.","confidence":0.8278040885925293,"confidence_rate":0.9973418664259315},{"cnt":[[125,632],[1983,632],[1983,675],[125,675]],"region":{"top_left_x":124,"top_left_y":631,"width":1860,"height":44},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"72756524a3a14318bfa1bd726aac8846","type":"text","conversion_output":true,"text":"6. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence","text_display":"\n6. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence","confidence":1,"confidence_rate":1},{"cnt":[[247,675],[1895,675],[1895,720],[247,720]],"region":{"top_left_x":247,"top_left_y":674,"width":1648,"height":46},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"87dd9ac17be242c7a9db7a14e2a5d521","type":"text","conversion_output":true,"text":"guides population screening: results from the NHANES III. Kidney Int. Jun 2002;61(6):2165-2175.","text_display":" guides population screening: results from the NHANES III. Kidney Int. Jun 2002;61(6):2165-2175.","confidence":1,"confidence_rate":1},{"cnt":[[125,722],[1996,722],[1996,763],[125,763]],"region":{"top_left_x":124,"top_left_y":721,"width":1872,"height":42},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3450e861a6a04bee90ebf54240b6c13a","type":"text","conversion_output":true,"text":"7. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. Jama.","text_display":"\n7. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. Jama.","confidence":0.99853515625,"confidence_rate":0.9999867936215969},{"cnt":[[249,765],[793,765],[793,806],[249,806]],"region":{"top_left_x":249,"top_left_y":764,"width":544,"height":42},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c470f2c2bc8e44b7a00f71e7949f2ecf","type":"text","conversion_output":true,"text":"Nov 7 2007;298(17):2038-2047.","text_display":" Nov 7 2007;298(17):2038-2047.","confidence":1,"confidence_rate":1},{"cnt":[[125,808],[1927,808],[1927,849],[125,849]],"region":{"top_left_x":124,"top_left_y":807,"width":1804,"height":42},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d919c29e65ca423491c47b66b738f26f","type":"text","conversion_output":true,"text":"8. Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP. Rapid rise in the incidence of","text_display":"\n8. Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP. Rapid rise in the incidence of","confidence":1,"confidence_rate":1},{"cnt":[[247,853],[1962,853],[1962,896],[247,896]],"region":{"top_left_x":247,"top_left_y":852,"width":1715,"height":44},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4fee2db59a454a58a53d598f9c4a2fad","type":"text","conversion_output":true,"text":"type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med. Jul 12","text_display":" type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med. Jul 12","confidence":0.99853515625,"confidence_rate":0.9999866735644114},{"cnt":[[249,896],[681,896],[681,939],[249,939]],"region":{"top_left_x":249,"top_left_y":895,"width":433,"height":44},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a1a46f987b174714877550b20bbaea6a","type":"text","conversion_output":true,"text":"1999;159(13):1450-1456.","text_display":" 1999;159(13):1450-1456.","confidence":1,"confidence_rate":1},{"cnt":[[125,939],[1919,939],[1919,982],[125,982]],"region":{"top_left_x":124,"top_left_y":938,"width":1795,"height":44},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"55f5bd9b2439494b861bdfc21d00e32b","type":"text","conversion_output":true,"text":"9. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of","text_display":"\n9. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of","confidence":1,"confidence_rate":1},{"cnt":[[249,984],[1996,984],[1996,1025],[249,1025]],"region":{"top_left_x":249,"top_left_y":983,"width":1747,"height":42},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a895c2d28ee44f43a1b89cf4425423dd","type":"text","conversion_output":true,"text":"changing demography and disease prevalence in the U.S. Diabetes Care. Nov 2001;24(11):1936-1940.","text_display":" changing demography and disease prevalence in the U.S. Diabetes Care. Nov 2001;24(11):1936-1940.","confidence":1,"confidence_rate":1},{"cnt":[[125,1027],[1953,1027],[1953,1070],[125,1070]],"region":{"top_left_x":124,"top_left_y":1026,"width":1829,"height":44},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f57e389fe9bb4660be4b288c73c98440","type":"text","conversion_output":true,"text":"10. Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann","text_display":"\n10. Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann","confidence":1,"confidence_rate":1},{"cnt":[[249,1070],[947,1070],[947,1113],[249,1113]],"region":{"top_left_x":249,"top_left_y":1069,"width":699,"height":44},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4bcc6f4e2a1d47f2a7ffbca786f47db1","type":"text","conversion_output":true,"text":"Intern Med. Jun 1 2004;140(11):945-950.","text_display":" Intern Med. Jun 1 2004;140(11):945-950.","confidence":1,"confidence_rate":1},{"cnt":[[125,1113],[1899,1113],[1899,1158],[125,1158]],"region":{"top_left_x":124,"top_left_y":1112,"width":1776,"height":47},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"803e0f3ef3744af5bd9ca0469c8bfbb8","type":"text","conversion_output":true,"text":"11. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care. Jan 2004;27","text_display":"\n11. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care. Jan 2004;27","confidence":1,"confidence_rate":1},{"cnt":[[249,1160],[522,1160],[522,1201],[249,1201]],"region":{"top_left_x":249,"top_left_y":1160,"width":274,"height":41},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"417553bd4a7d47979d23fb28eed89978","type":"text","conversion_output":true,"text":"Suppl 1:S79-83.","text_display":" Suppl 1:S79-83.","confidence":1,"confidence_rate":1},{"cnt":[[125,1203],[1841,1203],[1841,1244],[125,1244]],"region":{"top_left_x":124,"top_left_y":1203,"width":1718,"height":41},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"02bca85b35094f39bdb6b10771c118a7","type":"text","conversion_output":true,"text":"12. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of","text_display":"\n12. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of","confidence":1,"confidence_rate":1},{"cnt":[[249,1246],[1656,1246],[1656,1291],[249,1291]],"region":{"top_left_x":249,"top_left_y":1246,"width":1408,"height":46},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"539278d20393458692852fb1f4004368","type":"text","conversion_output":true,"text":"microalbuminuria in type 1 diabetes. N Engl J Med. Jun 5 2003;348(23):2285-2293.","text_display":" microalbuminuria in type 1 diabetes. N Engl J Med. Jun 5 2003;348(23):2285-2293.","confidence":0.8916213512420654,"confidence_rate":0.9987402037636905},{"cnt":[[125,1291],[1854,1291],[1854,1334],[125,1334]],"region":{"top_left_x":124,"top_left_y":1291,"width":1731,"height":44},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9a0686e2abc54187ac30577fe774a4c0","type":"text","conversion_output":true,"text":"13. Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with","text_display":"\n13. Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with","confidence":1,"confidence_rate":1},{"cnt":[[249,1336],[1893,1336],[1893,1377],[249,1377]],"region":{"top_left_x":249,"top_left_y":1336,"width":1644,"height":42},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4883eb724a604c0c8e8a207376274502","type":"text","conversion_output":true,"text":"diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration:","text_display":" diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration:","confidence":0.9858527183532715,"confidence_rate":0.9998546196666674},{"cnt":[[249,1379],[1644,1379],[1644,1420],[249,1420]],"region":{"top_left_x":249,"top_left_y":1379,"width":1395,"height":42},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"10d5b49e30b34339b6903564674a8b13","type":"text","conversion_output":true,"text":"results of a 4-year follow-up study. J Am Soc Nephrol. May 2005;16(5):1404-1412.","text_display":" results of a 4-year follow-up study. J Am Soc Nephrol. May 2005;16(5):1404-1412.","confidence":1,"confidence_rate":1},{"cnt":[[125,1422],[1953,1422],[1953,1465],[125,1465]],"region":{"top_left_x":124,"top_left_y":1422,"width":1829,"height":44},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d75425932b914b509252270cce1234ad","type":"text","conversion_output":true,"text":"14. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of","text_display":"\n14. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of","confidence":0.99853515625,"confidence_rate":0.9999857678907678},{"cnt":[[249,1465],[1972,1465],[1972,1508],[249,1508]],"region":{"top_left_x":249,"top_left_y":1465,"width":1724,"height":44},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2ac7eb8cd1d54312befe49bb9c93dd76","type":"text","conversion_output":true,"text":"nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney","text_display":" nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney","confidence":1,"confidence_rate":1},{"cnt":[[249,1508],[733,1508],[733,1553],[249,1553]],"region":{"top_left_x":249,"top_left_y":1508,"width":484,"height":46},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cc5d901c4f844cbe865017667b4c921a","type":"text","conversion_output":true,"text":"Int. Jan 2003;63(1):225-232.","text_display":" Int. Jan 2003;63(1):225-232.","confidence":1,"confidence_rate":1},{"cnt":[[125,1555],[1968,1555],[1968,1596],[125,1596]],"region":{"top_left_x":124,"top_left_y":1555,"width":1844,"height":42},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"53b0ccc002a34cd39bd44de7ede2e1b6","type":"text","conversion_output":true,"text":"15. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J","text_display":"\n15. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J","confidence":0.9702291488647461,"confidence_rate":0.9997201965648681},{"cnt":[[245,1598],[986,1598],[986,1639],[245,1639]],"region":{"top_left_x":244,"top_left_y":1598,"width":743,"height":42},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0eea8c296982409ab9e0f67ce27d69ae","type":"text","conversion_output":true,"text":"Am Soc Nephrol. 1998;9(12 Suppl):S16-23.","text_display":" Am Soc Nephrol. 1998;9(12 Suppl):S16-23.","confidence":0.9804871038068086,"confidence_rate":0.9995621895091618},{"cnt":[[125,1641],[1944,1641],[1944,1682],[125,1682]],"region":{"top_left_x":124,"top_left_y":1641,"width":1821,"height":42},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b38bd2526d0d4d109798da6aca8983d1","type":"text","conversion_output":true,"text":"16. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death,","text_display":"\n16. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death,","confidence":1,"confidence_rate":1},{"cnt":[[249,1687],[1792,1687],[1792,1729],[249,1729]],"region":{"top_left_x":249,"top_left_y":1686,"width":1543,"height":44},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f1ffb41d8c0a496ead6f6949f76845f3","type":"text","conversion_output":true,"text":"cardiovascular events, and hospitalization. N Engl J Med. Sep 23 2004;351(13):1296-1305.","text_display":" cardiovascular events, and hospitalization. N Engl J Med. Sep 23 2004;351(13):1296-1305.","confidence":0.99853515625,"confidence_rate":0.9999847301407262},{"cnt":[[125,1729],[1983,1729],[1983,1772],[125,1772]],"region":{"top_left_x":124,"top_left_y":1729,"width":1860,"height":44},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1ffc75ae9508428f8152628af4af2712","type":"text","conversion_output":true,"text":"17. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal","text_display":"\n17. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal","confidence":1,"confidence_rate":1},{"cnt":[[249,1775],[1936,1775],[1936,1815],[249,1815]],"region":{"top_left_x":249,"top_left_y":1774,"width":1687,"height":42},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ce5fd16633cd499385ef85c15d2c7a45","type":"text","conversion_output":true,"text":"replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol.","text_display":" replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol.","confidence":0.9580078125,"confidence_rate":0.9995875913519684},{"cnt":[[249,1818],[672,1818],[672,1861],[249,1861]],"region":{"top_left_x":249,"top_left_y":1817,"width":424,"height":44},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ef9456f041114245b663888ea823c4b4","type":"text","conversion_output":true,"text":"Feb 2005;16(2):489-495.","text_display":" Feb 2005;16(2):489-495.","confidence":1,"confidence_rate":1},{"cnt":[[125,1863],[1891,1863],[1891,1906],[125,1906]],"region":{"top_left_x":124,"top_left_y":1862,"width":1767,"height":44},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"df086bc29be841b08f62bb2757031a25","type":"text","conversion_output":true,"text":"18. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events","text_display":"\n18. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events","confidence":0.9970722198486328,"confidence_rate":0.999972075870994},{"cnt":[[249,1908],[1476,1908],[1476,1949],[249,1949]],"region":{"top_left_x":249,"top_left_y":1907,"width":1227,"height":42},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"baf399fb885f4f9aa4494d651d0a834a","type":"text","conversion_output":true,"text":"among elderly persons. N Engl J Med. May 19 2005;352(20):2049-2060.","text_display":" among elderly persons. N Engl J Med. May 19 2005;352(20):2049-2060.","confidence":0.99755859375,"confidence_rate":0.9999674086465526},{"cnt":[[125,1951],[1826,1951],[1826,1992],[125,1992]],"region":{"top_left_x":124,"top_left_y":1950,"width":1703,"height":42},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"20d44130d2a84eb5bf1855ed1b9ea0e6","type":"text","conversion_output":true,"text":"19. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and","text_display":"\n19. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and","confidence":1,"confidence_rate":1},{"cnt":[[249,1994],[1429,1994],[1429,2035],[249,2035]],"region":{"top_left_x":249,"top_left_y":1993,"width":1180,"height":42},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"aa618dce40aa4cf38d2c9da56639bf19","type":"text","conversion_output":true,"text":"nephropathy. An update. Hypertension. Dec 1995;26(6 Pt 1):869-879.","text_display":" nephropathy. An update. Hypertension. Dec 1995;26(6 Pt 1):869-879.","confidence":1,"confidence_rate":1},{"cnt":[[122,2037],[1876,2037],[1876,2078],[122,2078]],"region":{"top_left_x":122,"top_left_y":2036,"width":1754,"height":42},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b87b71485dc24ff1933c34db18705665","type":"text","conversion_output":true,"text":"20. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of","text_display":"\n20. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of","confidence":1,"confidence_rate":1},{"cnt":[[249,2123],[249,2080],[1871,2082],[1871,2125]],"region":{"top_left_x":249,"top_left_y":2079,"width":1623,"height":46},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"579d8c6f67e74531920dd0533adaa32a","type":"text","conversion_output":true,"text":"cardiovascular disease: a statement from the American Heart Association Councils on Kidney in","text_display":" cardiovascular disease: a statement from the American Heart Association Councils on Kidney in","confidence":1,"confidence_rate":1},{"cnt":[[249,2127],[1936,2127],[1936,2168],[249,2168]],"region":{"top_left_x":249,"top_left_y":2126,"width":1687,"height":42},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bf497ee78f784207b258e9e454236ace","type":"text","conversion_output":true,"text":"Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and","text_display":" Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and","confidence":0.9990234375,"confidence_rate":0.999990229651252},{"cnt":[[249,2170],[1210,2170],[1210,2211],[249,2211]],"region":{"top_left_x":249,"top_left_y":2169,"width":961,"height":42},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"560e07e4aff7432fa72f4907c0a0b111","type":"text","conversion_output":true,"text":"Prevention. Circulation. Oct 28 2003;108(17):2154-2169.","text_display":" Prevention. Circulation. Oct 28 2003;108(17):2154-2169.","confidence":1,"confidence_rate":1},{"cnt":[[122,2213],[1944,2213],[1944,2254],[122,2254]],"region":{"top_left_x":122,"top_left_y":2212,"width":1823,"height":42},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e77e6215e8064fc396e4fbe550ebd031","type":"text","conversion_output":true,"text":"21. de Boer IH, Astor BC, Kramer H, et al. Mild elevations of urine albumin excretion are associated with","text_display":"\n21. de Boer IH, Astor BC, Kramer H, et al. Mild elevations of urine albumin excretion are associated with","confidence":1,"confidence_rate":1},{"cnt":[[247,2256],[1764,2256],[1764,2299],[247,2299]],"region":{"top_left_x":247,"top_left_y":2255,"width":1517,"height":44},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"23394d2d7d1c43e49785ae26e1b40d32","type":"text","conversion_output":true,"text":"atherogenic lipoprotein abnormalities in the Multi-Ethnic Study of AtherosIcerosis (MESA).","text_display":" atherogenic lipoprotein abnormalities in the Multi-Ethnic Study of AtherosIcerosis (MESA).","confidence":0.6014629845740274,"confidence_rate":0.9946628169689701},{"cnt":[[247,2299],[1102,2299],[1102,2344],[247,2344]],"region":{"top_left_x":247,"top_left_y":2298,"width":856,"height":46},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"49cd67c889984421b8bfa3943792b1ed","type":"text","conversion_output":true,"text":"Atherosclerosis [Epub ahead of print]. Aug 42007.","text_display":" Atherosclerosis [Epub ahead of print]. Aug 42007.","confidence":1,"confidence_rate":1},{"cnt":[[122,2346],[1944,2346],[1944,2387],[122,2387]],"region":{"top_left_x":122,"top_left_y":2346,"width":1823,"height":41},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1de8e29e18c44d82a4343e40e430adce","type":"text","conversion_output":true,"text":"22. de Boer IH, Astor BC, Kramer H, et al. Lipoprotein Abnormalities Associated with Mild Impairment of","text_display":"\n22. de Boer IH, Astor BC, Kramer H, et al. Lipoprotein Abnormalities Associated with Mild Impairment of","confidence":1,"confidence_rate":1},{"cnt":[[249,2389],[1893,2389],[1893,2432],[249,2432]],"region":{"top_left_x":249,"top_left_y":2389,"width":1644,"height":44},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"158b256b81e0452885996db0b2ce5040","type":"text","conversion_output":true,"text":"Kidney Function in the Multi-Ethnic Study of Atherosclerosis. Clin J Am Soc Nephrol. Dec 52007.","text_display":" Kidney Function in the Multi-Ethnic Study of Atherosclerosis. Clin J Am Soc Nephrol. Dec 52007.","confidence":0.99853515625,"confidence_rate":0.9999851928603086},{"cnt":[[122,2432],[1880,2432],[1880,2477],[122,2477]],"region":{"top_left_x":122,"top_left_y":2432,"width":1758,"height":46},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"65530c3b9d9b4a3a852188cd119f2a9b","type":"text","conversion_output":true,"text":"23. Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease:","text_display":"\n23. Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease:","confidence":0.9990234375,"confidence_rate":0.9999906949037896},{"cnt":[[247,2477],[1729,2477],[1729,2520],[247,2520]],"region":{"top_left_x":247,"top_left_y":2477,"width":1483,"height":44},"line":55,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"eed4c1c9bdda4acc8b8f15a0e5e6fd33","type":"text","conversion_output":true,"text":"comparison of traditional and novel risk factors. Jama. Apr 13 2005;293(14):1737-1745.","text_display":" comparison of traditional and novel risk factors. Jama. Apr 13 2005;293(14):1737-1745.","confidence":0.9990234375,"confidence_rate":0.9999896060152111},{"cnt":[[1955,2582],[2007,2582],[2007,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2582,"width":52,"height":46},"line":56,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4238993b1a9d4d618c4305ca69032c45","type":"page_info","conversion_output":false,"text":"24","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-25","page":25,"lines":[{"cnt":[[120,125],[1962,125],[1962,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":1842,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f326b3a3ba1a481e8d6ba6e1361af73b","type":"text","conversion_output":true,"text":"24. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis. Jun 2003;41(5","text_display":"\n24. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis. Jun 2003;41(5","confidence":0.99853515625,"confidence_rate":0.9999861706835268},{"cnt":[[245,172],[483,172],[483,217],[245,217]],"region":{"top_left_x":244,"top_left_y":171,"width":240,"height":46},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c90362dc671f4ffb93479470c8cf1ead","type":"text","conversion_output":true,"text":"Suppl):11-17.","text_display":" Suppl):11-17.","confidence":1,"confidence_rate":1},{"cnt":[[120,215],[1979,215],[1979,260],[120,260]],"region":{"top_left_x":120,"top_left_y":214,"width":1859,"height":46},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d41779134ac84138a0e98bd5812a3ae7","type":"text","conversion_output":true,"text":"25. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in","text_display":"\n25. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in","confidence":1,"confidence_rate":1},{"cnt":[[245,258],[1880,258],[1880,305],[245,305]],"region":{"top_left_x":244,"top_left_y":257,"width":1636,"height":49},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"864049afc94244eabafb4ff12ef60dce","type":"text","conversion_output":true,"text":"patients with moderate to severe chronic kidney disease. Kidney Int. Mar 2004;65(3):1009-1016.","text_display":" patients with moderate to severe chronic kidney disease. Kidney Int. Mar 2004;65(3):1009-1016.","confidence":1,"confidence_rate":1},{"cnt":[[120,301],[1878,301],[1878,350],[120,350]],"region":{"top_left_x":120,"top_left_y":300,"width":1758,"height":51},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ef45f5de958e40f48dad2f4b30653d03","type":"text","conversion_output":true,"text":"26. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of Oral Calcitriol with","text_display":"\n26. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of Oral Calcitriol with","confidence":0.99951171875,"confidence_rate":0.9999951643631956},{"cnt":[[245,346],[1472,346],[1472,393],[245,393]],"region":{"top_left_x":244,"top_left_y":345,"width":1228,"height":49},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2fdd4ba032fd4c2bb2b9923487780fa4","type":"text","conversion_output":true,"text":"Improved Survival in Nondialyzed CKD. J Am Soc Nephrol. May 72008.","text_display":" Improved Survival in Nondialyzed CKD. J Am Soc Nephrol. May 72008.","confidence":0.53466796875,"confidence_rate":0.9910954631220613},{"cnt":[[120,389],[1904,389],[1904,436],[120,436]],"region":{"top_left_x":120,"top_left_y":388,"width":1784,"height":49},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4f656008530e43748281a137ce3a9f26","type":"text","conversion_output":true,"text":"27. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among","text_display":"\n27. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among","confidence":1,"confidence_rate":1},{"cnt":[[245,434],[1618,434],[1618,479],[245,479]],"region":{"top_left_x":244,"top_left_y":433,"width":1374,"height":47},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ab6e999a963f4406b853ff44bf7d75a3","type":"text","conversion_output":true,"text":"people with chronic kidney disease. J Am Soc Nephrol. Feb 2005;16(2):520-528.","text_display":" people with chronic kidney disease. J Am Soc Nephrol. Feb 2005;16(2):520-528.","confidence":0.9501953125,"confidence_rate":0.9993771730200582},{"cnt":[[120,477],[1972,477],[1972,526],[120,526]],"region":{"top_left_x":120,"top_left_y":476,"width":1853,"height":51},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5a3ac0c8dc054da085e73b84441b7e90","type":"text","conversion_output":true,"text":"28. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease.","text_display":"\n28. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease.","confidence":0.99951171875,"confidence_rate":0.9999956392907748},{"cnt":[[245,520],[821,520],[821,569],[245,569]],"region":{"top_left_x":244,"top_left_y":519,"width":577,"height":51},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2152c9ad55254db2bd4233e05b60348e","type":"text","conversion_output":true,"text":"Kidney Int. Jan 2009;75(1):88-95.","text_display":" Kidney Int. Jan 2009;75(1):88-95.","confidence":0.69921875,"confidence_rate":0.9906286182432489},{"cnt":[[120,563],[1992,563],[1992,612],[120,612]],"region":{"top_left_x":120,"top_left_y":562,"width":1872,"height":51},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e0358d106feb485ea9d8594e3de939b0","type":"text","conversion_output":true,"text":"29. Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and","text_display":"\n29. Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and","confidence":0.99560546875,"confidence_rate":0.9999603231692639},{"cnt":[[245,610],[1815,610],[1815,655],[245,655]],"region":{"top_left_x":244,"top_left_y":610,"width":1572,"height":46},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1ac3cbcf8fec456797396d9879b792df","type":"text","conversion_output":true,"text":"all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. Nov","text_display":" all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. Nov","confidence":0.99853515625,"confidence_rate":0.9999848875607663},{"cnt":[[245,653],[664,653],[664,700],[245,700]],"region":{"top_left_x":244,"top_left_y":653,"width":420,"height":48},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1047dac23c5f4f2bb38fcf7fab1466d4","type":"text","conversion_output":true,"text":"2005;16(11):3403-3410.","text_display":" 2005;16(11):3403-3410.","confidence":1,"confidence_rate":1},{"cnt":[[120,696],[1927,696],[1927,746],[120,746]],"region":{"top_left_x":120,"top_left_y":696,"width":1808,"height":50},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d5b9325579754a6f97a3add12d37bfd6","type":"text","conversion_output":true,"text":"30. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in Type 1","text_display":"\n30. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in Type 1","confidence":1,"confidence_rate":1},{"cnt":[[247,741],[1858,741],[1858,788],[247,788]],"region":{"top_left_x":247,"top_left_y":741,"width":1612,"height":48},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3a4ffe17649b4e3bb16ce5afb2927d4a","type":"text","conversion_output":true,"text":"(insulin-dependent) diabetes: an epidemiological study. Diabetologia. Dec 1983;25(6):496-501.","text_display":" (insulin-dependent) diabetes: an epidemiological study. Diabetologia. Dec 1983;25(6):496-501.","confidence":0.9877986907958984,"confidence_rate":0.9998747389044982},{"cnt":[[120,786],[1871,786],[1871,831],[120,831]],"region":{"top_left_x":120,"top_left_y":786,"width":1752,"height":46},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fd656ab10ba74f25a3e74015c00a2fbc","type":"text","conversion_output":true,"text":"31. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin","text_display":"\n31. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin","confidence":1,"confidence_rate":1},{"cnt":[[245,829],[1764,829],[1764,879],[245,879]],"region":{"top_left_x":244,"top_left_y":829,"width":1520,"height":50},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c67de7c703394f57b5a3f16032d8a189","type":"text","conversion_output":true,"text":"dependent diabetes mellitus. Br Med J (Clin Res Ed). Jun 27 1987;294(6588):1651-1654.","text_display":" dependent diabetes mellitus. Br Med J (Clin Res Ed). Jun 27 1987;294(6588):1651-1654.","confidence":0.95263671875,"confidence_rate":0.9994783979576216},{"cnt":[[120,872],[1927,872],[1927,922],[120,922]],"region":{"top_left_x":120,"top_left_y":872,"width":1808,"height":50},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7bfcbd703ef64db0a1a879bbe020554f","type":"text","conversion_output":true,"text":"32. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent","text_display":"\n32. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent","confidence":1,"confidence_rate":1},{"cnt":[[245,917],[1721,917],[1721,965],[245,965]],"region":{"top_left_x":244,"top_left_y":917,"width":1477,"height":48},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"de3190bc7d4a45d5a048e255ccf9e0d3","type":"text","conversion_output":true,"text":"diabetes: 10 year observational follow up study. Bmj. Sep 28 1996;313(7060):779-784.","text_display":" diabetes: 10 year observational follow up study. Bmj. Sep 28 1996;313(7060):779-784.","confidence":0.99951171875,"confidence_rate":0.9999948589553403},{"cnt":[[120,958],[1916,958],[1916,1008],[120,1008]],"region":{"top_left_x":120,"top_left_y":958,"width":1797,"height":50},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"eae11c1871324e91bd821e2285dabfa8","type":"text","conversion_output":true,"text":"33. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart","text_display":"\n33. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart","confidence":1,"confidence_rate":1},{"cnt":[[245,1003],[1626,1003],[1626,1051],[245,1051]],"region":{"top_left_x":244,"top_left_y":1003,"width":1383,"height":48},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fbf9a673e77b40369910ce8280aab36a","type":"text","conversion_output":true,"text":"failure in diabetic and nondiabetic individuals. Jama. Jul 25 2001;286(4):421-426","text_display":" failure in diabetic and nondiabetic individuals. Jama. Jul 25 2001;286(4):421-426","confidence":0.8838987350463867,"confidence_rate":0.9986143005645763},{"cnt":[[120,1048],[1876,1048],[1876,1096],[120,1096]],"region":{"top_left_x":120,"top_left_y":1048,"width":1756,"height":48},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3352162d964e4f3fbcfdb2d33c08841b","type":"text","conversion_output":true,"text":"34. de Boer IH, Katz R, Cao JJ, et al. Cystatin C, albuminuria, and mortality among older adults with","text_display":"\n34. de Boer IH, Katz R, Cao JJ, et al. Cystatin C, albuminuria, and mortality among older adults with","confidence":0.99951171875,"confidence_rate":0.9999953924587458},{"cnt":[[245,1091],[1016,1091],[1016,1137],[245,1137]],"region":{"top_left_x":244,"top_left_y":1091,"width":773,"height":46},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0f43cadabd97464e947292143f3583af","type":"text","conversion_output":true,"text":"diabetes mellitus. Diabetes Care. Jul 82009.","text_display":" diabetes mellitus. Diabetes Care. Jul 82009.","confidence":0.99951171875,"confidence_rate":0.999989825041388},{"cnt":[[120,1137],[1869,1137],[1869,1184],[120,1184]],"region":{"top_left_x":120,"top_left_y":1136,"width":1750,"height":48},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"91c63aa9ec7c49538ccc31520488eeaf","type":"text","conversion_output":true,"text":"35. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular","text_display":"\n35. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular","confidence":1,"confidence_rate":1},{"cnt":[[245,1182],[1886,1182],[1886,1227],[245,1227]],"region":{"top_left_x":244,"top_left_y":1181,"width":1643,"height":46},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fd693240dc6b4b4d9c5404b478b71895","type":"text","conversion_output":true,"text":"protection in type 2 diabetic patients with nephropathy. Circulation. Aug 24 2004;110(8):921-927.","text_display":" protection in type 2 diabetic patients with nephropathy. Circulation. Aug 24 2004;110(8):921-927.","confidence":0.53125,"confidence_rate":0.9941604266196593},{"cnt":[[120,1225],[1996,1225],[1996,1274],[120,1274]],"region":{"top_left_x":120,"top_left_y":1224,"width":1876,"height":51},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e53525fb080343b79ec2f402fca4310f","type":"text","conversion_output":true,"text":"36. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type","text_display":"\n36. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type","confidence":1,"confidence_rate":1},{"cnt":[[245,1268],[1717,1268],[1717,1317],[245,1317]],"region":{"top_left_x":244,"top_left_y":1267,"width":1473,"height":50},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8fb7a8b1b3c34646b938210491484320","type":"text","conversion_output":true,"text":"2 diabetic nephropathy: lessons from RENAAL. Kidney Int. Jun 2004;65(6):2309-2320.","text_display":" 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. Jun 2004;65(6):2309-2320.","confidence":0.95458984375,"confidence_rate":0.9994597562895634},{"cnt":[[120,1311],[1936,1311],[1936,1360],[120,1360]],"region":{"top_left_x":120,"top_left_y":1310,"width":1816,"height":50},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4489857a2aa44e729a178aa44c013c65","type":"text","conversion_output":true,"text":"37. Rifkin DE, Shlipak MG, Katz R, et al. Rapid kidney function decline and mortality risk in older adults.","text_display":"\n37. Rifkin DE, Shlipak MG, Katz R, et al. Rapid kidney function decline and mortality risk in older adults.","confidence":1,"confidence_rate":1},{"cnt":[[245,1354],[1111,1354],[1111,1403],[245,1403]],"region":{"top_left_x":244,"top_left_y":1353,"width":867,"height":50},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0d4449dce2074deaa4bd39385f185954","type":"text","conversion_output":true,"text":"Arch Intern Med. Nov 10 2008;168(20):2212-2218.","text_display":" Arch Intern Med. Nov 10 2008;168(20):2212-2218.","confidence":0.994140625,"confidence_rate":0.9998931582809106},{"cnt":[[120,1401],[1996,1401],[1996,1448],[120,1448]],"region":{"top_left_x":120,"top_left_y":1400,"width":1876,"height":49},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8fe3ba054f754d5c9cf73755f4459c22","type":"text","conversion_output":true,"text":"38. Hallan S, Astor B, Romundstad S, Aasarod K, Kvenild K, Coresh J. Association of Kidney Function and","text_display":"\n38. Hallan S, Astor B, Romundstad S, Aasarod K, Kvenild K, Coresh J. Association of Kidney Function and","confidence":0.99951171875,"confidence_rate":0.9999954777833909},{"cnt":[[245,1444],[1949,1444],[1949,1491],[245,1491]],"region":{"top_left_x":244,"top_left_y":1443,"width":1705,"height":49},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d4afe241335d49afbdb6faf02c5386ee","type":"text","conversion_output":true,"text":"Albuminuria With Cardiovascular Mortality in Older vs Younger Individuals: The HUNT II Study. Arch","text_display":" Albuminuria With Cardiovascular Mortality in Older vs Younger Individuals: The HUNT II Study. Arch","confidence":1,"confidence_rate":1},{"cnt":[[245,1487],[1021,1487],[1021,1536],[245,1536]],"region":{"top_left_x":244,"top_left_y":1486,"width":777,"height":51},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3503b6b7bcea49cc928ccc1b9dbf7a8d","type":"text","conversion_output":true,"text":"Intern Med. Dec 10 2007;167(22):2490-2496 .","text_display":" Intern Med. Dec 10 2007;167(22):2490-2496 .","confidence":0.4956965446472168,"confidence_rate":0.9863336298738913},{"cnt":[[120,1532],[2000,1532],[2000,1579],[120,1579]],"region":{"top_left_x":120,"top_left_y":1531,"width":1881,"height":49},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d60f401c5e5e47d880b050bbc60425f5","type":"text","conversion_output":true,"text":"39. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes","text_display":"\n39. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes","confidence":1,"confidence_rate":1},{"cnt":[[245,1575],[1936,1575],[1936,1622],[245,1622]],"region":{"top_left_x":244,"top_left_y":1574,"width":1692,"height":49},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9d21bba342f54a1fab2ffd9c7538a77e","type":"text","conversion_output":true,"text":"Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group.","text_display":" Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group.","confidence":0.9985356330871582,"confidence_rate":0.9999851976838389},{"cnt":[[245,1620],[907,1620],[907,1665],[245,1665]],"region":{"top_left_x":244,"top_left_y":1619,"width":663,"height":47},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5604298149de424ca4d7d61b52bdd5da","type":"text","conversion_output":true,"text":"Kidney Int. Jun 1995;47(6):1703-1720.","text_display":" Kidney Int. Jun 1995;47(6):1703-1720.","confidence":0.97802734375,"confidence_rate":0.9994711482130111},{"cnt":[[120,1663],[1970,1663],[1970,1712],[120,1712]],"region":{"top_left_x":120,"top_left_y":1662,"width":1851,"height":51},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9d106112f2694dacb0368a86fe2b1aa6","type":"text","conversion_output":true,"text":"40. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of","text_display":"\n40. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of","confidence":1,"confidence_rate":1},{"cnt":[[245,1708],[1921,1708],[1921,1755],[245,1755]],"region":{"top_left_x":244,"top_left_y":1708,"width":1677,"height":48},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5a75c91e95c24b9b9602eda9492bd612","type":"text","conversion_output":true,"text":"diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.","text_display":" diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.","confidence":0.9951210021972656,"confidence_rate":0.9999515760341715},{"cnt":[[245,1753],[932,1753],[932,1798],[245,1798]],"region":{"top_left_x":244,"top_left_y":1753,"width":689,"height":46},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b5282a3517bb4aaaa1ec1e20292a0997","type":"text","conversion_output":true,"text":"Jama. Nov 22 2003;290(16):2159-2167.","text_display":" Jama. Nov 22 2003;290(16):2159-2167.","confidence":0.99853515625,"confidence_rate":0.9999666842440162},{"cnt":[[120,1796],[1951,1796],[1951,1841],[120,1841]],"region":{"top_left_x":120,"top_left_y":1796,"width":1831,"height":46},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a9c07a1888694c6a8c895f4bcede5fca","type":"text","conversion_output":true,"text":"41. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment","text_display":"\n41. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment","confidence":1,"confidence_rate":1},{"cnt":[[245,1839],[1983,1839],[1983,1886],[245,1886]],"region":{"top_left_x":244,"top_left_y":1839,"width":1740,"height":48},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"eed5481bde7c4c5f8042e8e092c5b406","type":"text","conversion_output":true,"text":"and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study","text_display":" and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study","confidence":0.99951171875,"confidence_rate":0.9999954777833909},{"cnt":[[247,1882],[1248,1882],[1248,1931],[247,1931]],"region":{"top_left_x":247,"top_left_y":1882,"width":1002,"height":50},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fc913de0432c415d909046450409061d","type":"text","conversion_output":true,"text":"(UKPDS) Group. Lancet. Sep 12 1998;352(9131):837-853.","text_display":" (UKPDS) Group. Lancet. Sep 12 1998;352(9131):837-853.","confidence":0.9980475902557373,"confidence_rate":0.9999679625102506},{"cnt":[[120,1927],[1983,1927],[1983,1974],[120,1974]],"region":{"top_left_x":120,"top_left_y":1927,"width":1864,"height":48},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6d68512ac3e040c19ddfb554a368f9fc","type":"text","conversion_output":true,"text":"42. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in","text_display":"\n42. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in","confidence":0.99951171875,"confidence_rate":0.9999955192715237},{"cnt":[[245,1972],[1571,1972],[1571,2017],[245,2017]],"region":{"top_left_x":244,"top_left_y":1972,"width":1327,"height":46},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b06b956c1a6e44dbbe24ec90863928a5","type":"text","conversion_output":true,"text":"patients with type 1 diabetes. N Engl J Med. Dec 22 2005;353(25):2643-2653.","text_display":" patients with type 1 diabetes. N Engl J Med. Dec 22 2005;353(25):2643-2653.","confidence":0.9853813648223877,"confidence_rate":0.9998287758194471},{"cnt":[[120,2015],[1921,2015],[1921,2060],[120,2060]],"region":{"top_left_x":120,"top_left_y":2015,"width":1801,"height":46},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"013a9c6bd1ad494889c1b9c472910aea","type":"text","conversion_output":true,"text":"43. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in","text_display":"\n43. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in","confidence":0.99658203125,"confidence_rate":0.9999673926902055},{"cnt":[[245,2058],[1566,2058],[1566,2108],[245,2108]],"region":{"top_left_x":244,"top_left_y":2058,"width":1323,"height":50},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"27e5095d822c46fcb7ae5d2c6a38582e","type":"text","conversion_output":true,"text":"patients with type 2 diabetes. N Engl J Med. Jun 12 2008;358(24):2560-2572.","text_display":" patients with type 2 diabetes. N Engl J Med. Jun 12 2008;358(24):2560-2572.","confidence":0.9849157333374023,"confidence_rate":0.9998232808331727},{"cnt":[[120,2103],[1972,2103],[1972,2151],[120,2151]],"region":{"top_left_x":120,"top_left_y":2103,"width":1853,"height":48},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"83d14fba145d4c58a93cfaad9905a727","type":"text","conversion_output":true,"text":"44. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N","text_display":"\n44. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N","confidence":0.9794921875,"confidence_rate":0.9998198334698736},{"cnt":[[245,2144],[1025,2144],[1025,2194],[245,2194]],"region":{"top_left_x":244,"top_left_y":2144,"width":781,"height":50},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"37fc07d367f340dd9f307dcc26ab9b8a","type":"text","conversion_output":true,"text":"Engl J Med. Jun 12 2008;358(24):2545-2559.","text_display":" Engl J Med. Jun 12 2008;358(24):2545-2559.","confidence":0.99951171875,"confidence_rate":0.9999902320377446},{"cnt":[[120,2191],[1949,2191],[1949,2237],[120,2237]],"region":{"top_left_x":120,"top_left_y":2191,"width":1829,"height":46},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c73ce2aa9ed6459aa3326aea1b6f373e","type":"text","conversion_output":true,"text":"45. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with","text_display":"\n45. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with","confidence":1,"confidence_rate":1},{"cnt":[[245,2234],[1257,2234],[1257,2282],[245,2282]],"region":{"top_left_x":244,"top_left_y":2234,"width":1013,"height":48},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bcc69041356b455fb132b7040a86d5e3","type":"text","conversion_output":true,"text":"type 2 diabetes. N Engl J Med. Jan 8 2009;360(2):129-139.","text_display":" type 2 diabetes. N Engl J Med. Jan 8 2009;360(2):129-139.","confidence":0.9040265351068228,"confidence_rate":0.9985173272171612},{"cnt":[[120,2277],[1901,2277],[1901,2327],[120,2327]],"region":{"top_left_x":120,"top_left_y":2277,"width":1782,"height":50},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bf5d4e439089429d82b7d4704a7d05bf","type":"text","conversion_output":true,"text":"46. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-","text_display":"\n46. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin","confidence":1,"confidence_rate":1},{"cnt":[[245,2322],[1863,2322],[1863,2370],[245,2370]],"region":{"top_left_x":244,"top_left_y":2322,"width":1619,"height":48},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"335484f6d4fd49808c759afd55111641","type":"text","conversion_output":true,"text":"angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent","text_display":"angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent","confidence":1,"confidence_rate":1},{"cnt":[[245,2368],[1674,2368],[1674,2413],[245,2413]],"region":{"top_left_x":244,"top_left_y":2367,"width":1430,"height":46},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fbaaaae763194ce184f295fdac57fe9d","type":"text","conversion_output":true,"text":"diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Bmj. Dec 9","text_display":" diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Bmj. Dec 9","confidence":1,"confidence_rate":1},{"cnt":[[245,2411],[728,2411],[728,2460],[245,2460]],"region":{"top_left_x":244,"top_left_y":2410,"width":485,"height":50},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3c52b8614b03486684bca1d2586e2bca","type":"text","conversion_output":true,"text":"2000;321(7274):1440-1444.","text_display":" 2000;321(7274):1440-1444.","confidence":0.9980475902557373,"confidence_rate":0.9999348581824669},{"cnt":[[1955,2582],[2007,2582],[2007,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2582,"width":52,"height":46},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8ce099b0a5ff46b0953b6bba0faf05d0","type":"page_info","conversion_output":false,"text":"25","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-26","page":26,"lines":[{"cnt":[[120,125],[1992,125],[1992,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":1872,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a4d7dd7be88640cca1515dcb8b48847d","type":"text","conversion_output":true,"text":"47. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan","text_display":"\n47. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan","confidence":1,"confidence_rate":1},{"cnt":[[245,172],[1923,172],[1923,217],[245,217]],"region":{"top_left_x":244,"top_left_y":171,"width":1679,"height":46},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4351bab2efd842c1892e7ded0a18f1f6","type":"text","conversion_output":true,"text":"on the development of diabetic nephropathy in patients with type 2 diabetes. NEngI J Med. Sep 20","text_display":" on the development of diabetic nephropathy in patients with type 2 diabetes. NEngI J Med. Sep 20","confidence":0.5209665298461914,"confidence_rate":0.9936892254492554},{"cnt":[[245,215],[642,215],[642,260],[245,260]],"region":{"top_left_x":244,"top_left_y":214,"width":399,"height":46},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b006e130b0ef4a0aa41d07174d7d0eff","type":"text","conversion_output":true,"text":"2001;345(12):870-878.","text_display":" 2001;345(12):870-878.","confidence":1,"confidence_rate":1},{"cnt":[[120,258],[1996,258],[1996,305],[120,305]],"region":{"top_left_x":120,"top_left_y":257,"width":1876,"height":49},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0d6e1fc16efd4c51a093efaa657c9516","type":"text","conversion_output":true,"text":"48. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist","text_display":"\n48. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist","confidence":1,"confidence_rate":1},{"cnt":[[245,301],[1691,301],[1691,350],[245,350]],"region":{"top_left_x":244,"top_left_y":300,"width":1447,"height":51},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0b792520170a427a8efa8024700597b9","type":"text","conversion_output":true,"text":"irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. Sep 20","text_display":" irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. Sep 20","confidence":0.891780993453267,"confidence_rate":0.9987421686614866},{"cnt":[[245,348],[642,348],[642,393],[245,393]],"region":{"top_left_x":244,"top_left_y":348,"width":399,"height":46},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"716548cad43d4aae849c1356ac670e94","type":"text","conversion_output":true,"text":"2001;345(12):851-860.","text_display":" 2001;345(12):851-860.","confidence":1,"confidence_rate":1},{"cnt":[[120,389],[1979,389],[1979,436],[120,436]],"region":{"top_left_x":120,"top_left_y":388,"width":1859,"height":49},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a3091b19bea343d7a3a40e3e8a02edd2","type":"text","conversion_output":true,"text":"49. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes","text_display":"\n49. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes","confidence":1,"confidence_rate":1},{"cnt":[[245,434],[1867,434],[1867,479],[245,479]],"region":{"top_left_x":244,"top_left_y":433,"width":1623,"height":47},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c8f45992af5e48538edfba652d26cdb5","type":"text","conversion_output":true,"text":"in patients with type 2 diabetes and nephropathy. N Engl J Med. Sep 20 2001;345(12):861-869.","text_display":" in patients with type 2 diabetes and nephropathy. N Engl J Med. Sep 20 2001;345(12):861-869.","confidence":0.9912109375,"confidence_rate":0.9999142957687052},{"cnt":[[120,477],[1923,477],[1923,524],[120,524]],"region":{"top_left_x":120,"top_left_y":476,"width":1803,"height":49},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2721ffcec4864c059ae082386f678143","type":"text","conversion_output":true,"text":"50. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes","text_display":"\n50. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes","confidence":1,"confidence_rate":1},{"cnt":[[245,520],[1717,520],[1717,569],[245,569]],"region":{"top_left_x":244,"top_left_y":519,"width":1473,"height":51},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6416a393059448b3bb56edbe3d4f5e37","type":"text","conversion_output":true,"text":"mellitus: a blood pressure-independent effect. Circulation. Aug 6 2002;106(6):672-678.","text_display":" mellitus: a blood pressure-independent effect. Circulation. Aug 6 2002;106(6):672-678.","confidence":0.9638671875,"confidence_rate":0.9996085684786136},{"cnt":[[120,563],[1974,563],[1974,612],[120,612]],"region":{"top_left_x":120,"top_left_y":562,"width":1855,"height":51},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6d495a70b4224e3c8acf316bb49f288b","type":"text","conversion_output":true,"text":"51. Ruggenenti P, Fassi A, llieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med.","text_display":"\n51. Ruggenenti P, Fassi A, llieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med.","confidence":0.9912357106804848,"confidence_rate":0.9999227843708264},{"cnt":[[245,610],[795,610],[795,655],[245,655]],"region":{"top_left_x":244,"top_left_y":610,"width":551,"height":46},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"89074c2fba974479a462011451cfaea4","type":"text","conversion_output":true,"text":"Nov 4 2004;351(19):1941-1951.","text_display":" Nov 4 2004;351(19):1941-1951.","confidence":1,"confidence_rate":1},{"cnt":[[120,653],[1515,653],[1515,698],[120,698]],"region":{"top_left_x":120,"top_left_y":653,"width":1395,"height":46},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6591d598a5664e21aead276d0b5b2c96","type":"text","conversion_output":true,"text":"52. Fieser L, Fieser M. Vitamin D. Steroids. New York: Reinhold; 1959:90-168.","text_display":"\n52. Fieser L, Fieser M. Vitamin D. Steroids. New York: Reinhold; 1959:90-168.","confidence":1,"confidence_rate":1},{"cnt":[[120,696],[1979,696],[1979,746],[120,746]],"region":{"top_left_x":120,"top_left_y":696,"width":1859,"height":50},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8ed2e42e09c94c9e90cb063264ec8536","type":"text","conversion_output":true,"text":"53. DeLuca HF. The vitamin D story: a collaborative effort of basic science and clinical medicine. Faseb J.","text_display":"\n53. DeLuca HF. The vitamin D story: a collaborative effort of basic science and clinical medicine. Faseb J.","confidence":1,"confidence_rate":1},{"cnt":[[245,743],[690,743],[690,788],[245,788]],"region":{"top_left_x":244,"top_left_y":743,"width":446,"height":46},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1f252da100cf449fb73e854629579449","type":"text","conversion_output":true,"text":"Mar 1 1988;2(3):224-236.","text_display":" Mar 1 1988;2(3):224-236.","confidence":0.98388671875,"confidence_rate":0.9994924878348068},{"cnt":[[120,786],[1996,786],[1996,831],[120,831]],"region":{"top_left_x":120,"top_left_y":786,"width":1876,"height":46},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9b7f22ef1e164e039de522908ce3c31e","type":"text","conversion_output":true,"text":"54. Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease.","text_display":"\n54. Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease.","confidence":1,"confidence_rate":1},{"cnt":[[245,829],[1016,829],[1016,879],[245,879]],"region":{"top_left_x":244,"top_left_y":829,"width":773,"height":50},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"86ebeb36e6f84570a696e23e3f922267","type":"text","conversion_output":true,"text":"N Engl J Med. Apr 13 1989;320(15):980-991.","text_display":" N Engl J Med. Apr 13 1989;320(15):980-991.","confidence":0.99951171875,"confidence_rate":0.9999902320377446},{"cnt":[[120,872],[1543,872],[1543,922],[120,922]],"region":{"top_left_x":120,"top_left_y":872,"width":1423,"height":50},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c9a195464bd74f4bb5106a863813a8eb","type":"text","conversion_output":true,"text":"55. Holick MF. Vitamin D deficiency. N Engl J Med. Jul 19 2007;357(3):266-281.","text_display":"\n55. Holick MF. Vitamin D deficiency. N Engl J Med. Jul 19 2007;357(3):266-281.","confidence":0.9587836265563965,"confidence_rate":0.9995107028427719},{"cnt":[[120,917],[1979,917],[1979,965],[120,965]],"region":{"top_left_x":120,"top_left_y":917,"width":1859,"height":48},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"348fa7afb121406cb90a4edde9add80c","type":"text","conversion_output":true,"text":"56. Mawer EB, Schaefer K, Lumb GA, Stanbury SW. The metabolism of isotopically labelled vitamin D3 in","text_display":"\n56. Mawer EB, Schaefer K, Lumb GA, Stanbury SW. The metabolism of isotopically labelled vitamin D3 in","confidence":0.99951171875,"confidence_rate":0.9999953924587458},{"cnt":[[245,958],[1674,958],[1674,1008],[245,1008]],"region":{"top_left_x":244,"top_left_y":958,"width":1430,"height":50},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ccf64f8aeffa4aa2b4852986d846380a","type":"text","conversion_output":true,"text":"man: the influence of the state of vitamin D nutrition. Clin Sci. Jan 1971;40(1):39-53.","text_display":" man: the influence of the state of vitamin D nutrition. Clin Sci. Jan 1971;40(1):39-53.","confidence":0.99951171875,"confidence_rate":0.9999946913130248},{"cnt":[[120,1005],[1921,1005],[1921,1051],[120,1051]],"region":{"top_left_x":120,"top_left_y":1005,"width":1801,"height":46},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c19606a3b27b4b608ea458302389e0d9","type":"text","conversion_output":true,"text":"57. Haddad JG, Jr., Hahn TJ. Natural and synthetic sources of circulating 25-hydroxyvitamin D in man.","text_display":"\n57. Haddad JG, Jr., Hahn TJ. Natural and synthetic sources of circulating 25-hydroxyvitamin D in man.","confidence":0.91845703125,"confidence_rate":0.9991978675703713},{"cnt":[[245,1048],[952,1048],[952,1096],[245,1096]],"region":{"top_left_x":244,"top_left_y":1048,"width":708,"height":48},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8acb926068cd4748a6f9d94b396a0c34","type":"text","conversion_output":true,"text":"Nature. Aug 24 1973;244(5417):515-517.","text_display":" Nature. Aug 24 1973;244(5417):515-517.","confidence":0.99951171875,"confidence_rate":0.9999893826542317},{"cnt":[[120,1091],[1946,1091],[1946,1139],[120,1139]],"region":{"top_left_x":120,"top_left_y":1091,"width":1827,"height":48},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d430febf7c9c4cfcb81aa493c6fa1947","type":"text","conversion_output":true,"text":"58. Adams JS, Clemens TL, Parrish JA, Holick MF. Vitamin-D synthesis and metabolism after ultraviolet","text_display":"\n58. Adams JS, Clemens TL, Parrish JA, Holick MF. Vitamin-D synthesis and metabolism after ultraviolet","confidence":1,"confidence_rate":1},{"cnt":[[245,1137],[1936,1137],[1936,1184],[245,1184]],"region":{"top_left_x":244,"top_left_y":1136,"width":1692,"height":48},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9ac138ec52e449c896b5eb59be1e9741","type":"text","conversion_output":true,"text":"irradiation of normal and vitamin-D-deficient subjects. N Engl J Med. Mar 25 1982;306(12):722-725.","text_display":" irradiation of normal and vitamin-D-deficient subjects. N Engl J Med. Mar 25 1982;306(12):722-725.","confidence":0.9902503434568644,"confidence_rate":0.999907575067281},{"cnt":[[120,1179],[1790,1179],[1790,1227],[120,1227]],"region":{"top_left_x":120,"top_left_y":1179,"width":1670,"height":48},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4ae864f787ee4e248c53ebb7181680cd","type":"text","conversion_output":true,"text":"59. Vicchio D, Yergey A, O'Brien K, Allen L, Ray R, Holick M. Quantification and kinetics of 25-","text_display":"\n59. Vicchio D, Yergey A, O'Brien K, Allen L, Ray R, Holick M. Quantification and kinetics of 25","confidence":1,"confidence_rate":1},{"cnt":[[245,1225],[1919,1225],[1919,1274],[245,1274]],"region":{"top_left_x":244,"top_left_y":1224,"width":1675,"height":51},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f55083c5b00740ca954b0837e774a58d","type":"text","conversion_output":true,"text":"hydroxyvitamin D3 by isotope dilution liquid chromatography/thermospray mass spectrometry. Biol","text_display":"hydroxyvitamin D3 by isotope dilution liquid chromatography/thermospray mass spectrometry. Biol","confidence":1,"confidence_rate":1},{"cnt":[[245,1268],[917,1268],[917,1317],[245,1317]],"region":{"top_left_x":244,"top_left_y":1267,"width":674,"height":50},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"86e16cf32a514a18ba5adba3ea30b539","type":"text","conversion_output":true,"text":"Mass Spectrom. Jan 1993;22(1):53-58.","text_display":" Mass Spectrom. Jan 1993;22(1):53-58.","confidence":0.9980475902557373,"confidence_rate":0.999952334838932},{"cnt":[[120,1313],[1871,1313],[1871,1360],[120,1360]],"region":{"top_left_x":120,"top_left_y":1312,"width":1752,"height":48},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5b16e82f016e4528947e14140051c35a","type":"text","conversion_output":true,"text":"60. Standing committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary reference","text_display":"\n60. Standing committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary reference","confidence":1,"confidence_rate":1},{"cnt":[[245,1354],[1850,1354],[1850,1403],[245,1403]],"region":{"top_left_x":244,"top_left_y":1353,"width":1606,"height":50},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"acb33eb0f8944723bb77b9c84f3a8229","type":"text","conversion_output":true,"text":"intakes: calcium, phosphorous, magnesium, vitamin D, and fluoride. Washington, DC: National","text_display":" intakes: calcium, phosphorous, magnesium, vitamin D, and fluoride. Washington, DC: National","confidence":0.9980475902557373,"confidence_rate":0.9999796427261641},{"cnt":[[245,1401],[638,1401],[638,1446],[245,1446]],"region":{"top_left_x":244,"top_left_y":1400,"width":395,"height":46},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"847f7b396afd4b9f8c274bd9e240ba1a","type":"text","conversion_output":true,"text":"Academy Press; 1997.","text_display":" Academy Press; 1997.","confidence":1,"confidence_rate":1},{"cnt":[[120,1444],[1893,1444],[1893,1491],[120,1491]],"region":{"top_left_x":120,"top_left_y":1443,"width":1773,"height":49},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7f9ea491977e4df9906269469dd520cf","type":"text","conversion_output":true,"text":"61. Barger-Lux MJ, Heaney RP, Dowell S, Chen TC, Holick MF. Vitamin D and its major metabolites:","text_display":"\n61. Barger-Lux MJ, Heaney RP, Dowell S, Chen TC, Holick MF. Vitamin D and its major metabolites:","confidence":1,"confidence_rate":1},{"cnt":[[245,1489],[1760,1489],[1760,1536],[245,1536]],"region":{"top_left_x":244,"top_left_y":1488,"width":1516,"height":49},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"49829700a05b43a38dc7e8e17a3faf72","type":"text","conversion_output":true,"text":"serum levels after graded oral dosing in healthy men. Osteoporos Int. 1998;8(3):222-230.","text_display":" serum levels after graded oral dosing in healthy men. Osteoporos Int. 1998;8(3):222-230.","confidence":1,"confidence_rate":1},{"cnt":[[120,1532],[1996,1532],[1996,1579],[120,1579]],"region":{"top_left_x":120,"top_left_y":1531,"width":1876,"height":49},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b20afa117efc4790b7d93fecb6a7510a","type":"text","conversion_output":true,"text":"62. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol","text_display":"\n62. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol","confidence":1,"confidence_rate":1},{"cnt":[[245,1577],[1858,1577],[1858,1622],[245,1622]],"region":{"top_left_x":244,"top_left_y":1576,"width":1615,"height":47},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"94914296717246ff814c712878e1fb74","type":"text","conversion_output":true,"text":"response to extended oral dosing with cholecalciferol. Am J Clin Nutr. Jan 2003;77(1):204-210.","text_display":" response to extended oral dosing with cholecalciferol. Am J Clin Nutr. Jan 2003;77(1):204-210.","confidence":0.99755859375,"confidence_rate":0.9999753094831817},{"cnt":[[120,1620],[1820,1620],[1820,1665],[120,1665]],"region":{"top_left_x":120,"top_left_y":1619,"width":1700,"height":47},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"036703c26ccf4126888104c215dbe437","type":"text","conversion_output":true,"text":"63. Halloran BP, Schaefer P, Lifschitz M, Levens M, Goldsmith RS. Plasma vitamin D metabolite","text_display":"\n63. Halloran BP, Schaefer P, Lifschitz M, Levens M, Goldsmith RS. Plasma vitamin D metabolite","confidence":1,"confidence_rate":1},{"cnt":[[245,1663],[1910,1663],[1910,1712],[245,1712]],"region":{"top_left_x":244,"top_left_y":1662,"width":1666,"height":51},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d1fa5d30fb5f4f9392c13f9c6e0a3422","type":"text","conversion_output":true,"text":"concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3. J Clin","text_display":" concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3. J Clin","confidence":0.9357717307068042,"confidence_rate":0.9993797839117152},{"cnt":[[245,1708],[1042,1708],[1042,1755],[245,1755]],"region":{"top_left_x":244,"top_left_y":1708,"width":798,"height":48},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d574f38600f1432fbd3a98013076934b","type":"text","conversion_output":true,"text":"Endocrinol Metab. Dec 1984;59(6):1063-1069.","text_display":" Endocrinol Metab. Dec 1984;59(6):1063-1069.","confidence":0.9975600242614746,"confidence_rate":0.999949106350744},{"cnt":[[120,1749],[1910,1749],[1910,1798],[120,1798]],"region":{"top_left_x":120,"top_left_y":1748,"width":1790,"height":51},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"aa54a70ef1d644e5ab0dd0bb6bca151c","type":"text","conversion_output":true,"text":"64. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic","text_display":"\n64. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic","confidence":1,"confidence_rate":1},{"cnt":[[245,1796],[1893,1796],[1893,1843],[245,1843]],"region":{"top_left_x":244,"top_left_y":1796,"width":1649,"height":48},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3a3c24458faf4b748386a1ac5fcf9bc5","type":"text","conversion_output":true,"text":"kidney disease. A single center observational study. Am J Nephrol. Sep-Oct 2004;24(5):503-510.","text_display":" kidney disease. A single center observational study. Am J Nephrol. Sep-Oct 2004;24(5):503-510.","confidence":0.9990234375,"confidence_rate":0.9999901309613475},{"cnt":[[122,1839],[1820,1839],[1820,1886],[122,1886]],"region":{"top_left_x":122,"top_left_y":1839,"width":1698,"height":48},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ccd1c0c76a174c96944b12a63da8d7f9","type":"text","conversion_output":true,"text":"65. de Boer IH. Vitamin D and glucose metabolism in chronic kidney disease. Curr Opin Nephrol","text_display":"\n65. de Boer IH. Vitamin D and glucose metabolism in chronic kidney disease. Curr Opin Nephrol","confidence":1,"confidence_rate":1},{"cnt":[[245,1882],[874,1882],[874,1931],[245,1931]],"region":{"top_left_x":244,"top_left_y":1882,"width":631,"height":50},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"24e7747aea2b4cb8af4260751cd315e1","type":"text","conversion_output":true,"text":"Hypertens. Nov 2008;17(6):566-572.","text_display":" Hypertens. Nov 2008;17(6):566-572.","confidence":0.99951171875,"confidence_rate":0.9999874769887185},{"cnt":[[122,1927],[1970,1927],[1970,1974],[122,1974]],"region":{"top_left_x":122,"top_left_y":1927,"width":1849,"height":48},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9314dcaf250648b2bfdaa430084eae03","type":"text","conversion_output":true,"text":"66. de Boer IH. Vitamin D deficiency. In: Himmelfarb J, Sayegh M, eds. Chronic Kidney Disease, Dialysis,","text_display":"\n66. de Boer IH. Vitamin D deficiency. In: Himmelfarb J, Sayegh M, eds. Chronic Kidney Disease, Dialysis,","confidence":0.9990234375,"confidence_rate":0.9999910363736797},{"cnt":[[245,1972],[1972,1972],[1972,2017],[245,2017]],"region":{"top_left_x":244,"top_left_y":1972,"width":1729,"height":46},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bedac5033d0c49818d57470701142ed3","type":"text","conversion_output":true,"text":"and Transplantation: Companion to Brenner and Rector's The Kidney, Third Edition. Philadelphia, PA:","text_display":" and Transplantation: Companion to Brenner and Rector's The Kidney, Third Edition. Philadelphia, PA:","confidence":0.9965858445502818,"confidence_rate":0.9999671159543637},{"cnt":[[245,2015],[507,2015],[507,2060],[245,2060]],"region":{"top_left_x":244,"top_left_y":2015,"width":264,"height":46},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"21525e3750ab498e8ffdc6a02d0a9db2","type":"text","conversion_output":true,"text":"Elsevier; 2009.","text_display":" Elsevier; 2009.","confidence":1,"confidence_rate":1},{"cnt":[[120,2058],[1846,2058],[1846,2108],[120,2108]],"region":{"top_left_x":120,"top_left_y":2058,"width":1726,"height":50},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"02f4fe9a45464cb193edd0071e91ca74","type":"text","conversion_output":true,"text":"67. de Boer IH, Kestenbaum B. Vitamin D in chronic kidney disease: is the jury in? Kidney Int. Oct","text_display":"\n67. de Boer IH, Kestenbaum B. Vitamin D in chronic kidney disease: is the jury in? Kidney Int. Oct","confidence":1,"confidence_rate":1},{"cnt":[[245,2105],[599,2105],[599,2151],[245,2151]],"region":{"top_left_x":244,"top_left_y":2105,"width":356,"height":46},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"dae7677a69e04f50a1efd99f64ecdce1","type":"text","conversion_output":true,"text":"2008;74(8):985-987.","text_display":" 2008;74(8):985-987.","confidence":1,"confidence_rate":1},{"cnt":[[122,2144],[1946,2144],[1946,2194],[122,2194]],"region":{"top_left_x":122,"top_left_y":2144,"width":1825,"height":50},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e976bd4b8d0a47e7b8426fbe5fb8487a","type":"text","conversion_output":true,"text":"68. de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS. 25-hydroxyvitamin D","text_display":"\n68. de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS. 25-hydroxyvitamin D","confidence":1,"confidence_rate":1},{"cnt":[[245,2191],[1979,2191],[1979,2237],[245,2237]],"region":{"top_left_x":244,"top_left_y":2191,"width":1735,"height":46},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0c4512325b884d44ad063fb4886b29be","type":"text","conversion_output":true,"text":"levels inversely associate with risk for developing coronary artery calcification. JAm Soc Nephrol. Aug","text_display":" levels inversely associate with risk for developing coronary artery calcification. JAm Soc Nephrol. Aug","confidence":0.95263671875,"confidence_rate":0.9995508264129674},{"cnt":[[245,2234],[642,2234],[642,2282],[245,2282]],"region":{"top_left_x":244,"top_left_y":2234,"width":399,"height":48},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8765bc76b6654beeab25483920f8cd37","type":"text","conversion_output":true,"text":"2009;20(8):1805-1812.","text_display":" 2009;20(8):1805-1812.","confidence":0.998046875,"confidence_rate":0.9999248091794406},{"cnt":[[120,2277],[1944,2277],[1944,2327],[120,2327]],"region":{"top_left_x":120,"top_left_y":2277,"width":1825,"height":50},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"432fa1f6eb0641a78fe17c58c1ec4133","type":"text","conversion_output":true,"text":"69. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. Jul 2005;289(1):F8-28.","text_display":"\n69. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. Jul 2005;289(1):F8-28.","confidence":1,"confidence_rate":1},{"cnt":[[122,2322],[1987,2322],[1987,2370],[122,2370]],"region":{"top_left_x":122,"top_left_y":2322,"width":1866,"height":48},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"952dde70cfbb4556acd5689d99b5352f","type":"text","conversion_output":true,"text":"70. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients","text_display":"\n70. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients","confidence":1,"confidence_rate":1},{"cnt":[[245,2368],[1274,2368],[1274,2413],[245,2413]],"region":{"top_left_x":244,"top_left_y":2367,"width":1031,"height":46},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ce61c7e6046746e2999111509ace4e58","type":"text","conversion_output":true,"text":"with kidney disease? Kidney Int. Nov 2005;68(5):1973-1981.","text_display":" with kidney disease? Kidney Int. Nov 2005;68(5):1973-1981.","confidence":1,"confidence_rate":1},{"cnt":[[120,2411],[1893,2411],[1893,2460],[120,2460]],"region":{"top_left_x":120,"top_left_y":2410,"width":1773,"height":50},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c44667fc6da24baeaf7b2362bd2bf434","type":"text","conversion_output":true,"text":"71. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor","text_display":"\n71. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor","confidence":1,"confidence_rate":1},{"cnt":[[245,2454],[1003,2454],[1003,2503],[245,2503]],"region":{"top_left_x":244,"top_left_y":2453,"width":760,"height":50},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c7a86587cb68475d8fea4782d1198f0d","type":"text","conversion_output":true,"text":"activation. Kidney Int. Jan 2006;69(1):33-43.","text_display":" activation. Kidney Int. Jan 2006;69(1):33-43.","confidence":0.99072265625,"confidence_rate":0.9998136044471383},{"cnt":[[1955,2582],[2009,2582],[2009,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2582,"width":54,"height":46},"line":55,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d08aeabca62a425ab77184f5e7e36e1e","type":"page_info","conversion_output":false,"text":"26","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-27","page":27,"lines":[{"cnt":[[120,125],[1962,125],[1962,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":1842,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f4076d21cac94378a8c5d7f2128a3007","type":"text","conversion_output":true,"text":"72. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine","text_display":"\n72. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine","confidence":0.99951171875,"confidence_rate":0.9999953924587458},{"cnt":[[245,172],[1622,172],[1622,217],[245,217]],"region":{"top_left_x":244,"top_left_y":171,"width":1379,"height":46},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9ceeaa37233c4ab2adafd23babff3a63","type":"text","conversion_output":true,"text":"regulator of the renin-angiotensin system. J Clin Invest. Jul 2002;110(2):229-238.","text_display":" regulator of the renin-angiotensin system. J Clin Invest. Jul 2002;110(2):229-238.","confidence":0.99462890625,"confidence_rate":0.999938098813284},{"cnt":[[120,215],[1979,215],[1979,260],[120,260]],"region":{"top_left_x":120,"top_left_y":214,"width":1859,"height":46},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f17e34d2a79d4291875ab26127731c48","type":"text","conversion_output":true,"text":"73. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of","text_display":"\n73. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of","confidence":0.99951171875,"confidence_rate":0.9999954355197808},{"cnt":[[245,258],[1901,258],[1901,305],[245,305]],"region":{"top_left_x":244,"top_left_y":257,"width":1658,"height":49},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4aeaa61562bb422da908b15ada4cde07","type":"text","conversion_output":true,"text":"the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. May 2004;89-90(1-","text_display":" the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. May 2004;89-90(1-","confidence":0.99951171875,"confidence_rate":0.9999950666738041},{"cnt":[[245,301],[449,301],[449,348],[245,348]],"region":{"top_left_x":244,"top_left_y":300,"width":206,"height":49},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e02da4a850f3477d90d0e854fc5cc9ee","type":"text","conversion_output":true,"text":"5):387-392.","text_display":"5):387-392.","confidence":0.9990234375,"confidence_rate":0.9999389368864386},{"cnt":[[120,346],[1916,346],[1916,393],[120,393]],"region":{"top_left_x":120,"top_left_y":345,"width":1797,"height":49},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1efe7004cfdc49cdafcb44bb7db1286b","type":"text","conversion_output":true,"text":"74. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the","text_display":"\n74. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the","confidence":0.99853515625,"confidence_rate":0.9999866735644114},{"cnt":[[245,391],[1532,391],[1532,436],[245,436]],"region":{"top_left_x":244,"top_left_y":391,"width":1288,"height":46},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6490903e95c9473aa2a99f1bab2bba57","type":"text","conversion_output":true,"text":"cardiovascular system. Am J Physiol Cell Physiol. Jan 2007;292(1):C82-97.","text_display":" cardiovascular system. Am J Physiol Cell Physiol. Jan 2007;292(1):C82-97.","confidence":1,"confidence_rate":1},{"cnt":[[120,434],[1846,434],[1846,479],[120,479]],"region":{"top_left_x":120,"top_left_y":433,"width":1726,"height":47},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a3db699c6d04418eacbd3667d26a0995","type":"text","conversion_output":true,"text":"75. Hitomi H, Kiyomoto H, Nishiyama A. Angiotensin II and oxidative stress. Curr Opin Cardiol. Jul","text_display":"\n75. Hitomi H, Kiyomoto H, Nishiyama A. Angiotensin II and oxidative stress. Curr Opin Cardiol. Jul","confidence":1,"confidence_rate":1},{"cnt":[[245,477],[599,477],[599,522],[245,522]],"region":{"top_left_x":244,"top_left_y":476,"width":356,"height":47},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8fe278c702f94046918f2cc0fe09f729","type":"text","conversion_output":true,"text":"2007;22(4):311-315.","text_display":" 2007;22(4):311-315.","confidence":0.99951171875,"confidence_rate":0.9999796501863057},{"cnt":[[120,520],[1953,520],[1953,569],[120,569]],"region":{"top_left_x":120,"top_left_y":519,"width":1833,"height":51},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"503c6a7e3ebe4c06a05f4be04ef4a4c2","type":"text","conversion_output":true,"text":"76. Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the","text_display":"\n76. Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the","confidence":1,"confidence_rate":1},{"cnt":[[245,563],[1697,563],[1697,612],[245,612]],"region":{"top_left_x":244,"top_left_y":562,"width":1454,"height":51},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f4cbcae6109845d0ae9b88a3061e1207","type":"text","conversion_output":true,"text":"systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. Jan","text_display":" systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. Jan","confidence":0.99951171875,"confidence_rate":0.9999943862169285},{"cnt":[[245,610],[647,610],[647,655],[245,655]],"region":{"top_left_x":244,"top_left_y":610,"width":403,"height":46},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1eca5e099d934dc2b7fd4b8f1ec38795","type":"text","conversion_output":true,"text":"2005;288(1):E125-132.","text_display":" 2005;288(1):E125-132.","confidence":1,"confidence_rate":1},{"cnt":[[120,653],[1901,653],[1901,700],[120,700]],"region":{"top_left_x":120,"top_left_y":653,"width":1782,"height":48},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9fad6a0241ee45dc95b48eb8767a8730","type":"text","conversion_output":true,"text":"77. Durvasula RV, Shankland SJ. The renin-angiotensin system in glomerular podocytes: mediator of","text_display":"\n77. Durvasula RV, Shankland SJ. The renin-angiotensin system in glomerular podocytes: mediator of","confidence":1,"confidence_rate":1},{"cnt":[[245,696],[1996,696],[1996,746],[245,746]],"region":{"top_left_x":244,"top_left_y":696,"width":1752,"height":50},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"33cbfe36b6b84b9baa8e62b865b6ee0b","type":"text","conversion_output":true,"text":"glomerulosclerosis and link to hypertensive nephropathy. Curr Hypertens Rep. May 2006;8(2):132-138.","text_display":" glomerulosclerosis and link to hypertensive nephropathy. Curr Hypertens Rep. May 2006;8(2):132-138.","confidence":0.99951171875,"confidence_rate":0.9999953038523912},{"cnt":[[120,741],[1992,741],[1992,788],[120,788]],"region":{"top_left_x":120,"top_left_y":741,"width":1872,"height":48},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"10f3540f61764fb99362152f4bbaa27f","type":"text","conversion_output":true,"text":"78. Resnick LM, Muller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to","text_display":"\n78. Resnick LM, Muller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to","confidence":0.9737398163415492,"confidence_rate":0.9997558909000476},{"cnt":[[245,786],[1764,786],[1764,831],[245,831]],"region":{"top_left_x":244,"top_left_y":786,"width":1520,"height":46},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d9796cd65de74dc38afa7d6dc549152c","type":"text","conversion_output":true,"text":"plasma renin activity and sodium metabolism. Ann Intern Med. Nov 1986;105(5):649-654.","text_display":" plasma renin activity and sodium metabolism. Ann Intern Med. Nov 1986;105(5):649-654.","confidence":1,"confidence_rate":1},{"cnt":[[120,829],[2000,829],[2000,874],[120,874]],"region":{"top_left_x":120,"top_left_y":829,"width":1881,"height":46},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"912d8132ae5543d0aef0df3fbfb62567","type":"text","conversion_output":true,"text":"79. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S. Vitamin D is related to blood pressure","text_display":"\n79. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S. Vitamin D is related to blood pressure","confidence":0.966796875,"confidence_rate":0.9997012228510076},{"cnt":[[245,872],[1931,872],[1931,920],[245,920]],"region":{"top_left_x":244,"top_left_y":872,"width":1688,"height":48},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"48877b279ea841e99ed5013336b64cd4","type":"text","conversion_output":true,"text":"and other cardiovascular risk factors in middle-aged men. Am J Hypertens. Sep 1995;8(9):894-901.","text_display":" and other cardiovascular risk factors in middle-aged men. Am J Hypertens. Sep 1995;8(9):894-901.","confidence":1,"confidence_rate":1},{"cnt":[[120,915],[1785,915],[1785,965],[120,965]],"region":{"top_left_x":120,"top_left_y":915,"width":1666,"height":50},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b1ff770e64f242009e692073a45859e9","type":"text","conversion_output":true,"text":"80. Kristal-Boneh E, Froom P, Harari G, Ribak J. Association of calcitriol and blood pressure in","text_display":"\n80. Kristal-Boneh E, Froom P, Harari G, Ribak J. Association of calcitriol and blood pressure in","confidence":1,"confidence_rate":1},{"cnt":[[245,958],[1302,958],[1302,1008],[245,1008]],"region":{"top_left_x":244,"top_left_y":958,"width":1058,"height":50},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6eba389f1223448b8ef895b72b2db8bd","type":"text","conversion_output":true,"text":"normotensive men. Hypertension. Nov 1997;30(5):1289-1294.","text_display":" normotensive men. Hypertension. Nov 1997;30(5):1289-1294.","confidence":0.99951171875,"confidence_rate":0.999992122603638},{"cnt":[[120,1003],[1970,1003],[1970,1051],[120,1051]],"region":{"top_left_x":120,"top_left_y":1003,"width":1851,"height":48},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"16bfb635500e47349d8313f2424a6b19","type":"text","conversion_output":true,"text":"81. Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident","text_display":"\n81. Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident","confidence":0.998046875,"confidence_rate":0.9999817288133145},{"cnt":[[245,1048],[1212,1048],[1212,1094],[245,1094]],"region":{"top_left_x":244,"top_left_y":1048,"width":968,"height":46},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"21b053cb228e4a669a553c67a4a67a48","type":"text","conversion_output":true,"text":"hypertension. Hypertension. May 2007;49(5):1063-1069.","text_display":" hypertension. Hypertension. May 2007;49(5):1063-1069.","confidence":1,"confidence_rate":1},{"cnt":[[120,1091],[1914,1091],[1914,1139],[120,1139]],"region":{"top_left_x":120,"top_left_y":1091,"width":1795,"height":48},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8358221b3acf487c9a895364f566625b","type":"text","conversion_output":true,"text":"82. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid","text_display":"\n82. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid","confidence":0.8394336700439453,"confidence_rate":0.9983184556052802},{"cnt":[[245,1134],[999,1134],[999,1184],[245,1184]],"region":{"top_left_x":244,"top_left_y":1134,"width":756,"height":50},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5e3c9640e9da4933a93b466b05240d9a","type":"text","conversion_output":true,"text":"Biochem Mol Biol. Oct 2005;97(1-2):93-101.","text_display":" Biochem Mol Biol. Oct 2005;97(1-2):93-101.","confidence":1,"confidence_rate":1},{"cnt":[[120,1179],[1944,1179],[1944,1227],[120,1227]],"region":{"top_left_x":120,"top_left_y":1179,"width":1825,"height":48},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8779ab4938694cef9e0a928596c6a374","type":"text","conversion_output":true,"text":"83. Giovannini L, Panichi V, Migliori M, et al. 1,25-dihydroxyvitamin D(3) dose-dependently inhibits LPS-","text_display":"\n83. Giovannini L, Panichi V, Migliori M, et al. 1,25-dihydroxyvitamin D(3) dose-dependently inhibits LPS","confidence":0.99755859375,"confidence_rate":0.9999777785074303},{"cnt":[[245,1225],[1837,1225],[1837,1270],[245,1270]],"region":{"top_left_x":244,"top_left_y":1224,"width":1593,"height":46},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"af71686f34dc4a30909be5105591259f","type":"text","conversion_output":true,"text":"induced cytokines production in PBMC modulating intracellular calcium. Transplant Proc. May","text_display":"induced cytokines production in PBMC modulating intracellular calcium. Transplant Proc. May","confidence":1,"confidence_rate":1},{"cnt":[[245,1268],[642,1268],[642,1313],[245,1313]],"region":{"top_left_x":244,"top_left_y":1267,"width":399,"height":46},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8a748e476a964004a005ed426cc031f2","type":"text","conversion_output":true,"text":"2001;33(3):2366-2368.","text_display":" 2001;33(3):2366-2368.","confidence":1,"confidence_rate":1},{"cnt":[[120,1311],[1996,1311],[1996,1360],[120,1360]],"region":{"top_left_x":120,"top_left_y":1310,"width":1876,"height":50},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"843b19fb4cab4461aeb9b77cd39f9171","type":"text","conversion_output":true,"text":"84. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic","text_display":"\n84. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic","confidence":1,"confidence_rate":1},{"cnt":[[245,1354],[1884,1354],[1884,1403],[245,1403]],"region":{"top_left_x":244,"top_left_y":1353,"width":1641,"height":50},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a23f104159f24c5d81b3a969958c8c1f","type":"text","conversion_output":true,"text":"patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin \\(D (3)\\) works as anti-inflammatory.","text_display":" patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin \\(D (3)\\) works as anti-inflammatory.","confidence":0.53021240234375,"confidence_rate":0.9940878488199427},{"cnt":[[245,1401],[1044,1401],[1044,1446],[245,1446]],"region":{"top_left_x":244,"top_left_y":1400,"width":801,"height":46},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"351cc8b1a8154994b206cc8f9fc50d06","type":"text","conversion_output":true,"text":"Diabetes Res Clin Pract. Jul 2007;77(1):47-57.","text_display":" Diabetes Res Clin Pract. Jul 2007;77(1):47-57.","confidence":0.9990234375,"confidence_rate":0.999980842543353},{"cnt":[[120,1444],[1876,1444],[1876,1491],[120,1491]],"region":{"top_left_x":120,"top_left_y":1443,"width":1756,"height":49},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"eb2552438abd4292a8f9f300c17332e0","type":"text","conversion_output":true,"text":"85. Reichel H, Koeffler HP, Tobler A, Norman AW. 1 alpha,25-Dihydroxyvitamin D3 inhibits gamma-","text_display":"\n85. Reichel H, Koeffler HP, Tobler A, Norman AW. 1 alpha,25-Dihydroxyvitamin D3 inhibits gamma","confidence":1,"confidence_rate":1},{"cnt":[[245,1487],[1944,1487],[1944,1536],[245,1536]],"region":{"top_left_x":244,"top_left_y":1486,"width":1701,"height":51},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a091df19a8894b38bb6025c9f33ff362","type":"text","conversion_output":true,"text":"interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA. May","text_display":"interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA. May","confidence":0.7358646392822266,"confidence_rate":0.9969067224436923},{"cnt":[[247,1532],[664,1532],[664,1577],[247,1577]],"region":{"top_left_x":247,"top_left_y":1531,"width":417,"height":46},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4e32dc502c754111bcad9b3e71c6ee5e","type":"text","conversion_output":true,"text":"1987;84(10):3385-3389.","text_display":" 1987;84(10):3385-3389.","confidence":1,"confidence_rate":1},{"cnt":[[120,1575],[1979,1575],[1979,1622],[120,1622]],"region":{"top_left_x":120,"top_left_y":1574,"width":1859,"height":49},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b7fb1007c3a54e8683ed85b566453eeb","type":"text","conversion_output":true,"text":"86. Panichi V, De Pietro S, Andreini B, et al. Calcitriol modulates in vivo and in vitro cytokine production: a","text_display":"\n86. Panichi V, De Pietro S, Andreini B, et al. Calcitriol modulates in vivo and in vitro cytokine production: a","confidence":1,"confidence_rate":1},{"cnt":[[245,1620],[1399,1620],[1399,1665],[245,1665]],"region":{"top_left_x":244,"top_left_y":1619,"width":1155,"height":47},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c0c68d053b894b5cb7463413c2bc0819","type":"text","conversion_output":true,"text":"role for intracellular calcium. Kidney Int. Nov 1998;54(5):1463-1469.","text_display":" role for intracellular calcium. Kidney Int. Nov 1998;54(5):1463-1469.","confidence":1,"confidence_rate":1},{"cnt":[[120,1663],[1927,1663],[1927,1708],[120,1708]],"region":{"top_left_x":120,"top_left_y":1662,"width":1808,"height":47},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"76e1e75c43c24517afa560d18112e8b8","type":"text","conversion_output":true,"text":"87. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis. Oct 2005;12(4):353-365.","text_display":"\n87. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis. Oct 2005;12(4):353-365.","confidence":1,"confidence_rate":1},{"cnt":[[120,1706],[1934,1706],[1934,1755],[120,1755]],"region":{"top_left_x":120,"top_left_y":1705,"width":1814,"height":51},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"055a35130a754f7981031d8cc0a48a49","type":"text","conversion_output":true,"text":"88. Okamura DM, Himmelfarb J. Tipping the redox balance of oxidative stress in fibrogenic pathways in","text_display":"\n88. Okamura DM, Himmelfarb J. Tipping the redox balance of oxidative stress in fibrogenic pathways in","confidence":1,"confidence_rate":1},{"cnt":[[245,1749],[1158,1749],[1158,1798],[245,1798]],"region":{"top_left_x":244,"top_left_y":1748,"width":915,"height":51},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2eba3a333462419d807c742b15f97694","type":"text","conversion_output":true,"text":"chronic kidney disease. Pediatr Nephrol. May 72009.","text_display":" chronic kidney disease. Pediatr Nephrol. May 72009.","confidence":1,"confidence_rate":1},{"cnt":[[120,1794],[1880,1794],[1880,1841],[120,1841]],"region":{"top_left_x":120,"top_left_y":1793,"width":1760,"height":49},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d2baae2840204eca9acf57e3c352bab7","type":"text","conversion_output":true,"text":"89. Zehnder D, Quinkler M, Eardley KS, et al. Reduction of the vitamin D hormonal system in kidney","text_display":"\n89. Zehnder D, Quinkler M, Eardley KS, et al. Reduction of the vitamin D hormonal system in kidney","confidence":1,"confidence_rate":1},{"cnt":[[245,1839],[1895,1839],[1895,1884],[245,1884]],"region":{"top_left_x":244,"top_left_y":1839,"width":1651,"height":46},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6005b1d755a840528cb4125e614c16fa","type":"text","conversion_output":true,"text":"disease is associated with increased renal inflammation. Kidney Int. Nov 2008;74(10):1343-1353.","text_display":" disease is associated with increased renal inflammation. Kidney Int. Nov 2008;74(10):1343-1353.","confidence":0.9990234375,"confidence_rate":0.999990229651252},{"cnt":[[120,1882],[1919,1882],[1919,1929],[120,1929]],"region":{"top_left_x":120,"top_left_y":1882,"width":1799,"height":48},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"20abc6b9a7c244d69f155942f9dd0f89","type":"text","conversion_output":true,"text":"90. Abe E, Miyaura C, Sakagami H, et al. Differentiation of mouse myeloid leukemia cells induced by 1","text_display":"\n90. Abe E, Miyaura C, Sakagami H, et al. Differentiation of mouse myeloid leukemia cells induced by 1","confidence":1,"confidence_rate":1},{"cnt":[[245,1927],[1695,1927],[1695,1974],[245,1974]],"region":{"top_left_x":244,"top_left_y":1927,"width":1452,"height":48},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b64833131b3b4efdaa604f3e22a754ef","type":"text","conversion_output":true,"text":"alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A. Aug 1981;78(8):4990-4994.","text_display":" alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A. Aug 1981;78(8):4990-4994.","confidence":0.9521715641021729,"confidence_rate":0.9994302780969765},{"cnt":[[120,1970],[1972,1970],[1972,2017],[120,2017]],"region":{"top_left_x":120,"top_left_y":1970,"width":1853,"height":48},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"527c4e45955b4bd3bb1d1c5354975de6","type":"text","conversion_output":true,"text":"91. Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence","text_display":"\n91. Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence","confidence":1,"confidence_rate":1},{"cnt":[[245,2015],[1863,2015],[1863,2060],[245,2060]],"region":{"top_left_x":244,"top_left_y":2015,"width":1619,"height":46},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"545adf39fe574157b80643e4a0de7460","type":"text","conversion_output":true,"text":"of receptors and inhibition of cell growth in culture. Endocrinology. Mar 1981;108(3):1083-1086.","text_display":" of receptors and inhibition of cell growth in culture. Endocrinology. Mar 1981;108(3):1083-1086.","confidence":1,"confidence_rate":1},{"cnt":[[120,2058],[1790,2058],[1790,2108],[120,2108]],"region":{"top_left_x":120,"top_left_y":2058,"width":1670,"height":50},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"913579a1c22549fda7c860e5a47ffe81","type":"text","conversion_output":true,"text":"92. Beer TM, Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer Res. Jul-Aug","text_display":"\n92. Beer TM, Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer Res. Jul-Aug","confidence":1,"confidence_rate":1},{"cnt":[[245,2103],[668,2103],[668,2151],[245,2151]],"region":{"top_left_x":244,"top_left_y":2103,"width":425,"height":48},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b42131ddafa84732ae201d15761e6b49","type":"text","conversion_output":true,"text":"2006;26(4A):2647-2651.","text_display":" 2006;26(4A):2647-2651.","confidence":0.998046875,"confidence_rate":0.9999275939238241},{"cnt":[[120,2144],[1901,2144],[1901,2194],[120,2194]],"region":{"top_left_x":120,"top_left_y":2144,"width":1782,"height":50},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"62f322395127445da5689d251de3487e","type":"text","conversion_output":true,"text":"93. Gonzalez-Sancho JM, Larriba MJ, Ordonez-Moran P, Palmer HG, Munoz A. Effects of 1alpha,25-","text_display":"\n93. Gonzalez-Sancho JM, Larriba MJ, Ordonez-Moran P, Palmer HG, Munoz A. Effects of 1alpha,25","confidence":0.99609375,"confidence_rate":0.9999604664448944},{"cnt":[[245,2191],[1934,2191],[1934,2237],[245,2237]],"region":{"top_left_x":244,"top_left_y":2191,"width":1690,"height":46},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5f0a588b963d4e028c4f9f25eb38f3dc","type":"text","conversion_output":true,"text":"dihydroxyvitamin D3 in human colon cancer cells. Anticancer Res. Jul-Aug 2006;26(4A):2669-2681.","text_display":"dihydroxyvitamin D3 in human colon cancer cells. Anticancer Res. Jul-Aug 2006;26(4A):2669-2681.","confidence":1,"confidence_rate":1},{"cnt":[[120,2234],[1964,2234],[1964,2279],[120,2279]],"region":{"top_left_x":120,"top_left_y":2234,"width":1844,"height":46},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"97692c21b1184dbfaa1c820f98c47069","type":"text","conversion_output":true,"text":"94. Masuda S, Jones G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions.","text_display":"\n94. Masuda S, Jones G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions.","confidence":0.9990234375,"confidence_rate":0.9999910363736797},{"cnt":[[245,2277],[956,2277],[956,2325],[245,2325]],"region":{"top_left_x":244,"top_left_y":2277,"width":713,"height":48},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cafe2d1d2afd47688512ef3611dc06fc","type":"text","conversion_output":true,"text":"Mol Cancer Ther. Apr 2006;5(4):797-808.","text_display":" Mol Cancer Ther. Apr 2006;5(4):797-808.","confidence":0.9990236759185791,"confidence_rate":0.9999778002237774},{"cnt":[[120,2322],[1854,2322],[1854,2368],[120,2368]],"region":{"top_left_x":120,"top_left_y":2322,"width":1735,"height":46},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"360f0b76e24244aa991c131393b75694","type":"text","conversion_output":true,"text":"95. Branisteanu DD, Leenaerts P, van Damme B, Bouillon R. Partial prevention of active Heymann","text_display":"\n95. Branisteanu DD, Leenaerts P, van Damme B, Bouillon R. Partial prevention of active Heymann","confidence":1,"confidence_rate":1},{"cnt":[[245,2368],[1768,2368],[1768,2413],[245,2413]],"region":{"top_left_x":244,"top_left_y":2367,"width":1525,"height":46},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1d0ce969841143eb80909131fe6f00fa","type":"text","conversion_output":true,"text":"nephritis by 1 alpha, 25 dihydroxyvitamin D3. Clin Exp Immunol. Dec 1993;94(3):412-417.","text_display":" nephritis by 1 alpha, 25 dihydroxyvitamin D3. Clin Exp Immunol. Dec 1993;94(3):412-417.","confidence":0.9970729344058782,"confidence_rate":0.999970088632778},{"cnt":[[120,2411],[1962,2411],[1962,2456],[120,2456]],"region":{"top_left_x":120,"top_left_y":2410,"width":1842,"height":46},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cb27981dd690438dad181d94fd264af8","type":"text","conversion_output":true,"text":"96. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of \\(1,25( OH ) 2\\) vitamin D3","text_display":"\n96. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of \\(1,25( OH ) 2\\) vitamin D3","confidence":0.9829986674121756,"confidence_rate":0.9998441256544912},{"cnt":[[245,2454],[1865,2454],[1865,2501],[245,2501]],"region":{"top_left_x":244,"top_left_y":2453,"width":1621,"height":48},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"51b0d4592a2341f2bd7220baf6f9beb9","type":"text","conversion_output":true,"text":"on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int. Jun 1998;53(6):1696-1705.","text_display":" on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int. Jun 1998;53(6):1696-1705.","confidence":0.99951171875,"confidence_rate":0.9999950666738041},{"cnt":[[1955,2582],[2007,2582],[2007,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2582,"width":52,"height":46},"line":55,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bb8b008d79304a5586cd0af722f4e0e2","type":"page_info","conversion_output":false,"text":"27","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-28","page":28,"lines":[{"cnt":[[120,125],[1966,125],[1966,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":1846,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"90abd1d771664596b5360abe4f3cf031","type":"text","conversion_output":true,"text":"97. Panichi V, Migliori M, Taccola D, et al. Effects of \\(1,25( OH ) 2 D 3\\) in experimental mesangial proliferative","text_display":"\n97. Panichi V, Migliori M, Taccola D, et al. Effects of \\(1,25( OH ) 2 D 3\\) in experimental mesangial proliferative","confidence":0.8127765962854028,"confidence_rate":0.9982882518676254},{"cnt":[[245,172],[1089,172],[1089,217],[245,217]],"region":{"top_left_x":244,"top_left_y":171,"width":846,"height":46},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3c7670f1851a4976ab379fb9e32a117b","type":"text","conversion_output":true,"text":"nephritis in rats. Kidney Int. Jul 2001;60(1):87-95.","text_display":" nephritis in rats. Kidney Int. Jul 2001;60(1):87-95.","confidence":0.8473162651062012,"confidence_rate":0.9970975315654165},{"cnt":[[120,215],[1957,215],[1957,260],[120,260]],"region":{"top_left_x":120,"top_left_y":214,"width":1838,"height":46},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e50def8851f84debaa9e363dab170b5e","type":"text","conversion_output":true,"text":"98. Makibayashi K, Tatematsu M, Hirata M, et al. A vitamin D analog ameliorates glomerular injury on rat","text_display":"\n98. Makibayashi K, Tatematsu M, Hirata M, et al. A vitamin D analog ameliorates glomerular injury on rat","confidence":1,"confidence_rate":1},{"cnt":[[245,258],[1308,258],[1308,305],[245,305]],"region":{"top_left_x":244,"top_left_y":257,"width":1065,"height":49},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"82e2f3656165479f952a8390c5c0bfae","type":"text","conversion_output":true,"text":"glomerulonephritis. Am J Pathol. May 2001;158(5):1733-1741.","text_display":" glomerulonephritis. Am J Pathol. May 2001;158(5):1733-1741.","confidence":0.9990234375,"confidence_rate":0.9999847338720312},{"cnt":[[120,301],[1979,301],[1979,350],[120,350]],"region":{"top_left_x":120,"top_left_y":300,"width":1859,"height":51},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"07d625992eb74aacb89dae574aa2871a","type":"text","conversion_output":true,"text":"99. Hirata M, Makibayashi K, Katsumata K, et al. 22-Oxacalcitriol prevents progressive glomerulosclerosis","text_display":"\n99. Hirata M, Makibayashi K, Katsumata K, et al. 22-Oxacalcitriol prevents progressive glomerulosclerosis","confidence":1,"confidence_rate":1},{"cnt":[[245,348],[1910,348],[1910,393],[245,393]],"region":{"top_left_x":244,"top_left_y":348,"width":1666,"height":46},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ca0a625c9fa746959bcf176465902d4e","type":"text","conversion_output":true,"text":"without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats.","text_display":" without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats.","confidence":1,"confidence_rate":1},{"cnt":[[245,391],[1164,391],[1164,436],[245,436]],"region":{"top_left_x":244,"top_left_y":391,"width":921,"height":46},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"613ada07c0a14ed686fe81d7199f542b","type":"text","conversion_output":true,"text":"Nephrol Dial Transplant. Dec 2002;17(12):2132-2137.","text_display":" Nephrol Dial Transplant. Dec 2002;17(12):2132-2137.","confidence":0.9970703125,"confidence_rate":0.9999476087397059},{"cnt":[[122,434],[1880,434],[1880,479],[122,479]],"region":{"top_left_x":122,"top_left_y":433,"width":1758,"height":47},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3f02ab54484d4ac1bb330be96e3f66c3","type":"text","conversion_output":true,"text":"100. Kuhlmann A, Haas CS, Gross ML, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and","text_display":"\n100. Kuhlmann A, Haas CS, Gross ML, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and","confidence":1,"confidence_rate":1},{"cnt":[[245,477],[1811,477],[1811,524],[245,524]],"region":{"top_left_x":244,"top_left_y":476,"width":1568,"height":49},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"720155eeb49846299562e6c037ee3c1e","type":"text","conversion_output":true,"text":"podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol. Mar","text_display":" podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol. Mar","confidence":1,"confidence_rate":1},{"cnt":[[245,522],[642,522],[642,569],[245,569]],"region":{"top_left_x":244,"top_left_y":522,"width":399,"height":48},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7b98444da48f4da4abb05117e24ad52c","type":"text","conversion_output":true,"text":"2004;286(3):F526-533.","text_display":" 2004;286(3):F526-533.","confidence":1,"confidence_rate":1},{"cnt":[[122,563],[1833,563],[1833,612],[122,612]],"region":{"top_left_x":122,"top_left_y":562,"width":1711,"height":51},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7d7dfdb997a34581ae55b19aa346cd38","type":"text","conversion_output":true,"text":"101. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic","text_display":"\n101. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic","confidence":1,"confidence_rate":1},{"cnt":[[245,610],[988,610],[988,655],[245,655]],"region":{"top_left_x":244,"top_left_y":610,"width":745,"height":46},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"dfcb3ab694e04b349085d178e93e698c","type":"text","conversion_output":true,"text":"viewpoint. Kidney Int. Jul 2008;74(1):22-36.","text_display":" viewpoint. Kidney Int. Jul 2008;74(1):22-36.","confidence":0.9990234375,"confidence_rate":0.9999800606141427},{"cnt":[[122,653],[1983,653],[1983,700],[122,700]],"region":{"top_left_x":122,"top_left_y":653,"width":1862,"height":48},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"aa739adae6254173b1d91ce683fb838c","type":"text","conversion_output":true,"text":"102. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin","text_display":"\n102. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin","confidence":1,"confidence_rate":1},{"cnt":[[245,698],[1966,698],[1966,746],[245,746]],"region":{"top_left_x":244,"top_left_y":698,"width":1722,"height":48},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"59a52dfcec6746e2a5650db915a348a0","type":"text","conversion_output":true,"text":"D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc","text_display":" D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc","confidence":0.99951171875,"confidence_rate":0.999995211771286},{"cnt":[[245,743],[1210,743],[1210,788],[245,788]],"region":{"top_left_x":244,"top_left_y":743,"width":966,"height":46},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"471f4085c5804677908622e96b9cf7c7","type":"text","conversion_output":true,"text":"Natl Acad Sci U S A. Oct 14 2008;105(41):15896-15901.","text_display":" Natl Acad Sci U S A. Oct 14 2008;105(41):15896-15901.","confidence":0.99951171875,"confidence_rate":0.9999919934665097},{"cnt":[[122,786],[1970,786],[1970,831],[122,831]],"region":{"top_left_x":122,"top_left_y":786,"width":1849,"height":46},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8097453159654f68956bf385c2710d37","type":"text","conversion_output":true,"text":"103. Verrotti A, Basciani F, Carle F, Morgese G, Chiarelli F. Calcium metabolism in adolescents and young","text_display":"\n103. Verrotti A, Basciani F, Carle F, Morgese G, Chiarelli F. Calcium metabolism in adolescents and young","confidence":1,"confidence_rate":1},{"cnt":[[245,829],[1962,829],[1962,874],[245,874]],"region":{"top_left_x":244,"top_left_y":829,"width":1718,"height":46},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"65ebdf9fb51d477f80cb2d100562ec3d","type":"text","conversion_output":true,"text":"adults with type 1 diabetes mellitus without and with persistent microalbuminuria. J Endocrinol Invest.","text_display":" adults with type 1 diabetes mellitus without and with persistent microalbuminuria. J Endocrinol Invest.","confidence":0.9990236759185791,"confidence_rate":0.9999912000297451},{"cnt":[[245,872],[677,872],[677,920],[245,920]],"region":{"top_left_x":244,"top_left_y":872,"width":433,"height":48},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"dc761601c84d4f1aae84345bf64351d6","type":"text","conversion_output":true,"text":"Mar 1999;22(3):198-202.","text_display":" Mar 1999;22(3):198-202.","confidence":1,"confidence_rate":1},{"cnt":[[122,915],[2000,915],[2000,965],[122,965]],"region":{"top_left_x":122,"top_left_y":915,"width":1879,"height":50},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"caf395f2ccb84ee3b25c8142ed910811","type":"text","conversion_output":true,"text":"104. Inukai T, Fujiwara Y, Tayama K, Aso Y, Takemura Y. Alterations in serum levels of 1 alpha,25(OH)2 D3","text_display":"\n104. Inukai T, Fujiwara Y, Tayama K, Aso Y, Takemura Y. Alterations in serum levels of 1 alpha,25(OH)2 D3","confidence":0.99560546875,"confidence_rate":0.9999610254003707},{"cnt":[[245,958],[1751,958],[1751,1008],[245,1008]],"region":{"top_left_x":244,"top_left_y":958,"width":1507,"height":50},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"af48fc697db548dcae4796d6c6b7b5e8","type":"text","conversion_output":true,"text":"and osteocalcin in patients with early diabetic nephropathy. Diabetes Res Clin Pract. Oct","text_display":" and osteocalcin in patients with early diabetic nephropathy. Diabetes Res Clin Pract. Oct","confidence":0.99951171875,"confidence_rate":0.999994804263518},{"cnt":[[245,1005],[556,1005],[556,1051],[245,1051]],"region":{"top_left_x":244,"top_left_y":1005,"width":313,"height":46},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0960821dce614fc5b67f22332d9af13d","type":"text","conversion_output":true,"text":"1997;38(1):53-59.","text_display":" 1997;38(1):53-59.","confidence":1,"confidence_rate":1},{"cnt":[[122,1048],[1901,1048],[1901,1094],[122,1094]],"region":{"top_left_x":122,"top_left_y":1048,"width":1780,"height":46},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f217c3e943c147b2bf43f19a172416df","type":"text","conversion_output":true,"text":"105. de Boer IH, loannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and","text_display":"\n105. de Boer IH, loannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and","confidence":0.99462890625,"confidence_rate":0.9999466789470377},{"cnt":[[245,1091],[1981,1091],[1981,1141],[245,1141]],"region":{"top_left_x":244,"top_left_y":1091,"width":1737,"height":50},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d049df6e60084481adfcefa9432ea202","type":"text","conversion_output":true,"text":"albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney","text_display":" albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney","confidence":1,"confidence_rate":1},{"cnt":[[245,1137],[694,1137],[694,1184],[245,1184]],"region":{"top_left_x":244,"top_left_y":1136,"width":450,"height":48},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"25b6bd13905d4b4981103653dc70919a","type":"text","conversion_output":true,"text":"Dis. Jul 2007;50(1):69-77.","text_display":" Dis. Jul 2007;50(1):69-77.","confidence":1,"confidence_rate":1},{"cnt":[[122,1179],[1979,1179],[1979,1227],[122,1227]],"region":{"top_left_x":122,"top_left_y":1179,"width":1857,"height":48},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5bb53bf481a648bfb52ff13cb08e7276","type":"text","conversion_output":true,"text":"106. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease.","text_display":"\n106. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease.","confidence":1,"confidence_rate":1},{"cnt":[[245,1225],[913,1225],[913,1270],[245,1270]],"region":{"top_left_x":244,"top_left_y":1224,"width":670,"height":46},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d79dc323638f490d9d2c308e3164005f","type":"text","conversion_output":true,"text":"Kidney Int. Dec 2005;68(6):2823-2828.","text_display":" Kidney Int. Dec 2005;68(6):2823-2828.","confidence":0.9990234375,"confidence_rate":0.9999767374218201},{"cnt":[[122,1268],[1923,1268],[1923,1313],[122,1313]],"region":{"top_left_x":122,"top_left_y":1267,"width":1801,"height":46},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c4f5b4cd90064f7c9c95c4e1f6a94d78","type":"text","conversion_output":true,"text":"107. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic","text_display":"\n107. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic","confidence":1,"confidence_rate":1},{"cnt":[[245,1311],[1824,1311],[1824,1360],[245,1360]],"region":{"top_left_x":244,"top_left_y":1310,"width":1581,"height":50},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"016d552e86bf4782bac3e34f91cffb38","type":"text","conversion_output":true,"text":"kidney disease: a randomized double-blind pilot trial. Hypertension. Aug 2008;52(2):249-255.","text_display":" kidney disease: a randomized double-blind pilot trial. Hypertension. Aug 2008;52(2):249-255.","confidence":1,"confidence_rate":1},{"cnt":[[122,1354],[1919,1354],[1919,1403],[122,1403]],"region":{"top_left_x":122,"top_left_y":1353,"width":1797,"height":50},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ee25351ff4a646bda16ea918d5675ae9","type":"text","conversion_output":true,"text":"108. Lambers Heerspink HJ, Agarwal R, Coyne DW, et al. The selective vitamin D receptor activator for","text_display":"\n108. Lambers Heerspink HJ, Agarwal R, Coyne DW, et al. The selective vitamin D receptor activator for","confidence":1,"confidence_rate":1},{"cnt":[[245,1401],[1828,1401],[1828,1446],[245,1446]],"region":{"top_left_x":244,"top_left_y":1400,"width":1585,"height":46},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b83b33b33b9e4fb1bceb60a39c940751","type":"text","conversion_output":true,"text":"albuminuria lowering (VITAL) study: study design and baseline characteristics. Am J Nephrol.","text_display":" albuminuria lowering (VITAL) study: study design and baseline characteristics. Am J Nephrol.","confidence":1,"confidence_rate":1},{"cnt":[[245,1444],[599,1444],[599,1489],[245,1489]],"region":{"top_left_x":244,"top_left_y":1443,"width":356,"height":46},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"05e01fa5c27846339c480c7e3abc0b9a","type":"text","conversion_output":true,"text":"2009;30(3):280-286.","text_display":" 2009;30(3):280-286.","confidence":0.99951171875,"confidence_rate":0.9999796501863057},{"cnt":[[122,1487],[1974,1487],[1974,1536],[122,1536]],"region":{"top_left_x":122,"top_left_y":1486,"width":1853,"height":51},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3e8b0c9792ae44ab8b4d628319613dd1","type":"text","conversion_output":true,"text":"109. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National","text_display":"\n109. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National","confidence":0.9946331977844238,"confidence_rate":0.9999510806944721},{"cnt":[[245,1532],[1717,1532],[1717,1577],[245,1577]],"region":{"top_left_x":244,"top_left_y":1531,"width":1473,"height":46},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"17a8f8280159442bb5aa7ca65f0b5462","type":"text","conversion_output":true,"text":"Health and Nutrition Examination Survey. Diabetes Care. Dec 2004;27(12):2813-2818.","text_display":" Health and Nutrition Examination Survey. Diabetes Care. Dec 2004;27(12):2813-2818.","confidence":1,"confidence_rate":1},{"cnt":[[122,1575],[1979,1575],[1979,1622],[122,1622]],"region":{"top_left_x":122,"top_left_y":1574,"width":1857,"height":49},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bf0d34256d4343218e52c1bb47909452","type":"text","conversion_output":true,"text":"110. Young BA, Katon WJ, Von Korff M, et al. Racial and ethnic differences in microalbuminuria prevalence","text_display":"\n110. Young BA, Katon WJ, Von Korff M, et al. Racial and ethnic differences in microalbuminuria prevalence","confidence":1,"confidence_rate":1},{"cnt":[[245,1620],[1772,1620],[1772,1665],[245,1665]],"region":{"top_left_x":244,"top_left_y":1619,"width":1529,"height":47},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"32b313a76d9f485faef726557e83d90f","type":"text","conversion_output":true,"text":"in a diabetes population: the pathways study. J Am Soc Nephrol. Jan 2005;16(1):219-228.","text_display":" in a diabetes population: the pathways study. J Am Soc Nephrol. Jan 2005;16(1):219-228.","confidence":1,"confidence_rate":1},{"cnt":[[122,1663],[1979,1663],[1979,1710],[122,1710]],"region":{"top_left_x":122,"top_left_y":1662,"width":1857,"height":49},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b11fed34143b4bbab088c63b7bc4e7a1","type":"text","conversion_output":true,"text":"111. Bryson CL, Ross HJ, Boyko EJ, Young BA. Racial and ethnic variations in albuminuria in the US Third","text_display":"\n111. Bryson CL, Ross HJ, Boyko EJ, Young BA. Racial and ethnic variations in albuminuria in the US Third","confidence":1,"confidence_rate":1},{"cnt":[[245,1706],[1983,1706],[1983,1755],[245,1755]],"region":{"top_left_x":244,"top_left_y":1705,"width":1740,"height":51},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"033ee304f9f54ea2aeadd9734e844792","type":"text","conversion_output":true,"text":"National Health and Nutrition Examination Survey (NHANES III) population: associations with diabetes","text_display":" National Health and Nutrition Examination Survey (NHANES III) population: associations with diabetes","confidence":0.99951171875,"confidence_rate":0.9999953485775026},{"cnt":[[245,1749],[1291,1749],[1291,1798],[245,1798]],"region":{"top_left_x":244,"top_left_y":1748,"width":1048,"height":51},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7822b4eb72be4ac29f47b6eab614cf25","type":"text","conversion_output":true,"text":"and level of CKD. Am J Kidney Dis. Nov 2006;48(5):720-726.","text_display":" and level of CKD. Am J Kidney Dis. Nov 2006;48(5):720-726.","confidence":1,"confidence_rate":1},{"cnt":[[120,1794],[1936,1794],[1936,1841],[120,1841]],"region":{"top_left_x":120,"top_left_y":1793,"width":1816,"height":49},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f653bbf2887c40429ea9ff1cff0ac61a","type":"text","conversion_output":true,"text":"112. Gao SW, Oliver DK, Das N, et al. Assessment of racial disparities in chronic kidney disease stage 3","text_display":"\n112. Gao SW, Oliver DK, Das N, et al. Assessment of racial disparities in chronic kidney disease stage 3","confidence":1,"confidence_rate":1},{"cnt":[[245,1839],[1934,1839],[1934,1886],[245,1886]],"region":{"top_left_x":244,"top_left_y":1839,"width":1690,"height":48},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e1c5d7623f8249a6bcf57610e9a2b980","type":"text","conversion_output":true,"text":"and 4 care in the department of defense health system. Clin J Am Soc Nephrol. Mar 2008;3(2):442-","text_display":" and 4 care in the department of defense health system. Clin J Am Soc Nephrol. Mar 2008;3(2):442","confidence":0.68115234375,"confidence_rate":0.996314794675836},{"cnt":[[245,1882],[329,1882],[329,1923],[245,1923]],"region":{"top_left_x":244,"top_left_y":1882,"width":85,"height":41},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b659001945ed46dd99c4fbc7cea120fd","type":"text","conversion_output":true,"text":"449.","text_display":"449.","confidence":1,"confidence_rate":1},{"cnt":[[120,1925],[1888,1925],[1888,1974],[120,1974]],"region":{"top_left_x":120,"top_left_y":1925,"width":1769,"height":50},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0481529a6b6e4b9b8f1b4093ee711ceb","type":"text","conversion_output":true,"text":"113. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Hernandez GT, O'Hare AM. White/black racial","text_display":"\n113. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Hernandez GT, O'Hare AM. White/black racial","confidence":0.99951171875,"confidence_rate":0.9999952582588333},{"cnt":[[245,1972],[1835,1972],[1835,2017],[245,2017]],"region":{"top_left_x":244,"top_left_y":1972,"width":1591,"height":46},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e1ef4b1bdf634fdd976606deaa45a46c","type":"text","conversion_output":true,"text":"differences in risk of end-stage renal disease and death. Am J Med. Jul 2009;122(7):672-678.","text_display":" differences in risk of end-stage renal disease and death. Am J Med. Jul 2009;122(7):672-678.","confidence":1,"confidence_rate":1},{"cnt":[[120,2015],[1992,2015],[1992,2065],[120,2065]],"region":{"top_left_x":120,"top_left_y":2015,"width":1872,"height":50},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7ec0891132fe4e6cb92dc7f7e5b391f8","type":"text","conversion_output":true,"text":"114. Nettleton JA, Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet","text_display":"\n114. Nettleton JA, Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet","confidence":0.5578954219818115,"confidence_rate":0.9950245235942538},{"cnt":[[245,2058],[823,2058],[823,2105],[245,2105]],"region":{"top_left_x":244,"top_left_y":2058,"width":579,"height":48},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fa35923545e94dc084a078dda0ac9cde","type":"text","conversion_output":true,"text":"Assoc. Mar 2005;105(3):428-440.","text_display":" Assoc. Mar 2005;105(3):428-440.","confidence":1,"confidence_rate":1},{"cnt":[[120,2101],[1989,2101],[1989,2151],[120,2151]],"region":{"top_left_x":120,"top_left_y":2101,"width":1870,"height":50},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6517cafa46bb4410b1505612fbb859da","type":"text","conversion_output":true,"text":"115. Siscovick DS, Raghunathan T, King I, et al. Dietary intake of long-chain \\(n -3\\) polyunsaturated fatty acids","text_display":"\n115. Siscovick DS, Raghunathan T, King I, et al. Dietary intake of long-chain \\(n -3\\) polyunsaturated fatty acids","confidence":0.7776889730945802,"confidence_rate":0.9979069550444165},{"cnt":[[245,2144],[1740,2144],[1740,2194],[245,2194]],"region":{"top_left_x":244,"top_left_y":2144,"width":1497,"height":50},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3448a6befc174f33b770102e106d74b2","type":"text","conversion_output":true,"text":"and the risk of primary cardiac arrest. Am J Clin Nutr. Jan 2000;71(1 Suppl):208S-212S.","text_display":" and the risk of primary cardiac arrest. Am J Clin Nutr. Jan 2000;71(1 Suppl):208S-212S.","confidence":0.9868490420120679,"confidence_rate":0.9998561169006898},{"cnt":[[122,2189],[1996,2189],[1996,2237],[122,2237]],"region":{"top_left_x":122,"top_left_y":2189,"width":1874,"height":48},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2ef3420c9192454caab8056dc3744db0","type":"text","conversion_output":true,"text":"116. Hu FB, Cho E, Rexrode KM, Albert CM, Manson JE. Fish and long-chain omega-3 fatty acid intake and","text_display":"\n116. Hu FB, Cho E, Rexrode KM, Albert CM, Manson JE. Fish and long-chain omega-3 fatty acid intake and","confidence":0.984375,"confidence_rate":0.9998528299243339},{"cnt":[[245,2234],[1721,2234],[1721,2282],[245,2282]],"region":{"top_left_x":244,"top_left_y":2234,"width":1477,"height":48},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3c2945d8c3bb4bdfade454886b0d9211","type":"text","conversion_output":true,"text":"risk of coronary heart disease and total mortality in diabetic women. Circulation. Apr 15","text_display":" risk of coronary heart disease and total mortality in diabetic women. Circulation. Apr 15","confidence":1,"confidence_rate":1},{"cnt":[[245,2277],[685,2277],[685,2325],[245,2325]],"region":{"top_left_x":244,"top_left_y":2277,"width":442,"height":48},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1e6848bf934e427291c5899b17cfda51","type":"text","conversion_output":true,"text":"2003;107(14):1852-1857.","text_display":" 2003;107(14):1852-1857.","confidence":0.9990234375,"confidence_rate":0.9999651063356614},{"cnt":[[120,2322],[1888,2322],[1888,2370],[120,2370]],"region":{"top_left_x":120,"top_left_y":2322,"width":1769,"height":48},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d88145d227e148b296afde243c9c3437","type":"text","conversion_output":true,"text":"117. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary","text_display":"\n117. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary","confidence":1,"confidence_rate":1},{"cnt":[[245,2368],[1983,2368],[1983,2413],[245,2413]],"region":{"top_left_x":244,"top_left_y":2367,"width":1740,"height":46},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1ac84c5acf3642aaaf66c789044a53a1","type":"text","conversion_output":true,"text":"events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.","text_display":" events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.","confidence":0.9990236759185791,"confidence_rate":0.9999907849387211},{"cnt":[[245,2411],[993,2411],[993,2456],[245,2456]],"region":{"top_left_x":244,"top_left_y":2410,"width":749,"height":46},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"76b3aab1507b42629f915054c71d5008","type":"text","conversion_output":true,"text":"Lancet. Mar 31 2007;369(9567):1090-1098.","text_display":" Lancet. Mar 31 2007;369(9567):1090-1098.","confidence":1,"confidence_rate":1},{"cnt":[[1955,2582],[2007,2582],[2007,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2582,"width":52,"height":46},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a36522f3903e4d959bb6965ac4aa370a","type":"page_info","conversion_output":false,"text":"28","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-29","page":29,"lines":[{"cnt":[[120,125],[1912,125],[1912,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":1793,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"84bb4acb431742a9b1574ae48f21849b","type":"text","conversion_output":true,"text":"118. McVeigh GE, Brennan GM, Johnston GD, et al. Dietary fish oil augments nitric oxide production or","text_display":"\n118. McVeigh GE, Brennan GM, Johnston GD, et al. Dietary fish oil augments nitric oxide production or","confidence":0.99951171875,"confidence_rate":0.9999953924587458},{"cnt":[[245,168],[1783,168],[1783,217],[245,217]],"region":{"top_left_x":244,"top_left_y":167,"width":1540,"height":50},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7ab13a93f1fd4b30a55d2aabaef5802a","type":"text","conversion_output":true,"text":"release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. Jan","text_display":" release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. Jan","confidence":1,"confidence_rate":1},{"cnt":[[245,215],[556,215],[556,260],[245,260]],"region":{"top_left_x":244,"top_left_y":214,"width":313,"height":46},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b18320e13b0147beb55a5cd9a85f44f3","type":"text","conversion_output":true,"text":"1993;36(1):33-38.","text_display":" 1993;36(1):33-38.","confidence":1,"confidence_rate":1},{"cnt":[[120,258],[1886,258],[1886,305],[120,305]],"region":{"top_left_x":120,"top_left_y":257,"width":1767,"height":49},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"050a4f378d944690bf07356d5c88e8bb","type":"text","conversion_output":true,"text":"119. Abe Y, El-Masri B, Kimball KT, et al. Soluble cell adhesion molecules in hypertriglyceridemia and","text_display":"\n119. Abe Y, El-Masri B, Kimball KT, et al. Soluble cell adhesion molecules in hypertriglyceridemia and","confidence":0.989750862121582,"confidence_rate":0.9999037240558876},{"cnt":[[245,301],[1981,301],[1981,350],[245,350]],"region":{"top_left_x":244,"top_left_y":300,"width":1737,"height":51},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b38a60fe9b18447fba7827e85f911301","type":"text","conversion_output":true,"text":"potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol. May 1998;18(5):723-731.","text_display":" potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol. May 1998;18(5):723-731.","confidence":1,"confidence_rate":1},{"cnt":[[120,346],[1953,346],[1953,393],[120,393]],"region":{"top_left_x":120,"top_left_y":345,"width":1833,"height":49},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6bae7fec282c4599b210c7f236ddc5c7","type":"text","conversion_output":true,"text":"120. Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ. Effect of eicosapentaenoic acid and","text_display":"\n120. Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ. Effect of eicosapentaenoic acid and","confidence":1,"confidence_rate":1},{"cnt":[[245,389],[1927,389],[1927,436],[245,436]],"region":{"top_left_x":244,"top_left_y":388,"width":1684,"height":49},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4afecf551d0644d48cdbf189a54820ff","type":"text","conversion_output":true,"text":"docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2","text_display":" docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2","confidence":1,"confidence_rate":1},{"cnt":[[245,434],[1373,434],[1373,479],[245,479]],"region":{"top_left_x":244,"top_left_y":433,"width":1129,"height":47},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"38cc004aa0904d4e8a54377e35051bdf","type":"text","conversion_output":true,"text":"diabetic subjects. Free Radic Biol Med. Oct 1 2003;35(7):772-781.","text_display":" diabetic subjects. Free Radic Biol Med. Oct 1 2003;35(7):772-781.","confidence":1,"confidence_rate":1},{"cnt":[[120,477],[2002,477],[2002,524],[120,524]],"region":{"top_left_x":120,"top_left_y":476,"width":1883,"height":49},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f712e5195c2a44ea8a566b2ddee91094","type":"text","conversion_output":true,"text":"121. Kesavulu MM, Kameswararao B, Apparao C, Kumar EG, Harinarayan CV. Effect of omega-3 fatty acids","text_display":"\n121. Kesavulu MM, Kameswararao B, Apparao C, Kumar EG, Harinarayan CV. Effect of omega-3 fatty acids","confidence":0.9980475902557373,"confidence_rate":0.9999813876191115},{"cnt":[[245,520],[1940,520],[1940,569],[245,569]],"region":{"top_left_x":244,"top_left_y":519,"width":1697,"height":51},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a50033f680c247c5b030a8b9a7d70796","type":"text","conversion_output":true,"text":"on lipid peroxidation and antioxidant enzyme status in type 2 diabetic patients. Diabetes Metab. Feb","text_display":" on lipid peroxidation and antioxidant enzyme status in type 2 diabetic patients. Diabetes Metab. Feb","confidence":1,"confidence_rate":1},{"cnt":[[245,563],[559,563],[559,612],[245,612]],"region":{"top_left_x":244,"top_left_y":562,"width":315,"height":51},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7677eafe1d3f4fcd930e77f8c56c5af0","type":"text","conversion_output":true,"text":"2002;28(1):20-26.","text_display":" 2002;28(1):20-26.","confidence":0.97607421875,"confidence_rate":0.9988998487170482},{"cnt":[[120,608],[1949,608],[1949,655],[120,655]],"region":{"top_left_x":120,"top_left_y":608,"width":1829,"height":48},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"31ae86a5b2b1491c9813133ff422d158","type":"text","conversion_output":true,"text":"122. Jain S, Gaiha M, Bhattacharjee J, Anuradha S. Effects of low-dose omega-3 fatty acid substitution in","text_display":"\n122. Jain S, Gaiha M, Bhattacharjee J, Anuradha S. Effects of low-dose omega-3 fatty acid substitution in","confidence":0.9873046875,"confidence_rate":0.9998838559581599},{"cnt":[[243,653],[1949,653],[1949,700],[243,700]],"region":{"top_left_x":242,"top_left_y":653,"width":1707,"height":48},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"de727d6475fc446086c9b0573f0ac2f0","type":"text","conversion_output":true,"text":"type-2 diabetes mellitus with special reference to oxidative stress--a prospective preliminary study. J","text_display":" type-2 diabetes mellitus with special reference to oxidative stress--a prospective preliminary study. J","confidence":0.8592934023533871,"confidence_rate":0.9985968663080933},{"cnt":[[245,696],[1085,696],[1085,746],[245,746]],"region":{"top_left_x":244,"top_left_y":696,"width":841,"height":50},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c2f3e6dec6a4496fba7fe6f9435175d2","type":"text","conversion_output":true,"text":"Assoc Physicians India. Aug 2002;50:1028-1033.","text_display":" Assoc Physicians India. Aug 2002;50:1028-1033.","confidence":0.99951171875,"confidence_rate":0.9999904235654993},{"cnt":[[120,741],[1953,741],[1953,788],[120,788]],"region":{"top_left_x":120,"top_left_y":741,"width":1833,"height":48},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"498e684a3f5b4dfb8e485b8c01a6528e","type":"text","conversion_output":true,"text":"123. Hagiwara S, Makita Y, Gu L, et al. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2","text_display":"\n123. Hagiwara S, Makita Y, Gu L, et al. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2","confidence":1,"confidence_rate":1},{"cnt":[[245,786],[1807,786],[1807,831],[245,831]],"region":{"top_left_x":244,"top_left_y":786,"width":1563,"height":46},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5700b10bc2f349b58dfdf146147971f4","type":"text","conversion_output":true,"text":"diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38","text_display":" diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38","confidence":1,"confidence_rate":1},{"cnt":[[245,829],[1390,829],[1390,879],[245,879]],"region":{"top_left_x":244,"top_left_y":829,"width":1147,"height":50},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a6886c05f4fd471ea0919ed0cb7e5e8f","type":"text","conversion_output":true,"text":"phosphorylation. Nephrol Dial Transplant. Mar 2006;21(3):605-615.","text_display":" phosphorylation. Nephrol Dial Transplant. Mar 2006;21(3):605-615.","confidence":1,"confidence_rate":1},{"cnt":[[120,872],[1876,872],[1876,922],[120,922]],"region":{"top_left_x":120,"top_left_y":872,"width":1756,"height":50},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e61a8b7fde2b4b2cb8b13f0e83bf62df","type":"text","conversion_output":true,"text":"124. Garman JH, Mulroney S, Manigrasso M, Flynn E, Maric C. Omega-3 fatty acid rich diet prevents","text_display":"\n124. Garman JH, Mulroney S, Manigrasso M, Flynn E, Maric C. Omega-3 fatty acid rich diet prevents","confidence":1,"confidence_rate":1},{"cnt":[[245,915],[1601,915],[1601,965],[245,965]],"region":{"top_left_x":244,"top_left_y":915,"width":1357,"height":50},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e150b3389d834228884890a3e49108b9","type":"text","conversion_output":true,"text":"diabetic renal disease. Am J Physiol Renal Physiol. Feb 2009;296(2):F306-316.","text_display":" diabetic renal disease. Am J Physiol Renal Physiol. Feb 2009;296(2):F306-316.","confidence":1,"confidence_rate":1},{"cnt":[[120,958],[1878,958],[1878,1008],[120,1008]],"region":{"top_left_x":120,"top_left_y":958,"width":1758,"height":50},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5791ee5e09ae43c68bdfb678a86174d7","type":"text","conversion_output":true,"text":"125. An WS, Kim HJ, Cho KH, Vaziri ND. Omega-3 Fatty Acid Supplementation Attenuates Oxidative","text_display":"\n125. An WS, Kim HJ, Cho KH, Vaziri ND. Omega-3 Fatty Acid Supplementation Attenuates Oxidative","confidence":1,"confidence_rate":1},{"cnt":[[245,1003],[1880,1003],[1880,1051],[245,1051]],"region":{"top_left_x":244,"top_left_y":1003,"width":1636,"height":48},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0560d81770e1486aa2cf4334a63f5770","type":"text","conversion_output":true,"text":"Stress, Inflammation and Tubulo-Interstitial Fibrosis in the Remnant Kidney. Am J Physiol Renal","text_display":" Stress, Inflammation and Tubulo-Interstitial Fibrosis in the Remnant Kidney. Am J Physiol Renal","confidence":1,"confidence_rate":1},{"cnt":[[245,1044],[604,1044],[604,1094],[245,1094]],"region":{"top_left_x":244,"top_left_y":1044,"width":360,"height":50},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9ceb7819af3349d09a0efae0a92dc895","type":"text","conversion_output":true,"text":"Physiol. Aug 52009.","text_display":" Physiol. Aug 52009.","confidence":1,"confidence_rate":1},{"cnt":[[122,1091],[1863,1091],[1863,1141],[122,1141]],"region":{"top_left_x":122,"top_left_y":1091,"width":1741,"height":50},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"56a062e1c1374c93998a6249d459d514","type":"text","conversion_output":true,"text":"126. Lee CT, Adler AI, Forouhi NG, et al. Cross-sectional association between fish consumption and","text_display":"\n126. Lee CT, Adler AI, Forouhi NG, et al. Cross-sectional association between fish consumption and","confidence":0.9716796875,"confidence_rate":0.9997211159008306},{"cnt":[[245,1134],[1949,1134],[1949,1184],[245,1184]],"region":{"top_left_x":244,"top_left_y":1134,"width":1705,"height":50},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"549b00d01b14408085812825cf2b4936","type":"text","conversion_output":true,"text":"albuminuria: the European Prospective Investigation of Cancer-Norfolk Study. Am J Kidney Dis. Nov","text_display":" albuminuria: the European Prospective Investigation of Cancer-Norfolk Study. Am J Kidney Dis. Nov","confidence":0.98095703125,"confidence_rate":0.9998115214766182},{"cnt":[[245,1177],[599,1177],[599,1227],[245,1227]],"region":{"top_left_x":244,"top_left_y":1177,"width":356,"height":50},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"28caf7c4796b46ddbf8fde8c8fdfa1fb","type":"text","conversion_output":true,"text":"2008;52(5):876-886.","text_display":" 2008;52(5):876-886.","confidence":1,"confidence_rate":1},{"cnt":[[120,1225],[1992,1225],[1992,1270],[120,1270]],"region":{"top_left_x":120,"top_left_y":1224,"width":1872,"height":46},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5849b946182543cdb7f245f4a77a8ce9","type":"text","conversion_output":true,"text":"127. Lauretani F, Semba RD, Bandinelli S, et al. Plasma polyunsaturated fatty acids and the decline of renal","text_display":"\n127. Lauretani F, Semba RD, Bandinelli S, et al. Plasma polyunsaturated fatty acids and the decline of renal","confidence":1,"confidence_rate":1},{"cnt":[[243,1268],[1033,1268],[1033,1317],[243,1317]],"region":{"top_left_x":242,"top_left_y":1267,"width":792,"height":50},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"21b092c1ce2c4470ae13ee1e10d40343","type":"text","conversion_output":true,"text":"function. Clin Chem. Mar 2008;54(3):475-481.","text_display":" function. Clin Chem. Mar 2008;54(3):475-481.","confidence":0.99951171875,"confidence_rate":0.9999900326925697},{"cnt":[[120,1311],[1940,1311],[1940,1360],[120,1360]],"region":{"top_left_x":120,"top_left_y":1310,"width":1821,"height":50},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"26c3b6b6670d4dc98ec981ad736ddf59","type":"text","conversion_output":true,"text":"128. Miller ER, 3rd, Juraschek SP, Appel LJ, et al. The effect of \\(n-3\\) long-chain polyunsaturated fatty acid","text_display":"\n128. Miller ER, 3rd, Juraschek SP, Appel LJ, et al. The effect of \\(n-3\\) long-chain polyunsaturated fatty acid","confidence":0.9592829772736877,"confidence_rate":0.9996385942596522},{"cnt":[[245,1354],[1944,1354],[1944,1403],[245,1403]],"region":{"top_left_x":244,"top_left_y":1353,"width":1701,"height":50},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bca7eb09a3524098909b68b422433494","type":"text","conversion_output":true,"text":"supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials. AmJ","text_display":" supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials. AmJ","confidence":0.5382871627807617,"confidence_rate":0.9941739892796393},{"cnt":[[245,1401],[885,1401],[885,1446],[245,1446]],"region":{"top_left_x":244,"top_left_y":1400,"width":642,"height":46},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"783e09027a3e45b69576126f21bf5bb1","type":"text","conversion_output":true,"text":"Clin Nutr. Jun 2009;89(6):1937-1945.","text_display":" Clin Nutr. Jun 2009;89(6):1937-1945.","confidence":1,"confidence_rate":1},{"cnt":[[120,1444],[1835,1444],[1835,1491],[120,1491]],"region":{"top_left_x":120,"top_left_y":1443,"width":1715,"height":49},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"450fd59422e14adc97c24e79caebc7b2","type":"text","conversion_output":true,"text":"129. Haines AP, Sanders TA, Imeson JD, et al. Effects of a fish oil supplement on platelet function,","text_display":"\n129. Haines AP, Sanders TA, Imeson JD, et al. Effects of a fish oil supplement on platelet function,","confidence":1,"confidence_rate":1},{"cnt":[[245,1487],[1794,1487],[1794,1536],[245,1536]],"region":{"top_left_x":244,"top_left_y":1486,"width":1550,"height":51},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f55fc0eb7b224f18b36e8318438f0da1","type":"text","conversion_output":true,"text":"haemostatic variables and albuminuria in insulin-dependent diabetics. Thromb Res. Sep 15","text_display":" haemostatic variables and albuminuria in insulin-dependent diabetics. Thromb Res. Sep 15","confidence":0.99951171875,"confidence_rate":0.9999946913130248},{"cnt":[[245,1530],[599,1530],[599,1577],[245,1577]],"region":{"top_left_x":244,"top_left_y":1529,"width":356,"height":48},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"802040c7323f4cfd850a536fb5f6f79d","type":"text","conversion_output":true,"text":"1986;43(6):643-655.","text_display":" 1986;43(6):643-655.","confidence":0.9956073760986328,"confidence_rate":0.9998165876629644},{"cnt":[[122,1573],[1987,1573],[1987,1622],[122,1622]],"region":{"top_left_x":122,"top_left_y":1572,"width":1866,"height":51},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ce83afb08ac04ce6a09cf335d066f5f9","type":"text","conversion_output":true,"text":"130. Jensen T, Stender S, Goldstein K, Holmer G, Deckert T. Partial normalization by dietary cod-liver oil of","text_display":"\n130. Jensen T, Stender S, Goldstein K, Holmer G, Deckert T. Partial normalization by dietary cod-liver oil of","confidence":0.99951171875,"confidence_rate":0.9999957157942815},{"cnt":[[245,1620],[1981,1620],[1981,1665],[245,1665]],"region":{"top_left_x":244,"top_left_y":1619,"width":1737,"height":47},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cfa4dc41fed647a4a3305bd9671b0233","type":"text","conversion_output":true,"text":"increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria.","text_display":" increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria.","confidence":1,"confidence_rate":1},{"cnt":[[245,1663],[1046,1663],[1046,1710],[245,1710]],"region":{"top_left_x":244,"top_left_y":1662,"width":803,"height":49},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"624f9e9900d548e0ac45d741a3c52b9b","type":"text","conversion_output":true,"text":"N Engl J Med. Dec 7 1989;321(23):1572-1577.","text_display":" N Engl J Med. Dec 7 1989;321(23):1572-1577.","confidence":0.99951171875,"confidence_rate":0.9999904235654993},{"cnt":[[120,1706],[1981,1706],[1981,1751],[120,1751]],"region":{"top_left_x":120,"top_left_y":1705,"width":1861,"height":46},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8b86567975714a00a83d6a6e2da80a61","type":"text","conversion_output":true,"text":"131. Hamazaki T, Takazakura E, Osawa K, Urakaze M, Yano S. Reduction in microalbuminuria in diabetics","text_display":"\n131. Hamazaki T, Takazakura E, Osawa K, Urakaze M, Yano S. Reduction in microalbuminuria in diabetics","confidence":0.99951171875,"confidence_rate":0.9999953924587458},{"cnt":[[245,1749],[1437,1749],[1437,1798],[245,1798]],"region":{"top_left_x":244,"top_left_y":1748,"width":1194,"height":51},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b430171806704f2fbc860d0bd161d9ee","type":"text","conversion_output":true,"text":"by eicosapentaenoic acid ethyl ester. Lipids. Sep 1990;25(9):541-545.","text_display":" by eicosapentaenoic acid ethyl ester. Lipids. Sep 1990;25(9):541-545.","confidence":1,"confidence_rate":1},{"cnt":[[122,1794],[1964,1794],[1964,1841],[122,1841]],"region":{"top_left_x":122,"top_left_y":1793,"width":1842,"height":49},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"114cfadf7e0b44859ed5a37335875c1c","type":"text","conversion_output":true,"text":"132. Shimizu H, Ohtani K, Tanaka Y, Sato N, Mori M, Shimomura Y. Long-term effect of eicosapentaenoic","text_display":"\n132. Shimizu H, Ohtani K, Tanaka Y, Sato N, Mori M, Shimomura Y. Long-term effect of eicosapentaenoic","confidence":1,"confidence_rate":1},{"cnt":[[245,1839],[1979,1839],[1979,1886],[245,1886]],"region":{"top_left_x":244,"top_left_y":1839,"width":1735,"height":48},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bcfc28e2762a4570b1d3efd7990e7d98","type":"text","conversion_output":true,"text":"acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. Diabetes Res Clin Pract.","text_display":" acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. Diabetes Res Clin Pract.","confidence":1,"confidence_rate":1},{"cnt":[[245,1882],[629,1882],[629,1931],[245,1931]],"region":{"top_left_x":244,"top_left_y":1882,"width":386,"height":50},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"efedff8bc0114c1e8c8a89e06ec5c11f","type":"text","conversion_output":true,"text":"Apr 1995;28(1):35-40.","text_display":" Apr 1995;28(1):35-40.","confidence":1,"confidence_rate":1},{"cnt":[[120,1927],[1972,1927],[1972,1974],[120,1974]],"region":{"top_left_x":120,"top_left_y":1927,"width":1853,"height":48},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"aec8bffb3a644186913bb6b141cd699c","type":"text","conversion_output":true,"text":"133. Rossing P, Hansen BV, Nielsen FS, Myrup B, Holmer G, Parving HH. Fish oil in diabetic nephropathy.","text_display":"\n133. Rossing P, Hansen BV, Nielsen FS, Myrup B, Holmer G, Parving HH. Fish oil in diabetic nephropathy.","confidence":0.99951171875,"confidence_rate":0.9999954777833909},{"cnt":[[245,1970],[1008,1970],[1008,2017],[245,2017]],"region":{"top_left_x":244,"top_left_y":1970,"width":764,"height":48},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"11a18bab4af24a66a2d7080ec7572f32","type":"text","conversion_output":true,"text":"Diabetes Care. Nov 1996;19(11):1214-1219.","text_display":" Diabetes Care. Nov 1996;19(11):1214-1219.","confidence":0.8076171875,"confidence_rate":0.9953658338509194},{"cnt":[[120,2015],[1921,2015],[1921,2065],[120,2065]],"region":{"top_left_x":120,"top_left_y":2015,"width":1801,"height":50},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"263b8d02a4f54b0c87455a41f16d164a","type":"text","conversion_output":true,"text":"134. Lungershausen YK, Howe PR, Clifton PM, et al. Evaluation of an omega-3 fatty acid supplement in","text_display":"\n134. Lungershausen YK, Howe PR, Clifton PM, et al. Evaluation of an omega-3 fatty acid supplement in","confidence":0.5390625,"confidence_rate":0.994132294439642},{"cnt":[[245,2058],[1583,2058],[1583,2105],[245,2105]],"region":{"top_left_x":244,"top_left_y":2058,"width":1340,"height":48},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fd9a879934f84ff699720da76e85e017","type":"text","conversion_output":true,"text":"diabetics with microalbuminuria. Ann N Y Acad Sci. Sep 20 1997;827:369-381.","text_display":" diabetics with microalbuminuria. Ann N Y Acad Sci. Sep 20 1997;827:369-381.","confidence":0.9965834617614746,"confidence_rate":0.9999587672605398},{"cnt":[[122,2101],[1893,2101],[1893,2151],[122,2151]],"region":{"top_left_x":122,"top_left_y":2101,"width":1771,"height":50},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b6447ad83f6d4d4ba28fb83f2a2bb30e","type":"text","conversion_output":true,"text":"135. Zeman M, Zak A, Vecka M, Tvrzicka E, Pisarikova A, Stankova B. N-3 fatty acid supplementation","text_display":"\n135. Zeman M, Zak A, Vecka M, Tvrzicka E, Pisarikova A, Stankova B. N-3 fatty acid supplementation","confidence":1,"confidence_rate":1},{"cnt":[[245,2144],[1987,2144],[1987,2194],[245,2194]],"region":{"top_left_x":244,"top_left_y":2144,"width":1744,"height":50},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"007e60d9e42547d6b3a04722484082f5","type":"text","conversion_output":true,"text":"decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. J Nutr","text_display":" decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. J Nutr","confidence":1,"confidence_rate":1},{"cnt":[[245,2189],[844,2189],[844,2237],[245,2237]],"region":{"top_left_x":244,"top_left_y":2189,"width":601,"height":48},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ead56d51ea11443faeaadc6e86d95372","type":"text","conversion_output":true,"text":"Biochem. Jun 2006;17(6):379-384.","text_display":" Biochem. Jun 2006;17(6):379-384.","confidence":0.6298828125,"confidence_rate":0.9875852343454997},{"cnt":[[122,2234],[1901,2234],[1901,2279],[122,2279]],"region":{"top_left_x":122,"top_left_y":2234,"width":1780,"height":46},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0de2aaa758a34a77a74a3bbd864e8f28","type":"text","conversion_output":true,"text":"136. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997.","text_display":"\n136. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997.","confidence":0.99951171875,"confidence_rate":0.9999952582588333},{"cnt":[[245,2277],[943,2277],[943,2322],[245,2322]],"region":{"top_left_x":244,"top_left_y":2277,"width":700,"height":46},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"adcc863ebd60449fae1570d595272c90","type":"text","conversion_output":true,"text":"Diabetes Care. Feb 1998;21(2):296-309.","text_display":" Diabetes Care. Feb 1998;21(2):296-309.","confidence":0.99951171875,"confidence_rate":0.9999886419133848},{"cnt":[[122,2320],[1897,2320],[1897,2370],[122,2370]],"region":{"top_left_x":122,"top_left_y":2320,"width":1776,"height":50},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"95fc5384621e4edd81d5f1cb0fa49867","type":"text","conversion_output":true,"text":"137. Lang JM, Buring JE, Rosner B, Cook N, Hennekens CH. Estimating the effect of the run-in on the","text_display":"\n137. Lang JM, Buring JE, Rosner B, Cook N, Hennekens CH. Estimating the effect of the run-in on the","confidence":1,"confidence_rate":1},{"cnt":[[245,2368],[1571,2368],[1571,2413],[245,2413]],"region":{"top_left_x":244,"top_left_y":2367,"width":1327,"height":46},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"14476f781d7447e481a8fd324788e7a7","type":"text","conversion_output":true,"text":"power of the Physicians' Health Study. Stat Med. Oct 1991;10(10):1585-1593.","text_display":" power of the Physicians' Health Study. Stat Med. Oct 1991;10(10):1585-1593.","confidence":0.99169921875,"confidence_rate":0.9998958126206443},{"cnt":[[122,2411],[2004,2411],[2004,2456],[122,2456]],"region":{"top_left_x":122,"top_left_y":2410,"width":1883,"height":46},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"be292d8f66fc4501a2edd8d52c3e4441","type":"text","conversion_output":true,"text":"138. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D","text_display":"\n138. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D","confidence":1,"confidence_rate":1},{"cnt":[[245,2454],[1055,2454],[1055,2503],[245,2503]],"region":{"top_left_x":244,"top_left_y":2453,"width":811,"height":50},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b4aa14fb39d14fd88d83f0a675c85e9b","type":"text","conversion_output":true,"text":"status. Osteoporos Int. Jul 2005;16(7):713-716.","text_display":" status. Osteoporos Int. Jul 2005;16(7):713-716.","confidence":0.99951171875,"confidence_rate":0.9999906077268363},{"cnt":[[1955,2582],[2007,2582],[2007,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2582,"width":52,"height":46},"line":55,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"30be0544853c4c1581e349efb66c24e1","type":"page_info","conversion_output":false,"text":"29","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-30","page":30,"lines":[{"cnt":[[120,125],[1910,125],[1910,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":1790,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"51c701a08554450a8f50f393b3bbf4b6","type":"text","conversion_output":true,"text":"139. Institute of Medicine Food and Nutrition Board. Dietary Reference Intakes: Calcium, Phosphorous,","text_display":"\n139. Institute of Medicine Food and Nutrition Board. Dietary Reference Intakes: Calcium, Phosphorous,","confidence":1,"confidence_rate":1},{"cnt":[[243,168],[1738,168],[1738,217],[243,217]],"region":{"top_left_x":242,"top_left_y":167,"width":1497,"height":50},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a15db14b73f6496180f386dd13139f09","type":"text","conversion_output":true,"text":"Magnesium, Vitamin D and Fluoride. Washington DC: National Academies Press; 1999.","text_display":" Magnesium, Vitamin D and Fluoride. Washington DC: National Academies Press; 1999.","confidence":0.99951171875,"confidence_rate":0.9999942541282946},{"cnt":[[120,213],[1843,213],[1843,260],[120,260]],"region":{"top_left_x":120,"top_left_y":212,"width":1724,"height":48},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"31661281e93b4ced85279d9f7d93306e","type":"text","conversion_output":true,"text":"140. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. Jan","text_display":"\n140. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. Jan","confidence":0.9990236759185791,"confidence_rate":0.9999902320377447},{"cnt":[[245,258],[535,258],[535,303],[245,303]],"region":{"top_left_x":244,"top_left_y":257,"width":291,"height":46},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d825f8455fa14941b3105a2aadfd1703","type":"text","conversion_output":true,"text":"2007;85(1):6-18.","text_display":" 2007;85(1):6-18.","confidence":1,"confidence_rate":1},{"cnt":[[120,301],[1876,301],[1876,350],[120,350]],"region":{"top_left_x":120,"top_left_y":300,"width":1756,"height":51},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"73d53a64ac7746dd949fc898e315b1b4","type":"text","conversion_output":true,"text":"141. Harris WS. International recommendations for consumption of long-chain omega- 3 fatty acids. J","text_display":"\n141. Harris WS. International recommendations for consumption of long-chain omega- 3 fatty acids. J","confidence":0.5202005169121549,"confidence_rate":0.9939107558729603},{"cnt":[[245,346],[1270,346],[1270,393],[245,393]],"region":{"top_left_x":244,"top_left_y":345,"width":1026,"height":49},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3d273522fae348a289230081d296100c","type":"text","conversion_output":true,"text":"Cardiovasc Med (Hagerstown). Sep 2007;8 Suppl 1:S50-52.","text_display":" Cardiovasc Med (Hagerstown). Sep 2007;8 Suppl 1:S50-52.","confidence":0.99951171875,"confidence_rate":0.999991860024828},{"cnt":[[120,389],[1987,389],[1987,436],[120,436]],"region":{"top_left_x":120,"top_left_y":388,"width":1868,"height":49},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"36ba6a6cce854eb9b5b436616c902e56","type":"text","conversion_output":true,"text":"142. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with","text_display":"\n142. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with","confidence":0.99951171875,"confidence_rate":0.9999956778810385},{"cnt":[[245,434],[1833,434],[1833,479],[245,479]],"region":{"top_left_x":244,"top_left_y":433,"width":1589,"height":47},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8b5492c90be94b63923ca11774f79713","type":"text","conversion_output":true,"text":"\\(n -3\\) polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-","text_display":" \\(n -3\\) polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI","confidence":0.9227915973169729,"confidence_rate":0.9992201890809651},{"cnt":[[245,477],[1927,477],[1927,524],[245,524]],"region":{"top_left_x":244,"top_left_y":476,"width":1684,"height":49},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"67392a54b483449d98679ff8819562ee","type":"text","conversion_output":true,"text":"Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet.","text_display":"Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet.","confidence":0.9990236759185791,"confidence_rate":0.9999907849387211},{"cnt":[[245,520],[797,520],[797,569],[245,569]],"region":{"top_left_x":244,"top_left_y":519,"width":554,"height":51},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c016d9e990dc4f1da903bdbf5be18411","type":"text","conversion_output":true,"text":"Aug 7 1999;354(9177):447-455.","text_display":" Aug 7 1999;354(9177):447-455.","confidence":1,"confidence_rate":1},{"cnt":[[120,563],[1985,563],[1985,612],[120,612]],"region":{"top_left_x":120,"top_left_y":562,"width":1866,"height":51},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5ff8a30fb67143f3aaafce51a6ff50df","type":"text","conversion_output":true,"text":"143. Astor BC, Hallan SI, Miller ER, 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk","text_display":"\n143. Astor BC, Hallan SI, Miller ER, 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk","confidence":0.99853515625,"confidence_rate":0.9999872529709615},{"cnt":[[245,608],[1727,608],[1727,657],[245,657]],"region":{"top_left_x":244,"top_left_y":608,"width":1484,"height":50},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"59ba5e73d5124b6eaca4d97084d2889d","type":"text","conversion_output":true,"text":"of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. May 15","text_display":" of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. May 15","confidence":1,"confidence_rate":1},{"cnt":[[245,653],[685,653],[685,700],[245,700]],"region":{"top_left_x":244,"top_left_y":653,"width":442,"height":48},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"10c1725c28ba4b83b6702cb5c6894fee","type":"text","conversion_output":true,"text":"2008;167(10):1226-1234.","text_display":" 2008;167(10):1226-1234.","confidence":0.99853515625,"confidence_rate":0.9999476471675111},{"cnt":[[120,696],[1923,696],[1923,746],[120,746]],"region":{"top_left_x":120,"top_left_y":696,"width":1803,"height":50},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c8bc3e268e504a8b83b32f9e2e3bba6b","type":"text","conversion_output":true,"text":"144. Brantsma AH, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. Extended prognostic value of","text_display":"\n144. Brantsma AH, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. Extended prognostic value of","confidence":1,"confidence_rate":1},{"cnt":[[245,741],[1934,741],[1934,788],[245,788]],"region":{"top_left_x":244,"top_left_y":741,"width":1690,"height":48},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"079247d49b6744e6ac3e158a2c75cc80","type":"text","conversion_output":true,"text":"urinary albumin excretion for cardiovascular events. J Am Soc Nephrol. Sep 2008;19(9):1785-1791.","text_display":" urinary albumin excretion for cardiovascular events. J Am Soc Nephrol. Sep 2008;19(9):1785-1791.","confidence":0.92236328125,"confidence_rate":0.9992001604516457},{"cnt":[[122,786],[1841,786],[1841,831],[122,831]],"region":{"top_left_x":122,"top_left_y":786,"width":1720,"height":46},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"94ddd2a30199451fa8f3702b892cc9cc","type":"text","conversion_output":true,"text":"145. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in","text_display":"\n145. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in","confidence":1,"confidence_rate":1},{"cnt":[[245,829],[1968,829],[1968,879],[245,879]],"region":{"top_left_x":244,"top_left_y":829,"width":1724,"height":50},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"96bffa522aed4e4a9d4c73d8fc57b376","type":"text","conversion_output":true,"text":"combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis.","text_display":" combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis.","confidence":0.998535871389322,"confidence_rate":0.9999864334115239},{"cnt":[[245,872],[677,872],[677,922],[245,922]],"region":{"top_left_x":244,"top_left_y":872,"width":433,"height":50},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b8cdd1b1e7ea44699bbbc6d01411ae70","type":"text","conversion_output":true,"text":"Mar 2008;51(3):395-406.","text_display":" Mar 2008;51(3):395-406.","confidence":0.9873297214508057,"confidence_rate":0.9995447025704467},{"cnt":[[120,915],[1983,915],[1983,965],[120,965]],"region":{"top_left_x":120,"top_left_y":915,"width":1864,"height":50},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"037ebf2308ae48eba776527a02c0f308","type":"text","conversion_output":true,"text":"146. Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin C measured by automated immunoassay:","text_display":"\n146. Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin C measured by automated immunoassay:","confidence":1,"confidence_rate":1},{"cnt":[[245,958],[2000,958],[2000,1008],[245,1008]],"region":{"top_left_x":244,"top_left_y":958,"width":1757,"height":50},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e5ce36406a7d48499678e826b3c41eae","type":"text","conversion_output":true,"text":"a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. Jan 1995;47(1):312-318.","text_display":" a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. Jan 1995;47(1):312-318.","confidence":1,"confidence_rate":1},{"cnt":[[120,1001],[1893,1001],[1893,1051],[120,1051]],"region":{"top_left_x":120,"top_left_y":1001,"width":1773,"height":50},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f2eecb3d606b4f0bab1bc5c436049ded","type":"text","conversion_output":true,"text":"147. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of","text_display":"\n147. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of","confidence":0.99853515625,"confidence_rate":0.9999862999285899},{"cnt":[[245,1048],[1760,1048],[1760,1096],[245,1096]],"region":{"top_left_x":244,"top_left_y":1048,"width":1516,"height":48},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9cd1c3019788464f813e9307d46a1f53","type":"text","conversion_output":true,"text":"glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. Jul","text_display":" glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. Jul","confidence":1,"confidence_rate":1},{"cnt":[[245,1091],[556,1091],[556,1139],[245,1139]],"region":{"top_left_x":244,"top_left_y":1091,"width":313,"height":48},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b276fbe58e1b414f99d89758f5567ce5","type":"text","conversion_output":true,"text":"2000;36(1):29-34.","text_display":" 2000;36(1):29-34.","confidence":1,"confidence_rate":1},{"cnt":[[122,1134],[1970,1134],[1970,1184],[122,1184]],"region":{"top_left_x":122,"top_left_y":1134,"width":1849,"height":50},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"255b46c6e98943fea1c2a3699f282ff5","type":"text","conversion_output":true,"text":"148. O'Riordan SE, Webb MC, Stowe HJ, et al. Cystatin C improves the detection of mild renal dysfunction","text_display":"\n148. O'Riordan SE, Webb MC, Stowe HJ, et al. Cystatin C improves the detection of mild renal dysfunction","confidence":0.9990234375,"confidence_rate":0.9999910363736797},{"cnt":[[245,1179],[1343,1179],[1343,1227],[245,1227]],"region":{"top_left_x":244,"top_left_y":1179,"width":1099,"height":48},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f1feb65879b1486a82b6dc0430237c61","type":"text","conversion_output":true,"text":"in older patients. Ann Clin Biochem. Nov 2003;40(Pt 6):648-655.","text_display":" in older patients. Ann Clin Biochem. Nov 2003;40(Pt 6):648-655.","confidence":1,"confidence_rate":1},{"cnt":[[120,1225],[1923,1225],[1923,1270],[120,1270]],"region":{"top_left_x":120,"top_left_y":1224,"width":1803,"height":46},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8db2fb29bc1348eabf14cadbb1452eb8","type":"text","conversion_output":true,"text":"149. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than","text_display":"\n149. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than","confidence":0.979520550230518,"confidence_rate":0.9998084251908496},{"cnt":[[245,1268],[1953,1268],[1953,1317],[245,1317]],"region":{"top_left_x":244,"top_left_y":1267,"width":1709,"height":50},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"48bd74fd644d4ae89d409ebd697c4c2e","type":"text","conversion_output":true,"text":"renal function and the impact on renal function measurement. Kidney Int. Apr 2004;65(4):1416-1421.","text_display":" renal function and the impact on renal function measurement. Kidney Int. Apr 2004;65(4):1416-1421.","confidence":1,"confidence_rate":1},{"cnt":[[120,1311],[1904,1311],[1904,1360],[120,1360]],"region":{"top_left_x":120,"top_left_y":1310,"width":1784,"height":50},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b5a9029b634e4acf8c157e622b6cd56c","type":"text","conversion_output":true,"text":"150. Stevens LA, Schmid CH, Greene T, et al. Factors other than glomerular filtration rate affect serum","text_display":"\n150. Stevens LA, Schmid CH, Greene T, et al. Factors other than glomerular filtration rate affect serum","confidence":1,"confidence_rate":1},{"cnt":[[245,1354],[1164,1354],[1164,1403],[245,1403]],"region":{"top_left_x":244,"top_left_y":1353,"width":921,"height":50},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0e200369fe574cbba8bab94e6faca188","type":"text","conversion_output":true,"text":"cystatin C levels. Kidney Int. Mar 2009;75(6):652-660.","text_display":" cystatin C levels. Kidney Int. Mar 2009;75(6):652-660.","confidence":0.99951171875,"confidence_rate":0.9999917220597181},{"cnt":[[120,1401],[1807,1401],[1807,1446],[120,1446]],"region":{"top_left_x":120,"top_left_y":1400,"width":1687,"height":46},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"631b4f39f33442549516c0632458f1f5","type":"text","conversion_output":true,"text":"151. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology. Sep","text_display":"\n151. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology. Sep","confidence":1,"confidence_rate":1},{"cnt":[[245,1444],[578,1444],[578,1491],[245,1491]],"region":{"top_left_x":244,"top_left_y":1443,"width":334,"height":49},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cf2e36f9fd48416e9f6cffa104e82c95","type":"text","conversion_output":true,"text":"1992;3(5):452-456.","text_display":" 1992;3(5):452-456.","confidence":0.9990234375,"confidence_rate":0.9999575209175736},{"cnt":[[122,1487],[1987,1487],[1987,1536],[122,1536]],"region":{"top_left_x":122,"top_left_y":1486,"width":1866,"height":51},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7a495e21085d469ba797a35365cbb6c3","type":"text","conversion_output":true,"text":"152. Rosner B, Glynn RJ. Power and sample size estimation for the Wilcoxon rank sum test with application","text_display":"\n152. Rosner B, Glynn RJ. Power and sample size estimation for the Wilcoxon rank sum test with application","confidence":0.99951171875,"confidence_rate":0.9999955600053285},{"cnt":[[245,1532],[1979,1532],[1979,1577],[245,1577]],"region":{"top_left_x":244,"top_left_y":1531,"width":1735,"height":46},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"58c4c867a4fd41178468fb1975faddba","type":"text","conversion_output":true,"text":"to comparisons of C statistics from alternative prediction models. Biometrics. Mar 2009;65(1):188-197.","text_display":" to comparisons of C statistics from alternative prediction models. Biometrics. Mar 2009;65(1):188-197.","confidence":0.683756663929671,"confidence_rate":0.9966414651119565},{"cnt":[[122,1575],[1957,1575],[1957,1622],[122,1622]],"region":{"top_left_x":122,"top_left_y":1574,"width":1836,"height":49},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"69260377f93b463a8048112550bafff5","type":"text","conversion_output":true,"text":"153. Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort R. First morning","text_display":"\n153. Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort R. First morning","confidence":1,"confidence_rate":1},{"cnt":[[245,1620],[1949,1620],[1949,1665],[245,1665]],"region":{"top_left_x":244,"top_left_y":1619,"width":1705,"height":47},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"22ed5ed34a994bf29594b3cea7055d95","type":"text","conversion_output":true,"text":"voids are more reliable than spot urine samples to assess microalbuminuria. JAm Soc Nephrol. Feb","text_display":" voids are more reliable than spot urine samples to assess microalbuminuria. JAm Soc Nephrol. Feb","confidence":0.66015625,"confidence_rate":0.9958967707545455},{"cnt":[[245,1663],[599,1663],[599,1708],[245,1708]],"region":{"top_left_x":244,"top_left_y":1662,"width":356,"height":47},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7e1d3db5c70542b69de966d5f500004a","type":"text","conversion_output":true,"text":"2009;20(2):436-443.","text_display":" 2009;20(2):436-443.","confidence":1,"confidence_rate":1},{"cnt":[[122,1706],[1979,1706],[1979,1755],[122,1755]],"region":{"top_left_x":122,"top_left_y":1705,"width":1857,"height":51},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"81162c0e74c44a078a459e86aaee638e","type":"text","conversion_output":true,"text":"154. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin","text_display":"\n154. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin","confidence":1,"confidence_rate":1},{"cnt":[[249,1749],[743,1749],[743,1798],[249,1798]],"region":{"top_left_x":249,"top_left_y":1748,"width":495,"height":51},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c0d2bf6b756a41b5a56732572ecf1016","type":"text","conversion_output":true,"text":"Trials. Jun 1981;2(2):93-113.","text_display":" Trials. Jun 1981;2(2):93-113.","confidence":1,"confidence_rate":1},{"cnt":[[122,1796],[1910,1796],[1910,1841],[122,1841]],"region":{"top_left_x":122,"top_left_y":1796,"width":1788,"height":46},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"18d69c7e1813410faf112203e0e75e1b","type":"text","conversion_output":true,"text":"155. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol. Oct","text_display":"\n155. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol. Oct","confidence":0.615234375,"confidence_rate":0.9956334173459074},{"cnt":[[247,1839],[642,1839],[642,1884],[247,1884]],"region":{"top_left_x":247,"top_left_y":1839,"width":396,"height":46},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"83f3d6e5a1b4413f8e6c128a2e1d7a5f","type":"text","conversion_output":true,"text":"1971;44(526):793-797.","text_display":" 1971;44(526):793-797.","confidence":1,"confidence_rate":1},{"cnt":[[122,1882],[1833,1882],[1833,1931],[122,1931]],"region":{"top_left_x":122,"top_left_y":1882,"width":1711,"height":50},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0def8d89bf744612b09c795b68811466","type":"text","conversion_output":true,"text":"156. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring","text_display":"\n156. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring","confidence":0.998046875,"confidence_rate":0.9999813807939509},{"cnt":[[245,1925],[1940,1925],[1940,1974],[245,1974]],"region":{"top_left_x":244,"top_left_y":1925,"width":1697,"height":50},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b26222bd83db49e6979b4be55cb2f36b","type":"text","conversion_output":true,"text":"prolonged observation of each patient. I. Introduction and design. Br J Cancer. Dec 1976;34(6):585-","text_display":" prolonged observation of each patient. I. Introduction and design. Br J Cancer. Dec 1976;34(6):585","confidence":0.775446679443121,"confidence_rate":0.997557640741061},{"cnt":[[245,1972],[329,1972],[329,2013],[245,2013]],"region":{"top_left_x":244,"top_left_y":1972,"width":85,"height":42},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ffcd20dc4d8a427dafecfa16ed77c0f5","type":"text","conversion_output":true,"text":"612.","text_display":"612.","confidence":1,"confidence_rate":1},{"cnt":[[122,2015],[1936,2015],[1936,2065],[122,2065]],"region":{"top_left_x":122,"top_left_y":2015,"width":1814,"height":50},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"49b0fde7e63b4aa0b12ffb627f69fbfa","type":"text","conversion_output":true,"text":"157. Geller NL, Pocock SJ. Interim analyses in randomized clinical trials: ramifications and guidelines for","text_display":"\n157. Geller NL, Pocock SJ. Interim analyses in randomized clinical trials: ramifications and guidelines for","confidence":1,"confidence_rate":1},{"cnt":[[245,2058],[1106,2058],[1106,2108],[245,2108]],"region":{"top_left_x":244,"top_left_y":2058,"width":863,"height":50},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4ff948b310c044c6b62e0ad30708f62c","type":"text","conversion_output":true,"text":"practitioners. Biometrics. Mar 1987;43(1):213-223.","text_display":" practitioners. Biometrics. Mar 1987;43(1):213-223.","confidence":0.98974609375,"confidence_rate":0.999812620472148},{"cnt":[[122,2101],[2002,2101],[2002,2151],[122,2151]],"region":{"top_left_x":122,"top_left_y":2101,"width":1881,"height":50},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6943dbc6f3064b839119d2c06f3d7a4e","type":"text","conversion_output":true,"text":"158. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. Sep 1979;35(3):549-","text_display":"\n158. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. Sep 1979;35(3):549","confidence":0.99951171875,"confidence_rate":0.9999957530481652},{"cnt":[[245,2144],[329,2144],[329,2189],[245,2189]],"region":{"top_left_x":244,"top_left_y":2144,"width":85,"height":46},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2af3e83d2cae4fdf9bf8afc4d1e3347d","type":"text","conversion_output":true,"text":"556.","text_display":"556.","confidence":1,"confidence_rate":1},{"cnt":[[122,2187],[1893,2187],[1893,2237],[122,2237]],"region":{"top_left_x":122,"top_left_y":2187,"width":1771,"height":50},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"77cb881b2a83456885c9f6b986764fd5","type":"text","conversion_output":true,"text":"159. DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. Jul 15-30","text_display":"\n159. DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. Jul 15-30","confidence":0.99658203125,"confidence_rate":0.9999670791635416},{"cnt":[[245,2234],[1113,2234],[1113,2279],[245,2279]],"region":{"top_left_x":244,"top_left_y":2234,"width":869,"height":46},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e199d89489224423883112e5684e0dc9","type":"text","conversion_output":true,"text":"1994;13(13-14):1341-1352; discussion 1353-1346.","text_display":" 1994;13(13-14):1341-1352; discussion 1353-1346.","confidence":0.99853515625,"confidence_rate":0.9999718096726914},{"cnt":[[122,2277],[1944,2277],[1944,2327],[122,2327]],"region":{"top_left_x":122,"top_left_y":2277,"width":1823,"height":50},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b50279931c53449dbe89d42dc79b9463","type":"text","conversion_output":true,"text":"160. Pocock SJ. Current controversies in data monitoring for clinical trials. Clin Trials. 2006;3(6):513-521.","text_display":"\n160. Pocock SJ. Current controversies in data monitoring for clinical trials. Clin Trials. 2006;3(6):513-521.","confidence":0.9990234375,"confidence_rate":0.9999914295135003},{"cnt":[[1955,2582],[2009,2582],[2009,2628],[1955,2628]],"region":{"top_left_x":1955,"top_left_y":2582,"width":54,"height":46},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9ea0007e2d5d47f5a98b22a4dbf46cc5","type":"page_info","conversion_output":false,"text":"30","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-31","page":31,"lines":[{"cnt":[[468,529],[1656,529],[1656,634],[468,634]],"region":{"top_left_x":468,"top_left_y":528,"width":1189,"height":106},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a8ea69db303a4459be4501c29550df17","type":"title","conversion_output":false,"children_ids":["d490ce8a461d40cfaa7ab4a23c3f71ce","3c4125a03bdc437f90a8fbc176ec9ac8"],"text":"","text_display":""},{"cnt":[[473,535],[1648,535],[1648,587],[473,587]],"region":{"top_left_x":472,"top_left_y":534,"width":1176,"height":53},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d490ce8a461d40cfaa7ab4a23c3f71ce","type":"text","conversion_output":true,"parent_id":"a8ea69db303a4459be4501c29550df17","text":"Randomized Clinical Trial of Vitamin D and Omega-3 Fatty Acids","text_display":"\n\n\\title{\nRandomized Clinical Trial of Vitamin D and Omega-3 Fatty Acids","confidence":1,"confidence_rate":1},{"cnt":[[804,580],[1317,580],[1317,629],[804,629]],"region":{"top_left_x":803,"top_left_y":580,"width":514,"height":50},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3c4125a03bdc437f90a8fbc176ec9ac8","type":"text","conversion_output":true,"parent_id":"a8ea69db303a4459be4501c29550df17","text":"for Diabetic Kidney Disease","text_display":" for Diabetic Kidney Disease\n}","confidence":1,"confidence_rate":1},{"cnt":[[606,700],[1519,700],[1519,900],[606,900]],"region":{"top_left_x":605,"top_left_y":700,"width":914,"height":201},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5ee1bc35abcc4d0b9991541645606003","type":"authors","conversion_output":false,"children_ids":["f6c10d372a764001805a791dbd021da9","602ecd64f0ee4ed0b95e1d565df01e8f","5c4f6faea70e410383946d5d831355ee","708b1bbd76964f29a952bec673e39b91"],"text":"","text_display":""},{"cnt":[[872,709],[1250,709],[1250,754],[872,754]],"region":{"top_left_x":872,"top_left_y":708,"width":379,"height":47},"line":5,"column":0,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"f6c10d372a764001805a791dbd021da9","type":"text","conversion_output":true,"parent_id":"5ee1bc35abcc4d0b9991541645606003","text":"Protocol Addendum","text_display":"\n\n\\author{\nProtocol Addendum","confidence":1,"confidence_rate":1},{"cnt":[[846,752],[1278,752],[1278,801],[846,801]],"region":{"top_left_x":846,"top_left_y":751,"width":433,"height":51},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"602ecd64f0ee4ed0b95e1d565df01e8f","type":"text","conversion_output":true,"parent_id":"5ee1bc35abcc4d0b9991541645606003","text":"Changes to analytic plan","text_display":" \\\\ Changes to analytic plan","confidence":1,"confidence_rate":1},{"cnt":[[614,795],[1508,795],[1508,849],[614,849]],"region":{"top_left_x":614,"top_left_y":794,"width":895,"height":55},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5c4f6faea70e410383946d5d831355ee","type":"text","conversion_output":true,"parent_id":"5ee1bc35abcc4d0b9991541645606003","text":"Submitted in NIH grant renewal application 3/2/2015","text_display":" \\\\ Submitted in NIH grant renewal application 3/2/2015","confidence":1,"confidence_rate":1},{"cnt":[[739,842],[1386,842],[1386,892],[739,892]],"region":{"top_left_x":739,"top_left_y":842,"width":647,"height":50},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"708b1bbd76964f29a952bec673e39b91","type":"text","conversion_output":true,"parent_id":"5ee1bc35abcc4d0b9991541645606003","text":"Implemented upon funding 2/24/2016","text_display":" \\\\ Implemented upon funding 2/24/2016\n}","confidence":0.9990234375,"confidence_rate":0.999974948015144}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-32","page":32,"lines":[{"cnt":[[116,120],[440,120],[440,176],[116,176]],"region":{"top_left_x":116,"top_left_y":120,"width":325,"height":57},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a2cc8a7006034e1f8044aaf878c822bf","type":"section_header","conversion_output":false,"children_ids":["9d8dac399fd7440da67e40c3cc3fb2a3"],"text":"","text_display":""},{"cnt":[[120,125],[436,125],[436,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":317,"height":51},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9d8dac399fd7440da67e40c3cc3fb2a3","type":"text","conversion_output":true,"parent_id":"a2cc8a7006034e1f8044aaf878c822bf","text":"15. Data analysis","text_display":"\n\n\\section*{15. Data analysis}","confidence":1,"confidence_rate":1},{"cnt":[[120,189],[1824,189],[1824,238],[120,238]],"region":{"top_left_x":120,"top_left_y":189,"width":1705,"height":50},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d1cd5e770f9c401ea18411104b105b34","type":"text","conversion_output":true,"text":"15a. Descriptive analyses. We will describe creation of the VITAL diabetes sub-cohort according to","text_display":"\n\n15a. Descriptive analyses. We will describe creation of the VITAL diabetes sub-cohort according to","confidence":1,"confidence_rate":1},{"cnt":[[120,234],[1837,234],[1837,281],[120,281]],"region":{"top_left_x":120,"top_left_y":234,"width":1717,"height":48},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"69979755b805435d9d72922b0c52f9a5","type":"text","conversion_output":true,"text":"CONSORT guidelines, including numbers of participants who consent to VITAL participation; report a","text_display":" CONSORT guidelines, including numbers of participants who consent to VITAL participation; report a","confidence":0.99951171875,"confidence_rate":0.9999952582588333},{"cnt":[[120,279],[1888,279],[1888,324],[120,324]],"region":{"top_left_x":120,"top_left_y":279,"width":1769,"height":46},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e1ec2326af5a4b66bccebec822156659","type":"text","conversion_output":true,"text":"diagnosis of diabetes; are approached for the DKD ancillary study; enroll in the DKD ancillary study; and","text_display":" diagnosis of diabetes; are approached for the DKD ancillary study; enroll in the DKD ancillary study; and","confidence":1,"confidence_rate":1},{"cnt":[[120,322],[1996,322],[1996,370],[120,370]],"region":{"top_left_x":120,"top_left_y":322,"width":1876,"height":48},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"10a0b28ad76344a6952876ff8b3f2f9b","type":"text","conversion_output":true,"text":"complete year 2 and 5 year biosample collections. We will document reasons that participants do not complete","text_display":" complete year 2 and 5 year biosample collections. We will document reasons that participants do not complete","confidence":0.99951171875,"confidence_rate":0.9999958958025558},{"cnt":[[120,365],[1919,365],[1919,415],[120,415]],"region":{"top_left_x":120,"top_left_y":365,"width":1799,"height":50},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"751a25984810435d9a00b680b3e1809b","type":"text","conversion_output":true,"text":"the proposed studies. Among participants recruited into the DKD ancillary study, we will compare baseline","text_display":" the proposed studies. Among participants recruited into the DKD ancillary study, we will compare baseline","confidence":1,"confidence_rate":1},{"cnt":[[120,408],[1824,408],[1824,458],[120,458]],"region":{"top_left_x":120,"top_left_y":408,"width":1705,"height":50},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"86b476c551d2444ba82ddb00475a256f","type":"text","conversion_output":true,"text":"characteristics of those who do and do not return at least one follow-up biosample collection. Among","text_display":" characteristics of those who do and do not return at least one follow-up biosample collection. Among","confidence":1,"confidence_rate":1},{"cnt":[[120,455],[1811,455],[1811,501],[120,501]],"region":{"top_left_x":120,"top_left_y":455,"width":1692,"height":46},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b8d183c1d1bc4aed9c46a9b4a4d6c213","type":"text","conversion_output":true,"text":"participants who return a follow-up biospecimen, we will describe by treatment assignment baseline","text_display":" participants who return a follow-up biospecimen, we will describe by treatment assignment baseline","confidence":1,"confidence_rate":1},{"cnt":[[120,498],[1515,498],[1515,546],[120,546]],"region":{"top_left_x":120,"top_left_y":498,"width":1395,"height":48},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"25ce2aec89da478592cef2d4399abc5b","type":"text","conversion_output":true,"text":"characteristics and changes in clinical characteristics over the course of the study.","text_display":" characteristics and changes in clinical characteristics over the course of the study.","confidence":1,"confidence_rate":1},{"cnt":[[120,561],[1858,561],[1858,608],[120,608]],"region":{"top_left_x":120,"top_left_y":560,"width":1739,"height":49},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"56fb0c8e0e544032a7c008fa2af52c4a","type":"text","conversion_output":true,"text":"15b. Study outcomes. With an extension of follow-up from 2 to 5 years, we will have sufficient time to","text_display":"\n15b. Study outcomes. With an extension of follow-up from 2 to 5 years, we will have sufficient time to","confidence":1,"confidence_rate":1},{"cnt":[[120,602],[1923,602],[1923,655],[120,655]],"region":{"top_left_x":120,"top_left_y":601,"width":1803,"height":55},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0599e0c98cca4b918b1e113d557a73f5","type":"text","conversion_output":true,"text":"effectively evaluate change in estimated GFR (eGFR), a clinically relevant outcome. \\({ }^{175-179}\\) Therefore, if this","text_display":" effectively evaluate change in estimated GFR (eGFR), a clinically relevant outcome. \\({ }^{175-179}\\) Therefore, if this","confidence":0.9990234375,"confidence_rate":0.9999921837133647},{"cnt":[[120,649],[1867,649],[1867,698],[120,698]],"region":{"top_left_x":120,"top_left_y":648,"width":1747,"height":51},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"47befb2976ed413992678c5a5cce7dce","type":"text","conversion_output":true,"text":"competitive renewal is funded, change in eGFR from baseline to year 5 will supplant 2 -year changes in","text_display":" competitive renewal is funded, change in eGFR from baseline to year 5 will supplant 2 -year changes in","confidence":0.94140625,"confidence_rate":0.9994658019294124},{"cnt":[[120,696],[1983,696],[1983,741],[120,741]],"region":{"top_left_x":120,"top_left_y":696,"width":1864,"height":46},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ee90a80298b64b42a0d7fb95052c6ed9","type":"text","conversion_output":true,"text":"albuminuria and eGFR as our primary study outcome. Change in eGFR will be calculated and summarized by","text_display":" albuminuria and eGFR as our primary study outcome. Change in eGFR will be calculated and summarized by","confidence":1,"confidence_rate":1},{"cnt":[[116,739],[1863,739],[1863,786],[116,786]],"region":{"top_left_x":116,"top_left_y":739,"width":1747,"height":48},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cea832f7e08d424083150dd2c333703d","type":"text","conversion_output":true,"text":"treatment group as \\(\\left[e G F R_{5}-e G F R_{0}\\right]\\), where \\(e G F R_{5}\\) represents eGFR at follow-up (year 5) and \\(e G F R_{0}\\)","text_display":" treatment group as \\(\\left[e G F R_{5}-e G F R_{0}\\right]\\), where \\(e G F R_{5}\\) represents eGFR at follow-up (year 5) and \\(e G F R_{0}\\)","confidence":0.5378805837098668,"confidence_rate":0.9953131487354188},{"cnt":[[116,782],[2000,782],[2000,827],[116,827]],"region":{"top_left_x":116,"top_left_y":782,"width":1885,"height":46},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"3d9cb1c2a6734c888af13139a0eb0c3e","type":"text","conversion_output":true,"text":"represents eGFR at baseline. As secondary outcomes, we will examine changes in urine ACR from baseline to","text_display":" represents eGFR at baseline. As secondary outcomes, we will examine changes in urine ACR from baseline to","confidence":1,"confidence_rate":1},{"cnt":[[116,825],[1921,825],[1921,872],[116,872]],"region":{"top_left_x":116,"top_left_y":825,"width":1805,"height":48},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"aa232648077a49cda7f3cc35478a7077","type":"text","conversion_output":true,"text":"years 2 and 5 , time to the development of rapid eGFR loss (loss of eGFR \\(\\geq 40 \\%\\) from baseline to year 2 or","text_display":" years 2 and 5 , time to the development of rapid eGFR loss (loss of eGFR \\(\\geq 40 \\%\\) from baseline to year 2 or","confidence":0.9951171875,"confidence_rate":0.9999595481539275},{"cnt":[[116,864],[1983,864],[1983,917],[116,917]],"region":{"top_left_x":116,"top_left_y":863,"width":1868,"height":55},"line":18,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e2ce51327e15447cb65ef86ace74e423","type":"text","conversion_output":true,"text":"\\(5)\\), \\({ }^{175-179}\\) and time to a composite of rapid eGFR loss, end stage renal disease (maintenance dialysis or kidney","text_display":" \\(5)\\), \\({ }^{175-179}\\) and time to a composite of rapid eGFR loss, end stage renal disease (maintenance dialysis or kidney","confidence":0.4179730862379074,"confidence_rate":0.9931005916328403},{"cnt":[[116,915],[1968,915],[1968,960],[116,960]],"region":{"top_left_x":116,"top_left_y":915,"width":1852,"height":46},"line":19,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"270fa1fc22674fc1bec0605c6e6536c6","type":"text","conversion_output":true,"text":"transplant verified by medical records review), or death. The composite outcome addresses large changes in","text_display":" transplant verified by medical records review), or death. The composite outcome addresses large changes in","confidence":1,"confidence_rate":1},{"cnt":[[116,958],[1996,958],[1996,1005],[116,1005]],"region":{"top_left_x":116,"top_left_y":958,"width":1880,"height":48},"line":20,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"746349cf23ce4cd38baeeb6c967dc872","type":"text","conversion_output":true,"text":"eGFR which have particularly high clinical importance and reduces the potential impact of competing risks that","text_display":" eGFR which have particularly high clinical importance and reduces the potential impact of competing risks that","confidence":0.99951171875,"confidence_rate":0.9999957530481652},{"cnt":[[116,1001],[862,1001],[862,1051],[116,1051]],"region":{"top_left_x":116,"top_left_y":1001,"width":746,"height":50},"line":21,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"705298cf4ec54aa2bcaebd9d29a679f0","type":"text","conversion_output":true,"text":"preclude assessment of eGFR at follow-up.","text_display":" preclude assessment of eGFR at follow-up.","confidence":1,"confidence_rate":1},{"cnt":[[120,1066],[1949,1066],[1949,1115],[120,1115]],"region":{"top_left_x":120,"top_left_y":1065,"width":1829,"height":51},"line":22,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"93940498c80a45c7bbcfadd42768ad31","type":"text","conversion_output":true,"text":"15c. Intention to treat and missing data. Analyses will be performed in accordance with the intent-to-treat","text_display":"\n15c. Intention to treat and missing data. Analyses will be performed in accordance with the intent-to-treat","confidence":1,"confidence_rate":1},{"cnt":[[120,1111],[1998,1111],[1998,1158],[120,1158]],"region":{"top_left_x":120,"top_left_y":1110,"width":1879,"height":49},"line":23,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"37397e2dd23c45cca875a7ab04331850","type":"text","conversion_output":true,"text":"principle, meaning that all participants who return at least one follow-up biosample will be included in analyses,","text_display":" principle, meaning that all participants who return at least one follow-up biosample will be included in analyses,","confidence":1,"confidence_rate":1},{"cnt":[[120,1156],[1944,1156],[1944,1201],[120,1201]],"region":{"top_left_x":120,"top_left_y":1155,"width":1825,"height":46},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cc947c9e63094d40b983f8f01738586a","type":"text","conversion_output":true,"text":"regardless of adherence or other characteristics observed after randomization. Multiple imputation for study","text_display":" regardless of adherence or other characteristics observed after randomization. Multiple imputation for study","confidence":1,"confidence_rate":1},{"cnt":[[120,1199],[1987,1199],[1987,1244],[120,1244]],"region":{"top_left_x":120,"top_left_y":1198,"width":1868,"height":46},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"330ec49423a74b53a81ac8a19ea1a38d","type":"text","conversion_output":true,"text":"participants missing year 5 eGFR will be conducted using chained equations, utilizing baseline data as well as","text_display":" participants missing year 5 eGFR will be conducted using chained equations, utilizing baseline data as well as","confidence":1,"confidence_rate":1},{"cnt":[[116,1237],[1966,1237],[1966,1291],[116,1291]],"region":{"top_left_x":116,"top_left_y":1237,"width":1850,"height":55},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d969a7682ebc4b2f9f603c9a9dd25c1a","type":"text","conversion_output":true,"text":"eGFR and urine ACR data available at year \\(2 .{ }^{180}\\) Results from 10 imputation datasets will be combined using","text_display":" eGFR and urine ACR data available at year \\(2 .{ }^{180}\\) Results from 10 imputation datasets will be combined using","confidence":0.9678880009198565,"confidence_rate":0.9997368177036303},{"cnt":[[120,1280],[402,1280],[402,1330],[120,1330]],"region":{"top_left_x":120,"top_left_y":1280,"width":282,"height":50},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d85a67b989a04e0fa5e69b41b5d36910","type":"text","conversion_output":true,"text":"Rubin's rules. \\({ }^{181}\\)","text_display":" Rubin's rules. \\({ }^{181}\\)","confidence":1,"confidence_rate":1},{"cnt":[[120,1349],[1974,1349],[1974,1399],[120,1399]],"region":{"top_left_x":120,"top_left_y":1349,"width":1855,"height":50},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e9f36eeaa58d494f97e8071c5491fb51","type":"text","conversion_output":true,"text":"15d. Treatment interaction. We will assess for interaction of the study interventions (vitamin D and omega- 3","text_display":"\n\n15d. Treatment interaction. We will assess for interaction of the study interventions (vitamin D and omega- 3","confidence":0.786773681640625,"confidence_rate":0.9979867801510999},{"cnt":[[116,1388],[1757,1388],[1757,1442],[116,1442]],"region":{"top_left_x":116,"top_left_y":1387,"width":1642,"height":55},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"92226c3f6ac84095b2878e56f13d6346","type":"text","conversion_output":true,"text":"fatty acids) for the primary outcome. \\({ }^{182}\\) We will use a linear mixed model to test for interaction: \\({ }^{183}\\)","text_display":" fatty acids) for the primary outcome. \\({ }^{182}\\) We will use a linear mixed model to test for interaction: \\({ }^{183}\\)","confidence":1,"confidence_rate":1},{"cnt":[[180,1457],[389,1457],[389,1506],[180,1506]],"region":{"top_left_x":180,"top_left_y":1456,"width":209,"height":51},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ecbb7a5d67184344b44e20ce922d5e89","type":"text","conversion_output":true,"text":"Equation 1:","text_display":"\n\nEquation 1:","confidence":1,"confidence_rate":1},{"cnt":[[389,1450],[1876,1450],[1876,1560],[389,1560]],"region":{"top_left_x":388,"top_left_y":1450,"width":1488,"height":110},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6ccdeb99b3e94c2b949cd5eb850d932b","type":"math","conversion_output":true,"text":"\\[\n\\begin{gathered}\ne G F R_{i j}=\\beta_{0}+\\beta_{1}\\left(\\text { vitamin } D_{i}\\right)+\\beta_{2}\\left(\\omega-3 F A_{i}\\right)+\\beta_{3}\\left(\\text { vitamin } D_{i} \\times \\omega-3 F A_{i}\\right)+\\beta_{4}\\left(\\text { vitamin } D_{i} \\times t_{i j}\\right) \\\\\n+\\beta_{5}\\left(\\omega-3 F A_{i} \\times t_{i j}\\right)+\\beta_{6}\\left(\\text { vitamin } D_{i} \\times \\omega-3 F A_{i} \\times t_{i j}\\right)+a_{i}+e_{i j}\n\\end{gathered}\n\\]","text_display":"\n\\[\n\\begin{gathered}\ne G F R_{i j}=\\beta_{0}+\\beta_{1}\\left(\\text { vitamin } D_{i}\\right)+\\beta_{2}\\left(\\omega-3 F A_{i}\\right)+\\beta_{3}\\left(\\text { vitamin } D_{i} \\times \\omega-3 F A_{i}\\right)+\\beta_{4}\\left(\\text { vitamin } D_{i} \\times t_{i j}\\right) \\\\\n+\\beta_{5}\\left(\\omega-3 F A_{i} \\times t_{i j}\\right)+\\beta_{6}\\left(\\text { vitamin } D_{i} \\times \\omega-3 F A_{i} \\times t_{i j}\\right)+a_{i}+e_{i j}\n\\end{gathered}\n\\]","confidence":0.6295616463487094,"confidence_rate":0.9984739988549215},{"cnt":[[116,1568],[1901,1568],[1901,1618],[116,1618]],"region":{"top_left_x":116,"top_left_y":1568,"width":1786,"height":50},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e1859742d3ce47e0ac51d6c0def6bdab","type":"text","conversion_output":true,"text":"where \\(i\\) denotes the \\(i\\) th participant and \\(j=0,2,5\\) represents the time period, \\(t\\) is time modeled categorically,","text_display":"\nwhere \\(i\\) denotes the \\(i\\) th participant and \\(j=0,2,5\\) represents the time period, \\(t\\) is time modeled categorically,","confidence":0.9936602079548038,"confidence_rate":0.9999495252907874},{"cnt":[[116,1611],[1815,1611],[1815,1661],[116,1661]],"region":{"top_left_x":116,"top_left_y":1611,"width":1700,"height":50},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b9aa100b0d8f409e9259bb01e09fe78e","type":"text","conversion_output":true,"text":"(vitamin \\(D\\) ) is active vitamin \\(D\\) treatment assignment (yes/no), ( \\(\\omega-3\\) FA) is active omega-3 treatment","text_display":" (vitamin \\(D\\) ) is active vitamin \\(D\\) treatment assignment (yes/no), ( \\(\\omega-3\\) FA) is active omega-3 treatment","confidence":0.6518247248255126,"confidence_rate":0.9962853548610886},{"cnt":[[116,1654],[1944,1654],[1944,1704],[116,1704]],"region":{"top_left_x":116,"top_left_y":1654,"width":1829,"height":50},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"06870ad7c6704480bc6ce0432363c217","type":"text","conversion_output":true,"text":"assignment ( \\(yes / no\\) ), \\(a_{i}\\) is a random effect for patient, and \\(\\varepsilon\\) is statistical error. A p value \\(<0.05\\) for \\(\\beta_{6}\\) will be","text_display":" assignment ( \\(yes / no\\) ), \\(a_{i}\\) is a random effect for patient, and \\(\\varepsilon\\) is statistical error. A p value \\(<0.05\\) for \\(\\beta_{6}\\) will be","confidence":0.858337630003001,"confidence_rate":0.9990212629378148},{"cnt":[[116,1697],[1962,1697],[1962,1747],[116,1747]],"region":{"top_left_x":116,"top_left_y":1697,"width":1846,"height":50},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"edcf1902ab54404a9a8204fb25b40590","type":"text","conversion_output":true,"text":"interpreted as evidence of interaction. If we observe interaction, all analyses will separately compare each of","text_display":" interpreted as evidence of interaction. If we observe interaction, all analyses will separately compare each of","confidence":1,"confidence_rate":1},{"cnt":[[116,1745],[1852,1745],[1852,1790],[116,1790]],"region":{"top_left_x":116,"top_left_y":1744,"width":1736,"height":46},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"1b672838709d46b69f74e43993fd2c13","type":"text","conversion_output":true,"text":"the 3 active treatment groups to the treatment group which receives (placebo + placebo). If there is no","text_display":" the 3 active treatment groups to the treatment group which receives (placebo + placebo). If there is no","confidence":0.6224384307861328,"confidence_rate":0.9958497715229245},{"cnt":[[116,1788],[1972,1788],[1972,1835],[116,1835]],"region":{"top_left_x":116,"top_left_y":1787,"width":1857,"height":48},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"ab3a197f194149bcae0fcccfe816ed89","type":"text","conversion_output":true,"text":"evidence of interaction, as hypothesized, all participants assigned to any active vitamin D will be compared to","text_display":" evidence of interaction, as hypothesized, all participants assigned to any active vitamin D will be compared to","confidence":0.95361328125,"confidence_rate":0.9995906264431031},{"cnt":[[116,1830],[1970,1830],[1970,1880],[116,1880]],"region":{"top_left_x":116,"top_left_y":1830,"width":1855,"height":50},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c0d8d3154e084ff288e8965864f7014d","type":"text","conversion_output":true,"text":"all participants assigned to placebo vitamin D , and all participants assigned to any active omega- 3 fatty acids","text_display":" all participants assigned to placebo vitamin D , and all participants assigned to any active omega- 3 fatty acids","confidence":0.868894966552034,"confidence_rate":0.9988940527349647},{"cnt":[[116,1876],[1420,1876],[1420,1927],[116,1927]],"region":{"top_left_x":116,"top_left_y":1875,"width":1305,"height":53},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f41d47c7afe14e5fa8b3175301a03be4","type":"text","conversion_output":true,"text":"will be compared to all participants assigned to placebo omega-3 fatty acids.","text_display":" will be compared to all participants assigned to placebo omega-3 fatty acids.","confidence":0.56201171875,"confidence_rate":0.9929974066675549},{"cnt":[[120,1938],[1931,1938],[1931,1987],[120,1987]],"region":{"top_left_x":120,"top_left_y":1937,"width":1812,"height":51},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b2f9d805e5d9498ba104a4c4ffbe43ce","type":"text","conversion_output":true,"text":"15e. Hypothesis testing. The primary outcome is a continuous variable which will be tested using a linear","text_display":"\n15e. Hypothesis testing. The primary outcome is a continuous variable which will be tested using a linear","confidence":1,"confidence_rate":1},{"cnt":[[116,1985],[1893,1985],[1893,2032],[116,2032]],"region":{"top_left_x":116,"top_left_y":1985,"width":1777,"height":48},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a482670832494fc5bb7abc1c8c71aec4","type":"text","conversion_output":true,"text":"mixed model with random intercepts. To test whether the change in eGFR differs by vitamin D treatment","text_display":" mixed model with random intercepts. To test whether the change in eGFR differs by vitamin D treatment","confidence":0.9028792381286621,"confidence_rate":0.9990366297300892},{"cnt":[[116,2028],[1454,2028],[1454,2078],[116,2078]],"region":{"top_left_x":116,"top_left_y":2028,"width":1339,"height":50},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7f3241126e0d469e8d9c6f4acfa93f77","type":"text","conversion_output":true,"text":"assignment in the absence of interaction with omega-3 fatty acids, we will test:","text_display":" assignment in the absence of interaction with omega-3 fatty acids, we will test:","confidence":0.99853515625,"confidence_rate":0.9999827540583306},{"cnt":[[180,2090],[1480,2090],[1480,2144],[180,2144]],"region":{"top_left_x":180,"top_left_y":2090,"width":1301,"height":55},"line":45,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"43741575f7364a959385dff41fe61830","type":"text","conversion_output":true,"text":"Equation 2: \\(e G F R_{i j}=\\beta_{0}+\\beta_{1}\\left(v i t a \\min D_{i}\\right)+\\beta_{2}\\left(t_{i j}\\right)+\\beta_{3}\\left(v i t a \\min D_{i} \\times t_{i j}\\right)+a_{i}+e_{i j}\\)","text_display":"\n\nEquation 2: \\(e G F R_{i j}=\\beta_{0}+\\beta_{1}\\left(v i t a \\min D_{i}\\right)+\\beta_{2}\\left(t_{i j}\\right)+\\beta_{3}\\left(v i t a \\min D_{i} \\times t_{i j}\\right)+a_{i}+e_{i j}\\)","confidence":0.2452208717579958,"confidence_rate":0.9909726325632344},{"cnt":[[116,2157],[1904,2157],[1904,2206],[116,2206]],"region":{"top_left_x":116,"top_left_y":2157,"width":1788,"height":50},"line":46,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a18e0481254e4e829fa4052097f07f50","type":"text","conversion_output":true,"text":"where \\(\\beta_{3}\\) represents the difference in change in eGFR over time, comparing those on active vitamin \\(D _{3}\\) to","text_display":"\nwhere \\(\\beta_{3}\\) represents the difference in change in eGFR over time, comparing those on active vitamin \\(D _{3}\\) to","confidence":0.9639790058135986,"confidence_rate":0.9997199952177392},{"cnt":[[116,2200],[1987,2200],[1987,2249],[116,2249]],"region":{"top_left_x":116,"top_left_y":2200,"width":1872,"height":50},"line":47,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8e798707a53b4cdfbbeb5b9445a8ecac","type":"text","conversion_output":true,"text":"those on placebo. The corresponding \\(95 \\%\\) confidence interval and \\(p\\)-value reflect statistical significance of the","text_display":" those on placebo. The corresponding \\(95 \\%\\) confidence interval and \\(p\\)-value reflect statistical significance of the","confidence":0.9766323280055076,"confidence_rate":0.9998077824981357},{"cnt":[[116,2245],[1944,2245],[1944,2292],[116,2292]],"region":{"top_left_x":116,"top_left_y":2245,"width":1829,"height":48},"line":48,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8377adc9a6624e828444093ec7a7a13b","type":"text","conversion_output":true,"text":"treatment effect. We will use this model to describe treatment effects at years 2 and 5 but reserve statistical","text_display":" treatment effect. We will use this model to describe treatment effects at years 2 and 5 but reserve statistical","confidence":0.99951171875,"confidence_rate":0.9999959967252418},{"cnt":[[116,2290],[1953,2290],[1953,2340],[116,2340]],"region":{"top_left_x":116,"top_left_y":2290,"width":1837,"height":50},"line":49,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d57b82bbde384993a69d12b872187353","type":"text","conversion_output":true,"text":"inference for year 5 alone. Corresponding equations will test the effect of omega- 3 treatment assignment on","text_display":" inference for year 5 alone. Corresponding equations will test the effect of omega- 3 treatment assignment on","confidence":0.9599609375,"confidence_rate":0.9996566750381439},{"cnt":[[116,2333],[1910,2333],[1910,2383],[116,2383]],"region":{"top_left_x":116,"top_left_y":2333,"width":1794,"height":50},"line":50,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"5d7d83834a964d9eb4b748a7820834ba","type":"text","conversion_output":true,"text":"eGFR as well as treatment effects on urine ACR, analyzed as a log-transformed continuous variable. The","text_display":" eGFR as well as treatment effects on urine ACR, analyzed as a log-transformed continuous variable. The","confidence":1,"confidence_rate":1},{"cnt":[[116,2376],[1983,2376],[1983,2426],[116,2426]],"region":{"top_left_x":116,"top_left_y":2376,"width":1868,"height":50},"line":51,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"512a0563b4c94aadb8ea86416114ebb8","type":"text","conversion_output":true,"text":"relatively large sample size makes it likely that few or no substantial differences in baseline characteristics will","text_display":" relatively large sample size makes it likely that few or no substantial differences in baseline characteristics will","confidence":1,"confidence_rate":1},{"cnt":[[116,2419],[1846,2419],[1846,2469],[116,2469]],"region":{"top_left_x":116,"top_left_y":2419,"width":1730,"height":50},"line":52,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"58320328d9d64010b9a3b4a6ec231dd9","type":"text","conversion_output":true,"text":"be present. In the event that any baseline characteristics are not balanced between treatment groups,","text_display":" be present. In the event that any baseline characteristics are not balanced between treatment groups,","confidence":0.994140625,"confidence_rate":0.9999445618340256},{"cnt":[[116,2466],[1901,2466],[1901,2512],[116,2512]],"region":{"top_left_x":116,"top_left_y":2466,"width":1786,"height":46},"line":53,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9d1d841cd31e40aead0da4e7ba13cd4d","type":"text","conversion_output":true,"text":"sensitivity analyses will add to the model additional terms for such baseline characteristics. If we observe","text_display":" sensitivity analyses will add to the model additional terms for such baseline characteristics. If we observe","confidence":1,"confidence_rate":1},{"cnt":[[116,2509],[1951,2509],[1951,2559],[116,2559]],"region":{"top_left_x":116,"top_left_y":2509,"width":1835,"height":50},"line":54,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8c812573f57146d4a2b63ea529b9018c","type":"text","conversion_output":true,"text":"differences by treatment group in medication use (e.g. glucose-lowering or antihypertensive medications) or","text_display":" differences by treatment group in medication use (e.g. glucose-lowering or antihypertensive medications) or","confidence":0.99658203125,"confidence_rate":0.9999694306159178},{"cnt":[[1972,2582],[2009,2582],[2009,2628],[1972,2628]],"region":{"top_left_x":1972,"top_left_y":2582,"width":37,"height":46},"line":55,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"58e16d4ad8af41a19c304d6f4069b379","type":"page_info","conversion_output":false,"text":"2","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]},{"image_id":"7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-33","page":33,"lines":[{"cnt":[[120,125],[1313,125],[1313,174],[120,174]],"region":{"top_left_x":120,"top_left_y":124,"width":1193,"height":51},"line":1,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c37a6ae769b244689478f37cbc975df7","type":"text","conversion_output":true,"text":"laboratory covariates (e.g. hemoglobin A1c, CRP, IL-6) over follow-up,","text_display":"\nlaboratory covariates (e.g. hemoglobin A1c, CRP, IL-6) over follow-up,","confidence":0.99951171875,"confidence_rate":0.9999934880145617},{"cnt":[[120,172],[1257,172],[1257,217],[120,217]],"region":{"top_left_x":120,"top_left_y":171,"width":1137,"height":46},"line":2,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b2bb1d9e08974540bdf402406d2a1f30","type":"text","conversion_output":true,"text":"we will explore whether such differences may mediate or attenuate","text_display":" we will explore whether such differences may mediate or attenuate","confidence":1,"confidence_rate":1},{"cnt":[[120,215],[1270,215],[1270,260],[120,260]],"region":{"top_left_x":120,"top_left_y":214,"width":1150,"height":46},"line":3,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"f00610bfa76842b98c328e81b74a7576","type":"text","conversion_output":true,"text":"treatment effects by adding terms for these covariates to the model.","text_display":" treatment effects by adding terms for these covariates to the model.","confidence":1,"confidence_rate":1},{"cnt":[[120,258],[1261,258],[1261,303],[120,303]],"region":{"top_left_x":120,"top_left_y":257,"width":1142,"height":46},"line":4,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"7e4157a6ae5a4d619472cdd22371e385","type":"text","conversion_output":true,"text":"We will assess secondary categorical outcomes using discrete Cox","text_display":" We will assess secondary categorical outcomes using discrete Cox","confidence":1,"confidence_rate":1},{"cnt":[[120,296],[664,296],[664,350],[120,350]],"region":{"top_left_x":120,"top_left_y":296,"width":544,"height":55},"line":5,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"0efba069be89450cb62c3eb9848a8b3b","type":"text","conversion_output":true,"text":"proportional hazards models. \\({ }^{184}\\)","text_display":" proportional hazards models. \\({ }^{184}\\)","confidence":1,"confidence_rate":1},{"cnt":[[120,365],[1315,365],[1315,415],[120,415]],"region":{"top_left_x":120,"top_left_y":365,"width":1195,"height":50},"line":6,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"4ad70b63b4ca41a18c3a313e38a48478","type":"text","conversion_output":true,"text":"15f. Subgroup analyses. For the vitamin D intervention, prespecified","text_display":"\n15f. Subgroup analyses. For the vitamin D intervention, prespecified","confidence":0.99755859375,"confidence_rate":0.999966515747709},{"cnt":[[120,408],[1257,408],[1257,458],[120,458]],"region":{"top_left_x":120,"top_left_y":408,"width":1137,"height":50},"line":7,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6b7d8bd07c3e451483598123d1ccf78a","type":"text","conversion_output":true,"text":"subgroup analyses will be based on baseline total and bioavailable","text_display":" subgroup analyses will be based on baseline total and bioavailable","confidence":0.99853515625,"confidence_rate":0.9999793534852197},{"cnt":[[120,455],[1231,455],[1231,501],[120,501]],"region":{"top_left_x":120,"top_left_y":455,"width":1112,"height":46},"line":8,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c2c692d70e50406887f3415cf2f9943f","type":"text","conversion_output":true,"text":"serum \\(25( OH )\\) D concentrations, urine ACR, and eGFR as well as","text_display":" serum \\(25( OH )\\) D concentrations, urine ACR, and eGFR as well as","confidence":0.6749450304718283,"confidence_rate":0.9945548230718787},{"cnt":[[120,498],[1210,498],[1210,544],[120,544]],"region":{"top_left_x":120,"top_left_y":498,"width":1090,"height":46},"line":9,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2ecf6f578d4a4f92a6e25d7e704656e7","type":"text","conversion_output":true,"text":"race/ethnicity: we hypothesize that effects will be greater among","text_display":" race/ethnicity: we hypothesize that effects will be greater among","confidence":1,"confidence_rate":1},{"cnt":[[120,541],[1308,541],[1308,589],[120,589]],"region":{"top_left_x":120,"top_left_y":541,"width":1189,"height":48},"line":10,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"93a5c0bdf4b6424f90837ab6f9bf06b2","type":"text","conversion_output":true,"text":"participants who have low \\(25( OH ) D\\) at baseline, who have DKD (urine","text_display":" participants who have low \\(25( OH ) D\\) at baseline, who have DKD (urine","confidence":0.6349690581773757,"confidence_rate":0.9943388474525043},{"cnt":[[120,580],[1154,580],[1154,632],[120,632]],"region":{"top_left_x":120,"top_left_y":580,"width":1034,"height":52},"line":11,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"98a194b0aaf549f19b0918e2ab21cf1b","type":"text","conversion_output":true,"text":"ACR \\(\\geq 30 mg / g\\) or eGFR \\(<60 mL / min / m ^{2}\\) ) at baseline, or are","text_display":" ACR \\(\\geq 30 mg / g\\) or eGFR \\(<60 mL / min / m ^{2}\\) ) at baseline, or are","confidence":0.9931640625,"confidence_rate":0.9999211593201485},{"cnt":[[120,623],[1300,623],[1300,677],[120,677]],"region":{"top_left_x":120,"top_left_y":623,"width":1180,"height":54},"line":12,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"d5bf19fa2f12458ea0be994942476339","type":"text","conversion_output":true,"text":"Caucasian. \\({ }^{185,186}\\) For the omega-3 fatty acid intervention, prespecified","text_display":" Caucasian. \\({ }^{185,186}\\) For the omega-3 fatty acid intervention, prespecified","confidence":0.99267578125,"confidence_rate":0.9999155073337173},{"cnt":[[120,675],[1302,675],[1302,722],[120,722]],"region":{"top_left_x":120,"top_left_y":674,"width":1182,"height":48},"line":13,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b9f5b5e902d847379ea5efe927e71104","type":"text","conversion_output":true,"text":"subgroup analyses will be based on baseline levels of EPA+DHA and","text_display":" subgroup analyses will be based on baseline levels of EPA+DHA and","confidence":1,"confidence_rate":1},{"cnt":[[120,718],[1313,718],[1313,767],[120,767]],"region":{"top_left_x":120,"top_left_y":717,"width":1193,"height":50},"line":14,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"36bfc91ac7044d589dc64998cf1bb4f0","type":"text","conversion_output":true,"text":"hsCRP: we hypothesize that effects will be greater among participants","text_display":" hsCRP: we hypothesize that effects will be greater among participants","confidence":0.99560546875,"confidence_rate":0.9999404853442438},{"cnt":[[120,761],[1214,761],[1214,810],[120,810]],"region":{"top_left_x":120,"top_left_y":760,"width":1094,"height":50},"line":15,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"aeb69ab56bd44a52a64acf7107b936ee","type":"text","conversion_output":true,"text":"who low levels of EPA+DHA or high concentrations of hsCRP at","text_display":" who low levels of EPA+DHA or high concentrations of hsCRP at","confidence":0.99853515625,"confidence_rate":0.9999774476745767},{"cnt":[[120,804],[1235,804],[1235,853],[120,853]],"region":{"top_left_x":120,"top_left_y":803,"width":1116,"height":50},"line":16,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"facc1d38b9534618a7eac1855da91aeb","type":"text","conversion_output":true,"text":"baseline. Effect modification will be tested by including interaction","text_display":" baseline. Effect modification will be tested by including interaction","confidence":0.99951171875,"confidence_rate":0.9999934000150488},{"cnt":[[120,851],[1283,851],[1283,896],[120,896]],"region":{"top_left_x":120,"top_left_y":850,"width":1163,"height":46},"line":17,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"11eb214aa2514b52aafaabbdb64c048b","type":"text","conversion_output":true,"text":"terms of treatment assignment with subgroup in linear mixed models","text_display":" terms of treatment assignment with subgroup in linear mixed models","confidence":1,"confidence_rate":1},{"cnt":[[1360,141],[1987,141],[1987,884],[1360,884]],"region":{"top_left_x":1360,"top_left_y":141,"width":627,"height":743},"line":18,"column":0,"font_size":23,"is_printed":true,"is_handwritten":false,"id":"451a409857884dde8f1e5dfb92048de4","type":"column","conversion_output":false,"children_ids":["09328dccd32841dcb2b3631570dc9cee","751db1ca87424839977aa2c51e8ed44e"],"text":"","text_display":""},{"cnt":[[1362,144],[1981,144],[1981,752],[1362,752]],"region":{"top_left_x":1362,"top_left_y":143,"width":619,"height":609},"line":19,"column":1,"font_size":18,"is_printed":true,"is_handwritten":false,"id":"09328dccd32841dcb2b3631570dc9cee","type":"chart","conversion_output":true,"parent_id":"451a409857884dde8f1e5dfb92048de4","selected_labels":["751db1ca87424839977aa2c51e8ed44e"],"text":"","text_display":"\n\n\\begin{figure}\n\\includegraphics[alt={},max width=\\textwidth]{https://cdn.mathpix.com/cropped/7a7af0c0-0a76-4ff9-b23a-f7968d4044f6-33.jpg?height=609&width=619&top_left_y=143&top_left_x=1362}\n\\captionsetup{labelformat=empty}\n\\caption{Figure 7. Study power by effect size for the primary outcome (difference in estimated GFR in \\(mL / min / 1.73 m^{2}\\) ).}\n\\end{figure}","subtype":"line"},{"cnt":[[1371,752],[1983,752],[1983,881],[1371,881]],"region":{"top_left_x":1370,"top_left_y":751,"width":614,"height":130},"line":20,"column":1,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"751db1ca87424839977aa2c51e8ed44e","type":"figure_label","conversion_output":false,"parent_id":"451a409857884dde8f1e5dfb92048de4","children_ids":["83dd5c90bad447b9a8c0ca31dbbf5d7a","f9cf03b7e2ff44ff945374d6084759a2","73564ef8c5f64bd6a025e5841dc3bf53"],"text":"","text_display":""},{"cnt":[[1379,761],[1970,761],[1970,801],[1379,801]],"region":{"top_left_x":1379,"top_left_y":760,"width":592,"height":42},"line":21,"column":1,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"83dd5c90bad447b9a8c0ca31dbbf5d7a","type":"text","conversion_output":false,"parent_id":"751db1ca87424839977aa2c51e8ed44e","text":"Figure 7. Study power by effect size for the","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[1379,797],[1944,797],[1944,836],[1379,836]],"region":{"top_left_x":1379,"top_left_y":797,"width":566,"height":39},"line":22,"column":1,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"f9cf03b7e2ff44ff945374d6084759a2","type":"text","conversion_output":false,"parent_id":"751db1ca87424839977aa2c51e8ed44e","text":"primary outcome (difference in estimated","text_display":"","confidence":1,"confidence_rate":1},{"cnt":[[1379,834],[1721,834],[1721,872],[1379,872]],"region":{"top_left_x":1379,"top_left_y":833,"width":342,"height":40},"line":23,"column":1,"font_size":28,"is_printed":true,"is_handwritten":false,"id":"73564ef8c5f64bd6a025e5841dc3bf53","type":"text","conversion_output":false,"parent_id":"751db1ca87424839977aa2c51e8ed44e","text":"GFR in \\(mL / min / 1.73 m^{2}\\) ).","text_display":"","confidence":0.9150850749574602,"confidence_rate":0.9981906543545198},{"cnt":[[120,889],[346,889],[346,939],[120,939]],"region":{"top_left_x":120,"top_left_y":889,"width":226,"height":50},"line":24,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"10f8e653f28c436bae9b4ea17a0d506d","type":"text","conversion_output":true,"text":"(Equation 2).","text_display":" (Equation 2).","confidence":1,"confidence_rate":1},{"cnt":[[120,958],[1992,958],[1992,1005],[120,1005]],"region":{"top_left_x":120,"top_left_y":958,"width":1872,"height":48},"line":25,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"9634f439b79b4551a5efd5205299f8fd","type":"text","conversion_output":true,"text":"15g. Exploratory adherence and efficacy analyses. All primary analyses will be performed according to the","text_display":"\n\n15g. Exploratory adherence and efficacy analyses. All primary analyses will be performed according to the","confidence":1,"confidence_rate":1},{"cnt":[[120,1001],[1893,1001],[1893,1051],[120,1051]],"region":{"top_left_x":120,"top_left_y":1001,"width":1773,"height":50},"line":26,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"479efb13481449a4b26c80976f316b7c","type":"text","conversion_output":true,"text":"intent-to-treat principle (Section D15e). We plan secondary, exploratory analyses for the following limited","text_display":" intent-to-treat principle (Section D15e). We plan secondary, exploratory analyses for the following limited","confidence":1,"confidence_rate":1},{"cnt":[[120,1044],[1989,1044],[1989,1094],[120,1094]],"region":{"top_left_x":120,"top_left_y":1044,"width":1870,"height":50},"line":27,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"eab87c54ba494f1db5f1454c644d4288","type":"text","conversion_output":true,"text":"purposes: (a) to evaluate whether null findings, if observed, are robust (i.e. not readily attributable to defects in","text_display":" purposes: (a) to evaluate whether null findings, if observed, are robust (i.e. not readily attributable to defects in","confidence":0.99951171875,"confidence_rate":0.9999959967252418},{"cnt":[[120,1091],[1899,1091],[1899,1137],[120,1137]],"region":{"top_left_x":120,"top_left_y":1091,"width":1780,"height":46},"line":28,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"a63c8ecb89a2416091aa295b0f11eed4","type":"text","conversion_output":true,"text":"the study interventions or their administration); and/or (b) to more comprehensively evaluate the potential","text_display":" the study interventions or their administration); and/or (b) to more comprehensively evaluate the potential","confidence":1,"confidence_rate":1},{"cnt":[[120,1134],[1901,1134],[1901,1179],[120,1179]],"region":{"top_left_x":120,"top_left_y":1134,"width":1782,"height":46},"line":29,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e9e26117fe424b0b9525a64f83e5c47a","type":"text","conversion_output":true,"text":"range of treatment effects, if treatment effects are observed. We understand and acknowledge that these","text_display":" range of treatment effects, if treatment effects are observed. We understand and acknowledge that these","confidence":1,"confidence_rate":1},{"cnt":[[120,1177],[1996,1177],[1996,1227],[120,1227]],"region":{"top_left_x":120,"top_left_y":1177,"width":1876,"height":50},"line":30,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"35198ff624274d5383c9a062ab938220","type":"text","conversion_output":true,"text":"analyses, which are based on data collected after randomization, may introduce bias into study results. We will","text_display":" analyses, which are based on data collected after randomization, may introduce bias into study results. We will","confidence":1,"confidence_rate":1},{"cnt":[[120,1222],[1987,1222],[1987,1270],[120,1270]],"region":{"top_left_x":120,"top_left_y":1222,"width":1868,"height":48},"line":31,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"8e02cf888ecf487390c21bc600f33fd7","type":"text","conversion_output":true,"text":"therefore use caution to limit their interpretation. We will first repeat analyses among the subset of participants","text_display":" therefore use caution to limit their interpretation. We will first repeat analyses among the subset of participants","confidence":1,"confidence_rate":1},{"cnt":[[116,1265],[1989,1265],[1989,1313],[116,1313]],"region":{"top_left_x":116,"top_left_y":1265,"width":1874,"height":48},"line":32,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"c134fb8511cc4cd6b7234247923837f5","type":"text","conversion_output":true,"text":"who report continuous adherence to \\(\\geq 80 \\%\\) of study medications. In addition, we will assess whether changes","text_display":" who report continuous adherence to \\(\\geq 80 \\%\\) of study medications. In addition, we will assess whether changes","confidence":0.9931640625,"confidence_rate":0.9999392991029856},{"cnt":[[116,1311],[1841,1311],[1841,1356],[116,1356]],"region":{"top_left_x":116,"top_left_y":1310,"width":1726,"height":46},"line":33,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"cbbd76c80919413c97a65c5187f25304","type":"text","conversion_output":true,"text":"in \\(25( OH ) D\\) and EPA+DHA levels are associated with changes in urine ACR and eGFR. For the latter","text_display":" in \\(25( OH ) D\\) and EPA+DHA levels are associated with changes in urine ACR and eGFR. For the latter","confidence":0.7955683574937211,"confidence_rate":0.9979040481620643},{"cnt":[[118,1354],[1987,1354],[1987,1401],[118,1401]],"region":{"top_left_x":118,"top_left_y":1353,"width":1870,"height":48},"line":34,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"23fd2ce921a24614b2e9cfe28f047138","type":"text","conversion_output":true,"text":"analyses, change in \\(25( OH ) D\\) concentrations or change in EPA+DHA concentration (continuous variables) will","text_display":" analyses, change in \\(25( OH ) D\\) concentrations or change in EPA+DHA concentration (continuous variables) will","confidence":0.9704273471182409,"confidence_rate":0.9997477734912192},{"cnt":[[116,1396],[1033,1396],[1033,1446],[116,1446]],"region":{"top_left_x":116,"top_left_y":1396,"width":918,"height":50},"line":35,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"e4055c4973b94e8b95922c2956eaa2af","type":"text","conversion_output":true,"text":"replace treatment assignment in linear mixed models.","text_display":" replace treatment assignment in linear mixed models.","confidence":1,"confidence_rate":1},{"cnt":[[120,1461],[1854,1461],[1854,1510],[120,1510]],"region":{"top_left_x":120,"top_left_y":1460,"width":1735,"height":51},"line":36,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"6da2d9778e87484096c688b89a14b68a","type":"text","conversion_output":true,"text":"D16. Power. We calculated power using simulation (2000 replications) and the following assumptions:","text_display":"\nD16. Power. We calculated power using simulation (2000 replications) and the following assumptions:","confidence":0.9199993421789259,"confidence_rate":0.9991985682031291},{"cnt":[[120,1506],[1936,1506],[1936,1553],[120,1553]],"region":{"top_left_x":120,"top_left_y":1506,"width":1816,"height":48},"line":37,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"53ab3723973a46db92468704cfda8c83","type":"text","conversion_output":true,"text":"independent and equal allocation of participants to each treatment; 1,058 participants ( \\(80 \\%\\) ) contributing at","text_display":" independent and equal allocation of participants to each treatment; 1,058 participants ( \\(80 \\%\\) ) contributing at","confidence":0.5061664593522437,"confidence_rate":0.9942463642938281},{"cnt":[[120,1551],[2000,1551],[2000,1596],[120,1596]],"region":{"top_left_x":120,"top_left_y":1551,"width":1881,"height":46},"line":38,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"b48f0940effa46fe97bfd6abd924805c","type":"text","conversion_output":true,"text":"least one follow-up blood sample (as supported in Section D10); variation in eGFR and its change over time as","text_display":" least one follow-up blood sample (as supported in Section D10); variation in eGFR and its change over time as","confidence":1,"confidence_rate":1},{"cnt":[[120,1594],[1841,1594],[1841,1641],[120,1641]],"region":{"top_left_x":120,"top_left_y":1594,"width":1722,"height":48},"line":39,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"456ed7cdd7e443d6a1b917846ff0c617","type":"text","conversion_output":true,"text":"observed in the preliminary data from our study population (Section D12); and no interaction between","text_display":" observed in the preliminary data from our study population (Section D12); and no interaction between","confidence":1,"confidence_rate":1},{"cnt":[[120,1637],[1757,1637],[1757,1687],[120,1687]],"region":{"top_left_x":120,"top_left_y":1637,"width":1638,"height":50},"line":40,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"bd42929426c341a6a43afacf6e42d775","type":"text","conversion_output":true,"text":"treatments. With these assumptions, we have \\(80 \\%\\) power (two-sided alpha \\(=0.05\\) ) to detect a 2.3","text_display":" treatments. With these assumptions, we have \\(80 \\%\\) power (two-sided alpha \\(=0.05\\) ) to detect a 2.3","confidence":0.984375,"confidence_rate":0.9998485849551062},{"cnt":[[120,1680],[1826,1680],[1826,1729],[120,1729]],"region":{"top_left_x":120,"top_left_y":1680,"width":1707,"height":50},"line":41,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"fb7efea52212400693a8a5a9925b630b","type":"text","conversion_output":true,"text":"\\(mL / min / 1.73 m^{2}\\) difference in eGFR at year 5, comparing each active treatment to placebo. Power for","text_display":" \\(mL / min / 1.73 m^{2}\\) difference in eGFR at year 5, comparing each active treatment to placebo. Power for","confidence":0.99853515625,"confidence_rate":0.9999874708675287},{"cnt":[[120,1727],[1953,1727],[1953,1772],[120,1772]],"region":{"top_left_x":120,"top_left_y":1727,"width":1833,"height":46},"line":42,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"65e6564ce3ba46f496dc174952136d67","type":"text","conversion_output":true,"text":"alternative effect sizes is shown in Figure 7. We do not present power for secondary outcomes because the","text_display":" alternative effect sizes is shown in Figure 7. We do not present power for secondary outcomes because the","confidence":1,"confidence_rate":1},{"cnt":[[120,1770],[1283,1770],[1283,1818],[120,1818]],"region":{"top_left_x":120,"top_left_y":1770,"width":1163,"height":48},"line":43,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"92e5bf880b3548738cb4f5fb13c38052","type":"text","conversion_output":true,"text":"incidence of these outcomes is difficult to predict with available data.","text_display":" incidence of these outcomes is difficult to predict with available data.","confidence":1,"confidence_rate":1},{"cnt":[[1972,2582],[2007,2582],[2007,2628],[1972,2628]],"region":{"top_left_x":1972,"top_left_y":2582,"width":35,"height":46},"line":44,"column":0,"font_size":35,"is_printed":true,"is_handwritten":false,"id":"2121688893554ac89ca78a35ac4ad115","type":"page_info","conversion_output":false,"text":"3","text_display":"","confidence":1,"confidence_rate":1}],"page_height":2750,"page_width":2125,"languages_detected":[]}]}